aid,aidtype,aidname,aiddesc,aidsrcid,aidsrcname,aidextid,aidmdate,cids,sids,geneids,aidcategories,protacxns,depcatg,pmids,rnai,dois,ecs,repacxns,annotation
1215347,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis in ,"Title: A refined cytochrome P540 IC&#xE2;&#x201A;&#x2026;&#xE2;&#x201A;&#x20AC; shift assay for reliably identifying CYP3A time-dependent inhibitors._|__|_Abstract: A refined cytochrome P450 (P450) enzyme IC&#x2085;&#x2080; shift assay for more accurately screening CYP3A time-dependent inhibitors (TDIs) is presented. In contrast to the regular IC&#x2085;&#x2080; shift assay, in which only one pair of P450 inhibition curves is generated, this modified method generates two pairs of inhibition curves; one pair",43,ChEMBL,1482921,20200624,"2520,3386,5035,12560,39186,392622,441074,5471349,6440498","103164872,103165728,103170049,103175312,103244854,103401109,103607227,103743925,104234145",1576,NULL,P08684,Curation Efforts|Research and Development,21393461,0,10.1124/dmd.111.038208,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215348,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by LC-MS/MS analysis,"Title: A refined cytochrome P540 IC&#xE2;&#x201A;&#x2026;&#xE2;&#x201A;&#x20AC; shift assay for reliably identifying CYP3A time-dependent inhibitors._|__|_Abstract: A refined cytochrome P450 (P450) enzyme IC&#x2085;&#x2080; shift assay for more accurately screening CYP3A time-dependent inhibitors (TDIs) is presented. In contrast to the regular IC&#x2085;&#x2080; shift assay, in which only one pair of P450 inhibition curves is generated, this modified method generates two pairs of inhibition curves; one pair",43,ChEMBL,1482922,20200624,"2520,3386,5035,12560,39186,392622,441074,5471349,6440498","103164872,103165728,103170049,103175312,103244854,103401109,103607227,103743925,104234145",1576,NULL,P08684,Curation Efforts|Research and Development,21393461,0,10.1124/dmd.111.038208,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215349,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 s,"Title: A refined cytochrome P540 IC&#xE2;&#x201A;&#x2026;&#xE2;&#x201A;&#x20AC; shift assay for reliably identifying CYP3A time-dependent inhibitors._|__|_Abstract: A refined cytochrome P450 (P450) enzyme IC&#x2085;&#x2080; shift assay for more accurately screening CYP3A time-dependent inhibitors (TDIs) is presented. In contrast to the regular IC&#x2085;&#x2080; shift assay, in which only one pair of P450 inhibition curves is generated, this modified method generates two pairs of inhibition curves; one pair",43,ChEMBL,1482923,20200624,"2520,3386,5035,12560,39186,392622,441074,5471349,6440498","103164872,103165728,103170049,103175312,103244854,103401109,103607227,103743925,104234145",1576,NULL,P08684,Curation Efforts|Research and Development,21393461,0,10.1124/dmd.111.038208,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215350,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.01 to 100 uM preincubated for 60 mins followed by testosterone treatment measured after 10 mins by refined CYP450 IC50 s,"Title: A refined cytochrome P540 IC&#xE2;&#x201A;&#x2026;&#xE2;&#x201A;&#x20AC; shift assay for reliably identifying CYP3A time-dependent inhibitors._|__|_Abstract: A refined cytochrome P450 (P450) enzyme IC&#x2085;&#x2080; shift assay for more accurately screening CYP3A time-dependent inhibitors (TDIs) is presented. In contrast to the regular IC&#x2085;&#x2080; shift assay, in which only one pair of P450 inhibition curves is generated, this modified method generates two pairs of inhibition curves; one pair",43,ChEMBL,1482924,20200624,"2520,3386,5035,12560,39186,392622,441074,5471349,6440498","103164872,103165728,103170049,103175312,103244854,103401109,103607227,103743925,104234145",1576,NULL,P08684,Curation Efforts|Research and Development,21393461,0,10.1124/dmd.111.038208,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
71588,100,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 16.3 uM; No time dependent inhibition was observed,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 16.3 uM; No time dependent inhibition was observed,43,ChEMBL,68756,20180908,44281364,103760068,2729,NULL,P48506,Curation Efforts|Research and Development,NULL,0,NULL,6.3.2.2,P48506,NULL
1218817,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488502,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218818,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488503,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218819,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488504,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218820,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488505,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218821,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488506,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218822,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488507,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218823,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488508,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218824,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488509,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218843,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491682,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218844,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491683,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218845,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491684,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218846,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491685,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218847,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491686,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218848,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491687,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218849,2,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491688,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218850,2,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491689,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218855,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of midazolam to 1'-hydroxymidazolam at 0.3 to 75 uM by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492491,20200624,24957182,103524061,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218856,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone at 0.3 to 75 uM by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492492,20200624,24957182,103524061,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218857,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of midazolam to 1'-hydroxymidazolam at 0.1 to 30 uM by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492493,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218858,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as conversion of testosterone to 6beta-hydroxytestosterone 0.1 to 30 uM by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492494,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1466032,100,Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone to 6beta-hydroxytestosterone conversion by measuring remaining activity at 30 uM preincubated for 60 mins followed by testosterone addition measured after ,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670929,20200622,"125487466,125487493,126568381,126568395,126568404,126568413,126568428,126568459,126568463,126568509,126568548,126568659,126568661,126568668,126568669,126568746,126568757,126568827,126568856,126584616,126584619,126584623,137660456","381837523,381838982,381840512,381841089,381842428,381842931,381844591,381844658,381844717,381845142,381847395,381854513,381855992,381857527,381858321,381860481,381863696,381865458,381869430,381869613,381869714,381885138,381885408",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
67008,100,Second-order rate constant for time-dependent inactivation of Human Leukocyte Elastase was determined; G means no time-dependent inhibition was observed,"Title: Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides._|__|_Abstract: A variety of 7 alpha-methoxycephalosporin ester and amide sulfones were prepared and tested to determine the structure-activity relations for inhibition of human leukocyte elastase (HLE), a serine protease which has been implicated in several degenerative lung and tissue diseases. The most potent IC50 values were obtained with neutral, lipophilic derivatives, with the esters being more",43,ChEMBL,64168,20181013,"14760233,14760241","103289173,103289631",1991,NULL,P08246,Curation Efforts|Research and Development,2391692,0,10.1021/jm00171a029,3.4.21.37,P08246,NULL
156881,100,The compound was tested for time dependent inhibition against carboxyl protease (pepsin); No inhibition,Title: Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin._|__|_Abstract: A series of pepstatin analogues having minimum structural requirements for tight-binding inhibition has been synthesized and tested on porcine pepsin. Subtle changes in the geometry and size of side chains at the valine-1 position of pepstatin were found to dramatically affect inhibitor potency as well a the type of kinetic behavior observed. The inhibitors re,43,ChEMBL,154135,20181002,"44378915,44379091,44379147","103421047,103421449,103421609",396892,NULL,P00791,Curation Efforts|Research and Development,6809942,0,10.1021/jm00349a005,3.4.23.1,P00791,NULL
156882,100,The compound was tested for time dependent inhibition against carboxyl protease (pepsin); Yes,Title: Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin._|__|_Abstract: A series of pepstatin analogues having minimum structural requirements for tight-binding inhibition has been synthesized and tested on porcine pepsin. Subtle changes in the geometry and size of side chains at the valine-1 position of pepstatin were found to dramatically affect inhibitor potency as well a the type of kinetic behavior observed. The inhibitors re,43,ChEMBL,154136,20181002,"44278232,44378838,44378872,44378925,44378990,44379004,44379064","103200874,103420877,103420936,103421071,103421199,103421229,103421384",396892,NULL,P00791,Curation Efforts|Research and Development,6809942,0,10.1021/jm00349a005,3.4.23.1,P00791,NULL
1295358,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as coversion of 6beta-hydroxytestosterone to testosterone by measuring remaining activity at 30 uM by UPLC analysis in presence of NADPH generating system,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572138,20180905,"89690957,89691019,89691044,89691065,89691096,89691162,89702226,89702566","336870831,336870832,336870833,336871261,336871262,336871263,336871264,336871688",1576,NULL,P08684,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1295359,100,Time dependent inhibition of CYP3A4 in human liver microsomes at 10 uM,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572139,20180905,89691439,336872037,1576,NULL,P08684,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
699805,2,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 30 mins,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860549,20200625,"24937010,24937637,46239494,49834039,49834218,57506726,57506727,57506732,57506734,57506741,57506743,57506744,59606002,60165513,60165514,60165805","163313941,163317371,163317372,163317373,163320840,163320842,163320843,163320844,163320845,163324216,163327677,163327678,163327679,163331205,163331206,163331225",1576,NULL,P08684,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1153217,100,Time dependent inhibition of human liver microsome CYP3A4 activity assessed as percentage remaining activity by measuring 6-beta-OH-testosterone formation at 15 uM for 15 mins using 200 uM testosterone as a substrate by LC/MS/MS analysis,"Title: Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP._|__|_Abstract: Based on their structural similarity to previously described compound AMG 009, indole-phenyl acetic acids were proposed to be potent dual inhibitors of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2) and prostanoid D receptor (DP or DP1). This series was equipotent to AMG 009 in binding assays against both receptors ",43,ChEMBL,1364475,20181004,"10483360,25106870,25106871,59864915,67242411,90479860,90644206,90644207,90644208,90644209","103705008,242645860,242645861,242645862,242645863,242645864,242645865,242645866,242645867,242645868",1576,NULL,P08684,Curation Efforts|Research and Development,24825301,0,10.1016/j.bmcl.2014.04.092,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1190263,100,Time-dependent inhibition of CYP3A4 (unknown origin) using midazolam as substrate assessed as AUC shift,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462154,20181006,"68276577,68277248,68277518,68277611,71727683,71727801,71728054,71818876,89793496,89793516,89793519,89795484,89795501,89795553,89795796,90655898","174493111,174503499,174518843,174518845,174518847,242633560,312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1576,NULL,P08684,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1190264,100,Time-dependent inhibition of CYP3A4 (unknown origin) using testosterone as substrate assessed as AUC shift,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462155,20181006,"68276577,68277248,68277518,68277611,71727683,71727801,71728054,71818876,89793496,89793516,89793519,89795484,89795501,89795553,89795796,90655898","174493111,174503499,174518843,174518845,174518847,242633560,312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1576,NULL,P08684,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1190275,100,Time-dependent inhibition of CYP2C9 in human liver microsomes assessed as AUC shift,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462166,20181006,89795553,312378107,1559,NULL,P11712,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1190276,100,Time-dependent inhibition of CYP2D6 in human liver microsomes assessed as AUC shift,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462167,20181006,89795553,312378107,1565,NULL,P10635,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,1.14.14.-,P10635,NULL
1217704,100,Time dependent inhibition of CYP1A2 (unknown origin) at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489413,20200624,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,392622,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103192563,103195217,103211583,103219094,103219164,103244854,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",1544,NULL,P05177,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,4.2.1.152",P05177,NULL
1217705,100,Time dependent inhibition of CYP2B6 (unknown origin) at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489414,20181007,"1775,1935,1983,2165,2519,2520,2554,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5733,6009,12560,38409,54687,60823,60846,77999,149096,158781,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181943,103184980,103189005,103190631,103191369,103195217,103211583,103219094,103292815,103532317,103554720,103558519,104234145,104234199,123083185",1555,NULL,P20813,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.13.-,P20813,NULL
1217706,100,Time dependent inhibition of CYP2C9 (unknown origin) at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489415,20181007,"1775,1935,1983,2165,2519,2520,2554,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5733,6009,12560,54687,60606,60823,60846,77999,149096,158781,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181943,103184980,103189005,103190631,103191369,103195217,103211583,103219094,103219164,103292815,103532317,103554720,103558519,103724173,104234145,104234199,123083185",1559,NULL,P11712,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1217707,100,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489416,20181007,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3397,3440,3696,3715,4463,4829,4913,4946,5329,5717,5733,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103195217,103211583,103219094,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",1557,NULL,P33261,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1217708,100,Time dependent inhibition of CYP2D6 (unknown origin) at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489417,20181007,"1775,1935,1983,2162,2333,2519,2520,2554,3033,3121,3152,3397,3440,3696,3715,4463,4829,4913,4946,5329,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181943,103183576,103184980,103189005,103191369,103192563,103195217,103211583,103219094,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",1565,NULL,P10635,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.-,P10635,NULL
1217709,100,Time dependent inhibition of CYP3A4 (unknown origin) at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489418,20181007,"1775,1935,2162,2165,2519,2520,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5733,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177883,103178995,103181943,103184980,103189005,103190631,103191369,103195217,103211583,103219094,103219164,103292815,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",1576,NULL,P08684,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217712,100,Time dependent inhibition of CYP2C8 (unknown origin) at 100 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489421,20181007,"1775,1935,1983,2162,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4913,4946,5329,5472,5733,6009,12560,38409,54687,60606,60823,60846,149096,158781,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103184980,103189005,103191369,103195217,103211583,103219094,103219164,103292815,103532317,103554720,103558519,103724173,104234145,104234199,104234246",1558,NULL,P10632,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.1,P10632,NULL
1217713,100,Time dependent inhibition of CYP3A4 (unknown origin) at 10 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489422,20181007,"1983,2162,2333,2554,2662,5717","103177753,103178971,103181002,103183576,103513016,104234246",1576,NULL,P08684,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217714,100,Time dependent inhibition of CYP2C8 (unknown origin) at 30 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489423,20181007,"2165,4829","103181943,103190631",1558,NULL,P10632,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.1,P10632,NULL
1217715,100,Time dependent inhibition of CYP2C8 (unknown origin) at 3 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489424,20181007,"2333,5717","103183576,103513016",1558,NULL,P10632,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.1,P10632,NULL
1217716,100,Time dependent inhibition of CYP2C8 (unknown origin) at 10 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489425,20181007,"5991,77999,392622,2733526","103170100,103192563,103244854,123083185",1558,NULL,P10632,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.1,P10632,NULL
1217717,100,Time dependent inhibition of CYP2C9 (unknown origin) at 30 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489426,20181007,"2162,2662,5991","103181002,103192563,104234246",1559,NULL,P11712,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1217718,100,Time dependent inhibition of CYP2C9 (unknown origin) at 1 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489427,20181007,2333,103513016,1559,NULL,P11712,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1217719,100,Time dependent inhibition of CYP2C9 (unknown origin) at 3 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489428,20181007,392622,103244854,1559,NULL,P11712,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1217720,100,Time dependent inhibition of CYP2C9 (unknown origin) at 10 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489429,20181007,"5717,38409","103166276,103183576",1559,NULL,P11712,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1217721,100,Time dependent inhibition of CYP2C19 in human liver microsomes at 10 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489430,20181007,"5472,5991,392622","103192563,103219164,103244854",1557,NULL,P33261,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1217722,100,Time dependent inhibition of CYP2C19 in human liver microsomes at 30 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489431,20181007,3386,103165728,1557,NULL,P33261,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1217723,100,Time dependent inhibition of CYP2D6 (unknown origin) at 10 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489432,20181007,"2165,3386,5472,392622","103165728,103190631,103219164,103244854",1565,NULL,P10635,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.-,P10635,NULL
1217724,100,Time dependent inhibition of CYP2D6 (unknown origin) at 30 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489433,20181007,"2162,2662","103181002,104234246",1565,NULL,P10635,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.14.-,P10635,NULL
1217725,100,Time dependent inhibition of CYP3A4 (unknown origin) at 50 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489434,20181007,5991,103192563,1576,NULL,P08684,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217726,100,Time dependent inhibition of CYP3A4 (unknown origin) at 1 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489435,20181007,392622,103244854,1576,NULL,P08684,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217730,100,Time dependent inhibition of CYP2B6 (unknown origin) at 30 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1490275,20181007,"2662,5991","103181002,103192563",1555,NULL,P20813,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.13.-,P20813,NULL
1217731,100,Time dependent inhibition of CYP2B6 (unknown origin) at 3 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1490276,20181007,2162,104234246,1555,NULL,P20813,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.13.-,P20813,NULL
1217732,100,Time dependent inhibition of CYP2B6 (unknown origin) at 10 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1490277,20181007,"2333,5717","103183576,103513016",1555,NULL,P20813,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.13.-,P20813,NULL
1217733,100,Time dependent inhibition of CYP2B6 (unknown origin) at 0.3 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1490278,20181007,"60606,392622","103244854,103724173",1555,NULL,P20813,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.13.-,P20813,NULL
1217734,100,Time dependent inhibition of CYP2B6 (unknown origin) at 0.1 uM by LC/MS system,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1490279,20181007,5472,103219164,1555,NULL,P20813,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,1.14.13.-,P20813,NULL
1231897,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as residual activity at 5 uM after 30 mins,"Title: Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability._|__|_Abstract: Protein kinase C theta (PKC&#x3B8;) plays a critical role in T cell signaling and has therapeutic potential for T cell-mediated diseases such as transplant rejection and rheumatoid arthritis. Here, a series of 2,4-diamino-5-fluoropyrimidine derivatives were prepared and evaluated for their inhibition of PKC&#x3B8;. Of t",43,ChEMBL,1500451,20200624,"68665038,122180028,122180029,122180030,122180031,122180040,122180041","318375076,318375077,318375078,318375079,318375080,318375089,318375090",1576,NULL,P08684,Curation Efforts|Research and Development,25982074,0,10.1016/j.bmc.2015.04.050,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1423418,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as testosterone 6beta-hydroxylation rate at 10 uM preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analy,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797923,20200619,"55245,71457203,145992760","123086577,163328281,404716283",NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423419,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as testosterone 6beta-hydroxylation rate at 2 uM preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analys,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797924,20200619,"71457203,145992760","163328281,404716283",NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423422,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as testosterone 6beta-hydroxylation rate at 50 uM preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analy,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797927,20200619,55245,123086577,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1209432,100,Time dependent inhibition of CYP1A2 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481988,20200625,65126,103618754,1544,NULL,P05177,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.14.1,4.2.1.152",P05177,NULL
1209433,100,Time dependent inhibition of CYP2B6 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481989,20200625,65126,103618754,1555,NULL,P20813,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,1.14.13.-,P20813,NULL
1209434,100,Time dependent inhibition of CYP2C8 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481990,20200625,65126,103618754,1558,NULL,P10632,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,1.14.14.1,P10632,NULL
1209435,100,Time dependent inhibition of CYP2C9 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481991,20200625,65126,103618754,1559,NULL,P11712,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1209436,100,Time dependent inhibition of CYP2C19 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481992,20200625,65126,103618754,1557,NULL,P33261,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1209437,100,Time dependent inhibition of CYP2D6 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481993,20200625,65126,103618754,1565,NULL,P10635,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,1.14.14.-,P10635,NULL
1209438,100,Time dependent inhibition of CYP2E1 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481994,20200625,65126,103618754,1571,NULL,P05181,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.13.n7,1.14.14.1",P05181,NULL
1209439,100,Time dependent inhibition of CYP3A4 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481995,20200625,65126,103618754,1576,NULL,P08684,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
156762,2,Tested for time dependent inhibition constant against porcine pepsin,"Title: Synthesis of analogues of pepstatin. Effect of structure in subsites P1', P2', and P2 on inhibition of porcine pepsin._|__|_Abstract: A series of pepstatin analogues having structural variations in the P2', P1', and P2 positions have been synthesized and tested for inhibition of porcine pepsin. The standard peptide for this study was Iva-Sta-Val-Ala-Iaa. Structural variations in the P2' and P1' positions have relatively little effect on Ki; however, small variations in the P2 position have a more dra",43,ChEMBL,154016,20181002,"44383184,44383203,44383563,44383571,44383654,44383739,90663544","103429980,103430009,103430703,103430721,103430881,103431048,242583156",396892,NULL,P00791,Curation Efforts|Research and Development,6406670,0,10.1021/jm00360a022,3.4.23.1,P00791,NULL
457069,100,Inhibition of CYP3A4 assessed as time dependent inhibition,Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608127,20180912,"45485800,45485803,45485807,46229904,46229905,46229906,46229907,46229908,46229909,46229910,46229911,46229912,46229913,46229914,46229915,46229916,46229917,46229918,46229919","103704720,103704723,103704727,103724604,103724605,103724606,103724607,103724608,103724609,103724610,103724611,103724612,103724613,103724614,103724615,103724616,103724617,103724618,103724619",1576,NULL,P08684,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
728062,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate up to 100 uM by LC-MS-MS analysis,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940628,20180925,45142457,164148325,1576,NULL,P08684,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
728066,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940632,20180925,"71601485,71601636","164128682,164145546",1576,NULL,P08684,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
728076,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate at 10 uM preincubated for 30 mins by LC-MS-MS analysis relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940642,20180925,"16222392,23653618,25012550,25013520,25013521,25013522,25013523,25013686,25013841,25013847,25014027,25014029,25014237,45142457,57541250,57541253,57541255,71601934,71601935,71602068,71602069,71602070,71602071","134448021,164128628,164128629,164128630,164128678,164128679,164128680,164128681,164131477,164131478,164134364,164137205,164142732,164142774,164142775,164145506,164145507,164145508,164145547,164145548,164148324,164148325,164148368",1576,NULL,P08684,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
728077,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate at 50 uM preincubated for 30 mins by LC-MS-MS analysis relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940643,20180925,16222392,134448021,1576,NULL,P08684,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1058557,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as inhibition of 6-beta-OH-testosterone formation measuring activity remaining by LC-MS/MS method,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277657,20180928,"11955209,72725212,72725272,72725273,72725335","194138497,194145424,194152265,194173045,194179931",1576,NULL,P08684,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212140,100,Time-dependent inhibition of CYP2B6 in human liver microsomes,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492960,20200624,9838675,174510203,1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212141,100,Time-dependent inhibition of CYP3A4 in human liver microsomes,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492961,20200624,9838675,174510203,1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1423058,100,Time dependent inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated with NADPH for 30 mins followed by substrate addition and measured after 15 mins by LC-MS analysis relative to control,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797563,20200619,"46244173,46244258,46244454,46244883,54761305,54761306,54761473,54761474,54761648,71584283,71584419,117906028,145980501,145981271,145981505,145983402,145986333,145987142,145987381,145989852,145990234,145991457,145992074,145992301,145992816","164128834,164128876,164140186,164142958,164142959,164148581,318406763,318406764,404673549,404697765,404698969,404699329,404699733,404702154,404706296,404707511,404707882,404711740,404712361,404714267,404715209,404715558,404716372,404716419,404718021",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1482774,100,Time-dependent inhibition of human liver microsomes CYP3A4,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700907,20200622,"78426574,78427773,90420193,90420346,90420407,90420624,90420765,117762542,117763631,117763635,117764297","336895202,381837450,381841832,381842801,381845037,381852982,381858777,381865495,381868165,381873039,381886864",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
66810,100,Compound was evaluated for the inhibitory activity against Human leukocyte elastase; time-dependent inhibition was not observed,Compound was evaluated for the inhibitory activity against Human leukocyte elastase; time-dependent inhibition was not observed,43,ChEMBL,63970,20180908,44313411,103273384,1991,NULL,P08246,Curation Efforts|Research and Development,NULL,0,NULL,3.4.21.37,P08246,NULL
71589,100,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 25.0 uM; Not determined,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 25.0 uM; Not determined,43,ChEMBL,68757,20180908,119565,124958357,2729,NULL,P48506,Curation Efforts|Research and Development,NULL,0,NULL,6.3.2.2,P48506,NULL
71590,100,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 5.1 uM.,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 5.1 uM.,43,ChEMBL,68758,20180908,44281529,124958650,2729,NULL,P48506,Curation Efforts|Research and Development,NULL,0,NULL,6.3.2.2,P48506,NULL
71591,100,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 5.7 uM.,Second order rate constant for time-dependent inhibition (Kinact/Ki) of Escherichia coli gamma-glutamylcysteine synthetase at a concentration of 5.7 uM.,43,ChEMBL,68759,20180908,10468169,103760067,2729,NULL,P48506,Curation Efforts|Research and Development,NULL,0,NULL,6.3.2.2,P48506,NULL
99580,100,Human leukocyte elastase (HLE) inhibitory activity is reported as kinetic constant (kobs/[I] - time dependent inhibition),Human leukocyte elastase (HLE) inhibitory activity is reported as kinetic constant (kobs/[I] - time dependent inhibition),43,ChEMBL,96774,20180908,"15035341,15934694,15934701","103273341,103411797,103412259",1991,NULL,P08246,Curation Efforts|Research and Development,NULL,0,NULL,3.4.21.37,P08246,NULL
202889,100,Time-dependent inhibition of semicarbazide-sensitive amine oxidase (SSAO),Time-dependent inhibition of semicarbazide-sensitive amine oxidase (SSAO),43,ChEMBL,200168,20180908,"15225533,22399685,44315840","103277934,103278347,174494453",29473,NULL,O08590,Curation Efforts|Research and Development,NULL,0,NULL,1.4.3.21,O08590,NULL
202890,100,Time-dependent inhibition of semicarbazide-sensitive amine oxidase (SSAO); ND means not determined,Time-dependent inhibition of semicarbazide-sensitive amine oxidase (SSAO); ND means not determined,43,ChEMBL,200169,20180908,"87488,417544","103277933,103278132",29473,NULL,O08590,Curation Efforts|Research and Development,NULL,0,NULL,1.4.3.21,O08590,NULL
219299,100,Rate constant against alpha-chymotrypsin from time dependent inhibition and reactivation data,Rate constant against alpha-chymotrypsin from time dependent inhibition and reactivation data,43,ChEMBL,216635,20180908,10468909,103344964,1504,NULL,P17538,Curation Efforts|Research and Development,NULL,0,NULL,3.4.21.1,P17538,NULL
219300,100,Rate constant against Alpha-chymotrypsin from time dependent inhibition and reactivation data,Rate constant against Alpha-chymotrypsin from time dependent inhibition and reactivation data,43,ChEMBL,216636,20180908,10468909,103344964,1504,NULL,P17538,Curation Efforts|Research and Development,NULL,0,NULL,3.4.21.1,P17538,NULL
730823,100,Time dependent inhibition of CYP1A2 (unknown origin),"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943391,20200626,"71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137990,164143535,164146268,164146269,164149158",1544,NULL,P05177,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,"1.14.14.1,4.2.1.152",P05177,NULL
730824,100,Time dependent inhibition of CYP2C19 (unknown origin),"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943392,20180926,"71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137990,164143535,164146268,164146269,164149158",1557,NULL,P33261,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
730825,100,Time dependent inhibition of CYP2C9 (unknown origin),"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943393,20180926,"71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137990,164143535,164146268,164146269,164149158",1559,NULL,P11712,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
730842,2,Time dependent inhibition of human CYP3A4 preincubated for 30 mins in presence of NADPH,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943410,20180926,"59239374,71604742,71604893,71604894,71604895,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164129458,164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149157,164149158",1576,NULL,P08684,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1077364,2,Time dependent inhibition of human recombinant MMP12 by SPR assay,Time dependent inhibition of human recombinant MMP12 by SPR assay,43,ChEMBL,1298985,20180929,"4218,132519,76314808,76325699,76332924","103185416,103339213,194147602,194168374,194182045",4321,NULL,P39900,Curation Efforts|Research and Development,NULL,0,NULL,3.4.24.65,P39900,NULL
1117915,100,Time-dependent inhibition of human full length GST-tagged SIRT1 expressed in Escherichia coli using H2N-HK-AcK-LM-COOH as substrate assessed as enzymatic deacetylation product formation at 5 to 10 uM by reverse-phase HPLC analysis,Time-dependent inhibition of human full length GST-tagged SIRT1 expressed in Escherichia coli using H2N-HK-AcK-LM-COOH as substrate assessed as enzymatic deacetylation product formation at 5 to 10 uM by reverse-phase HPLC analysis,43,ChEMBL,1331982,20181002,90665503,242612806,23411,NULL,Q96EB6,Curation Efforts|Research and Development,NULL,0,NULL,"2.3.1.-,2.3.1.286",Q96EB6,NULL
1119257,2,Time-dependent inhibition of Trypanosoma cruzi trypanothione reductase assessed as dissociation constants for enzyme-inhibitor binding using TS2 as substrate by DTNB-coupled assay,Time-dependent inhibition of Trypanosoma cruzi trypanothione reductase assessed as dissociation constants for enzyme-inhibitor binding using TS2 as substrate by DTNB-coupled assay,43,ChEMBL,1331637,20181002,"30830,76333161,90667533","103294730,194182343,242615713",NULL,NULL,P28593,Curation Efforts|Research and Development,NULL,0,NULL,1.8.1.12,P28593,NULL
1119258,2,Time-dependent inhibition of Trypanosoma cruzi trypanothione reductase assessed as stabilization of enzyme-inhibitor complexes using TS2 as substrate by DTNB-coupled assay,Time-dependent inhibition of Trypanosoma cruzi trypanothione reductase assessed as stabilization of enzyme-inhibitor complexes using TS2 as substrate by DTNB-coupled assay,43,ChEMBL,1331638,20181002,"30830,76333161,90667533","103294730,194182343,242615713",NULL,NULL,P28593,Curation Efforts|Research and Development,NULL,0,NULL,1.8.1.12,P28593,NULL
1119267,100,Time-dependent inhibition of Trypanosoma cruzi trypanothione reductase using TS2 as substrate by DTNB-coupled assay,Time-dependent inhibition of Trypanosoma cruzi trypanothione reductase using TS2 as substrate by DTNB-coupled assay,43,ChEMBL,1331647,20181002,90667537,242615717,NULL,NULL,P28593,Curation Efforts|Research and Development,NULL,0,NULL,1.8.1.12,P28593,NULL
1121338,100,Time-dependent inhibition of PDGF-BB-induced Rac activation in human SMC assessed as intracellular Rac-GTP level at 25 uM incubated prior to PDGF-BB stimulation for 2 mins by G-LISA,Time-dependent inhibition of PDGF-BB-induced Rac activation in human SMC assessed as intracellular Rac-GTP level at 25 uM incubated prior to PDGF-BB stimulation for 2 mins by G-LISA,43,ChEMBL,1331350,20181002,2026662,103665499,NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1153729,100,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as enzyme activity preincubated for 30 mins before substrate addition by LC-MS analysis,"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361476,20181004,"90644316,90644317,90644318","242647214,242647215,242647216",1576,NULL,P08684,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1165826,2,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433186,20181005,"44633765,46190694,46190695","312360588,312360605,312360606",1576,NULL,P08684,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1219231,100,Time-dependent inhibition of CYP3A in human liver microsomes assessed as testosterone 6-hydroxylation using testosterone as substrate by LC-MS/MS analysis in presence of NADPH,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488629,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219236,100,Time-dependent inhibition of CYP3A in human liver microsomes assessed as testosterone 6-hydroxylation using testosterone as substrate measured after 25-fold diution by LC-MS/MS analysis in presence of NADPH,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489446,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219237,100,Time-dependent inhibition of CYP3A in human liver microsomes assessed as midazolam 1'-hydroxylation using midazolam as substrate by LC-MS/MS analysis in presence of NADPH,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489447,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219238,100,Time-dependent inhibition of CYP3A in human liver microsomes assessed as midazolam 1'-hydroxylation using midazolam as substrate measured after 25-fold diution by LC-MS/MS analysis in presence of NADPH,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489448,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219239,2,Time-dependent inhibition of CYP3A in human liver microsomes assessed as testosterone 6-hydroxylation using testosterone as substrate by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489449,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219240,2,Time-dependent inhibition of CYP3A in human liver microsomes assessed as midazolam 1'-hydroxylation using midazolam as substrate by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489450,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219242,100,Time-dependent inhibition of CYP3A in human liver microsomes treated with carfilzomib up to 30 uM by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489452,20181007,"90092286,118753380","312467140,312467258",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219244,2,Time-dependent inhibition of CYP3A in human liver microsomes preincubated for 30 mins with carfilzomib by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489454,20181007,"11556711,118753464","103652542,312467259",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1260600,2,Time-dependent inhibition of full length human fusion His6 tagged LSD1 expressed in Escherichia coli BL21(DE3) cells using H3K4me2 peptide substrate preincubated for 5 mins by peroxidase-coupled method,Time-dependent inhibition of full length human fusion His6 tagged LSD1 expressed in Escherichia coli BL21(DE3) cells using H3K4me2 peptide substrate preincubated for 5 mins by peroxidase-coupled method,43,ChEMBL,1538367,20180904,102313434,336881410,23028,NULL,O60341,Curation Efforts|Research and Development,NULL,0,NULL,1.14.99.66,O60341,NULL
1260601,100,Time-dependent inhibition of full length human fusion His6 tagged LSD1 expressed in Escherichia coli BL21(DE3) cells assessed as enzyme inactivation using H3K4me2 peptide substrate preincubated for 5 mins by peroxidase-coupled method,Time-dependent inhibition of full length human fusion His6 tagged LSD1 expressed in Escherichia coli BL21(DE3) cells assessed as enzyme inactivation using H3K4me2 peptide substrate preincubated for 5 mins by peroxidase-coupled method,43,ChEMBL,1538368,20180904,102313434,336881410,23028,NULL,O60341,Curation Efforts|Research and Development,NULL,0,NULL,1.14.99.66,O60341,NULL
1263794,100,Time dependent inhibition of human MAO-B preincubated at twice the IC50 for 0 to 60 mins,Time dependent inhibition of human MAO-B preincubated at twice the IC50 for 0 to 60 mins,43,ChEMBL,1542727,20180904,53322381,124967634,4129,NULL,P27338,Curation Efforts|Research and Development,NULL,0,NULL,1.4.3.4,P27338,NULL
1298620,100,Time dependent inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 using D-AMC substrate measured over 40 mins by fluorescence based assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573069,20180906,"53251433,53251434,67235559,127045757,127045758,127045759,127045760,127045761,127045984,127046052,127046192,127046193,127046194,127046387,127046635,127046636,127046637,127046638,127046788,127046789,127046790,127046791,127047497,127047498,127047499,127047500,127047501,127047752","336897709,336897710,336897711,336897712,336897713,336897998,336898094,336898273,336898274,336898275,336898276,336898545,336898546,336898899,336898900,336898901,336898902,336899116,336899117,336899118,336899119,336900162,336900163,336900164,336900165,336900166,336900167,336900503",2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1300226,2,Time dependent inhibition of CYP3A4 in human liver microsomes,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576653,20180906,127052897,336907555,1576,NULL,P08684,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1322821,100,Time-dependent inhibition of recombinant human MAOA using kynuramine as substrate assessed as decrease in formation of 4-hydroxyquinoline at 2 times IC50 preincubated for 15 to 60 mins followed by substrate addition measured after 15 mins by fluorescence ,Time-dependent inhibition of recombinant human MAOA using kynuramine as substrate assessed as decrease in formation of 4-hydroxyquinoline at 2 times IC50 preincubated for 15 to 60 mins followed by substrate addition measured after 15 mins by fluorescence assay,43,ChEMBL,1619934,20180907,"4380,1909002,132969040,132969041,132969042,134140107,134142875,134156912","103167716,374292655,374297558,374297925,374307857,374323111,374337181,374357780",4128,NULL,P21397,Curation Efforts|Research and Development,NULL,0,NULL,1.4.3.4,P21397,NULL
1322826,100,Time-dependent inhibition of recombinant human MAOB using kynuramine as substrate assessed as decrease in formation of 4-hydroxyquinoline at 2 times IC50 preincubated for 15 to 60 mins followed by substrate addition measured after 15 mins by fluorescence ,Time-dependent inhibition of recombinant human MAOB using kynuramine as substrate assessed as decrease in formation of 4-hydroxyquinoline at 2 times IC50 preincubated for 15 to 60 mins followed by substrate addition measured after 15 mins by fluorescence assay,43,ChEMBL,1619939,20180907,"26757,1909002,132969040,132969041,132969042,134140107,134142875,134156912","103252336,374292655,374297558,374297925,374307857,374323111,374337181,374357780",4129,NULL,P27338,Curation Efforts|Research and Development,NULL,0,NULL,1.4.3.4,P27338,NULL
1340141,0,Time-dependent inhibition of pig brain TRH-DE using Glp-His-ProAMC as substrate at 400 uM preincubated for 75 mins by DPP-4-based continuous fluorometric method,Time-dependent inhibition of pig brain TRH-DE using Glp-His-ProAMC as substrate at 400 uM preincubated for 75 mins by DPP-4-based continuous fluorometric method,43,ChEMBL,1637409,20180908,14376756,103294774,NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1340142,0,Time-dependent inhibition of pig brain TRH-DE using Glp-His-ProAMC as substrate at 160 uM preincubated for 75 mins by DPP-4-based continuous fluorometric method,Time-dependent inhibition of pig brain TRH-DE using Glp-His-ProAMC as substrate at 160 uM preincubated for 75 mins by DPP-4-based continuous fluorometric method,43,ChEMBL,1637410,20180908,9905902,374316078,NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1340143,0,Time-dependent inhibition of pig brain TRH-DE using Glp-His-ProAMC as substrate at 1 uM preincubated for 75 mins by DPP-4-based continuous fluorometric method,Time-dependent inhibition of pig brain TRH-DE using Glp-His-ProAMC as substrate at 1 uM preincubated for 75 mins by DPP-4-based continuous fluorometric method,43,ChEMBL,1637411,20180908,10255308,374282551,NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1412308,100,Irreversible time dependent inhibition of human recombinant MAOA at 2 times IC50 using kynuramine as substrate preincubated up to 60 mins followed by 45 uM substrate addition by fluorescence assay,Irreversible time dependent inhibition of human recombinant MAOA at 2 times IC50 using kynuramine as substrate preincubated up to 60 mins followed by 45 uM substrate addition by fluorescence assay,43,ChEMBL,1786807,20200619,"4380,145979433","103167716,404696141",NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1412309,100,Irreversible time dependent inhibition of human recombinant MAOB at 2 times IC50 using kynuramine as substrate preincubated up to 60 mins followed by 30 uM substrate addition by fluorescence assay,Irreversible time dependent inhibition of human recombinant MAOB at 2 times IC50 using kynuramine as substrate preincubated up to 60 mins followed by 30 uM substrate addition by fluorescence assay,43,ChEMBL,1786808,20200619,"26757,145979433","103252336,404696141",NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1416370,100,Time-dependent inhibition of recombinant human MAO-B at 0.003 uM using p-tyramine as substrate preincubated for 15 to 60 mins followed by substrate addition and compound dilution to IC50 by Amplex red reagent based fluorescence assay,Time-dependent inhibition of recombinant human MAO-B at 0.003 uM using p-tyramine as substrate preincubated for 15 to 60 mins followed by substrate addition and compound dilution to IC50 by Amplex red reagent based fluorescence assay,43,ChEMBL,1790875,20200619,145992136,404715292,NULL,NULL,NULL,Curation Efforts|Research and Development,NULL,0,NULL,NULL,NULL,NULL
1464977,100,Time-dependent inhibition of human CYP2C9,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696888,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464978,100,Time-dependent inhibition of human CYP3A4,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696889,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464980,100,Time-dependent inhibition of human CYP2C9 measured after 30 mins relative to initial IC50,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696891,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464981,100,Time-dependent inhibition of human CYP3A4 measured after 30 mins relative to initial IC50,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696892,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
330336,100,Inhibition of Aquifex aeolicus LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478362,20200704,11546620,103565388,1193363,NULL,O67648,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,3.5.1.108,O67648,NULL
330337,2,Inhibition of Escherichia coli LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478363,20200704,"9823454,9839581,11546620","103329335,103565346,103565388",NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330338,2,Inhibition of Escherichia coli LpxC Q202W/G210S mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478364,20200704,"9823454,9839581,11546620","103329335,103565346,103565388",NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330339,2,Inhibition of Rhizobium leguminosarum LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478365,20181023,"9823454,9839581,11546620","103329335,103565346,103565388",NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330340,2,Inhibition of Rhizobium leguminosarum LpxC S214G mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478366,20200704,"9823454,9839581,11546620","103329335,103565346,103565388",NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330341,2,Inhibition of Rhizobium leguminosarum LpxC W206Q/S214G mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478367,20200704,"9823454,9839581,11546620","103329335,103565346,103565388",NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330342,100,Inhibition of Rhizobium leguminosarum LpxC at 0.5 uM,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478368,20181023,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330343,100,Inhibition of Escherichia coli LpxC at 4 nM,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478369,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
420056,100,Inhibition of mouse COX2 under saturated substrate level preincubated at 140 nM for 17 mins by TLC,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571400,20180910,"5352624,44224199","103183701,103683869",19225,NULL,Q05769,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,Q05769,NULL
420057,100,Inhibition of ovine COX1 under saturated substrate level preincubated at 115 nM for 17 mins by TLC,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571401,20180910,"5352624,44224199","103183701,103683869",443551,NULL,P05979,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,P05979,NULL
420058,2,Inhibition of COX2,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571402,20180910,"3715,4711697","103163840,103616344",5743,NULL,P35354,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,P35354,NULL
420059,2,Inhibition of COX1,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571403,20180910,"3715,4711697","103163840,103616344",5742,NULL,P23219,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,P23219,NULL
420060,2,Competitive inhibition of mouse COX2 under reduced substrate concentration by TLC,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571404,20180910,"5352624,11688434,44224199","103183701,103644017,103683869",19225,NULL,Q05769,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,Q05769,NULL
420061,2,Competitive inhibition of ovine COX1 under reduced substrate concentration by TLC,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571405,20180910,"5352624,11688434,44224199","103183701,103644017,103683869",443551,NULL,P05979,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,P05979,NULL
420062,100,Inhibition of mouse COX2 under saturated substrate level by TLC,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571406,20180910,5352624,103183701,19225,NULL,Q05769,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,Q05769,NULL
420063,100,Inhibition of ovine COX1 under saturated substrate level by TLC,"Title: The influence of double bond geometry in the inhibition of cyclooxygenases by sulindac derivatives._|__|_Abstract: Sulindac sulfide is a benzylidene-indene that is a potent, time-dependent inhibitor of cyclooxygenases-1 and -2. Removal of the 2'-methyl group from the indene ring dramatically reduces time-dependent inhibition of both enzymes but also changes the geometry of the benzylidene double bond from Z to E. Herein, we explore the importance of double bond geometry on cyclooxygenase inhibition. ",43,ChEMBL,571407,20180910,5352624,103183701,443551,NULL,P05979,Curation Efforts|Research and Development,19427206,0,10.1016/j.bmcl.2009.04.078,1.14.99.1,P05979,NULL
641843,100,Time dependent inhibition of human recombinant MAOA expressed in insect cells using kynuramine as substrate at 5 uM preincubated up to 40 mins before kynuramine substrate addition,"Title: Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines._|__|_Abstract: A novel class of N-substituted tetrahydropyridine derivatives was found to have multiple kinetic mechanisms of monoamine oxidase A inhibition. Eleven structurally similar tetrahydropyridine derivatives were synthesized and evaluated as inhibitors of MAO-A and MAO-B. The most potent MAO-A inhibitor in the series, 2,4-dichlorophenoxypropyl analog 12, displayed time-dependent m",43,ChEMBL,799291,20180921,15521042,136931500,4128,NULL,P21397,Curation Efforts|Research and Development,22078410,0,10.1016/j.bmc.2011.10.038,1.4.3.4,P21397,NULL
1218840,2,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as unbound inhibitor concentration required for half maximal enzyme inactivation after 2 to 10 mins by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491679,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218859,2,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as residual enzyme activity after 2 to 10 mins by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492495,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218860,2,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as residual enzyme activity after 2 to 10 mins by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492496,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218861,2,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as unbound inhibitor concentration required for half maximal enzyme inactivation after 2 to 10 mins by LC-MS/MS analysis,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1492497,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1222894,2,Time-dependent inhibition of human CES1 assessed as hydrolysis of 4NPA to 4NP preincubated for 10 mins followed by 4NPA addition,"Title: Reversible inhibition of human carboxylesterases by acyl glucuronides._|__|_Abstract: Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively. Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.T",43,ChEMBL,1494241,20200624,16084218,312466915,1066,NULL,P23141,Curation Efforts|Research and Development,23386702,0,10.1124/dmd.112.050252,"3.1.1.1,3.1.1.56",P23141,NULL
1222895,2,Time-dependent inhibition of human CES1 assessed as hydrolysis of 4NPA to 4NP preincubated for 30 mins followed by 4NPA addition,"Title: Reversible inhibition of human carboxylesterases by acyl glucuronides._|__|_Abstract: Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively. Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.T",43,ChEMBL,1494242,20200624,16084218,312466915,1066,NULL,P23141,Curation Efforts|Research and Development,23386702,0,10.1124/dmd.112.050252,"3.1.1.1,3.1.1.56",P23141,NULL
1222896,2,Time-dependent inhibition of human CES1 assessed as hydrolysis of 4NPA to 4NP preincubated for 60 mins followed by 4NPA addition,"Title: Reversible inhibition of human carboxylesterases by acyl glucuronides._|__|_Abstract: Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively. Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.T",43,ChEMBL,1494243,20200624,16084218,312466915,1066,NULL,P23141,Curation Efforts|Research and Development,23386702,0,10.1124/dmd.112.050252,"3.1.1.1,3.1.1.56",P23141,NULL
1466028,100,Inhibition of CDK8 in human SW480 cells assessed as reduction in STAT1 phosphorylation at Ser727 residues up to 30 nM after 1 day by Western blot method,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670925,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466029,2,Inhibition of kinase tracer 236 binding to full length N terminal GST-tagged human CDK8 (1 to 464 end residues) /CycC ( 1 to 283 end residues) expressed in baculovirus expression system after 60 min by TR-FRET assay,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670926,20200622,"125487466,125487493,126568381,126568395,126568404,126568413,126568428,126568459,126568463,126568478,126568496,126568503,126568509,126568548,126568570,126568590,126568629,126568659,126568661,126568663,126568668,126568669,126568696,126568714,126568746,126568757,126568827,126568853,126568856,126568894,126584616,126584619,126584623,137660456","381837523,381838982,381840512,381841089,381842428,381842931,381844591,381844658,381844717,381845142,381847395,381848601,381852761,381854513,381855992,381857527,381858321,381860481,381861271,381861799,381863696,381865458,381865799,381868232,381869151,381869430,381869613,381869714,381880826,381884275,381885138,381885408,381887640,381887793",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466030,2,Inhibition of kinase tracer 236 binding to GST-tagged CDK19/CycC (unknown origin) after 60 min by TR-FRET assay,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670927,20200622,"126568463,126568496,126568659,126568661,126584623","381841089,381865458,381868232,381869430,381869714",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466031,2,Inhibition of CDK8 in human SW480 cells assessed as reduction in IFN-gamma induced STAT1 phosphorylation at Ser727 residues preincubated for 2 hrs followed by IFN-gamma addition measured after 1 hr by In-cell western assay,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670928,20200622,"125487466,125487493,126568381,126568395,126568404,126568413,126568428,126568459,126568463,126568478,126568496,126568503,126568509,126568548,126568570,126568590,126568629,126568659,126568661,126568663,126568668,126568669,126568696,126568714,126568746,126568757,126568827,126568853,126568856,126568894,126584616,126584619,126584623,137660456","381837523,381838982,381840512,381841089,381842428,381842931,381844591,381844658,381844717,381845142,381847395,381848601,381852761,381854513,381855992,381857527,381858321,381860481,381861271,381861799,381863696,381865458,381865799,381868232,381869151,381869430,381869613,381869714,381880826,381884275,381885138,381885408,381887640,381887793",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466033,100,"Total clearance in mouse at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670930,20200622,"126568463,126568590,126568661","381841089,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466034,100,"Cmax in mouse at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670931,20200622,"126568413,126568463,126568590,126568661","381841089,381844591,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466035,100,"AUC (0 to 8 hrs) in mouse at 1 mg/kg, po administered as cassette dose by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670932,20200622,"126568413,126568463,126568590,126568661","381841089,381844591,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466036,100,"MRT in mouse at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670933,20200622,"126568413,126568463,126568590,126568661","381841089,381844591,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466037,100,Oral bioavailability in mouse at 1 mg/kg administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670934,20200622,"126568413,126568463,126568590,126568661","381841089,381844591,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466038,100,Intrinsic clearance in human liver microsomes at 1 umol/L after 15 to 30 mins in presence of NADPH by LC/MS/MS analysis,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670935,20200622,"126568413,126568463,126568496,126568590,126568661","381841089,381844591,381868232,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466039,100,Intrinsic clearance in mouse liver microsomes at 1 umol/L after 15 to 30 mins in presence of NADPH by LC/MS/MS analysis,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670936,20200622,"126568413,126568463,126568496,126568590,126568661","381841089,381844591,381868232,381869714,381884275",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466040,100,Solubility of the compound at pH 6.8,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670937,20200622,"125487466,125487493,126568395,126568404,126568413,126568428,126568459,126568509,126568661,126568668,126568669,126568746,126568757,126568827,126584616,126584619","381838982,381840512,381841089,381842428,381842931,381844591,381844717,381845142,381847395,381854513,381855992,381858321,381860481,381863696,381869613,381885408",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466041,2,Antiproliferative activity against human RPMI8226 cells after 168 hrs by by Celltiter-Glo luminescent assay,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670938,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466042,2,Antiproliferative activity against human EOL-1 cells after 168 hrs by by Celltiter-Glo luminescent assay,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670939,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466043,100,"Antitumor activity against human RPMI8226 cells xenografted in C.B17/Icr-scid/scid Jcl mouse assessed as tumor growth at 15 mg/kg, po bid after 2 weeks relative to control","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670940,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466044,100,"Antitumor activity against human RPMI8226 cells xenografted in C.B17/Icr-scid/scid Jcl mouse assessed as tumor growth at 30 mg/kg, po bid after 2 weeks relative to control","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670941,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466045,100,"Toxicity in C.B17/Icr-scid/scid Jcl mouse xenografted with human RPMI8226 cells assessed as change in body weight at 15 mg/kg, po bid after 2 weeks","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670942,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466046,100,"Toxicity in C.B17/Icr-scid/scid Jcl mouse xenografted with human RPMI8226 cells assessed as change in body weight at 30 mg/kg, po bid after 2 weeks relative to control","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670943,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466047,100,"In vivo inhibition of STAT1 phosphorylation at Ser727 residues in C.B17/Icr-scid/scid Jcl mouse xenografted with human RPMI8226 cells at 15 to 30 mg/kg, po bid treated for 2 weeks measured over 2 to 8 hrs post dose by Western blot analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670944,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466048,100,Inhibition of CDK8 in human EOL1 cells assessed as reduction in STAT1 phosphorylation at Ser727 residues up to 30 nM after 1 day by Western blot method,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670945,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466049,100,Inhibition of CDK8 in human RPMI8226 cells assessed as reduction in STAT1 phosphorylation at Ser727 residues up to 30 nM after 1 day by Western blot method,"Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670946,20200622,126568413,381844591,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466050,100,"Drug metabolism in mouse plasma assessed as formation of (E)-3-(4-(1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-(morpholinomethyl)phenyl)acrylamide at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670947,20200622,126568661,381841089,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466051,100,"Drug metabolism in mouse plasma assessed as formation of (E)-4-(1-methyl-1H-pyrazol-4-yl)-3-(3-(4-(morpholinomethyl)phenylamino)-3-oxoprop-1-enyl)pyridine 1-oxide at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670948,20200622,126568661,381841089,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466052,100,"Drug metabolism in mouse plasma assessed as formation of (E)-3-(4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-((3-oxomorpholino)methyl)phenyl)acrylamide at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670949,20200622,126568661,381841089,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466053,100,"Drug metabolism in mouse plasma assessed as formation of (E)-N-(4-((2-hydroxyethylamino)methyl)phenyl)-3-(4-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)acrylamide at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670950,20200622,126568661,381841089,NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
1466054,100,"Drug level in mouse plasma treated with (E)-3-(4-(1-Methyl-1H-pyrazol-4-yl)pyridin-3-yl)-N-(4-(morpholinomethyl)phenyl)acrylamide at 1 mg/kg, po administered as cassette dose measured up to 8 hrs by LC/MS/MS analysis","Title: Studies of CDK 8/19 inhibitors: Discovery of novel and selective CDK8/19 dual inhibitors and elimination of their CYP3A4 time-dependent inhibition potential._|__|_Abstract: In this article, synthetic studies around a pyridylacrylamide-based hit compound (1), utilizing structure-based drug design guided by CDK8 docking models, is discussed. Modification of the pendant 4-fluorophenyl group to various heteroaromatic rings was conducted aiming an interaction with the proximal amino acids, and then replac",43,ChEMBL,1670951,20200622,"126568496,126568554,137638333,137651626","381839786,381846951,381866571,381868232",NULL,NULL,NULL,Curation Efforts|Research and Development,28392276,0,10.1016/j.bmc.2017.03.049,NULL,NULL,NULL
159827,100,Maximum absorbance for formation of reversible-enzyme-ligand complexes with human placental aromatase (PL1),"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157086,20181012,44307719,103261139,1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159828,100,Maximum absorbance for formation of reversible-enzyme-ligand complexes with human placental aromatase (PL1),"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157087,20181012,"6013,6128,11273,9904788,20431159,44307720,44307837,44307933","103168552,103261140,103261449,103261644,103261671,103366083,104234228,160671208",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159829,100,Dithiothreitol (10 nM) reactivation of human placental aromatase following 1.0 uM inactivation for 10 minutes,"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157088,20181012,"19001,9904788,44307933,44308115,44308116","103228142,103261671,103262089,103262090,160671208",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159830,100,Dithiothreitol (10 nM) reactivation of human placental aromatase following 1.0 uM inactivation for 5 minutes,"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157089,20181012,"11273,19001,44307719,44307720,44307746,44308100,44308117","103228142,103261139,103261140,103261210,103262056,103262091,103366083",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159831,2,Binding affinity constant for formation of reversible enzyme-ligand complex with human placental aromatase (PL1),"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157090,20181012,"6013,6128,11273,9904788,20431159,44307720,44307837,44307933","103168552,103261140,103261449,103261644,103261671,103366083,104234228,160671208",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159832,2,Binding affinity for formation of reversible enzyme-ligand complexes with human placental aromatase (PL2),"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157091,20181012,44307719,103261139,1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159833,2,Binding affinity(KI) for formation of reversible enzyme-ligand complex with human placental aromatase (PL2),"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157092,20181012,"11273,9904788,44307720,44307837,44307933","103261140,103261449,103261671,103366083,160671208",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159834,100,Ratio of Kcat and KI for human placental microsome aromatase,"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157093,20200628,"11273,9904788,44307719,44307720,44307837,44307933","103261139,103261140,103261449,103261671,103366083,160671208",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
159835,100,Catalytic constant (Kcat) for reversible enzyme-ligand complex formation with human placental aromatase (PL2),"Title: Interactions of thiol-containing androgens with human placental aromatase._|__|_Abstract: A series of thiol androgens were synthesized and investigated to characterize structural features important for the inhibition of aromatase. Analogues of androstenedione with thiol groups in either the 2 alpha-, 10 beta-, or 19-positions caused time-dependent inhibition of human placental aromatase. When their KI and kcat values were compared with those of 4-hydroxyandrost-4-ene-3,17-dione (4-OHa) and 10 beta-pr",43,ChEMBL,157094,20181012,"11273,9904788,44307719,44307720,44307837,44307933","103261139,103261140,103261449,103261671,103366083,160671208",1588,NULL,P11511,Curation Efforts|Research and Development,2909733,0,10.1021/jm00121a037,1.14.14.14,P11511,NULL
330344,2,Activity of Escherichia coli LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478370,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330345,100,Ratio of Kcat to Km for Escherichia coli LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478371,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330346,2,Activity of Escherichia coli LpxC Q202W/G210S mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478372,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330347,100,Ratio of Kcat to Km of Escherichia coli LpxC Q202W/G210S mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478373,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330348,2,Activity of Rhizobium leguminosarum LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478374,20181023,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330349,100,Ratio of Kcat to Km of Rhizobium leguminosarum LpxC,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478375,20181023,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330350,2,Activity of Rhizobium leguminosarum LpxC S214G mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478376,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330351,100,Ratio of Kcat to Km of Rhizobium leguminosarum LpxC S214G mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478377,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330352,2,Activity of Rhizobium leguminosarum LpxC W206Q/S214G mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478378,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
330353,100,Ratio of Kcat to Km of Rhizobium leguminosarum LpxC W206Q/S214G mutant,"Title: Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding._|__|_Abstract: The UDP-3-O-(R-3-hydroxyacyl)-N-acetylglucosamine deacetylase LpxC is an essential enzyme of lipid A biosynthesis in Gram-negative bacteria and a promising antibiotic target. CHIR-090, the most potent LpxC inhibitor discovered to date, displays two-step time-dependent inhibition and kills a wide range of Gram-negative pathogens as effectively as ciprofloxacin",43,ChEMBL,478379,20200704,11546620,103565388,NULL,NULL,NULL,Curation Efforts|Research and Development,18025458,0,10.1073/pnas.0709412104,NULL,NULL,NULL
623099,2,Inhibition of human purified steroid sulfatase,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773110,20200629,"127676,14334327","103350841,134452861",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623100,2,Inhibition of steroid sulfatase in human intact MCF7 cells,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773111,20200629,5287541,103197875,412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623101,100,Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate as substrate at 10 uM by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773112,20200629,"11403786,56658391,56658532,56661880,56670232,56682390","134434986,134435186,134438821,134449005,134461942,134462131",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623102,2,Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate after 10 mins by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773113,20200629,"5870,233494,233496,233497,233498,238388,10713699,10780656,10957163,11403786,11530377,15081867,23661325,23661503,56658390,56658391,56658532,56661880,56670232,56675651,56680387,56682390","103460398,103483583,103608915,124961869,124962354,124975586,134434984,134434985,134434986,134435186,134438820,134438821,134445040,134446580,134449005,134454339,134454340,134458137,134460468,134461941,134461942,134462131",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623103,100,Reversible inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate as substrate at 50 uM after 10 mins by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773114,20200629,56682390,134462131,412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623104,2,Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate after 5 mins by Kitz-Wilson plot analysis,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773115,20200629,"14334327,56670232","134449005,134452861",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623105,100,Ratio of Kinact to Ki for human steroid sulfatase after 5 mins by Kitz-Wilson plot analysis,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773116,20200629,"14334327,56670232","134449005,134452861",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623106,100,Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate at 10 uM after 60 mins by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773117,20200629,56661655,134438479,412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623107,100,Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate at 1 uM after 60 mins by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773118,20200629,56670232,134449005,412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623108,100,Inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate at 50 uM by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773119,20200629,"238388,10780656,23661325,56680387","124961869,124962354,134445040,134460468",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623109,2,Non-Competitive inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate by Lineweaver-Burk plot analysis,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773120,20200629,233497,134458137,412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623110,2,Mixed type inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate by Lineweaver-Burk plot analysis,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773121,20200629,"10713699,56658390","103608915,134434985",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623111,100,Aqueous solubility of the compound,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773122,20200629,56658391,134434986,NULL,NULL,NULL,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,NULL,NULL,NULL
623112,100,Reversible inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate assessed as enzyme activity recovery at 1 uM after 60 mins by fluorescence assay,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773123,20200629,"14334327,56670232","134449005,134452861",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
623113,2,Reversible inhibition of human steroid sulfatase using 4-methylumbelliferyl sulfate substrate by Lineweaver-Burk plot analysis,Title: Inhibition of steroid sulfatase with 4-substituted estrone and estradiol derivatives._|__|_Abstract: Steroid sulfatase (STS) catalyzes the desulfation of biologically inactive sulfated steroids to yield biologically active desulfated steroids and is currently being examined as a target for therapeutic intervention for the treatment of breast cancer. We previously demonstrated that 4-formyl estrone is a time- and concentration-dependent inhibitor of STS. We have prepared a series of 4-formylated estro,43,ChEMBL,773124,20200629,"14334327,56670232","134449005,134452861",412,NULL,P08842,Curation Efforts|Research and Development,21925885,0,10.1016/j.bmc.2011.08.046,3.1.6.2,P08842,NULL
1218812,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(3,5-dihydroxy-2-(4-oxo-2-((R)-1-(N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamido)ethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl)phe","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1487735,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218813,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(2,4-dihydroxy-5-(4-oxo-2-((R)-1-(N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamido)ethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl)phe","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1487736,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218814,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(2,6-dihydroxy-3-(4-oxo-2-((R)-1-(N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamido)ethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl)phe","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1487737,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218815,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated compound formation treated with [3H]-(R)-N-(1-(3-(4-hydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide ","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1487738,20200624,10348416,"312466970,312467288",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218816,100,Inactivation of recombinant CYP3A4 (unknown origin) using testosterone as substrate assessed as partition ratio up to 30 uM preincubated for 5 mins followed by dialysis measured after 4 hrs,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488501,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218825,100,Ratio of IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition to IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488510,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218826,100,Ratio of IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by 10-fold dilution and substrate addition to IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 3,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488511,20200624,"39186,11757854,24957182","103164872,103524061,136940280",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218827,100,Ratio of IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition to IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488512,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218828,100,Ratio of IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins followed by 10-fold dilution and substrate addition to IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 9,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488513,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218829,100,Inactivation of recombinant CYP3A4 (unknown origin) using midazolam as substrate assessed as recovery of enzyme activity at 1 uM preincubated for 5 mins followed by dialysis measured after 4 hrs,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488514,20200624,427302,103309927,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218830,100,Inactivation of recombinant CYP3A4 (unknown origin) using testosterone as substrate assessed as recovery of enzyme activity at 1 uM preincubated for 5 mins followed by dialysis measured after 4 hrs,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488515,20200624,427302,103309927,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218831,100,Inactivation of recombinant CYP3A4 (unknown origin) using midazolam as substrate assessed as recovery of enzyme activity at 1 uM preincubated for 5 mins followed by dialysis measured after 24 hrs,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488516,20200624,427302,103309927,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218832,100,Inactivation of recombinant CYP3A4 (unknown origin) using testosterone as substrate assessed as recovery of enzyme activity at 1 uM preincubated for 5 mins followed by dialysis measured after 24 hrs,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488517,20200624,427302,103309927,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218833,100,Inactivation of recombinant CYP3A4 (unknown origin) using midazolam as substrate assessed as partition ratio up to 30 uM preincubated for 5 mins followed by dialysis measured after 4 hrs,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488518,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218834,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (R)-N-(1-(3-(3,4-dihydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide formation preincubated for 5 mins","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488519,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218835,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (R)-N-(1-(3-(2,4-dihydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide formation preincubated for 5 mins","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488520,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218836,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-compound formation treated with (R)-N-(1-(3-(4-hydroxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-([2-3H]pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide preincub","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488521,20200624,"118753513,118753514,118753515,118753516,118753517,118753518,118753519,118753520","312467343,312467344,312467345,312467346,312467347,312467348,312467349,312467350",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218837,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(4,5-dihydroxy-2-(4-oxo-2-((R)-1-(N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamido)ethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl)phe","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488522,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218838,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(2,3-dihydroxy-5-(4-oxo-2-((R)-1-(N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamido)ethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl)phe","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488523,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218839,100,"Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated (S)-2-amino-5-((R)-1-(carboxymethylamino)-3-(2,3-dihydroxy-6-(4-oxo-2-((R)-1-(N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamido)ethyl)pyrido[2,3-d]pyrimidin-3(4H)-yl)phe","Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1488524,20200624,118753480,312467287,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218841,100,Ratio of Kinact to Ki for CYP3A4 in human liver microsomes using midazolam as substrate,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491680,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218842,100,Ratio of Kinact to Ki for CYP3A4 in human liver microsomes using testosterone as substrate,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491681,20200624,11757854,136940280,1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218851,100,Ratio of IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins to IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 30 mins in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491690,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218852,100,Ratio of IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins to IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491691,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218853,100,Ratio of IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins to IC50 for CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 90 mins in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491692,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1218854,100,Ratio of IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins to IC50 for CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 90 mins in presence of NADPH,"Title: Sequential metabolism of AMG 487, a novel CXCR3 antagonist, results in formation of quinone reactive metabolites that covalently modify CYP3A4 Cys239 and cause time-dependent inhibition of the enzyme._|__|_Abstract: CYP3A4-mediated biotransformation of (R)-N-(1-(3-(4-ethoxyphenyl)-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yl)ethyl)-N-(pyridin-3-ylmethyl)-2-(4-(trifluoromethoxy)phenyl)acetamide (AMG 487) was previously shown to generate an inhibitory metabolite linked to dose- and time-dependent pharm",43,ChEMBL,1491693,20200624,"39186,24957182","103164872,103524061",1576,NULL,P08684,Curation Efforts|Research and Development,22517972,0,10.1124/dmd.112.045708,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1453927,100,Time dependent inhibition of recombinant human full length Cdc7 (1 to 574 residues)/human N-terminal GST-tagged ASK (1 to 674 residues) expressed in baculovirus expression system using N-terminal His-tagged MCM2 as substrate in presence of 50 uM by TR-FRE,"Title: 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase._|__|_Abstract: In order to increase the success rate for developing new Cdc7 inhibitors for cancer therapy, we explored a new chemotype which can comply with the previously-constructed pharmacophore model. Substitution of a pyridine ring of a serendipitously-identified Cdc7 inhibitor 2b with a 3-methylpyrazole resulted in a 4-fold increa",43,ChEMBL,1685786,20200621,"136333907,136443837,136603274,137648287,137661818","381841296,381858208,381859438,381861662,381887159",NULL,NULL,NULL,Curation Efforts|Research and Development,28533114,0,10.1016/j.bmc.2017.04.044,NULL,NULL,NULL
716982,100,Time dependent inhibition of CYP3A4,"Title: Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction._|__|_Abstract: (S)-1-((4-(3-(6-Amino-5-methoxypyridin-3-yl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-ol, 1, was recently identified as a potent inhibitor of the oncogenic kinase bRAF. Compounds containing 3-methoxy-2-aminopyridine, as in 1, comprised a promising lead series because of their high ligand efficiency and excellent ADME profile. H",43,ChEMBL,884725,20180924,57856282,163329258,1576,NULL,P08684,Curation Efforts|Research and Development,23116892,0,10.1016/j.bmcl.2012.10.011,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
716986,100,Time dependent inhibition of human liver microsome CYP3A4 assessed as change in midazolam metabolism at 60 uM by two-step reaction,"Title: Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction._|__|_Abstract: (S)-1-((4-(3-(6-Amino-5-methoxypyridin-3-yl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-ol, 1, was recently identified as a potent inhibitor of the oncogenic kinase bRAF. Compounds containing 3-methoxy-2-aminopyridine, as in 1, comprised a promising lead series because of their high ligand efficiency and excellent ADME profile. H",43,ChEMBL,884729,20180924,"25147503,25181759,25183619,25183759,57856282,71450712,71452535,71454299","163315515,163315516,163318991,163322434,163322435,163329256,163329257,163329258",1576,NULL,P08684,Curation Efforts|Research and Development,23116892,0,10.1016/j.bmcl.2012.10.011,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209594,2,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485684,20200625,445643,103164549,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209595,2,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485685,20200625,445643,103164549,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209596,100,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound for 2.5 to 30 mins followed by addition of 20-fold diluted buffer with 20 uM MDZ by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485686,20200625,445643,103164549,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209597,100,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound for 2.5 to 30 mins followed by addition of 20-fold diluted buffer with 20 uM MDZ by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485687,20200625,445643,103164549,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209598,100,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated at 2 uM followed by addition of 20-fold diluted buffer with 20 uM MDZ by LC-MS method in presence of NADPH,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485688,20200625,445643,103164549,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209599,100,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated at 2 uM followed by addition of 20-fold diluted buffer with 20 uM MDZ by LC-MS method in presence of NADPH,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485689,20200625,445643,103164549,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209600,2,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485690,20200625,445643,103164549,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209601,2,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated with compound before substrate addition by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485691,20200625,445643,103164549,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209602,2,Reversible competitive inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485692,20200625,445643,103164549,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209603,100,Ratio of IC50 for human CYP3A4 expressed in supersomes by coincubation study to IC50 for human CYP3A4 expressed in supersomes by preincubation study,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485693,20200625,445643,103164549,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209604,100,Ratio of IC50 for human CYP3A5 expressed in supersomes by coincubation study to IC50 for human CYP3A5 expressed in supersomes by preincubation study,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485694,20200625,445643,103164549,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209605,100,Apparent oral intrinsic clearance in renal transplant patient,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485695,20200625,5284373,103230651,NULL,NULL,NULL,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,NULL,NULL,NULL
1209606,2,Competitive inhibition of CYP3A in human liver microsomes,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485697,20200625,445643,103164549,NULL,NULL,NULL,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,NULL,NULL,NULL
1209607,2,Competitive inhibition of CYP3A4 in human liver microsomes,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485698,20200625,5284373,103230651,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209608,2,Competitive inhibition of recombinant CYP3A4 (unknown origin) expressed in supersomes,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1485699,20200625,5284373,103230651,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209609,2,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation after 7.5 mins by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486437,20200625,5284373,103230651,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209610,2,Inhibition of human CYP3A4 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated for 15 mins before substrate addition by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486438,20200625,5284373,103230651,1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209611,2,Inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486439,20200625,"445643,5284373","103164549,103230651",NULL,NULL,NULL,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,NULL,NULL,NULL
1209612,2,Inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes preincubated for 15 mins before substrate addition by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486440,20200625,"445643,5284373","103164549,103230651",NULL,NULL,NULL,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,NULL,NULL,NULL
1209613,2,Reversible competitive inhibition of human CYP3A4-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486441,20200625,"445643,5284373","103164549,103230651",1576,NULL,P08684,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1209614,2,Reversible competitive inhibition of CYP3A-mediated 1'-OH midazolam formation in human liver microsomes after 7.5 mins by nonlinear regression study,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486442,20200625,"445643,5284373","103164549,103230651",NULL,NULL,NULL,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,NULL,NULL,NULL
1209615,100,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation at 0.25 to 10 uM after 7.5 mins by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486443,20200625,5284373,103230651,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209616,100,Inhibition of human CYP3A5 expressed in supersomes assessed inhibition of 1'-OH midazolam formation preincubated at 0.25 to 10 uM for 15 mins before substrate addition by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1486444,20200625,5284373,103230651,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209617,100,Inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes at 0.25 to 10 uM after 7.5 mins by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1487249,20200625,5284373,103230651,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
1209618,100,Inhibition of human CYP3A5-mediated 1'-OH midazolam formation in human liver microsomes preincubated at 0.25 to 10 uM for 15 mins before substrate addition by LC-MS method,"Title: Cyclosporine A- and tacrolimus-mediated inhibition of CYP3A4 and CYP3A5 in vitro._|__|_Abstract: Cyclosporine A (CsA) and tacrolimus (Tac) are immunosuppressive drugs used in the majority of patients with solid organ transplants, generally in combination with a wide range of drugs. CsA and Tac seem not only to be substrates of CYP3A but have also been described as inhibitors of CYP3A. For CsA, in particular, inhibition of CYP3A has been suggested as the main mechanism of interactions seen clinically ",43,ChEMBL,1487250,20200625,5284373,103230651,1577,NULL,P20815,Curation Efforts|Research and Development,22205779,0,10.1124/dmd.111.043018,1.14.14.1,P20815,NULL
614638,100,Competitive inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764649,20180919,15949613,123084702,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614639,100,Competitive inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764650,20180919,15949613,123084702,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614640,2,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764651,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614641,2,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764652,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614642,2,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 in presence of ATP measured without preincubation by AlphaScreen analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764653,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614643,2,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 preincubated for 120 mins in presence of ATP by AlphaScreen analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764654,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614644,2,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 after 10 mins by Global fit analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764655,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614645,100,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as dissociation half life,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764656,20180919,"216239,15949613","103420820,123084702",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614646,100,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 in presence of ATP by AlphaScreen analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764657,20180919,216239,103420820,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614648,2,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 after 60 mins by activity based 100 fold dilution assay,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764659,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614649,2,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 after 60 mins by ligand displacement based enzyme-inhibitor dilution assay,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764660,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614650,100,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by activity based 100 fold dilution assay,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764661,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614651,100,Inhibition of human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by ligand displacement based enzyme-inhibitor dilution assay,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764662,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614652,100,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by activity based 100 fold dilution assay,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764663,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614653,100,Inhibition of human N-terminal His-tagged phosphorylated VEGFR2 assessed as dissociation half life after 60 mins by ligand displacement based enzyme-inhibitor dilution assay,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764664,20180919,"44259,216239,5329102,15949613","103175813,103420820,123084702,123092436",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614657,100,Inhibition of VEGF-induced autophosphorylation of tyrosine 1175 residue on VEGFR2 expressed in HEK293 cells at 100 nM after 1 hr by ELISA,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764668,20180919,"5329102,15949613","103175813,123084702",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614658,100,Inhibition of VEGF-induced autophosphorylation of tyrosine 1175 residue on VEGFR2 expressed in HEK293 cells at 100 nM measured 96 hrs post inhibitor washout by ELISA,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764669,20180919,"5329102,15949613","103175813,123084702",3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
1211492,100,Inhibition of human CYP2E1-mediated chlorzoxazone hydroxylase activity at 2.5 to 40 mM by LC-MS/MS analysis,"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493679,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211493,100,Inhibition of human CYP2E1-mediated chlorzoxazone hydroxylase activity at 2.5 to 40 mM after 72 hrs by LC-MS/MS analysis in presence of 1 mM NADPH,"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493680,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211494,2,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity by HPLC analysis,"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493681,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211495,100,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 2.5 mM after 72 hrs preincubation by HPLC analysis (RVb = 100%),"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493682,20200624,"1367,12124","103168755,103318474",1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211496,100,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 20 mM after 72 hrs preincubation by HPLC analysis (RVb = 100%),"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493683,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211497,100,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 40 mM after 72 hrs preincubation by HPLC analysis (RVb = 100%),"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493684,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211498,100,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 20 mM after 72 hrs preincubation by HPLC analysis in presence of 1 mM NADPH (RVb = 100%),"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493685,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211499,100,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 20 mM after 72 hrs preincubation by HPLC analysis in presence of 1 mM NADPH and 5 mM glutathione (RVb = 100%),"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493686,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1211500,100,Inhibition of human CYP2E1 assessed as chlorzoxazone 6-hydroxylase activity at 40 mM after 72 hrs preincubation by HPLC analysis in presence of 1 mM NADPH (RVb = 100%),"Title: Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen._|__|_Abstract: The hypothesis that N-acetyl-m-aminophenol (AMAP), the meta isomer of acetaminophen, will covalently bind to and inhibit human CYP2E1 in a time- and NADPH-dependent manner was investigated. Liquid chromatography/electrospray ionization-mass spectrometry analysis indicated that AMAP metabolites (i.e., AMAP*) selectively and covalently modified CYP2E1 apoprotein in a ratio of 1.4:1 (A",43,ChEMBL,1493687,20200624,12124,103168755,1571,NULL,P05181,Curation Efforts|Research and Development,22613176,0,10.1124/dmd.112.045492,"1.14.13.n7,1.14.14.1",P05181,NULL
1239160,100,Time-dependent inhibition of human microsomal CYP1A2-dependent methoxyresorufin-O-demethylase activity assessed as half inhibition time by spectrofluorimetric analysis in presence of NADPH regenerating solution,"Title: A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2._|__|_Abstract: In humans, cytochrome P450 1A2 is the major enzyme metabolizing environmental arylamines or heterocyclic amines into carcinogens. Since evidence shows that planar triangle-shaped molecules are capable of selectively inhibiting P450 1A2, 16 triangular flavone, and coumarin derivatives were designed and synthesized for these studies. Among these compounds, ",43,ChEMBL,1508798,20200624,"12412902,122184915","318382155,318382156",1544,NULL,P05177,Curation Efforts|Research and Development,26222195,0,10.1021/acs.jmedchem.5b00494,"1.14.14.1,4.2.1.152",P05177,NULL
1256983,2,Time-dependent inhibition of CYP1A2 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526175,20200702,71571306,318396538,1544,NULL,P05177,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,"1.14.14.1,4.2.1.152",P05177,NULL
1256984,2,Time-dependent inhibition of CYP2B6 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526176,20181009,71571306,318396538,1555,NULL,P20813,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,1.14.13.-,P20813,NULL
1256985,2,Time-dependent inhibition of CYP2C8 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526308,20181009,71571306,318396538,1558,NULL,P10632,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,1.14.14.1,P10632,NULL
1256986,2,Time-dependent inhibition of CYP2C9 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526309,20181009,71571306,318396538,1559,NULL,P11712,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1256987,2,Time-dependent inhibition of CYP2C19 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526310,20181009,71571306,318396538,1557,NULL,P33261,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1256988,2,Time-dependent inhibition of CYP2D6 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526311,20181009,71571306,318396538,1565,NULL,P10635,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,1.14.14.-,P10635,NULL
1256989,2,Time-dependent inhibition of CYP3A4 in human liver microsomes,"Title: Discovery of 2-(6-(5-Chloro-2-methoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide (PF-06282999): A Highly Selective Mechanism-Based Myeloperoxidase Inhibitor for the Treatment of Cardiovascular Diseases._|__|_Abstract: Myeloperoxidase (MPO) is a heme peroxidase that catalyzes the production of hypochlorous acid. Clinical evidence suggests a causal role for MPO in various autoimmune and inflammatory disorders including vasculitis and cardiovascular and Parkinson's diseases, implying ",43,ChEMBL,1526312,20181009,71571306,318396538,1576,NULL,P08684,Curation Efforts|Research and Development,26509551,0,10.1021/acs.jmedchem.5b00963,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1373460,100,Time dependent inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction pre-incubated for 10 to 70 mins before CMNPC substrate addition by fluorescence based assay,"Title: Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase._|__|_Abstract: Multi-target inhibitors have become increasing popular as a means to leverage the advantages of poly-pharmacology while simplifying drug delivery. Here, we describe dual inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), two targets known to synergize when treating inflammatory and neuropathic pain. The structure activity relat",43,ChEMBL,1752867,20200618,"1383884,16756850,130431469,130431481","103455066,174517375,404686062,404686829",NULL,NULL,NULL,Curation Efforts|Research and Development,29366648,0,10.1016/j.bmcl.2018.01.003,NULL,NULL,NULL
1373461,100,Time dependent inhibition of human recombinant soluble epoxide hydrolase expressed in baculovirus-infected High Five cells S9 fraction pre-incubated for 10 to 70 mins before CMNPC substrate addition by fluorescence based assay relative to untreated contro,"Title: Identification and optimization of soluble epoxide hydrolase inhibitors with dual potency towards fatty acid amide hydrolase._|__|_Abstract: Multi-target inhibitors have become increasing popular as a means to leverage the advantages of poly-pharmacology while simplifying drug delivery. Here, we describe dual inhibitors for soluble epoxide hydrolase (sEH) and fatty acid amide hydrolase (FAAH), two targets known to synergize when treating inflammatory and neuropathic pain. The structure activity relat",43,ChEMBL,1752868,20200618,1383884,103455066,NULL,NULL,NULL,Curation Efforts|Research and Development,29366648,0,10.1016/j.bmcl.2018.01.003,NULL,NULL,NULL
614647,100,Ratio of IC50 for human N-terminal His-tagged phosphorylated VEGFR2 to IC50 for human N-terminal His-tagged non-phosphorylated VEGFR2,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764658,20200629,5329102,103175813,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614654,100,Binding affinity to human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as association constant by surface plasmon resonance analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764665,20180919,15949613,123084702,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614655,100,Binding affinity to human N-terminal His-tagged non-phosphorylated VEGFR2 assessed as dissociation constant by surface plasmon resonance analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764666,20180919,15949613,123084702,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
614656,2,Binding affinity to human N-terminal His-tagged non-phosphorylated VEGFR2 by surface plasmon resonance analysis,"Title: Biochemical characterization of a novel type-II VEGFR2 kinase inhibitor: comparison of binding to non-phosphorylated and phosphorylated VEGFR2._|__|_Abstract: A pyrrolo[3,2-d]pyrimidine-based type-II vascular endothelial growth factor receptor 2 (VEGFR2) kinase inhibitor, compound 20d, displayed time-dependent inhibition of the non-phosphorylated catalytic domain of VEGFR2. In contrast, 20d did not show time-dependent inhibition of the phosphorylated enzyme. Dissociation of 20d from non-phosphorylate",43,ChEMBL,764667,20180919,15949613,123084702,3791,NULL,P35968,Curation Efforts|Research and Development,21885287,0,10.1016/j.bmc.2011.08.002,2.7.10.1,P35968,NULL
637859,100,Time dependent inhibition of Saccharomyces cerevisiae alpha-glucosidase using 4-nitrophenyl alpha-D-glucopyranoside as substrate,"Title: Virtual ligand screening of &#xCE;&#xB1;-glucosidase: Identification of a novel potent noncarbohydrate mimetic inhibitor._|__|_Abstract: 5-Thiazoleacetamide derivatives of AR122 and AR125 were screened as &#x3B1;-glucosidase inhibitors by in silico high-throughput screening from commercial drug-like small compound libraries. Inhibition of &#x3B1;-glucosidase with AR122 and AR125 is time dependent: with no preincubation, AR122 and AR125 are relatively moderate inhibitors, but interestingly, after a 12",43,ChEMBL,795307,20200626,"137630247,137630248","136926383,136942580",NULL,NULL,NULL,Curation Efforts|Research and Development,22154663,0,10.1016/j.bmcl.2011.11.084,NULL,NULL,NULL
195225,100,Influence (2 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 10 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192499,20180930,390798,103292922,NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195226,100,Influence (2 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 20 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192500,20180930,390798,103292922,NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195227,100,Influence (2 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 30 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192501,20180930,390798,103292922,NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195228,100,Influence (2 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 5 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192502,20180930,390798,103292922,NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195229,100,Influence (5 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 10 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192503,20180930,"14005,5280343,5355836","103167027,103173414,103183744",NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195230,100,Influence (5 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 20 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192504,20180930,"14005,5280343,5355836","103167027,103173414,103183744",NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195231,100,Influence (5 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 30 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192505,20180930,"14005,5280343,5355836","103167027,103173414,103183744",NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195232,100,Influence (5 uM) on transacetylase catalyzed time dependent activation of NADPH cytochrome C reductase at pre-incubation time being 5 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192506,20180930,"14005,5280343,5355836","103167027,103173414,103183744",NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
706290,100,Time dependent inhibition of CYP3A4 assessed as shift in AUC of enzyme activity,"Title: Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors._|__|_Abstract: The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak",43,ChEMBL,874033,20180923,58063117,163314555,1576,NULL,P08684,Curation Efforts|Research and Development,23061660,0,10.1021/jm3012239,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
706292,2,Time dependent inhibition of CYP3A4,"Title: Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors._|__|_Abstract: The discovery of somatic Jak2 mutations in patients with chronic myeloproliferative neoplasms has led to significant interest in discovering selective Jak2 inhibitors for use in treating these disorders. A high-throughput screening effort identified the pyrazolo[1,5-a]pyrimidine scaffold as a potent inhibitor of Jak2. Optimization of lead compounds 7a-b and 8 in this chemical series for activity against Jak",43,ChEMBL,874035,20180923,58063117,163314555,1576,NULL,P08684,Curation Efforts|Research and Development,23061660,0,10.1021/jm3012239,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217167,100,Time dependent inhibition of CYP3A5*1/*1 in human liver microsomes assessed as midazolam 1'-hydroxylase activity at 0.56 uM after 10 mins by dilution method,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1485339,20200624,71315139,312466714,NULL,NULL,NULL,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,NULL,NULL,NULL
1217168,100,Time dependent inhibition of CYP3A5*1/*3 in human liver microsomes assessed as midazolam 1'-hydroxylase activity at 0.56 uM after 10 mins by dilution method,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1485340,20200624,71315139,312466714,NULL,NULL,NULL,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,NULL,NULL,NULL
1217169,100,Time dependent inhibition of CYP3A5*3/*3 in human liver microsomes assessed as midazolam 1'-hydroxylase activity at 0.56 uM after 10 mins by dilution method,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1485341,20200624,71315139,312466714,NULL,NULL,NULL,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,NULL,NULL,NULL
1217176,100,Time dependent inhibition of human CYP2C9 diclofenac 4'-hydroxylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486101,20200624,71315139,312466714,1559,NULL,P11712,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1217177,100,Time dependent inhibition of human CYP2C19 S-mephenytoin 4'-hydroxylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486102,20200624,71315139,312466714,1557,NULL,P33261,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1217178,100,Time dependent inhibition of human CYP2D6 dextromethorphan O-demethylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486103,20200624,71315139,312466714,1565,NULL,P10635,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,1.14.14.-,P10635,NULL
1217179,100,Time dependent inhibition of human CYP3A midazolam 1'-hydroxylase activity assessed as decrease in enzyme activity at 1 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486104,20200624,71315139,312466714,NULL,NULL,NULL,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,NULL,NULL,NULL
1217180,100,Time dependent inhibition of human CYP3A testosterone 6beta-hydroxylase activity assessed as decrease in enzyme activity at 5 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486105,20200624,71315139,312466714,NULL,NULL,NULL,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,NULL,NULL,NULL
1217181,100,Time dependent inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A4 harboring human P450 oxidoreductase and b5 assessed as decrease in enzyme activity at 0.050 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486106,20200624,71315139,312466714,1576,NULL,P08684,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217182,100,Time dependent inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A4 in presence of human P450 oxidoreductase and b5 assessed as decrease in enzyme activity at 0.050 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486107,20200624,71315139,312466714,1576,NULL,P08684,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217183,100,Time dependent inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A5 harboring human P450 oxidoreductase and b5 assessed as decrease in enzyme activity at 2 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486108,20200624,71315139,312466714,1577,NULL,P20815,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,1.14.14.1,P20815,NULL
1217184,100,Time dependent inhibition of testosterone 6beta-hydroxylase activity of human recombinant CYP3A5 in presence of human P450 oxidoreductase and b5 assessed as decrease in enzyme activity at 2 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486109,20200624,71315139,312466714,1577,NULL,P20815,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,1.14.14.1,P20815,NULL
1217185,100,Time dependent inhibition of midazolam 1'-hydroxylase activity of human recombinant CYP3A7 harboring human P450 oxidoreductase and b5 assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1486110,20200624,71315139,312466714,1551,NULL,P24462,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,1.14.14.1,P24462,NULL
1217215,100,Time dependent inhibition of human CYP1A2 phenacetin O-deethylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1487669,20200624,71315139,312466714,1544,NULL,P05177,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,"1.14.14.1,4.2.1.152",P05177,NULL
1217216,100,Time dependent inhibition of human CYP2B6 bupropion hydroxylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1487670,20200624,71315139,312466714,1555,NULL,P20813,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,1.14.13.-,P20813,NULL
1217217,100,Time dependent inhibition of human CYP2C8 paclitaxel 6alpha-hydroxylase activity assessed as decrease in enzyme activity at 100 uM preincubated for 30 mins by IC25-shift assay,"Title: Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs._|__|_Abstract: CYP3cide (PF-4981517; 1-methyl-3-[1-methyl-5-(4-methylphenyl)-1H-pyrazol-4-yl]-4-[(3S)-3-piperidin-1-ylpyrrolidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine) is a potent, efficient, and specific time-dependent inactivator of human CYP3A4. When investigating its inhibitory properties, an extreme meta",43,ChEMBL,1487671,20200624,71315139,312466714,1558,NULL,P10632,Curation Efforts|Research and Development,22645092,0,10.1124/dmd.112.045302,1.14.14.1,P10632,NULL
46546,100,Compound was evaluated for inhibition constant for the non-time dependent inhibition of Calpain 1; no inhibition,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,43689,20181016,10765270,174485094,823,NULL,P07384,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.52,P07384,NULL
46547,100,Compound was evaluated for inhibition constant for the non-time dependent inhibition of Calpain 1; not determined,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,43690,20181016,44368657,103400728,823,NULL,P07384,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.52,P07384,NULL
46548,2,Inhibition constant for the non time dependent inhibition of calpain 1,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,43691,20181016,10746284,174520950,823,NULL,P07384,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.52,P07384,NULL
46549,100,Inhibition constant for the non time dependent inhibition of calpain 1; no inhibition,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,43692,20181016,44368829,103401154,823,NULL,P07384,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.52,P07384,NULL
46706,100,Compound was evaluated for inhibition constant for the non-time dependent inhibition of Calpain 2; not determined,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,43849,20181016,10765270,174485094,397393,NULL,P43367,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.53,P43367,NULL
46707,2,Inhibition constant for the non time dependent inhibition of Calpain 2,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,43850,20181016,"10746284,44368657","103400728,174520950",397393,NULL,P43367,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.53,P43367,NULL
48392,2,Compound was evaluated for inhibition constant for the non-time dependent inhibition of Cathepsin H.,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,45535,20181016,10765270,174485094,1512,NULL,P09668,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.16,P09668,NULL
48393,2,Inhibition constant for the non time dependent inhibition of Cathepsin H,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,45536,20181016,10668225,174510704,1512,NULL,P09668,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.16,P09668,NULL
48394,100,Inhibition constant for the non time dependent inhibition of Cathepsin H; no inhibition,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,45537,20181016,10668225,174510704,1512,NULL,P09668,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.16,P09668,NULL
48395,2,Inhibition constant for the non time dependent inhibition of cathepsin H,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,45538,20181016,"10746284,10770036","174490115,174520950",1512,NULL,P09668,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.16,P09668,NULL
48396,100,Inhibition constant for the non time dependent inhibition of cathepsin H; no inhibition,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,45539,20181016,44368829,103401154,1512,NULL,P09668,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.16,P09668,NULL
51495,2,Inhibitory activity was measured against Coagulation factor X,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,48639,20181016,"10502109,10742017","103387314,103387612",2159,NULL,P00742,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.6,P00742,NULL
51496,100,Inhibitory activity was measured against Coagulation factor X; Not tested,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,48640,20181016,10695507,103388037,2159,NULL,P00742,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.6,P00742,NULL
67007,100,Second-order rate constant for time-dependent inactivation of Human Leukocyte Elastase was determined,"Title: Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides._|__|_Abstract: A variety of 7 alpha-methoxycephalosporin ester and amide sulfones were prepared and tested to determine the structure-activity relations for inhibition of human leukocyte elastase (HLE), a serine protease which has been implicated in several degenerative lung and tissue diseases. The most potent IC50 values were obtained with neutral, lipophilic derivatives, with the esters being more",43,ChEMBL,64167,20181013,"9799757,10854087,14760247,14760249,14760262","103273932,103288704,103289619,103289621,103289681",1991,NULL,P08246,Curation Efforts|Research and Development,2391692,0,10.1021/jm00171a029,3.4.21.37,P08246,NULL
67009,100,Second-order rate constant for time-dependent inactivation of Human Leukocyte Elastase was determined; H means an inverse progress curve was observed,"Title: Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides._|__|_Abstract: A variety of 7 alpha-methoxycephalosporin ester and amide sulfones were prepared and tested to determine the structure-activity relations for inhibition of human leukocyte elastase (HLE), a serine protease which has been implicated in several degenerative lung and tissue diseases. The most potent IC50 values were obtained with neutral, lipophilic derivatives, with the esters being more",43,ChEMBL,64169,20181013,"14760235,14760237,14760239,14760243","103289172,103289602,103289630,103289657",1991,NULL,P08246,Curation Efforts|Research and Development,2391692,0,10.1021/jm00171a029,3.4.21.37,P08246,NULL
67010,100,Second-order rate constant for time-dependent inactivation of leukocyte elastase,"Title: Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides._|__|_Abstract: A variety of 7 alpha-methoxycephalosporin ester and amide sulfones were prepared and tested to determine the structure-activity relations for inhibition of human leukocyte elastase (HLE), a serine protease which has been implicated in several degenerative lung and tissue diseases. The most potent IC50 values were obtained with neutral, lipophilic derivatives, with the esters being more",43,ChEMBL,64170,20181013,"10373301,14760208,14760210,14760264,14760266,14760300,14760302,14760304,14760310,14760313,14760319,14760321,14760323","103273797,103273799,103288924,103288954,103289272,103289273,103289404,103289419,103289448,103289449,103289683,103289741,103298852",1991,NULL,P08246,Curation Efforts|Research and Development,2391692,0,10.1021/jm00171a029,3.4.21.37,P08246,NULL
99436,2,Inhibitory activity was measured against human leukocyte elastase.,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,96630,20181016,"10502109,10695507,10742017","103387314,103387612,103388037",1991,NULL,P08246,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.37,P08246,NULL
156764,2,The compound was tested for inhibition of carboxyl protease (pepsin) inhibition,Title: Synthesis of analogues of the carboxyl protease inhibitor pepstatin. Effect of structure in subsite P3 on inhibition of pepsin._|__|_Abstract: A series of pepstatin analogues having minimum structural requirements for tight-binding inhibition has been synthesized and tested on porcine pepsin. Subtle changes in the geometry and size of side chains at the valine-1 position of pepstatin were found to dramatically affect inhibitor potency as well a the type of kinetic behavior observed. The inhibitors re,43,ChEMBL,154018,20181002,"44278232,44378838,44378872,44378915,44378925,44378990,44379004,44379064,44379091,44379147","103200874,103420877,103420936,103421047,103421071,103421199,103421229,103421384,103421449,103421609",396892,NULL,P00791,Curation Efforts|Research and Development,6809942,0,10.1021/jm00349a005,3.4.23.1,P00791,NULL
157819,2,Inhibitory activity was measured against plasmin.,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,155077,20181016,"10502109,10742017","103387314,103387612",5340,NULL,P00747,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.7,P00747,NULL
157820,100,Inhibitory activity was measured against plasmin; Not tested,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,155078,20181016,10695507,103388037,5340,NULL,P00747,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.7,P00747,NULL
210808,2,Inhibitory activity was measured against thrombin.,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,208122,20181016,"10502109,10695507,10742017","103387314,103387612,103388037",2147,NULL,P00734,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.5,P00734,NULL
213373,2,Inhibitory activity was measured against human mast cell tryptase.,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,210692,20181016,"10502109,10504321,10504386,10504894,10526456,10527664,10528106,10600275,10622602,10624038,10640306,10647648,10647871,10695507,10742017,10790297,10835053,44363121,44363176,44363284,44363315,44363347,44363389","103387314,103387315,103387318,103387339,103387343,103387344,103387468,103387534,103387535,103387536,103387611,103387612,103387764,103387791,103387792,103387846,103387867,103387990,103388013,103388036,103388037,103388038,103388091","7177,23430,25823",NULL,"Q15661,Q9BZJ3,Q9NRR2",Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,"3.4.21.-,3.4.21.59","Q15661,Q9BZJ3,Q9NRR2",NULL
215242,2,Inhibitory activity was measured against trypsin.,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,212561,20181016,"10502109,10742017","103387314,103387612","5644,5645,5646",NULL,"P07477,P07478,P35030",Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.4,"P07477,P07478,P35030",NULL
215243,100,Inhibitory activity was measured against trypsin; Not tested,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,212562,20181016,10695507,103388037,"5644,5645,5646",NULL,"P07477,P07478,P35030",Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.4,"P07477,P07478,P35030",NULL
215656,2,Inhibitory activity was measured against urokinase.,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,212975,20181016,"10502109,10742017","103387314,103387612",5328,NULL,P00749,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.73,P00749,NULL
215657,100,Inhibitory activity was measured against urokinase; Not tested,"Title: 1,2-Benzisothiazol-3-one 1,1-dioxide inhibitors of human mast cell tryptase._|__|_Abstract: A library of compounds were prepared by reacting 2-(bromomethyl)-1, 2-benzisothiazol-3(2H)-one 1,1-dioxide (5) with commercially available carboxylic acids in the presence of potassium carbonate or a tertiary amine base. From this library, (1,1-dioxido-3-oxo-1, 2-benzisothiazol-2(3H)-yl)methyl N-[(phenylmethoxy)carbonyl]-beta-alanate (7b) emerged as a potent inhibitor of human mast cell tryptase (IC50 = 0.85 m",43,ChEMBL,212976,20181016,10695507,103388037,5328,NULL,P00749,Curation Efforts|Research and Development,9822554,0,10.1021/jm9804580,3.4.21.73,P00749,NULL
219365,2,Inhibition constant for the non time dependent inhibition of cathepsin H,"Title: New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid._|__|_Abstract: Three different types of peptides containing aziridine-2, 3-dicarboxylic acid (Azi) as an electrophilic alpha-amino acid at different positions within the peptide chain (type I, N-acylated aziridines with Azi as C-terminal amino acid; type II, N-unsubstituted aziridines with Azi as N-terminal amino acid; type III, N-acylated bispeptidyl derivatives of Azi) have bee",43,ChEMBL,216701,20181016,44368657,103400728,1512,NULL,P09668,Curation Efforts|Research and Development,10052963,0,10.1021/jm981061z,3.4.22.16,P09668,NULL
318593,2,Inhibition of human recombinant FPPS expressed in Escherichia coli BL21,Title: Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase._|__|_Abstract: The nitrogen-containing bisphosphonates (N-BPs) are the main drugs currently used to treat diseases characterized by excessive bone resorption. The major molecular target of N-BPs is farnesylpyrophosphate synthase. N-BPs inhibit the enzyme by a mechanism that involves time dependent isomerization of the e,43,ChEMBL,466619,20181023,"1023,2088,4674,5245,57637,60852,68740,71237,128523,405368,405372,405374,405386,406401,5276531,5276533,9847474,9994754,10014835,10424622,10468166,11011374,12735335,14231197,15230199,15230201,44450243","103219240,103228757,103240370,103240839,103240897,103240987,103241002,103241003,103241106,103241144,103241208,103241347,103241771,103265985,103312923,103313949,103314021,103314212,103314244,103470386,103542335,103565747,103565749,103565798,103565847,103565848,103760657",2224,NULL,P14324,Curation Efforts|Research and Development,18327899,0,10.1021/jm7015733,"2.5.1.1,2.5.1.10",P14324,NULL
318594,2,Inhibition of human recombinant FPPS expressed in Escherichia coli BL21 after 10 mins,Title: Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase._|__|_Abstract: The nitrogen-containing bisphosphonates (N-BPs) are the main drugs currently used to treat diseases characterized by excessive bone resorption. The major molecular target of N-BPs is farnesylpyrophosphate synthase. N-BPs inhibit the enzyme by a mechanism that involves time dependent isomerization of the e,43,ChEMBL,466620,20181023,"1023,2088,4674,5245,57637,60852,68740,71237,128523,405368,405372,405374,405386,406401,5276531,5276533,9847474,9994754,10014835,10424622,10468166,11011374,12735335,14231197,15230199,15230201,44450243","103219240,103228757,103240370,103240839,103240897,103240987,103241002,103241003,103241106,103241144,103241208,103241347,103241771,103265985,103312923,103313949,103314021,103314212,103314244,103470386,103542335,103565747,103565749,103565798,103565847,103565848,103760657",2224,NULL,P14324,Curation Efforts|Research and Development,18327899,0,10.1021/jm7015733,"2.5.1.1,2.5.1.10",P14324,NULL
318595,100,Inhibition of bone resorption in rat assessed as phosphate,Title: Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase._|__|_Abstract: The nitrogen-containing bisphosphonates (N-BPs) are the main drugs currently used to treat diseases characterized by excessive bone resorption. The major molecular target of N-BPs is farnesylpyrophosphate synthase. N-BPs inhibit the enzyme by a mechanism that involves time dependent isomerization of the e,43,ChEMBL,466621,20181023,"2088,4674,5245,57637,60852,68740,71237,128523,405372,405374,405386,406401,5276531,5276533,9847474,9994754,10014835,10424622,10468166,11011374,12735335,14231197,15230201","103219240,103228757,103240370,103240839,103240897,103240987,103241002,103241003,103241106,103241208,103241347,103241771,103265985,103312923,103313949,103314021,103314212,103314244,103470386,103542335,103565747,103565749,103565847",NULL,NULL,NULL,Curation Efforts|Research and Development,18327899,0,10.1021/jm7015733,NULL,NULL,NULL
399397,100,Increase in sheep placental cotyledons COX2 activity assessed as PGE2 production at 1 mM after 15 mins,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547426,20181025,247704,103221326,443460,NULL,P79208,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,P79208,NULL
399398,100,Increase in bovine seminal microsomal COX1 activity assessed as PGE2 production at 4 mM after 15 mins,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547427,20181025,247704,103221326,282022,NULL,O62664,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,O62664,NULL
399399,100,Increase in bovine seminal microsomal COX1 activity assessed as PGE2 production at 1.95 mM,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547428,20181025,247704,103221326,282022,NULL,O62664,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,O62664,NULL
399400,100,Increase in sheep placental cotyledons COX2 activity assessed as PGE2 production at 1.95 mM,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547429,20181025,247704,103221326,443460,NULL,P79208,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,P79208,NULL
399401,2,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547430,20181025,"2244,3672,3715,9064,5280459","103163840,103164874,103174500,103284478,123094711",282022,NULL,O62664,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,O62664,NULL
399402,2,Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547431,20181025,"2244,3672,3715,9064,5280459","103163840,103164874,103174500,103284478,123094711",443460,NULL,P79208,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,P79208,NULL
399403,100,Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547432,20200703,"2244,3672,3715,9064","103163840,103164874,103174500,123094711",NULL,NULL,NULL,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,NULL,NULL,NULL
399404,2,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production preincubated for 10 mins,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547433,20181025,"2244,3672,3715,4553,9064,156391,5280459","103163840,103164874,103165236,103174500,103210646,103284478,123094711",282022,NULL,O62664,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,O62664,NULL
399405,2,Inhibition of sheep placental cotyledons COX2 assessed as PGE2 production preincubated for 10 mins,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547434,20181025,"2244,3672,3715,4553,9064,156391,5280459","103163840,103164874,103165236,103174500,103210646,103284478,123094711",443460,NULL,P79208,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,P79208,NULL
399406,100,Selectivity ratio of IC50 for sheep placental cotyledons COX2 to IC50 for bovine seminal microsomal COX1 preincubated for 10 mins,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547435,20200703,"2244,3672,3715,4553,9064,156391","103163840,103164874,103165236,103174500,103210646,123094711",NULL,NULL,NULL,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,NULL,NULL,NULL
399407,100,Inhibition of bovine seminal microsomal COX1 assessed as PGE2 production at 100 uM preincubated for 10 mins,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547436,20181025,4553,103165236,282022,NULL,O62664,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,O62664,NULL
399408,2,Activity of bovine seminal microsomal COX1,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547437,20181025,444899,103178961,282022,NULL,O62664,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,O62664,NULL
399409,2,Activity of sheep placental cotyledons COX2,Title: Development of a radiochemical cyclooxygenase-1 and -2 in vitro assay for identification of natural products as inhibitors of prostaglandin biosynthesis._|__|_Abstract: A radiochemical enzyme assay for studying cyclooxygenase (COX)-catalyzed prostaglandin biosynthesis in vitro was optimized with respect to both COX-1 and COX-2 activity. The assay can be used to assess the relative selectivity of plant-derived inhibitors on COX-1 and COX-2 Assay conditions were optimized for both enzymes with respect ,43,ChEMBL,547438,20181025,444899,103178961,443460,NULL,P79208,Curation Efforts|Research and Development,9461646,0,10.1021/np970343j,1.14.99.1,P79208,NULL
688190,2,Time dependent inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate at 3 to 100 uM up to 120 mins,"Title: Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases._|__|_Abstract: In the search for anti-SARS-CoV, tanshinones derived from Salvia miltiorrhiza were found to be specific and selective inhibitors for the SARS-CoV 3CL(pro) and PL(pro), viral cysteine proteases. A literature search for studies involving the seven isolated tanshinone hits showed that at present, none have been identified as coronaviral protease inhibitors. We have identified that all of the isolated tan",43,ChEMBL,848934,20200625,"114917,160142,160254,164676,318797,11425923,14610613","103227294,103456480,103456665,103456666,103498954,103521465,163312872",1489680,NULL,P0C6U8,Curation Efforts|Research and Development,22884354,0,10.1016/j.bmc.2012.07.038,"3.4.19.12,3.4.22.-,3.4.22.69",P0C6U8,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
688305,100,Time dependent inhibition of SARS-CoV 3CLpro expressed in Escherichia coli BL21 (DE3) using Dabcyl-KNSTLQSGLRKE-Edan as substrate at 1 to 100 uM by FRET analysis,"Title: Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases._|__|_Abstract: In the search for anti-SARS-CoV, tanshinones derived from Salvia miltiorrhiza were found to be specific and selective inhibitors for the SARS-CoV 3CL(pro) and PL(pro), viral cysteine proteases. A literature search for studies involving the seven isolated tanshinone hits showed that at present, none have been identified as coronaviral protease inhibitors. We have identified that all of the isolated tan",43,ChEMBL,849049,20200625,"114917,160142,164676,318797,11425923,14610613","103227294,103456665,103456666,103498954,103521465,163312872",1489680,NULL,P0C6U8,Curation Efforts|Research and Development,22884354,0,10.1016/j.bmc.2012.07.038,"3.4.19.12,3.4.22.-,3.4.22.69",P0C6U8,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
688306,100,Time dependent inhibition of SARS-CoV PLpro expressed in Escherichia coli BL21 (DE3) using Arg-Leu-Arg-Gly-Gly-AMC as substrate at IC50 by fluorescence assay,"Title: Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases._|__|_Abstract: In the search for anti-SARS-CoV, tanshinones derived from Salvia miltiorrhiza were found to be specific and selective inhibitors for the SARS-CoV 3CL(pro) and PL(pro), viral cysteine proteases. A literature search for studies involving the seven isolated tanshinone hits showed that at present, none have been identified as coronaviral protease inhibitors. We have identified that all of the isolated tan",43,ChEMBL,849050,20200625,"114917,160142,160254,164676,318797,11425923,14610613","103227294,103456480,103456665,103456666,103498954,103521465,163312872",1489680,NULL,P0C6U8,Curation Efforts|Research and Development,22884354,0,10.1016/j.bmc.2012.07.038,"3.4.19.12,3.4.22.-,3.4.22.69",P0C6U8,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
699795,100,Inhibition of CYP3A4 in human liver microsomes,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860539,20200625,"11634899,57506723","163313964,163320864",1576,NULL,P08684,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
699797,2,Inhibition of human PI3Kdelta-mediated AKT phosphorylation at S473 in Ri-1 cells after 30 mins by electrochemiluminescence assay in presence of human serum albumin and alpha1 acid glycoprotein,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860541,20200625,"49820826,49820977,49832773,49832939,49833295,57506734,57506735,57506736,57506737,57506739,57506741,57506743,57506744,59605427,59606002,60165805","163313939,163313940,163313941,163317370,163317371,163317372,163320838,163320839,163320840,163320862,163320863,163331205,163331225,163331226,163338083,163338104",5293,NULL,O00329,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,2.7.1.153,O00329,NULL
1190261,2,Inhibition of human C-terminal His6-tagged NAMPT expressed in Escherichia coli Rosetta(DE3) incubated for 15 mins prior to substrate addition measured after 30 mins,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462152,20200625,"68276577,68277248,68277935,71726495,71727460,71727683,71727801,71727928,71728054,71728058,71818876,89785082,89793496,89793516,89793519,89793535,89795476,89795479,89795484,89795501,89795553,89795596,89795599,89795666,89795715,89795796,90012681,90012714,118160922,118193528,118193544,118726259,118726260","174487940,174518843,174518845,174518847,312378096,312378097,312378098,312378099,312378100,312378101,312378102,312378103,312378104,312378105,312378106,312378107,312378108,312378109,312378110,312378111,312378112,312378113,312378114,312378115,312378116,312378117,312378118,312378119,312378120,312378121,312378122,312378123,312378124",10135,NULL,P43490,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,2.4.2.12,P43490,NULL
1190269,2,Reversible inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462160,20181006,"68276577,71727801,71728054,89793496,89793516,89793519,89795484,89795501,89795553,89795796","312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1576,NULL,P08684,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1190270,2,Reversible inhibition of CYP3A4 in human liver microsomes using testosterone as substrate,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462161,20181006,"68276577,71727801,71728054,89793496,89793516,89793519,89795484,89795501,89795553,89795796","312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1576,NULL,P08684,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1190271,2,Reversible inhibition of CYP2D6 in human liver microsomes,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462162,20181006,"68276577,71727801,71728054,89793496,89793516,89793519,89795484,89795501,89795553,89795796","312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1565,NULL,P10635,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,1.14.14.-,P10635,NULL
1190272,2,Reversible inhibition of CYP1A2 in human liver microsomes,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462163,20200625,"68276577,71727801,71728054,89793496,89793516,89793519,89795484,89795501,89795553,89795796","312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1544,NULL,P05177,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,4.2.1.152",P05177,NULL
1190273,2,Reversible inhibition of CYP2C19 in human liver microsomes,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462164,20181006,"68276577,71727801,71728054,89793496,89793516,89793519,89795484,89795501,89795553,89795796","312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1557,NULL,P33261,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1190274,2,Reversible inhibition of CYP2C9 in human liver microsomes,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462165,20181006,"68276577,71727801,71728054,89793496,89793516,89793519,89795484,89795501,89795553,89795796","312378102,312378104,312378105,312378107,312378112,312378113,312378117,312378119,312378121,312378124",1559,NULL,P11712,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1190299,100,"Antitumor activity against human HT1080 cells xenografted in NCR mouse assessed as tumor growth inhibition at 50 mg/kg, po bid after 5 days relative to vehicle-treated control","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462190,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1231896,2,Inhibition of human full length PKCtheta assessed as fluorescence intensity after 60 mins,"Title: Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability._|__|_Abstract: Protein kinase C theta (PKC&#x3B8;) plays a critical role in T cell signaling and has therapeutic potential for T cell-mediated diseases such as transplant rejection and rheumatoid arthritis. Here, a series of 2,4-diamino-5-fluoropyrimidine derivatives were prepared and evaluated for their inhibition of PKC&#x3B8;. Of t",43,ChEMBL,1500450,20200624,"68665038,122180028,122180029,122180030,122180031,122180032,122180033,122180034,122180035,122180036,122180037,122180038,122180039,122180040,122180041","318375076,318375077,318375078,318375079,318375080,318375081,318375082,318375083,318375084,318375085,318375086,318375087,318375088,318375089,318375090",5588,NULL,Q04759,Curation Efforts|Research and Development,25982074,0,10.1016/j.bmc.2015.04.050,2.7.11.13,Q04759,NULL
1239159,2,Time-dependent inhibition of human microsomal CYP1A2-dependent methoxyresorufin-O-demethylase activity by spectrofluorimetric analysis in presence of NADPH regenerating solution,"Title: A Ligand-Based Drug Design. Discovery of 4-Trifluoromethyl-7,8-pyranocoumarin as a Selective Inhibitor of Human Cytochrome P450 1A2._|__|_Abstract: In humans, cytochrome P450 1A2 is the major enzyme metabolizing environmental arylamines or heterocyclic amines into carcinogens. Since evidence shows that planar triangle-shaped molecules are capable of selectively inhibiting P450 1A2, 16 triangular flavone, and coumarin derivatives were designed and synthesized for these studies. Among these compounds, ",43,ChEMBL,1508797,20200624,"61322,11206660,12412902,91755082,122184915,122184918,122184919,122184920,122184965,122184966,122184967,122184968","103238721,318382155,318382156,318382159,318382160,318382161,318382162,318382163,318382231,318382232,318382233,318382234",1544,NULL,P05177,Curation Efforts|Research and Development,26222195,0,10.1021/acs.jmedchem.5b00494,"1.14.14.1,4.2.1.152",P05177,NULL
1250078,2,Inhibition of CYP3A (unknown origin) using testosterone as substrate,Title: Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System._|__|_Abstract: Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes may incur serious undesirable drug-drug interactions and in rare cases drug-induced idiosyncratic toxicity. The reactive metabolites are often generated through multiple sequential biotransformations and form adducts with CYP enzymes to inactivate their function. The complexity of these processes makes addressing TDI liability very chall,43,ChEMBL,1520077,20200624,"71539661,74983298,122192303,122192304,122192305,122192306,122192307,122192308,122192309,122192310,122192311,122192312,122192313","318392658,318392659,318392660,318392661,318392662,318392663,318392664,318392665,318392666,318392667,318392668,318392669,318392670",NULL,NULL,NULL,Curation Efforts|Research and Development,26288695,0,10.1021/acsmedchemlett.5b00191,NULL,NULL,NULL
1250079,2,Inhibition of CYP3A (unknown origin) using midazolam as substrate,Title: Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System._|__|_Abstract: Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes may incur serious undesirable drug-drug interactions and in rare cases drug-induced idiosyncratic toxicity. The reactive metabolites are often generated through multiple sequential biotransformations and form adducts with CYP enzymes to inactivate their function. The complexity of these processes makes addressing TDI liability very chall,43,ChEMBL,1520078,20200624,"71539661,74983298,122192303,122192304,122192305,122192306,122192307,122192308,122192309,122192310,122192311,122192312,122192313","318392658,318392659,318392660,318392661,318392662,318392663,318392664,318392665,318392666,318392667,318392668,318392669,318392670",NULL,NULL,NULL,Curation Efforts|Research and Development,26288695,0,10.1021/acsmedchemlett.5b00191,NULL,NULL,NULL
1250080,2,Inhibition of CYP3A (unknown origin),Title: Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System._|__|_Abstract: Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes may incur serious undesirable drug-drug interactions and in rare cases drug-induced idiosyncratic toxicity. The reactive metabolites are often generated through multiple sequential biotransformations and form adducts with CYP enzymes to inactivate their function. The complexity of these processes makes addressing TDI liability very chall,43,ChEMBL,1520079,20200624,71539661,318392658,NULL,NULL,NULL,Curation Efforts|Research and Development,26288695,0,10.1021/acsmedchemlett.5b00191,NULL,NULL,NULL
1274617,100,Time-dependent inhibition of microsomal CYP3A4 (unknown origin) using midazolam as substrate assessed as alpha-hydroxymidazolam-d4 at 10 uM pre-incubated for 12 mins before NADPH addition formation after 30 mins by LC-MS/MS analysis,"Title: Discovery and Characterization of 2-Acylaminoimidazole Microsomal Prostaglandin E Synthase-1 Inhibitors._|__|_Abstract: As part of a program aimed at the discovery of antinociceptive therapy for inflammatory conditions, a screening hit was found to inhibit microsomal prostaglandin E synthase-1 (mPGES-1) with an IC50 of 17.4 &#x3BC;M. Structural information was used to improve enzyme potency by over 1000-fold. Addition of an appropriate substituent alleviated time-dependent cytochrome P450 3A4 (CYP3A4",43,ChEMBL,1552428,20200623,"16070041,67970797,71059525,71059686,71059857,71059962,118987004,127025226,127025527","103578954,312362039,336865676,336865677,336866132,336866133,336866144,336866145,336866146",1576,NULL,P08684,Curation Efforts|Research and Development,26653180,0,10.1021/acs.jmedchem.5b01249,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1295356,2,Displacement of [125I]-MCH(4 to 19) from human MCHR1 expressed in CHO cell membranes after 1 hr by liquid scintillation counting,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572136,20180905,"71660914,71660915,71660917,89690368,89690864,89690957,89690973,89691019,89691032,89691044,89691057,89691065,89691096,89691143,89691144,89691162,89691193,89691216,89691247,89691264,89691284,89691349,89691416,89691439,89691535,89702226,89702566,121386280","336868160,336868161,336868162,336868163,336868164,336868165,336868608,336869488,336869489,336869913,336869914,336869915,336869916,336869917,336870831,336870832,336870833,336871259,336871260,336871261,336871262,336871263,336871264,336871688,336872037,336876217,336876218,336876639",2847,NULL,Q99705,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,Q99705,NULL
1295357,2,Displacement of [125I]-MCH(4-19) from rat MCHR1 expressed in CHO cell membranes after 1 hr by liquid scintillation counting,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572137,20180905,"71660914,71660915,71660917,89690864,89690957,89690973,89691019,89691032,89691044,89691057,89691065,89691096,89691143,89691144,89691162,89691193,89691216,89691247,89691264,89691284,89691349,89691535,89702226,89702566","336868160,336868161,336868162,336868163,336868164,336868165,336868608,336869488,336869489,336869913,336869914,336869915,336869916,336869917,336870831,336870832,336870833,336871259,336871260,336871261,336871262,336871263,336871264,336871688",83567,NULL,P97639,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,P97639,NULL
1295360,100,GSH reactivity in human liver microsomes at 30 uM after 30 mins in presence of GSH by LC/MS analysis based GSH trapping assay,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572252,20180905,"89691044,89702566","336871264,336871688",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295361,100,Oral bioavailability in Sprague-Dawley rat plasma at 1 mg/kg administered through cassette dosing by LC/MS/MS analysis,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572253,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295362,2,Antagonist activity at human MCHR1 expressed in CHO cells assessed as change in MCH(4 to 19)-stimulated Ca2+ concentration by Ca2+ mobilization assay,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572254,20180905,"89691096,89702226","336870831,336871263",2847,NULL,Q99705,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,Q99705,NULL
1295363,100,"Total clearance in Sprague-Dawley rat plasma at 0.1 mg/kg, iv administered through cassette dosing by LC/MS/MS analysis","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572255,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295364,100,"Volume of distribution in steady state in Sprague-Dawley rat plasma at 0.1 mg/kg, iv administered through cassette dosing by LC/MS/MS analysis","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572256,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295365,100,"Cmax in Sprague-Dawley rat at 1 mg/kg, po administered through cassette dosing by LC/MS/MS analysis","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572257,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295366,100,"Tmax in Sprague-Dawley rat plasma at 1 mg/kg, po administered through cassette dosing by LC/MS/MS analysis","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572258,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295367,100,"AUC( 0 to 8 hrs) Sprague-Dawley rat plasma at 1 mg/kg, po administered through cassette dosing by LC/MS/MS analysis","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572259,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295368,100,"Anorectic effect in DIO-F344/Jcl rat assessed as inhibition of food intake at 3 mg/kg, po administered 2 hrs before onset of dark period for 2 days","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572260,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295369,100,"Anorectic effect in DIO-F344/Jcl rat assessed as inhibition of food intake at 10 mg/kg, po administered 2 hrs before onset of dark period for 2 days","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572261,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295370,100,Anorectic effect in orally dosed DIO-F344/Jcl rat assessed as inhibition of food intake administered 2 hrs before onset of dark period for 2 days,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572262,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295371,100,"Antiobesity activity in DIO-F344/Jcl rat assessed as reduction in body weight at 3 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572263,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295372,100,"Antiobesity activity in DIO-F344/Jcl rat assessed as reduction in body weight at 10 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572264,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295373,100,"Anorectic effect in DIO-F344/Jcl rat assessed as cumulative food intake at 3 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572265,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295374,100,"Anorectic effect in DIO-F344/Jcl rat assessed as cumulative food intake at 10 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572266,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295375,100,"Anorectic effect in DIO-F344/Jcl rat assessed as cumulative food intake at 1 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572267,20180905,5210,103498411,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295376,100,"Antiobesity activity in DIO-F344/Jcl rat assessed as reduction in body weight at 1 mg/kg, po dosed for 2 weeks and measured every 2 or 3 days relative to vehicle control","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572268,20180905,5210,103498411,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295377,100,Solubility of compound at pH 6.8,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572269,20180905,"89691096,89702226","336870831,336871263",NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295378,2,"Free plasma concentration in DIO-F344/Jcl rat at 10 mg/kg, po","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572270,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295379,100,Fraction unbound in po dosed DIO-F344/Jcl rat plasma,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572271,20200624,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295380,2,"Trough plasma concentration in DIO-F344/Jcl rat at 10 mg/kg, po","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572272,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295381,100,Ratio of drug level in brain to plasma in po dosed DIO-F344/Jcl rat,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572273,20200624,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295382,100,"Antiobesity activity in MCHR1-deficient mouse assessed as reduction in body weight at 10 and 30 mg/kg, po dosed for 3 days","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572274,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295383,100,"Antiobesity activity in wild-type litter mate mouse assessed as reduction in body weight at 10 and 30 mg/kg, po dosed for 3 days","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572275,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295384,100,"Anorectic effect in MCHR1-deficient mouse assessed as reduction in food intake at 10 and 30 mg/kg, po dosed for 3 days","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572276,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295385,2,Inhibition of human ERG by patch clamp test,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572277,20180905,89702226,336871263,3757,NULL,Q12809,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,Q12809,NULL
1295386,100,Drug uptake in po dosed DIO-F344/Jcl rat brain,"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572278,20180905,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1295387,100,"Ratio of Free plasma concentration in DIO-F344/Jcl rat at 10 mg/kg, po to IC50 for Antagonist activity at human MCHR1 expressed in CHO cells","Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel 1-(1H-benzimidazol-6-yl)pyridin-2(1H)-one derivatives and design to avoid CYP3A4 time-dependent inhibition._|__|_Abstract: Melanin-concentrating hormone (MCH) is an attractive target for antiobesity agents, and numerous drug discovery programs are dedicated to finding small-molecule MCH receptor 1 (MCHR1) antagonists. We recently reported novel pyridine-2(1H)-ones as aliphatic amine-free MCHR1 antagonists that structurally feature",43,ChEMBL,1572279,20200624,89702226,336871263,NULL,NULL,NULL,Curation Efforts|Research and Development,27112449,0,10.1016/j.bmc.2016.04.011,NULL,NULL,NULL
1373193,2,Time dependent inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli using P-NPP as substrate preincubated with enzyme for 30 mins by UV-spectrophotometric method,"Title: Inhibition of protein tyrosine phosphatase 1B (PTP1B) and &#xCE;&#xB1;-glucosidase by xanthones from Cratoxylum cochinchinense, and their kinetic characterization._|__|_Abstract: Cratoxylum cochinchinense displayed significant inhibition against protein tyrosine phosphatase 1B (PTP1B) and &#x3B1;-glucosidase, both of which are key target enzymes to attenuate diabetes and obesity. The compounds responsible for both enzymes inhibition were identified as twelve xanthones (1-12) among which compounds 1 a",43,ChEMBL,1752600,20200618,145966924,404677462,NULL,NULL,NULL,Curation Efforts|Research and Development,29306546,0,10.1016/j.bmc.2017.12.043,NULL,NULL,NULL
1410370,100,Time-dependent inhibition of NADPH-reduced recombinant rat TrxR1 expressed in Escherichia coli harboring gor mutant assessed as suppression of DTNB reduction at 1 uM measured every 5 mins for 1 hr,"Title: Manumycin A Is a Potent Inhibitor of Mammalian Thioredoxin Reductase-1 (TrxR-1)._|__|_Abstract: The anticancer effect of manumycin A (Man A) has been attributed to the inhibition of farnesyl transferase (FTase), an enzyme that is responsible for post-translational modification of Ras proteins. However, we have discovered that Man A inhibits mammalian cytosolic thioredoxin reductase 1 (TrxR-1) in a time-dependent manner, with an IC50 of 272 nM with preincubation and 1586 nM without preincubation. The ",43,ChEMBL,1784839,20200619,6438330,103214617,NULL,NULL,NULL,Curation Efforts|Research and Development,29670693,0,10.1021/acsmedchemlett.7b00489,NULL,NULL,NULL
1423404,2,Inhibition of recombinant human BACE1 expressed in HEK293 cells,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797909,20200619,"15947487,71455427,71457203,71460877,71492530,145979438,145980015,145981185,145981356,145981628,145982062,145986900,145987073,145989886,145990244,145991888,145992760,145993306,145993573,145994215","163324837,163328201,163328281,163335303,336899268,404696147,404697029,404698837,404699085,404699506,404700176,404707145,404707408,404711792,404712375,404714902,404716283,404717132,404717570,404718691",NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423405,2,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate preincubated for 30 mins followed by substrate/NADPH addition measured after 10 mins by LC-MS/MS analysis,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797910,20200619,"15947487,71455427,71457203,71460877,71492530,145979438,145980015,145981185,145981356,145981628,145982062,145986900,145987073,145989886,145990244,145991888,145992760,145993306,145993573,145994215","163324837,163328201,163328281,163335303,336899268,404696147,404697029,404698837,404699085,404699506,404700176,404707145,404707408,404711792,404712375,404714902,404716283,404717132,404717570,404718691",NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423406,2,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate after 30 mins in presence of NADPH measured by LC-MS/MS analysis,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797911,20200619,71457203,163328281,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
440648,2,Inhibition of CYP3A in human liver microsomes assessed as hydroxymidazolam formation by time dependent inhibition assay,"Title: Discovery of azetidinyl ketolides for the treatment of susceptible and multidrug resistant community-acquired respiratory tract infections._|__|_Abstract: Respiratory tract bacterial strains are becoming increasingly resistant to currently marketed macrolide antibiotics. The current alternative telithromycin (1) from the newer ketolide class of macrolides addresses resistance but is hampered by serious safety concerns, hepatotoxicity in particular. We have discovered a novel series of azetidinyl keto",43,ChEMBL,591826,20180911,"3002190,45482734,45482735,45482739,45482740,136123532","103323138,103696791,103696792,103696796,103696797,103696798",NULL,NULL,NULL,Curation Efforts|Research and Development,19775168,0,10.1021/jm900729s,NULL,NULL,NULL
657031,100,Inhibition of CYP3A4 assessed as time dependent inhibition of conversion of testosterone to 6-beta-hydroxy-testosterone at 10 uM,"Title: Design and synthesis of potent, isoxazole-containing renin inhibitors._|__|_Abstract: The design and optimization of a novel isoxazole S(1) linker for renin inhibitor is described herein. This effort culminated in the identification of compound 18, an orally bioavailable, sub-nanomolar renin inhibitor even in the presence of human plasma. When compound 18 was found to inhibit CYP3A4 in a time dependent manner, two strategies were pursued that successfully delivered equipotent compounds with minimal T",43,ChEMBL,814103,20180921,"46931619,46932044,46932045,46932046,46932047,46932048,46932049,46932136,46932138,46932139,46932141,46932234,46932235,46932237,46932512,46932514,46932704,56963091,58083331,58083336,58083358,70687502","136926215,160667054,160667055,160672375,160672376,160683021,160683022,160683023,160683024,160683025,160688346,160688347,160688374,160688375,160693851,160693852,160693853,160699210,160699211,160699229,160704572,160704573",1576,NULL,P08684,Curation Efforts|Research and Development,22450130,0,10.1016/j.bmcl.2012.03.014,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
699787,100,"Drug metabolism in rat liver microsomes assessed as metabolite M4 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860531,20200625,24937010,163327677,NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699788,100,"Drug metabolism in rat liver microsomes assessed as metabolite M2 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860532,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699789,100,"Drug metabolism in rat liver microsomes assessed as metabolite M3 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860533,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699790,100,"Drug metabolism in rat liver microsomes assessed as metabolite M1 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860534,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699791,100,"Drug metabolism in human liver microsomes assessed as metabolite M4 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860535,20200625,24937010,163327677,NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699792,100,"Drug metabolism in human liver microsomes assessed as metabolite M3 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860536,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699793,100,"Drug metabolism in human liver microsomes assessed as metabolite M2 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860537,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699794,100,"Drug metabolism in human liver microsomes assessed as metabolite M1 formation preincubated for 30 mins in presence of NADPH, UDPGA and GSH","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860538,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699796,100,Ratio of IC50 for human PI3Kdelta-mediated AKT phosphorylation at S473 in Ri-1 cells to IC50 for PI3Kdelta,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860540,20200625,"57506734,59605427","163317370,163331225",5293,NULL,O00329,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,2.7.1.153,O00329,NULL
699798,100,Metabolic stability in rat liver microsomes,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860542,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699799,100,Metabolic stability in human liver microsomes,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860543,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699800,100,"Volume of distribution at steady state in hairless Wistar rat at 0.5 mg/kg, iv and 2 mg/kg, po","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860544,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699801,100,"Clearance in hairless Wistar rat at 0.5 mg/kg, iv and 2 mg/kg, po","Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860545,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699802,100,Oral bioavailability in hairless Wistar rat at 2 mg/kg,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860546,20200625,"24937010,46239494","163327677,163327678",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699803,100,Ratio of Kinact to Ki for human CYP3A4,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860547,20200625,"24937010,46239494","163327677,163327678",1576,NULL,P08684,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
699804,100,Selectivity ratio of IC50 for PI3Kgamma to IC50 for PI3Kdelta,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860548,20200625,"11634899,17755052,24937010,24937637,46239494,49834039,49834218,57494011,57506723,57506726,57506727,57506732,57506741,57506743,57506744,59606002,60165513,60165514,60165805","103605815,163313941,163313964,163317371,163317372,163317373,163320840,163320841,163320842,163320843,163320844,163320845,163320864,163324216,163327677,163327678,163327679,163331205,163331206",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699806,100,Selectivity ratio of IC50 for PI3Kbeta to IC50 for PI3Kdelta,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860550,20200625,"11634899,17755052,24937010,24937637,46239494,49834039,49834218,57494011,57506723,57506726,57506727,57506732,57506741,57506743,57506744,59606002,60165513,60165514,60165805","103605815,163313941,163313964,163317371,163317372,163317373,163320840,163320841,163320842,163320843,163320844,163320845,163320864,163324216,163327677,163327678,163327679,163331205,163331206",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699927,100,Selectivity ratio of IC50 for PI3Kalpha to IC50 for PI3Kdelta,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860671,20200625,"11634899,17755052,24937010,24937637,46239494,49820826,49820977,49832773,49832939,49833295,49834039,49834218,57494011,57506723,57506726,57506727,57506732,57506734,57506735,57506736,57506737,57506739,57506741,57506743,57506744,59605427,59606002,60165513,60165514,60165805","103605815,163313939,163313940,163313941,163313964,163317370,163317371,163317372,163317373,163320838,163320839,163320840,163320841,163320842,163320843,163320844,163320845,163320862,163320863,163320864,163324216,163327677,163327678,163327679,163331205,163331206,163331225,163331226,163338083,163338104",NULL,NULL,NULL,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,NULL,NULL,NULL
699928,2,Binding affinity to PI3Kdelta after 30 mins by competitive fluorescence polarization assay,"Title: Discovery of novel PI3-kinase &#xCE;&#xB4; specific inhibitors for the treatment of rheumatoid arthritis: taming CYP3A4 time-dependent inhibition._|__|_Abstract: PI3K&#x3B4; is a lipid kinase and a member of a larger family of enzymes, PI3K class IA(&#x3B1;, &#x3B2;, &#x3B4;) and IB (&#x3B3;), which catalyze the phosphorylation of PIP2 to PIP3. PI3K&#x3B4; is mainly expressed in leukocytes, where it plays a critical, nonredundant role in B cell receptor mediated signaling and provides an attractive o",43,ChEMBL,860672,20200625,"11634899,17755052,24937010,24937637,46239494,49820826,49820977,49832773,49832939,49833295,49834039,49834218,57494011,57506723,57506726,57506727,57506732,57506734,57506735,57506736,57506737,57506739,57506741,57506743,57506744,59605427,59606002,60165513,60165514,60165805","103605815,163313939,163313940,163313941,163313964,163317370,163317371,163317372,163317373,163320838,163320839,163320840,163320841,163320842,163320843,163320844,163320845,163320862,163320863,163320864,163324216,163327677,163327678,163327679,163331205,163331206,163331225,163331226,163338083,163338104",5293,NULL,O00329,Curation Efforts|Research and Development,22626259,0,10.1021/jm3003747,2.7.1.153,O00329,NULL
1075101,2,Time-dependent inhibition of recombinant rat FAAH expressed in Escherichia coli assessed as breakdown of [14C]-oleamide preincubated for 6 hrs by Dixon plot analysis,"Title: Design, synthesis, and characterization of &#xCE;&#xB1;-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase._|__|_Abstract: A series of &#x3B1;-ketooxazoles incorporating electrophiles at the C5 position of the pyridyl ring of 2 (OL-135) and related compounds were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269. From this series, a subset of the candidate inhibitors exhibited time",43,ChEMBL,1296376,20200620,"10427006,71665477,71665478,76310897,76314536,76318113,76325440,76328981,76328983,76332655,76332657,76332658,76332659,76336259,76336260,76336262","103439500,194140314,194147180,194154052,194154053,194154054,194167951,194174755,194174757,194181643,194181645,194181646,194181647,194188469,194188470,194188472","29347,100911581",NULL,P97612,Curation Efforts|Research and Development,24456116,0,10.1021/jm401820q,"3.1.1.-,3.5.1.99",P97612,NULL
1075102,2,Time-dependent inhibition of recombinant rat FAAH expressed in Escherichia coli assessed as breakdown of [14C]-oleamide preincubated for 3 hrs by Dixon plot analysis,"Title: Design, synthesis, and characterization of &#xCE;&#xB1;-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase._|__|_Abstract: A series of &#x3B1;-ketooxazoles incorporating electrophiles at the C5 position of the pyridyl ring of 2 (OL-135) and related compounds were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269. From this series, a subset of the candidate inhibitors exhibited time",43,ChEMBL,1296377,20200620,"10427006,71665477,71665478,76310897,76314536,76318113,76321804,76325440,76328981,76328983,76328985,76332655,76332656,76332657,76332658,76332659,76336259,76336260,76336262","103439500,194140314,194147180,194154052,194154053,194154054,194161028,194167951,194174755,194174757,194174759,194181643,194181644,194181645,194181646,194181647,194188469,194188470,194188472","29347,100911581",NULL,P97612,Curation Efforts|Research and Development,24456116,0,10.1021/jm401820q,"3.1.1.-,3.5.1.99",P97612,NULL
1075103,2,Time-dependent inhibition of recombinant rat FAAH expressed in Escherichia coli assessed as breakdown of [14C]-oleamide preincubated for 1 hr by Dixon plot analysis,"Title: Design, synthesis, and characterization of &#xCE;&#xB1;-ketoheterocycles that additionally target the cytosolic port Cys269 of fatty acid amide hydrolase._|__|_Abstract: A series of &#x3B1;-ketooxazoles incorporating electrophiles at the C5 position of the pyridyl ring of 2 (OL-135) and related compounds were prepared and examined as inhibitors of fatty acid amide hydrolase (FAAH) that additionally target the cytosolic port Cys269. From this series, a subset of the candidate inhibitors exhibited time",43,ChEMBL,1296378,20200620,"10427006,71665477,71665478,76310897,76318113,76321804,76328981,76328983,76332658,76332659,76336259,76336260,76336262","103439500,194140314,194154052,194154053,194154054,194161028,194174755,194174757,194181646,194181647,194188469,194188470,194188472","29347,100911581",NULL,P97612,Curation Efforts|Research and Development,24456116,0,10.1021/jm401820q,"3.1.1.-,3.5.1.99",P97612,NULL
1134306,100,Time-dependent inhibition of 20beta-hydroxy steroid dehydrogenase in Streptomyces hydrogenans assessed as inhibition of cortisone production at 50 uM,"Title: Synthesis of medroxyprogesterone bromoacetate for affinity labeling._|__|_Abstract: Medroxyprogesterone bromoacetate (17alpha-hydroxy-6alpha-methyl-4-pregnene-3,20-dione 17-bromoacetate) was synthesized by reaction of 17alpha-hydroxy-6alpha-methyl-4-pregnene-3,20-dione with bromoacetic acid--trifluoroacetic anhydride followed by treatment of the intermediate with dilute ethanolic HBr. The product forms conjugates with L-cysteine, L-histidine, and L-methionine and inactivates 20beta-hydroxy steroid de",43,ChEMBL,1347281,20181003,90672808,242627964,NULL,NULL,P19992,Curation Efforts|Research and Development,874959,0,10.1021/jm00216a019,1.1.1.53,P19992,NULL
1153218,2,Displacement of [3H]-PGD2 from human CRTH2 expressed in HEK293 cells in buffer solution with 0.5% bovine serum albumin by scintillation counting,"Title: Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP._|__|_Abstract: Based on their structural similarity to previously described compound AMG 009, indole-phenyl acetic acids were proposed to be potent dual inhibitors of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2) and prostanoid D receptor (DP or DP1). This series was equipotent to AMG 009 in binding assays against both receptors ",43,ChEMBL,1364476,20181004,"10483360,25106870,25106871,59864915,67242411,90479860,90644206,90644207,90644208,90644209","103705008,242645860,242645861,242645862,242645863,242645864,242645865,242645866,242645867,242645868",11251,NULL,Q9Y5Y4,Curation Efforts|Research and Development,24825301,0,10.1016/j.bmcl.2014.04.092,NULL,Q9Y5Y4,NULL
1153219,2,Displacement of [3H]-PGD2 from human CRTH2 expressed in HEK293 cells in presence of 50% human plasma by scintillation counting,"Title: Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP._|__|_Abstract: Based on their structural similarity to previously described compound AMG 009, indole-phenyl acetic acids were proposed to be potent dual inhibitors of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2) and prostanoid D receptor (DP or DP1). This series was equipotent to AMG 009 in binding assays against both receptors ",43,ChEMBL,1364477,20181004,"25106870,25106871,59864915,67242411,90479860,90644206,90644207,90644208,90644209","242645860,242645861,242645862,242645863,242645864,242645865,242645866,242645867,242645868",11251,NULL,Q9Y5Y4,Curation Efforts|Research and Development,24825301,0,10.1016/j.bmcl.2014.04.092,NULL,Q9Y5Y4,NULL
1153220,2,Displacement of [3H]-PGD2 from human DP receptor expressed in HEK293 cells in buffer solution with 0.5% bovine serum albumin by scintillation counting,"Title: Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP._|__|_Abstract: Based on their structural similarity to previously described compound AMG 009, indole-phenyl acetic acids were proposed to be potent dual inhibitors of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2) and prostanoid D receptor (DP or DP1). This series was equipotent to AMG 009 in binding assays against both receptors ",43,ChEMBL,1364478,20181004,"10483360,25106870,25106871,59864915,67242411,90479860,90644206,90644207,90644208,90644209","103705008,242645860,242645861,242645862,242645863,242645864,242645865,242645866,242645867,242645868",5729,NULL,Q13258,Curation Efforts|Research and Development,24825301,0,10.1016/j.bmcl.2014.04.092,NULL,Q13258,NULL
1153221,2,Displacement of [3H]-PGD2 from human DP receptor expressed in HEK293 cells in presence of 50% human plasma by scintillation counting,"Title: Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP._|__|_Abstract: Based on their structural similarity to previously described compound AMG 009, indole-phenyl acetic acids were proposed to be potent dual inhibitors of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2) and prostanoid D receptor (DP or DP1). This series was equipotent to AMG 009 in binding assays against both receptors ",43,ChEMBL,1364479,20181004,"25106870,25106871,59864915,67242411,90479860,90644206,90644207,90644208,90644209","242645860,242645861,242645862,242645863,242645864,242645865,242645866,242645867,242645868",5729,NULL,Q13258,Curation Efforts|Research and Development,24825301,0,10.1016/j.bmcl.2014.04.092,NULL,Q13258,NULL
1153222,100,Drug metabolism in human liver microsomes assessed CYP3A4-mediated compound-GSH adduct formation,"Title: Solving time-dependent CYP3A4 inhibition for a series of indole-phenylacetic acid dual antagonists of the PGD(2) receptors CRTH2 and DP._|__|_Abstract: Based on their structural similarity to previously described compound AMG 009, indole-phenyl acetic acids were proposed to be potent dual inhibitors of chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2 or DP2) and prostanoid D receptor (DP or DP1). This series was equipotent to AMG 009 in binding assays against both receptors ",43,ChEMBL,1364480,20181004,90644207,242645860,1576,NULL,P08684,Curation Efforts|Research and Development,24825301,0,10.1016/j.bmcl.2014.04.092,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1190262,2,Antiproliferative activity against human A2780 cells after 72 hrs by SRB method,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462153,20181006,"68276577,68277248,68277935,71726495,71727460,71727683,71727801,71727928,71728054,71728058,71818876,89785082,89793496,89793516,89793519,89793535,89795476,89795479,89795484,89795501,89795553,89795596,89795599,89795666,89795715,89795796,90012681,90012714,118160922,118193528,118193544,118726259,118726260","174487940,174518843,174518845,174518847,312378096,312378097,312378098,312378099,312378100,312378101,312378102,312378103,312378104,312378105,312378106,312378107,312378108,312378109,312378110,312378111,312378112,312378113,312378114,312378115,312378116,312378117,312378118,312378119,312378120,312378121,312378122,312378123,312378124",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190265,2,Kinetic solubility of the compound in aqueous buffer at pH 7.4 after 24 hrs,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462156,20181006,"68276577,68277248,68277611,68277935,71726495,71727460,71727683,71727801,71727928,71728054,71728058,71818876,89785082,89793496,89793516,89793519,89793535,89795476,89795479,89795484,89795501,89795553,89795596,89795599,89795666,89795715,89795796,90012681,90012714,118160922,118193528,118193544,118726259,118726260","174487940,174493111,174518843,174518845,174518847,312378096,312378097,312378098,312378099,312378100,312378101,312378102,312378103,312378104,312378105,312378106,312378107,312378108,312378109,312378110,312378111,312378112,312378113,312378114,312378115,312378116,312378117,312378118,312378119,312378120,312378121,312378122,312378123,312378124",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190266,2,Thermodynamic solubility of the compound in aqueous buffer at pH 7.4 after 24 hrs,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462157,20181006,"68277611,71728054,89793496,89793516,89795553","174493111,312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190267,100,Apparent permeability from apical to basolateral side in MDCK cells,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462158,20181006,"68276577,68277248,68277935,71726495,71727460,71727683,71727801,71727928,71728054,71728058,71818876,89785082,89793496,89793516,89793519,89793535,89795476,89795479,89795484,89795501,89795553,89795596,89795599,89795666,89795715,89795796,90012681,90012714,118160922,118193528,118193544,118726259,118726260","174487940,174518843,174518845,174518847,312378096,312378097,312378098,312378099,312378100,312378101,312378102,312378103,312378104,312378105,312378106,312378107,312378108,312378109,312378110,312378111,312378112,312378113,312378114,312378115,312378116,312378117,312378118,312378119,312378120,312378121,312378122,312378123,312378124",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190268,100,Apparent permeability from basolateral to apical side in MDCK cells,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462159,20181006,"68276577,68277248,68277935,71726495,71727460,71727683,71727801,71727928,71728054,71728058,71818876,89785082,89793496,89793516,89793519,89793535,89795476,89795479,89795484,89795501,89795553,89795596,89795599,89795666,89795715,89795796,90012681,90012714,118160922,118193528,118193544,118726259,118726260","174487940,174518843,174518845,174518847,312378096,312378097,312378098,312378099,312378100,312378101,312378102,312378103,312378104,312378105,312378106,312378107,312378108,312378109,312378110,312378111,312378112,312378113,312378114,312378115,312378116,312378117,312378118,312378119,312378120,312378121,312378122,312378123,312378124",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190277,100,Fraction unbound in human plasma,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462168,20200625,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190278,100,Fraction unbound in rat plasma,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462169,20200625,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190279,100,Fraction unbound in dog plasma,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462170,20200625,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190280,100,Fraction unbound in mouse plasma,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462171,20200625,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190281,100,"Clearance in rat at 1 mg/kg, iv","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462172,20181006,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190282,100,"Clearance in dog at 1 mg/kg, iv","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462173,20181006,"71728054,89793516","312378117,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190283,100,"Half life in rat at 1 mg/kg, iv","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462174,20181006,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190284,100,"Half life in dog at 1 mg/kg, iv","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462175,20181006,"71728054,89793516","312378117,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190285,100,"Volume of distribution at steady state in rat at 1 mg/kg, iv","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462176,20181006,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190286,100,"Volume of distribution at steady state in dog at 1 mg/kg, iv","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462177,20181006,"71728054,89793516","312378117,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190287,100,"AUC in rat at 5 mg/kg, po","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462178,20181006,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190288,100,"AUC in dog at 5 mg/kg, po","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462179,20181006,"71728054,89793516","312378117,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190289,2,"Cmax in rat at 5 mg/kg, po","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462180,20181006,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190290,2,"Cmax in dog at 5 mg/kg, po","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462181,20181006,"71728054,89793516","312378117,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190291,100,Oral bioavailability in rat at 5 mg/kg,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462182,20181006,"71728054,89793496,89793516,89795553","312378107,312378117,312378119,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190292,100,Oral bioavailability in dog at 5 mg/kg,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462183,20181006,"71728054,89793516","312378117,312378121",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190293,2,Antiproliferative activity against human HT1080 cells after 72 hrs by SRB method,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462184,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190294,100,Antiproliferative activity against human HT1080 cells after 72 hrs by SRB method in presence on NMN,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462185,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190295,2,Antiproliferative activity against human PC3 cells after 72 hrs by SRB method,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462186,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190296,100,Antiproliferative activity against human PC3 cells after 72 hrs by SRB method in presence on NMN,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462187,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190297,2,Antiproliferative activity against human HCT116 cells after 72 hrs by SRB method,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462188,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190298,100,Antiproliferative activity against human HCT116 cells after 72 hrs by SRB method in presence on NMN,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462189,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190300,100,"Toxicity in NCR mouse xenografted with human HT1080 cells assessed as body weight loss at 50 mg/kg, po bid administered for 5 days measured after 16 days","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462191,20181006,89793516,312378121,NULL,Toxicity,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190301,100,"Antitumor activity against human HT1080 cells xenografted in NCR mouse at 50 mg/kg, po bid administered for 5 days measured after 16 days relative to vehicle-treated control","Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462192,20200625,89793516,312378121,NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1190302,100,Antiproliferative activity against human A2780 cells after 72 hrs by SRB method in presence on NMN,"Title: Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility._|__|_Abstract: Herein we report the optimization efforts to ameliorate the potent CYP3A4 time-dependent inhibition (TDI) and low aqueous solubility exhibited by a previously identified lead compound from our NAMPT inhibitor program (1, GNE-617). Metabolite identification studies pinpointed the imidazopyridine moiety present in 1 as the likel",43,ChEMBL,1462193,20181006,"68276577,68277248,68277935,71726495,71727460,71727683,71727801,71727928,71728054,71728058,71818876,89785082,89793496,89793516,89793519,89793535,89795476,89795479,89795484,89795501,89795553,89795596,89795599,89795666,89795715,89795796,90012681,90012714,118160922,118193528,118193544,118726259,118726260","174487940,174518843,174518845,174518847,312378096,312378097,312378098,312378099,312378100,312378101,312378102,312378103,312378104,312378105,312378106,312378107,312378108,312378109,312378110,312378111,312378112,312378113,312378114,312378115,312378116,312378117,312378118,312378119,312378120,312378121,312378122,312378123,312378124",NULL,NULL,NULL,Curation Efforts|Research and Development,25556090,0,10.1016/j.bmcl.2014.12.026,NULL,NULL,NULL
1215383,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes at 10 uM measured after 1.5 min in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1482957,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215384,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as enzyme remaining activity at 10 uM measured after 1.5 min in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1482958,20200624,9830209,312466424,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215385,2,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1482959,20200624,"60663,9830209","103229908,312466424",1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215386,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent glutathione,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492279,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215387,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent semicarbazide,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492280,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215388,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent potassium cyanide,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492281,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215389,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent methyl hydroxylamine,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492282,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215390,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent N-acetyl cysteine,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492283,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215391,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent N-acetyl lysine,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492284,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215392,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent superoxide dismutase,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492285,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215393,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent catalase,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492286,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215394,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH and 1 mM nucleophilic trapping agent dimethyl pyrroline N-oxide,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492287,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215395,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as decrease in CYP3A4-CO binding at 10 uM preincubated for 5 mins measured after 12 hrs by LC-tandem mass spectrometry analysis in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492288,20200624,"60663,9830209","103229908,312466424",1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215396,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as decrease in CYP3A4-CO binding at 10 uM preincubated for 5 mins measured after overnight washout with 100 mM potassium phosphate buffer by LC-tandem mass spectrometry an,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492289,20200624,"60663,9830209","103229908,312466424",1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215399,100,Inhibition of recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as decrease in heme level at 10 uM preincubation for 5 mins by LC/UV/MS analysis in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492292,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1217710,100,Covalent binding in human liver microsomes measured per mg of protein using radiolabelled compound at 10 uM after 1 hr incubation by liquid scintillation counting,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489419,20181007,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,392622,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103192563,103195217,103211583,103219094,103219164,103244854,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",NULL,NULL,NULL,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,NULL,NULL,NULL
1217711,100,Metabolic activation in human liver microsomes assessed as [3H]GSH adduct formation rate measured per mg of protein at 100 uM by [3H]GSH trapping assay,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489420,20181007,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,392622,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103192563,103195217,103211583,103219094,103219164,103244854,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",NULL,NULL,NULL,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,NULL,NULL,NULL
1217727,100,Intrinsic clearance for reactive metabolites formation per mg of protein in human liver microsomes based on [3H]GSH adduct formation rate at 100 uM by [3H]GSH trapping assay,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489436,20181007,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,392622,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103192563,103195217,103211583,103219094,103219164,103244854,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",NULL,NULL,NULL,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,NULL,NULL,NULL
1217728,100,Intrinsic clearance for reactive metabolites formation per mg of protein based on cytochrome P450 (unknown origin) inactivation rate by TDI assay,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489437,20181007,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,392622,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103192563,103195217,103211583,103219094,103219164,103244854,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",NULL,NULL,NULL,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,NULL,NULL,NULL
1217729,100,Intrinsic clearance for reactive metabolites formation assessed as summation of [3H]GSH adduct formation rate-based reactive metabolites formation and cytochrome P450 (unknown origin) inactivation rate-based reactive metabolites formation,"Title: Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites._|__|_Abstract: Covalent binding (CB) of reactive metabolites (RMs) is potentially involved in severe adverse drug reactions. Because the CB assay is of low throughput and costly, a qualitative trapping assay using agents such as [(35)S]GSH is often performed in the early stages of drug discovery. However, trapping methods alone cannot replace the CB assay. We hypoth",43,ChEMBL,1489438,20181007,"1775,1935,1983,2162,2165,2333,2519,2520,2554,2662,3033,3121,3152,3386,3397,3440,3696,3715,4463,4829,4913,4946,5329,5472,5717,5733,5991,6009,12560,38409,54687,60606,60823,60846,77999,149096,158781,392622,2733526,54678486,135398737,135398745","103163840,103164240,103164546,103164951,103165325,103165562,103165728,103165751,103165765,103166276,103167682,103170100,103172304,103172342,103175312,103177753,103177883,103178971,103178995,103181002,103181943,103183576,103184980,103189005,103190631,103191369,103192563,103195217,103211583,103219094,103219164,103244854,103292815,103513016,103532317,103554720,103558519,103724173,104234145,104234199,104234246,123083185",NULL,NULL,NULL,Curation Efforts|Research and Development,21467212,0,10.1124/dmd.111.039180,NULL,NULL,NULL
1231898,100,"Net efflux ratio, ratio of efflux ratio of pig LLC-PK1 cells expressing MDR1 to efflux ratio of wild type pig LLC-PK1 cells at 1 uM after 3 hrs by LC/MS/MS analysis","Title: Optimization of 2,4-diamino-5-fluoropyrimidine derivatives as protein kinase C theta inhibitors with mitigated time-dependent drug-drug interactions and P-gp liability._|__|_Abstract: Protein kinase C theta (PKC&#x3B8;) plays a critical role in T cell signaling and has therapeutic potential for T cell-mediated diseases such as transplant rejection and rheumatoid arthritis. Here, a series of 2,4-diamino-5-fluoropyrimidine derivatives were prepared and evaluated for their inhibition of PKC&#x3B8;. Of t",43,ChEMBL,1500452,20200624,"68665038,122180028,122180029,122180030,122180031,122180032,122180033,122180034,122180035,122180036,122180037,122180038,122180039,122180040,122180041","318375076,318375077,318375078,318375079,318375080,318375081,318375082,318375083,318375084,318375085,318375086,318375087,318375088,318375089,318375090",NULL,NULL,NULL,Curation Efforts|Research and Development,25982074,0,10.1016/j.bmc.2015.04.050,NULL,NULL,NULL
1250081,100,Drug metabolism in human hepatocytes at 5 mM by LC/MS analysis,Title: Probing Mechanisms of CYP3A Time-Dependent Inhibition Using a Truncated Model System._|__|_Abstract: Time-dependent inhibition (TDI) of cytochrome P450 (CYP) enzymes may incur serious undesirable drug-drug interactions and in rare cases drug-induced idiosyncratic toxicity. The reactive metabolites are often generated through multiple sequential biotransformations and form adducts with CYP enzymes to inactivate their function. The complexity of these processes makes addressing TDI liability very chall,43,ChEMBL,1520080,20200624,71539661,318392658,NULL,NULL,NULL,Curation Efforts|Research and Development,26288695,0,10.1021/acsmedchemlett.5b00191,NULL,NULL,NULL
1275222,100,"Time dependent inhibition of recombinant Trypanosoma brucei trypanothione reductase preincubated for 10 mins in presence of NADPH, tryparedoxin, T(SH)2 followed by addition of hydrogen peroxide","Title: Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase._|__|_Abstract: A number of phenothiazine-, phenoxazine- and related tricyclics-derived chloroacetamides were synthesized and evaluated in vitro for antiprotozoal activities against Leishmania major (L. major) promastigotes. Several analogs were remarkably potent inhibitors, with antileishmanial activities being comparable or superior to those of the r",43,ChEMBL,1552579,20180905,"69920,127026790","124966335,336867920",NULL,NULL,P39051,Curation Efforts|Research and Development,26708110,0,10.1016/j.ejmech.2015.11.023,1.8.1.12,P39051,NULL
1275223,100,"Time dependent inhibition of Trypanosoma brucei tryparedoxin peroxidase preincubated for 10 mins in presence of NADPH, tryparedoxin, T(SH)2 followed by addition of hydrogen peroxide","Title: Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase._|__|_Abstract: A number of phenothiazine-, phenoxazine- and related tricyclics-derived chloroacetamides were synthesized and evaluated in vitro for antiprotozoal activities against Leishmania major (L. major) promastigotes. Several analogs were remarkably potent inhibitors, with antileishmanial activities being comparable or superior to those of the r",43,ChEMBL,1552580,20180905,"69920,127026790","124966335,336867920",NULL,NULL,Q9GU47,Curation Efforts|Research and Development,26708110,0,10.1016/j.ejmech.2015.11.023,NULL,Q9GU47,NULL
1275224,2,"Time dependent inhibition of recombinant Trypanosoma brucei trypanothione reductase preincubated with protein for 10 to 180 mins followed by NADPH, trypanothione disulphide addition","Title: Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase._|__|_Abstract: A number of phenothiazine-, phenoxazine- and related tricyclics-derived chloroacetamides were synthesized and evaluated in vitro for antiprotozoal activities against Leishmania major (L. major) promastigotes. Several analogs were remarkably potent inhibitors, with antileishmanial activities being comparable or superior to those of the r",43,ChEMBL,1552581,20180905,"69920,3304561,10632580,10803696,127026790","124966335,134463544,163332025,336865603,336867920",NULL,NULL,P39051,Curation Efforts|Research and Development,26708110,0,10.1016/j.ejmech.2015.11.023,1.8.1.12,P39051,NULL
1423407,100,"Anti-alzheimer activity in rat assessed as reduction in amyloid beta40 levels in cerebrospinal fluid at 10 mg/kg, po relative to control","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797912,20200619,"71457203,145981185,145982062,145987073,145992760,145993306","163328281,404698837,404700176,404707408,404716283,404717132",NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423408,100,"Anti-alzheimer activity in rat assessed as reduction in amyloid beta40 levels in cerebrospinal fluid at 30 mg/kg, po relative to control","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797913,20200619,"71492530,145980015,145994215","336899268,404697029,404718691",NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423409,100,"AUC (0 to infinity) in Han Wistar rat at 10 mg/kg, po","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797914,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423410,2,"Cmax in Han Wistar rat at 10 mg/kg, po","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797915,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423411,100,Oral bioavailability in Han Wistar rat at 10 mg/kg,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797916,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423412,100,"Clearance in Han Wistar rat at 2 mg/kg, iv","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797917,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423413,100,"Volume of distribution at steady state in Han Wistar rat at 2 mg/kg, iv","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797918,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423414,100,"Half life in Han Wistar rat at 2 mg/kg, iv","Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797919,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423415,100,Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated oxidative defluorinated metabolite formation at 20 uM after 60 min in presence of NADPH by LC-HRMS analysis,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797920,20200619,71457203,163328281,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423416,100,Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated N-demethylated oxidative defluorinated metabolite formation at 20 uM after 60 min in presence of NADPH by LC-HRMS analysis,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797921,20200619,71457203,163328281,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423417,100,Drug metabolism in human liver microsomes assessed as CYP3A4 -mediated N-demethylated oxidative defluorinated metabolite formation at 20 uM after 60 min in presence of NADPH and GSH by LC-HRMS analysis,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797922,20200619,71457203,163328281,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423420,100,Protein binding in rat plasma,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797925,20200619,145992760,404716283,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
1423421,100,Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated oxidative defluorinated metabolite formation at 20 uM after 60 min in presence of NADPH and GSH by LC-HRMS analysis,"Title: Overcoming Time-Dependent Inhibition (TDI) of Cytochrome P450 3A4 (CYP3A4) Resulting from Bioactivation of a Fluoropyrimidine Moiety._|__|_Abstract: Herein we describe structure-activity relationship (SAR) and metabolite identification (Met-ID) studies that provided insight into the origin of time-dependent inhibition (TDI) of cytochrome P450 3A4 (CYP3A4) by compound 1. Collectively, these efforts revealed that bioactivation of the fluoropyrimidine moiety of 1 led to reactive metabolite formation via",43,ChEMBL,1797926,20200619,71457203,163328281,NULL,NULL,NULL,Curation Efforts|Research and Development,30388368,0,10.1021/acs.jmedchem.8b01326,NULL,NULL,NULL
88433,100,"Compound was tested for time dependent inhibition of hexokinase activity after 6 hr, at 0 degrees celsius, with 10 mM ATP derivative in yeast hexokinase","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85621,20181002,53807650,312366013,NULL,NULL,NULL,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,NULL,NULL,NULL
88434,100,"Compound was tested for time dependent inhibition of hexokinase activity after 6 hr, at 0 degrees celsius, with 10 mM ATP derivative in yeast hexokinase","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85622,20181002,5957,103176950,NULL,NULL,NULL,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,NULL,NULL,NULL
88435,100,"Time dependent inhibition of hexokinase activity after 6 hr, at 0 degrees celsius, with 10 mM ATP derivative in yeast.","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85623,20181002,"73348320,73351397,73351398,90655755,90674931,118718966,118718969,118718970,118718972,118718973,118718975,118718976,118718977,118718978,118718979,118718981,118718983,118718986,118718987,118718989","174494821,174505243,174505244,242632283,242632285,312365999,312366002,312366003,312366005,312366006,312366008,312366009,312366010,312366011,312366012,312366015,312366017,312366021,312366022,312366024",NULL,NULL,NULL,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,NULL,NULL,NULL
88436,100,"Compound was tested for time dependent inhibition of hexokinase activity after 6 h at 0 degrees celsius, with 10 mM compound in yeast hexokinase","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85624,20181002,"118718974,118718980","312366007,312366014",NULL,NULL,NULL,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,NULL,NULL,NULL
88437,100,"Compound was tested for time dependent inhibition of hexokinase activity after 6 hr, at 0 degrees celsius, with 10 mM ATP derivative in yeast hexokinase","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85625,20181002,"118718967,118718971,118718988","312366000,312366004,312366023",NULL,NULL,NULL,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,NULL,NULL,NULL
88441,100,"Time dependent inhibition of Hexokinase type III activity after 6 hr, at 0 degrees celsius, at 10 mM compound","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85629,20181002,"53807650,90655755,90674931","242632283,242632285,312366013",25060,NULL,P27926,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,2.7.1.1,P27926,NULL
88442,100,"Time dependent inhibition of Hexokinase type III activity after 6 h, at 0 degrees celsius, at 10 mM","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85630,20181002,"5957,53856279,73348320,73351397,73351398,118718966,118718967,118718968,118718969,118718970,118718971,118718973,118718974,118718975,118718976,118718977,118718978,118718979,118718980,118718981,118718983,118718986,118718987,118718988,118718989,118718991,118718992","103176950,174494821,174500046,174505243,174505244,312365999,312366000,312366001,312366002,312366003,312366004,312366006,312366007,312366008,312366009,312366010,312366011,312366012,312366014,312366015,312366017,312366021,312366022,312366023,312366024,312366026,312366027",25060,NULL,P27926,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,2.7.1.1,P27926,NULL
88446,100,"Time dependent inhibition of Hexokinase type I activity after 6 h, at 0 degrees celsius, at 10 mM compound","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85634,20181002,"5957,53807650,53856279,73348320,73351397,73351398,90655755,90674931,118718966,118718967,118718968,118718969,118718970,118718971,118718973,118718975,118718976,118718977,118718978,118718979,118718980,118718981,118718983,118718986,118718987,118718988,118718989,118718991,118718992","103176950,174494821,174500046,174505243,174505244,242632283,242632285,312365999,312366000,312366001,312366002,312366003,312366004,312366006,312366008,312366009,312366010,312366011,312366012,312366013,312366014,312366015,312366017,312366021,312366022,312366023,312366024,312366026,312366027",25058,NULL,P05708,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,2.7.1.1,P05708,NULL
88447,100,"Time dependent inhibition of Hexokinase, type I activity after 6 h, at 0 degrees celsius, at 10 mM compound","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85635,20181002,118718974,312366007,25058,NULL,P05708,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,2.7.1.1,P05708,NULL
88451,100,"Time dependent inhibition of hexokinase 2 activity after 6 h, at 10 mM compound","Title: Use of adenine nucleotide derivatives to assess the potential of exo-active-site-directed reagents as species- or isozyme-specific enzyme inactivators. 5. Interactions of adenosine 5'-triphosphate derivatives with rat pyruvate kinases, Escherichia coli thymidine kinase, and yeast and rat hexokinases._|__|_Abstract: Adenosine 5'-triphosphate (ATP) derivatives of the types N6-R-ATP [R = (CH2)nNHCOCH2I, (CH2)nNHCO-(CH2)mNHCOCH2I, or (CH2)nCON(Me)(CH2)mN(Me)CO(CH2)nNHCOCH2I], N6-Me-N6-R-ATP [R = (CH2)nN-",43,ChEMBL,85639,20181002,"5957,53807650,53856279,73348320,73351397,73351398,90655755,90674931,118718966,118718967,118718968,118718969,118718970,118718971,118718973,118718974,118718975,118718976,118718977,118718978,118718979,118718980,118718981,118718983,118718986,118718987,118718988,118718989,118718991,118718992","103176950,174494821,174500046,174505243,174505244,242632283,242632285,312365999,312366000,312366001,312366002,312366003,312366004,312366006,312366007,312366008,312366009,312366010,312366011,312366012,312366013,312366014,312366015,312366017,312366021,312366022,312366023,312366024,312366026,312366027",25059,NULL,P27881,Curation Efforts|Research and Development,7040662,0,10.1021/jm00346a011,2.7.1.1,P27881,NULL
150886,100,Effect on the time of half-inactivation of ornithine decarboxylase at 10 uM concentration,Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,148133,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
150887,100,Effect on the time of half-inactivation of ornithine decarboxylase in the presence of 10 uM concentration + 1 mM D-2-methylornithine,Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,148134,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
150888,100,Effect on the time of half-inactivation of ornithine decarboxylase in the presence of 10 uM concentration + 1 mM L-2-methylornithine,Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,148135,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
150889,100,Effect on the time of half-inactivation of ornithine decarboxylase in the presence of 10 uM concentration + 1 mM L-ornithine,Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,148136,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
632539,100,Time-dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone at 10 uM after 30 mins,"Title: Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines._|__|_Abstract: The discovery and SAR of a novel series of spirocyclic renin inhibitors are described herein. It was found that by restricting the northern aromatic plate to the bioactive conformation through spirocyclization, increase in renin potency and decrease in hERG affinity could both be realized. When early members of this series were found to be potent time-dependent CYP3",43,ChEMBL,789987,20180920,"42641334,50905013,56837192,57390807,57390808,57390809,57392623,57392624,57394339,57394340,57394341,57394342,57394343,57394344,57394345,57396095,57396096,57396097,57396098,57396099,57396100,57397916,57399556,57401306,57401307,57401308,57401309,57403067","136920728,136921930,136921931,136921932,136925234,136925235,136928464,136928465,136928466,136928467,136928468,136928469,136928470,136928471,136931677,136931678,136931679,136931680,136931681,136931682,136935140,136938245,136941469,136941470,136941471,136941472,136941473,136944674",1576,NULL,P08684,Curation Efforts|Research and Development,22071301,0,10.1016/j.bmcl.2011.10.013,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
638629,100,Time dependent inhibition of Clostridium botulinum BoNT/A light chain-mediated SNAP-25 substrate cleavage by FRET assay,"Title: Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors._|__|_Abstract: Botulinum neurotoxins (BoNTs) are the most lethal of biological substances, and are categorized as class A biothreat agents by the Centers for Disease Control and Prevention. There are currently no drugs to treat the deadly flaccid paralysis resulting from BoNT intoxication. Among the seven BoNT serotypes, the development of therapeutics to counter BoNT/A is a priority (due to its long half-life in the neuronal ",43,ChEMBL,796077,20200626,50943150,136945886,NULL,NULL,P10845,Curation Efforts|Research and Development,22082667,0,10.1016/j.bmc.2011.10.062,3.4.24.69,P0DPI0,NULL
641653,100,Time dependent inhibition of CYP3A4,"Title: Discovery of potent and specific CXCR3 antagonists._|__|_Abstract: The optimization of a series of 8-aza-quinazolinone analogs for antagonist activity against the CXCR3 receptor is reported. Compounds were optimized to avoid the formation of active metabolites and time-dependent-inhibitors of CYP3A4. In addition, antagonists showed potent against CXCR3 activity in whole blood and optimized to avoid activity in the chromosomal aberration assay. Compound 25 was identified as having the optimal balance ",43,ChEMBL,799101,20180921,"46883311,57392002,57400685,57402460,57402461","103744215,136924020,136940279,136943459,136943460",1576,NULL,P08684,Curation Efforts|Research and Development,22130135,0,10.1016/j.bmcl.2011.10.120,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
748510,100,Time-dependent inhibition of wild type human COX2 expressed in insect cells using [1-14C]-arachidonic acid as substrate assessed as remaining activity at 25000 nM measured for 30 secs by thin layer chromatographic analysis,"Title: The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor._|__|_Abstract: Indomethacin is a potent, time-dependent, nonselective inhibitor of the cyclooxygenase enzymes (COX-1 and COX-2). Deletion of the 2'-methyl group of indomethacin produces a weak, reversible COX inhibitor, leading us to explore functionality at that position. Here, we report that substitution of the 2'-methyl group of indomethacin with trifluoromethyl produces CF3-indomethacin, a tight-binding inh",43,ChEMBL,961939,20200629,71655553,174501412,5743,NULL,P35354,Curation Efforts|Research and Development,23687559,0,10.1021/ml400066a,1.14.99.1,P35354,NULL
1206956,100,Time-dependent inhibition of 6-His-N-terminal tagged human PTP1B expressed in Escherichia coli BL21 (DE3) cells using pNPP as substrate treated with compound prior to substrate addition by plate reader analysis,"Title: Is RK-682 a promiscuous enzyme inhibitor? Synthesis and in vitro evaluation of protein tyrosine phosphatase inhibition of racemic RK-682 and analogues._|__|_Abstract: RK-682 (1) is a natural product known to selectively inhibit protein tyrosine phosphatases (PTPases) and is used commercially as a positive control for phosphatase inhibition in in vitro assays. Protein phosphatases are involved in several human diseases including diabetes, cancer and inflammation, and are considered important targets f",43,ChEMBL,1476534,20181006,"54685915,54697955,118737612","103535742,312394058,312394059",5770,NULL,P18031,Curation Efforts|Research and Development,25938987,0,10.1016/j.ejmech.2015.04.036,3.1.3.48,P18031,NULL
1215382,2,Binding affinity to CYP3A4 (unknown origin),"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1482956,20200624,"60663,9830209","103229908,312466424",1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215397,100,Binding affinity to recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as metabolite intermediate complex formation at 10 uM for 0 to 45 mins by UV-spectrometry,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492290,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215398,100,Effect on CYP3A4 (unknown origin) apoprotein formation at 10 uM pre-incubated for 3 mins by mass spectrometry analysis in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492291,20200624,"5035,60663","103170049,103229908",1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215400,100,Effect on recombinant CYP3A4 (unknown origin) expressed in baculosomes assessed as heme level LC/UV/MS analysis in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492293,20200624,5035,103170049,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1215401,100,Ratio of Kinact to Ki for recombinant CYP3A4 (unknown origin) expressed in baculosomes in presence of 1 mM NADPH,"Title: Mechanism-based inactivation of cytochrome P450 3A4 by mibefradil through heme destruction._|__|_Abstract: Mibefradil (Posicor) was developed as a calcium channel blocker for the treatment of chronic hypertension. The compound was withdrawn from the market in 1998 because of the potential for rhabdomyolysis, renal failure, or bradycardia when it was coadministered with other drugs. Mibefradil has previously been shown to be a potent reversible (IC(50) = 0.3-2 &#x3BC;M) and mechanism-based (K(i) = 2.3",43,ChEMBL,1492294,20200624,60663,103229908,1576,NULL,P08684,Curation Efforts|Research and Development,21447734,0,10.1124/dmd.111.038505,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1450582,2,Time dependent inhibition of CYP2C8 in human liver microsomes after 5 mins by LC-MS/MS analysis,"Title: Glucuronides as Potential Anionic Substrates of Human Cytochrome P450 2C8 (CYP2C8)._|__|_Abstract: Glucuronidation is in general considered as a terminal metabolic step that leads to direct elimination of drugs and generally abolishes their biological activity. However, there is growing evidence to suggest that glucuronides can be ligands of human CYP2C8, making CYP2C8 distinct from the other CYP isoforms. Several classes of glucuronide conjugates, which include acyl glucuronides, ether glucuronides,",43,ChEMBL,1668616,20200621,137631529,381836726,NULL,NULL,NULL,Curation Efforts|Research and Development,28653847,0,10.1021/acs.jmedchem.7b00510,NULL,NULL,NULL
1209425,2,Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by ATP detection based assay,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481981,20200625,"65126,2733526","103170100,103618754",NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209426,100,Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 24 hrs by LDH release assay,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481982,20200625,"65126,2733526","103170100,103618754",NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209427,2,Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by LDH release assay,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481983,20200625,"65126,2733526","103170100,103618754",NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209428,100,Induction of apoptosis in human hepatocytes assessed as caspase 3/7 activation by caspase-Glo 3/7 assay,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481984,20200625,"65126,2733526","103170100,103618754",NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209429,100,Induction of CYP3A4 mRNA expression in human hepatocytes at 10 uM after 48 hrs relative to untreated control,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481985,20200625,65126,103618754,NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209430,100,Induction of CYP2B6 mRNA expression in human hepatocytes at 10 uM after 48 hrs relative to untreated control,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481986,20200625,65126,103618754,NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209431,100,Induction of SULT2A1 mRNA expression in human hepatocytes at 10 uM after 48 hrs relative to untreated control,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481987,20200625,65126,103618754,NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209440,2,Inhibition of CYP2C9 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1481996,20200625,65126,103618754,1559,NULL,P11712,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1209441,100,Cytotoxicity against human hepatocytes assessed as loss of nuclei after 24 hrs at 50 to 100 uM,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1483573,20200625,65126,103618754,NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209442,100,Cytotoxicity against human hepatocytes assessed as cytoplasm granulation with vacuoles after 24 hrs at 50 to 100 uM,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1483574,20200625,65126,103618754,NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209443,100,Cytotoxicity against human hepatocytes assessed as cell viability after 24 hrs at 100 uM by ATP detection based assay,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1483575,20200625,65126,103618754,NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209444,2,Cytotoxicity against human hepatocytes assessed as reduction in cell viability after 4 hrs by ATP detection based assay,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1483576,20200625,"65126,2733526","103170100,103618754",NULL,NULL,NULL,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,NULL,NULL,NULL
1209445,2,Inhibition of CYP3A4 activity in human hepatocytes after 30 mins by liquid chromatography/tandem mass spectroscopy,"Title: In vitro hepatotoxicity and cytochrome P450 induction and inhibition characteristics of carnosic acid, a dietary supplement with antiadipogenic properties._|__|_Abstract: Carnosic acid is a phenolic diterpene isolated from rosemary (Rosmarinus officinalis), which may have anticancer, antiadipogenic, and anti-inflammatory properties. Recently, carnosic acid was shown to prevent weight gain and hepatic steatosis in a mouse model of obesity and type II diabetes. Based on these results, carnosic acid has",43,ChEMBL,1489768,20200625,65126,103618754,1576,NULL,P08684,Curation Efforts|Research and Development,22531045,0,10.1124/dmd.112.044909,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1356612,100,Time dependent inhibition of human CDK12 incubated for 0 to 5 hrs using ULight-4E-BP1 (Thr37/Thr46) substrate by LANCE system based assay,Title: Discovery of 3-Benzyl-1-( trans-4-((5-cyanopyridin-2-yl)amino)cyclohexyl)-1-arylurea Derivatives as Novel and Selective Cyclin-Dependent Kinase 12 (CDK12) Inhibitors._|__|_Abstract: Cyclin-dependent kinase 12 (CDK12) plays a key role in the coordination of transcription with elongation and mRNA processing. CDK12 mutations found in tumors and CDK12 inhibition sensitize cancer cells to DNA-damaging reagents and DNA-repair inhibitors. This suggests that CDK12 inhibitors are potential therapeutics for ca,43,ChEMBL,1735973,20200618,"118025540,134813906","404662345,404663629",NULL,NULL,NULL,Curation Efforts|Research and Development,30067358,0,10.1021/acs.jmedchem.8b00683,NULL,NULL,NULL
1479495,100,Time-dependent inhibition of human CYP2D6 at 2 uM using fluorogenic substrate by fluorometric method,"Title: Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor._|__|_Abstract: Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via intravenous route. With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivatives were prepared and screened for Cdk inhibition ",43,ChEMBL,1697620,20200622,137628639,381865418,NULL,NULL,NULL,Curation Efforts|Research and Development,29370702,0,10.1021/acs.jmedchem.7b01765,NULL,NULL,NULL
1479496,100,Time-dependent inhibition of human CYP2C9 at 2 uM using fluorogenic substrate by fluorometric method,"Title: Discovery and Preclinical Development of IIIM-290, an Orally Active Potent Cyclin-Dependent Kinase Inhibitor._|__|_Abstract: Rohitukine (1), a chromone alkaloid isolated from Indian medicinal plant Dysoxylum binectariferum, has inspired the discovery of flavopiridol and riviciclib, both of which are bioavailable only via intravenous route. With the objective to address the oral bioavailability issue of this scaffold, four series of rohitukine derivatives were prepared and screened for Cdk inhibition ",43,ChEMBL,1697621,20200622,137628639,381865418,NULL,NULL,NULL,Curation Efforts|Research and Development,29370702,0,10.1021/acs.jmedchem.7b01765,NULL,NULL,NULL
50457,100,Second order rate constant for the inactivation of cathepsin B at pH 6.0 was reported; No time dependent inhibition observed,"Title: Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases._|__|_Abstract: Aziridine derivatives of E-64 have been synthesized, and their characterization against the cysteine proteases cathepsin B, cathepsin L, and papain is reported. The inhibition was found to be strongly pH-dependent, with maximum activity observed at pH 4, indicating that the protonated aziridinium ion form of the inhibitor is the more reactive form. At low pH, the p",43,ChEMBL,47601,20181014,73350039,174500241,64529,NULL,P00787,Curation Efforts|Research and Development,7636871,0,10.1021/jm00016a011,3.4.22.1,P00787,NULL
155424,100,Second order rate constant for the inactivation of papain at pH 6.5 was reported; No time dependent inhibition observed,"Title: Aziridine analogs of [[trans-(epoxysuccinyl)-L-leucyl]amino]-4-guanidinobutane (E-64) as inhibitors of cysteine proteases._|__|_Abstract: Aziridine derivatives of E-64 have been synthesized, and their characterization against the cysteine proteases cathepsin B, cathepsin L, and papain is reported. The inhibition was found to be strongly pH-dependent, with maximum activity observed at pH 4, indicating that the protonated aziridinium ion form of the inhibitor is the more reactive form. At low pH, the p",43,ChEMBL,152678,20181014,11741460,174505422,110813108,NULL,P00784,Curation Efforts|Research and Development,7636871,0,10.1021/jm00016a011,3.4.22.2,P00784,NULL
156763,2,Tested for time independent inhibition constant against porcine pepsin,"Title: Synthesis of analogues of pepstatin. Effect of structure in subsites P1', P2', and P2 on inhibition of porcine pepsin._|__|_Abstract: A series of pepstatin analogues having structural variations in the P2', P1', and P2 positions have been synthesized and tested for inhibition of porcine pepsin. The standard peptide for this study was Iva-Sta-Val-Ala-Iaa. Structural variations in the P2' and P1' positions have relatively little effect on Ki; however, small variations in the P2 position have a more dra",43,ChEMBL,154017,20181002,"444340,44382862,44382866,44383445,44383502,44383576,44383883,44384134,44384372,44384508","103217528,103429343,103429352,103430493,103430608,103430726,103431370,103431898,103432343,103432602",396892,NULL,P00791,Curation Efforts|Research and Development,6406670,0,10.1021/jm00360a022,3.4.23.1,P00791,NULL
402402,2,Inhibition of COX2-catalyzed prostaglandin biosynthesis after 10 mins of preincubation,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550431,20181024,"3672,3715,4553,10494,64945,156391","103163840,103165236,103174500,103210646,103324264,103350986",5743,NULL,P35354,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,1.14.99.1,P35354,NULL
402403,2,Inhibition of COX1-catalyzed prostaglandin biosynthesis 10 mins of preincubation,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550432,20181024,"3672,3715,4553,10494,64945,156391","103163840,103165236,103174500,103210646,103324264,103350986",5742,NULL,P23219,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,1.14.99.1,P23219,NULL
402404,100,Ratio of IC50 for COX2 to IC50 for COX1,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550433,20200704,"3672,3715,4553,10494,64945,156391","103163840,103165236,103174500,103210646,103324264,103350986",NULL,NULL,NULL,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,NULL,NULL,NULL
402405,100,Inhibition of COX1-catalyzed prostaglandin biosynthesis at 100 ug/ml without preincubation,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550434,20181024,64945,103350986,5742,NULL,P23219,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,1.14.99.1,P23219,NULL
402406,100,Inhibition of COX1-catalyzed prostaglandin biosynthesis at 200 ug/ml without preincubation,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550435,20181024,64945,103350986,5742,NULL,P23219,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,1.14.99.1,P23219,NULL
402407,100,Increase in inhibition of COX2-catalyzed prostaglandin biosynthesis at 100 ug/ml after 10 mins of preincubation,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550436,20181024,64945,103350986,5743,NULL,P35354,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,1.14.99.1,P35354,NULL
402408,100,Increase in inhibition of COX2-catalyzed prostaglandin biosynthesis at 200 ug/ml after 10 mins of preincubation,"Title: Ursolic acid from Plantago major, a selective inhibitor of cyclooxygenase-2 catalyzed prostaglandin biosynthesis._|__|_Abstract: A hexane extract of Plantago major was investigated by bioactivity-directed fractionation, using an in vitro cyclooxygenase-2 (COX-2) catalyzed prostaglandin biosynthesis inhibition assay, and resulted in the isolation of ursolic acid (1). This triterpenoid showed a significant COX-2 inhibitory effect, directly on the enzyme activity, with an IC50 value of 130 microM and a ",43,ChEMBL,550437,20181024,64945,103350986,5743,NULL,P35354,Curation Efforts|Research and Development,9784154,0,10.1021/np980088i,1.14.99.1,P35354,NULL
1365115,2,Time-dependent inhibition of recombinant human N-terminal His-tagged JAK3 catalytic domain (795 to 1124 residues) expressed in sf21 cells using biotinylated peptide substrate after 1 hr by DELFIA,"Title: Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting._|__|_Abstract: Janus kinases (JAKs) are a family of four cytosolic protein kinases with a high degree of structural similarity. Due to its very restricted role in immune regulation, JAK3 was promoted as an excellent target for immunosuppression for more than a decade, but clinical validation of this concept is still elusive. During the last years, speculation arose that kinase activity of JAK1, which cooperates wi",43,ChEMBL,1744503,20200618,11416425,404676596,NULL,NULL,NULL,Curation Efforts|Research and Development,28844493,0,10.1016/j.bmcl.2017.07.079,NULL,NULL,NULL
1365116,2,Time-dependent inhibition of recombinant human N-terminal His-tagged JAK2 (826 to 1132 residues) expressed in sf21 cells using biotinylated peptide substrate after 1 hr by DELFIA,"Title: Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting._|__|_Abstract: Janus kinases (JAKs) are a family of four cytosolic protein kinases with a high degree of structural similarity. Due to its very restricted role in immune regulation, JAK3 was promoted as an excellent target for immunosuppression for more than a decade, but clinical validation of this concept is still elusive. During the last years, speculation arose that kinase activity of JAK1, which cooperates wi",43,ChEMBL,1744504,20200618,11416425,404676596,NULL,NULL,NULL,Curation Efforts|Research and Development,28844493,0,10.1016/j.bmcl.2017.07.079,NULL,NULL,NULL
1482798,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as time for maximum reduction in LPA 18:2 at 3 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700931,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482820,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as time for maximum reduction in LPA 18:2 at 10 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700953,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482821,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as time for maximum reduction in LPA 18:2 at 30 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700954,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
56742,2,In vitro inhibition against hog kidney diamine oxidase,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,53889,20181012,14049939,103230585,26,In vitro,P19801,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,1.4.3.22,P19801,NULL
150883,2,In vitro inhibition against ornithine decarboxylase,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,148130,20181012,"126431,14049939,44293141","103217862,103230225,103230585",24609,In vitro,P09057,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,4.1.1.17,P09057,NULL
202893,2,In vitro inhibition against rat aorta semicarbazide-sensitive amine oxidase,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,200172,20200628,14049939,103230585,NULL,NULL,NULL,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,NULL,NULL,NULL
754750,100,Time dependent inhibition of CYP3A4 (unknown origin) expressed in baculovirus-infected insect cell microsomes,"Title: Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery._|__|_Abstract: Calcitonin gene-related peptide (CGRP) receptor antagonists have been shown to be efficacious as abortive migraine therapeutics with the absence of cardiovascular liabilities that are associated with t",43,ChEMBL,969011,20180927,53472683,174491756,1576,NULL,P08684,Curation Efforts|Research and Development,23632269,0,10.1016/j.bmcl.2013.04.012,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
774103,100,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as remaining activity at 10 uM preincubated for 12 mins by HPLC-MS/MS analysis relative to control,"Title: Discovery of a novel series of potent non-nucleoside inhibitors of hepatitis C virus NS5B._|__|_Abstract: Hepatitis C virus (HCV) is a major global public health problem. While the current standard of care, a direct-acting antiviral (DAA) protease inhibitor taken in combination with pegylated interferon and ribavirin, represents a major advancement in recent years, an unmet medical need still exists for treatment modalities that improve upon both efficacy and tolerability. Toward those ends, much eff",43,ChEMBL,984597,20180928,"44601452,44624151,44624488,49784695,59156709,67070065","174488584,174498772,174509155,174519322,174519323,174524591",1576,NULL,P08684,Curation Efforts|Research and Development,24069953,0,10.1021/jm401266k,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1154355,100,Time dependent inhibition of Mycobacterium smegmatis recombinant DprE1 using farnesylphosphoryl-beta-D-ribofuranose as substrate assessed as conversion of amplex red to resorufin at 4.6 to 3333 nM,"Title: 4-aminoquinolone piperidine amides: noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity._|__|_Abstract: 4-Aminoquinolone piperidine amides (AQs) were identified as a novel scaffold starting from a whole cell screen, with potent cidality on Mycobacterium tuberculosis (Mtb). Evaluation of the minimum inhibitory concentrations, followed by whole genome sequencing of mutants raised against AQs, identified decaprenylphosphoryl-&#x3B2;-d-ribose 2'-epimerase (DprE1",43,ChEMBL,1365797,20200618,90644462,242649583,NULL,NULL,NULL,Curation Efforts|Research and Development,24871036,0,10.1021/jm5005978,NULL,NULL,NULL
1200285,100,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate up to 100 uM by LC/MS/MS analysis,"Title: Synthesis, SAR, and series evolution of novel oxadiazole-containing 5-lipoxygenase activating protein inhibitors: discovery of 2-[4-(3-{(r)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-N,N-dimethyl-acetamide (BI 665915)._|__|_Abstract: The synthesis, structure-activity relationship (SAR), and evolution of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are described. The use of structure-guided drug design ",43,ChEMBL,1472065,20181006,66764813,312390293,1576,NULL,P08684,Curation Efforts|Research and Development,25671290,0,10.1021/jm501185j,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1444662,2,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated with enzyme in presence of NADPH followed by substrate addition,"Title: Sulfonamides as Selective NaV1.7 Inhibitors: Optimizing Potency, Pharmacokinetics, and Metabolic Properties to Obtain Atropisomeric Quinolinone (AM-0466) that Affords Robust in Vivo Activity._|__|_Abstract: Because of its strong genetic validation, NaV1.7 has attracted significant interest as a target for the treatment of pain. We have previously reported on a number of structurally distinct bicyclic heteroarylsulfonamides as NaV1.7 inhibitors that demonstrate high levels of selectivity over other Na",43,ChEMBL,1662668,20200620,"86344136,86344330,86344510,117737118,117739617,117748926,117749324,124221798,124221975","374294738,374312073,374313943,374320480,374322655,374325102,374329820,374341892,374355010",NULL,NULL,NULL,Curation Efforts|Research and Development,28324649,0,10.1021/acs.jmedchem.6b01850,NULL,NULL,NULL
1456326,100,Time dependent inhibition of recombinant human PTP1B (1 to 322 residues) expressed in Escherichia coli at 0.47 uM using pNPP as substrate preincubated with enzyme for 60 mins by UV-spectrophotometric method,"Title: Competitive protein tyrosine phosphatase 1B (PTP1B) inhibitors, prenylated caged xanthones from Garcinia hanburyi and their inhibitory mechanism._|__|_Abstract: Protein tyrosine phosphatase 1B (PTP1B) plays important role in diabetes, obesity and cancer. The methanol extract of the gum resin of Garcinia hanburyi (G. hanburyi) showed potent PTP1B inhibition at 10&#xB5;g/ml. The active compounds were identified as prenylated caged xanthones (1-9) which inhibited PTP1B in dose-dependent manner. Carboxyb",43,ChEMBL,1688190,20200621,9852185,103687631,NULL,NULL,NULL,Curation Efforts|Research and Development,28318895,0,10.1016/j.bmc.2017.03.010,NULL,NULL,NULL
1464935,100,Antagonist activity at human histamine H1 receptor expressed in CHO cells assessed as slower-compound washout time for inhibition of histamine-induced intracellular calcium mobilization pretreated for 30 mins followed by subsequent histamine addition at 9,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696842,20200622,"137634700,137637727,137646948,137659034","381841487,381846040,381859706,381883040",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464936,100,Antagonist activity at human histamine H1 receptor expressed in CHO cells assessed as faster-compound washout time for inhibition of histamine-induced intracellular calcium mobilization pretreated for 30 mins followed by subsequent histamine addition at 9,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696843,20200622,25190435,381853272,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1482819,100,"Time at which plasma concentration reach in vitro mouse plasma IC50 in C57BL/6Rj mouse at 3 mg/kg, po administered as single dose via gavage","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700952,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
23587,100,Pharmacokinetic parameter half life was determined,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,20708,20181012,14049939,103230585,NULL,NULL,NULL,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,NULL,NULL,NULL
23588,100,Pharmacokinetic parameter half life was determined,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,20709,20181012,"126431,44293141","103217862,103230225",NULL,NULL,NULL,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,NULL,NULL,NULL
33221,100,The compound was evaluated for in Vitro binding of AFB1 to DNA in rat liver microsomes; Pre-incubation time being 10 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,30350,20180930,"14005,390798,5280343,5355836","103167027,103173414,103183744,103292922",26760,In vitro,P38918,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,1.-.-.-,P38918,NULL
33222,100,The compound was evaluated for in Vitro binding of AFB1 to DNA in rat liver microsomes; Pre-incubation time being 20 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,30351,20180930,"14005,390798,5280343,5355836","103167027,103173414,103183744,103292922",26760,In vitro,P38918,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,1.-.-.-,P38918,NULL
33223,100,The compound was evaluated for in Vitro binding of AFB1 to DNA in rat liver microsomes; Pre-incubation time being 30 mins,"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,30352,20180930,"14005,390798,5280343,5355836","103167027,103173414,103183744,103292922",26760,In vitro,P38918,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,1.-.-.-,P38918,NULL
95401,100,The compound was tested for the inhibitory activity against L-orinithine carboxylase at 12.5 mg/kg dose; Not Determined,Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92595,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95402,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat testis at dose 25 mg/kg, ip); Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92596,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95403,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat testis at dose 50 mg/kg, ip); Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92597,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95404,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat testis at dose 12.5 mg/kg, ip; Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92598,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95405,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat thymus at dose 25 mg/kg, ip); Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92599,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95406,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat thymus at dose 50 mg/kg, ip); Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92600,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95407,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in ventral prostate of the rat at dose 25 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92601,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95408,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in ventral prostate of the rat at dose 50 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92602,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95409,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in ventral prostate of the rat at dose 12.5 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92603,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95410,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat testis. dose 200 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92604,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95411,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat testis at dose 100 mg/kg, ip); Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92605,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95412,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat thymus at dose 100 mg/kg, ip); Not Determined",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92606,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95413,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in rat thymus. dose 200 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92607,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95414,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase in ventral prostate of the rat dose 200 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92608,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
95415,100,"The compound was tested for the inhibitory activity against L-orinithine carboxylase inventral prostate of the rat at dose 100 mg/kg, ip)",Title: alpha-Ethynyl and alpha-vinyl analogues of ornithine as enzyme-activated inhibitors of mammalian ornithine decarboxylase._|__|_Abstract: alpha-Ethynyl- and alpha-vinylornithine were designed and synthesized as potential enzyme-activated inhibitors of mammalian ornithine decarboxylase. These two new inhibitors produce both immediate and time-dependent inhibition of rat liver ornithine decarboxylase in vitro. The inhibitions exhibition saturation kinetics. The apparent dissociation constants (KI) are 1,43,ChEMBL,92609,20181001,9834021,103251505,24609,NULL,P09057,Curation Efforts|Research and Development,7205870,0,10.1021/jm00133a005,4.1.1.17,P09057,NULL
150878,100,Half inactivation of ODC at 5 uM concentration,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,148125,20181012,14049939,103230585,24609,NULL,P09057,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,4.1.1.17,P09057,NULL
150879,100,Half inactivation of ODC at 5 uM concentration along with 1 mM L-methylornithine,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,148126,20181012,14049939,103230585,24609,NULL,P09057,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,4.1.1.17,P09057,NULL
150880,100,Half inactivation of ODC at 5 uM concentration along with 1 mM L-ornithine,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,148127,20181012,14049939,103230585,24609,NULL,P09057,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,4.1.1.17,P09057,NULL
199923,100,Association constant against S-adenosyl-L-methionine decarboxylase,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,197197,20200628,14049939,103230585,262,NULL,P17707,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,4.1.1.50,P17707,NULL
199924,2,Association constant against S-adenosyl-L-methionine-decarboxylase,"Title: 2,2-Difluoro-5-hexyne-1,4-diamine: a potent enzyme-activated inhibitor of ornithine decarboxylase._|__|_Abstract: 2,2-Difluoro-5-hexyne-1,4-diamine was prepared in an eight-step sequence from ethyl 2,2-difluoro-4-pentenoate and tested as an inhibitor of mammalian ornithine decarboxylase. It produces a time-dependent inhibition of the enzyme in vitro which shows saturation kinetics, with KI = 10 microM and tau 1/2 = 2.4 min. In rats, it produces a rapid, long-lasting, and dose-dependent decrease of or",43,ChEMBL,197198,20181012,1045,103229337,262,NULL,P17707,Curation Efforts|Research and Development,2909729,0,10.1021/jm00121a031,4.1.1.50,P17707,NULL
603397,100,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone at 10 uM relative to control,Title: Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines._|__|_Abstract: An SAR campaign aimed at decreasing the overall lipophilicity of renin inhibitors such as 1 is described herein. It was found that replacement of the northern appendage in 1 with an N-methyl pyridone and subsequent re-optimization of the benzyl amide handle afforded compounds with in vitro and in vivo profiles suitable for further profiling. An unexpected C,43,ChEMBL,753407,20180919,"44462719,44473168,44479308,44479309,44479310,44479563,44479566,44479809,44481065,44481067,44481316,44481318,44481321,44481860,44481861,44481862,44482139,44482409,44512857,54580283,56659572,56660076,56663526,56663528,56666970,56668837,56669910,56670429,56673420,56673914,56676730,56677248,56683392,56683889,56683890","131272660,134436725,134437743,134440631,134440632,134441619,134441620,134441626,134441627,134441628,134445401,134445421,134445422,134445423,134445424,134445425,134445426,134448345,134448346,134449378,134452230,134453233,134456019,134457036,134459819,134459820,134460850,134463648,134463649,134463650,134463651,134464644,134464645,134464646,134464647",1576,NULL,P08684,Curation Efforts|Research and Development,21621998,0,10.1016/j.bmcl.2011.05.013,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
603587,2,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone preincubated for 30 mins,Title: Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines._|__|_Abstract: An SAR campaign aimed at decreasing the overall lipophilicity of renin inhibitors such as 1 is described herein. It was found that replacement of the northern appendage in 1 with an N-methyl pyridone and subsequent re-optimization of the benzyl amide handle afforded compounds with in vitro and in vivo profiles suitable for further profiling. An unexpected C,43,ChEMBL,753597,20180919,44462719,134445422,1576,NULL,P08684,Curation Efforts|Research and Development,21621998,0,10.1016/j.bmcl.2011.05.013,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
603588,2,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone,Title: Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of pyridone-substituted piperidines._|__|_Abstract: An SAR campaign aimed at decreasing the overall lipophilicity of renin inhibitors such as 1 is described herein. It was found that replacement of the northern appendage in 1 with an N-methyl pyridone and subsequent re-optimization of the benzyl amide handle afforded compounds with in vitro and in vivo profiles suitable for further profiling. An unexpected C,43,ChEMBL,753598,20180919,44462719,134445422,1576,NULL,P08684,Curation Efforts|Research and Development,21621998,0,10.1016/j.bmcl.2011.05.013,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
655816,100,Time dependent inhibition of CYP3A4 upto 50 uM,"Title: Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer._|__|_Abstract: Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-p",43,ChEMBL,812888,20180921,16654980,160699332,1576,NULL,P08684,Curation Efforts|Research and Development,24900266,0,10.1021/ml200156t,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
655817,100,Time dependent inhibition of CYP2C9 upto 50 uM,"Title: Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer._|__|_Abstract: Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-p",43,ChEMBL,812889,20180921,16654980,160699332,1559,NULL,P11712,Curation Efforts|Research and Development,24900266,0,10.1021/ml200156t,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
655818,100,Time dependent inhibition of CYP2D6 upto 50 uM,"Title: Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer._|__|_Abstract: Phosphoinositide-3-kinases (PI3Ks) are important oncology targets due to the deregulation of this signaling pathway in a wide variety of human cancers. Herein we describe the structure guided optimization of a series of 2-morpholino, 4-substituted, 6-heterocyclic pyrimidines where the pharmacokinetic properties were improved by modulating the electronics of the 6-p",43,ChEMBL,812890,20180921,16654980,160699332,1565,NULL,P10635,Curation Efforts|Research and Development,24900266,0,10.1021/ml200156t,1.14.14.-,P10635,NULL
711829,100,Time dependent inhibition of Pseudomonas aeruginosa aryl sulfatase at 20 to 200 mM by spectrophotometry,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,879572,20180924,"71457686,71459595","163329001,163332593",879288,NULL,P51691,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,P51691,NULL
711832,100,Time dependent inhibition of Klebsiella pneumoniae aryl sulfatase assessed as QM-adduct formation at 5 mM by MALDI-ToF mass spectrometry,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,879575,20180924,145948343,163336002,NULL,NULL,Q9X759,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,Q9X759,NULL
711833,100,Time dependent inhibition of Pseudomonas aeruginosa aryl sulfatase assessed as QM-adduct formation at 5 mM by MALDI-ToF mass spectrometry,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,879576,20180924,145948343,163336002,879288,NULL,P51691,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,P51691,NULL
711835,100,Time dependent inhibition of human aryl sulfatase G at 0.1 uM to 1000 uM by para-nitrocatechol sulfate-based colorimetric assay,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,879578,20180924,145948343,163336002,22901,NULL,Q96EG1,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,Q96EG1,NULL
711836,100,Time dependent inhibition of Klebsiella pneumoniae aryl sulfatase at 5 uM to 500 uM by para-nitrocatechol sulfate-based colorimetric assay,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,879579,20180924,145948343,163336002,NULL,NULL,Q9X759,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,Q9X759,NULL
711837,100,Time dependent inhibition of Pseudomonas aeruginosa aryl sulfatase at 10 nM to 1000000 nM by para-nitrocatechol sulfate-based colorimetric assay,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,879580,20180924,145948343,163336002,879288,NULL,P51691,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,P51691,NULL
712530,100,Time dependent inhibition of Klebsiella pneumoniae aryl sulfatase at 20 to 200 mM by spectrophotometry,"Title: Evaluation of sulfatase-directed quinone methide traps for proteomics._|__|_Abstract: Sulfatases hydrolytically cleave sulfate esters through a unique catalytic aldehyde, which is introduced by a posttranslational oxidation. To profile active sulfatases in health and disease, activity-based proteomic tools are needed. Herein, quinone methide (QM) traps directed against sulfatases are evaluated as activity-based proteomic probes (ABPPs). Starting from a p-fluoromethylphenyl sulfate scaffold, enzymatic",43,ChEMBL,880273,20180924,"71457686,71459595","163329001,163332593",NULL,NULL,Q9X759,Curation Efforts|Research and Development,21570853,0,10.1016/j.bmc.2011.04.044,3.1.6.1,Q9X759,NULL
715557,100,Time-dependent inhibition of cytochrome P450,"Title: Discovery of tetrahydropyridopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia._|__|_Abstract: We describe the discovery of potent and orally bioavailable tetrahydropyridopyrimidine inhibitors of phosphodiesterase 10A by systematic optimization of a novel HTS lead. Lead compound THPP-1 exhibits nanomolar potencies, excellent pharmacokinetic properties, and a clean off-target profile. It displays in vivo target engagement as measured by increased rat striatal cGMP levels u",43,ChEMBL,883300,20180924,49821991,163339280,NULL,NULL,NULL,Curation Efforts|Research and Development,22892116,0,10.1016/j.bmcl.2012.07.072,NULL,NULL,NULL
732413,2,Time-dependent inhibition of CYP3A4 in human liver microsome using midazolam as substrate by TDI shift assay,"Title: Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349._|__|_Abstract: Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathwa",43,ChEMBL,944981,20180926,"44815590,59239077,59239114,59239165,59239348,59239424,67178880,67276455","163328661,164129045,164129046,164134724,164137576,164137578,164140374,164148754",1576,NULL,P08684,Curation Efforts|Research and Development,24900569,0,10.1021/ml3003132,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1058544,100,Mean residence time in beagle dog,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277644,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058550,100,Mean residence time in monkey,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277650,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058553,100,"Mean residence time in Sprague-Dawley rat at 0.5 mg/kg, iv and 2 mg/kg, po","Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277653,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1213958,100,Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487052,20200624,"42641863,118753201","136939844,312466663",1544,NULL,P05177,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,"1.14.14.1,4.2.1.152",P05177,NULL
1213959,100,Time dependent inhibition of CYP2B6 in human liver microsomes using bupropion as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487053,20181007,"42641863,118753201","136939844,312466663",1555,NULL,P20813,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,1.14.13.-,P20813,NULL
1213960,100,Time dependent inhibition of CYP2C8 in human liver microsomes using paclitaxel as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487054,20181007,"42641863,118753201","136939844,312466663",1558,NULL,P10632,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,1.14.14.1,P10632,NULL
1213961,100,Time dependent inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487055,20181007,"42641863,118753201","136939844,312466663",1559,NULL,P11712,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1213962,100,Time dependent inhibition of CYP2C19 in human liver microsomes using (S)-Mephenytoin as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487056,20181007,"42641863,118753201","136939844,312466663",1557,NULL,P33261,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1213963,100,Time dependent inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487057,20181007,"42641863,118753201","136939844,312466663",1565,NULL,P10635,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,1.14.14.-,P10635,NULL
1213964,100,Time dependent inhibition of CYP2E1 in human liver microsomes using chlorzoxazone as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487058,20181007,"42641863,118753201","136939844,312466663",1571,NULL,P05181,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,"1.14.13.n7,1.14.14.1",P05181,NULL
1213965,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate at 10 uM by LC-MS/MS analysis,"Title: Predicting the drug interaction potential of AMG 853, a dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors._|__|_Abstract: 2-(4-(4-(tert-Butylcarbamoyl)-2-(2-chloro-4-cyclopropylphenylsulfonamido)phenoxy)-5-chloro-2-fluorophenyl)acetic acid (AMG 853) is an orally bioavailable and potent dual antagonist of the D-prostanoid and chemoattractant receptor-homologous molecule expressed on T helper 2 cells receptors. The drug interact",43,ChEMBL,1487059,20181007,"42641863,118753201","136939844,312466663",1576,NULL,P08684,Curation Efforts|Research and Development,22930276,0,10.1124/dmd.112.047928,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1242792,100,Time dependent inhibition of CYP3A4 (unknown origin) at 50 uM,"Title: Discovery of novel triazolobenzazepinones as &#xCE;&#xB3;-secretase modulators with central A&#xCE;&#xB2;42 lowering in rodents and rhesus monkeys._|__|_Abstract: Synthesis and SAR studies of novel triazolobenzazepinones as gamma secretase modulators (GSMs) are presented in this communication. Starting from our azepinone leads, optimization studies toward improving central lowering of A&#x3B2;42 led to the discovery of novel benzo-fused azepinones. Several benzazepinones were profiled in vivo and fou",43,ChEMBL,1512253,20200624,59472574,318386330,1576,NULL,P08684,Curation Efforts|Research and Development,26212776,0,10.1016/j.bmcl.2015.07.003,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1267488,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of pyrazolopyrimidine phosphodiesterase 10A inhibitors for the treatment of schizophrenia._|__|_Abstract: Herein, we present the identification of a novel class of pyrazolopyrimidine phosphodiesterase 10A (PDE10A) inhibitors. Beginning with a lead molecule (1) identified through a fragment-based drug discovery (FBDD) effort, lead optimization was enabled by rational design, X-ray crystallography, metabolic and off-target profiling, and fragment scaffold-hopping. We highlight the discovery o",43,ChEMBL,1544081,20180904,76903477,318454501,1576,NULL,P08684,Curation Efforts|Research and Development,26602277,0,10.1016/j.bmcl.2015.11.013,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1305417,100,Time-dependent inhibition of human kidney type glutaminase (124 to 669 residues) using L-[3H]-glutamine as substrate by topcount method,"Title: Allosteric Glutaminase Inhibitors Based on a 1,4-Di(5-amino-1,3,4-thiadiazol-2-yl)butane Scaffold._|__|_Abstract: A series of allosteric kidney-type glutaminase (GLS) inhibitors were designed and synthesized using 1,4-di(5-amino-1,3,4-thiadiazol-2-yl)butane as a core scaffold. A variety of modified phenylacetyl groups were incorporated into the 5-amino group of the two thiadiazole rings in an attempt to facilitate additional binding interactions with the allosteric binding site of GLS. Among the newl",43,ChEMBL,1582439,20180906,"71577426,118657427","318438757,336906903",2744,NULL,O94925,Curation Efforts|Research and Development,27200176,0,10.1021/acsmedchemlett.6b00060,3.5.1.2,O94925,NULL
1458410,100,Time dependent inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells assessed as decrease in H2O2 production at 50 nM after 15 mins by amplex red-based fluorescence assay,"Title: Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?_|__|_Abstract: Because of the lack of significant disease-modifying drugs for neurodegenerative disorders, a pressing need for new chemical entities endowed with IMAO-B still exists. Within this framework, and for the first time, a study was performed to compare coumarin- and chomone-3-phenylcarboxamide scaffolds. Compounds 10a and 10b were the most potent, selective, and reversible noncompetitive IMAO-B. The benzopyrone sp2 oxygen a",43,ChEMBL,1690276,20200621,26757,103252336,NULL,NULL,NULL,Curation Efforts|Research and Development,28753307,0,10.1021/acs.jmedchem.7b00918,NULL,NULL,NULL
1458414,100,Time dependent inhibition of human recombinant microsomal MAOB expressed in baculovirus infected BTI-TN-5B1- 4 cells assessed as decrease in H2O2 production at 200 nM after 15 mins by amplex red-based fluorescence assay,"Title: Coumarin versus Chromone Monoamine Oxidase B Inhibitors: Quo Vadis?_|__|_Abstract: Because of the lack of significant disease-modifying drugs for neurodegenerative disorders, a pressing need for new chemical entities endowed with IMAO-B still exists. Within this framework, and for the first time, a study was performed to compare coumarin- and chomone-3-phenylcarboxamide scaffolds. Compounds 10a and 10b were the most potent, selective, and reversible noncompetitive IMAO-B. The benzopyrone sp2 oxygen a",43,ChEMBL,1690280,20200621,3052776,103233337,NULL,NULL,NULL,Curation Efforts|Research and Development,28753307,0,10.1021/acs.jmedchem.7b00918,NULL,NULL,NULL
66491,2,In vitro inhibition of Human Leukocyte Elastase (HLE),"Title: Inhibition of human leukocyte elastase. 2. Inhibition by substituted cephalosporin esters and amides._|__|_Abstract: A variety of 7 alpha-methoxycephalosporin ester and amide sulfones were prepared and tested to determine the structure-activity relations for inhibition of human leukocyte elastase (HLE), a serine protease which has been implicated in several degenerative lung and tissue diseases. The most potent IC50 values were obtained with neutral, lipophilic derivatives, with the esters being more",43,ChEMBL,63651,20181013,"9799757,10026572,10087296,10854087,14760206,14760208,14760210,14760212,14760231,14760233,14760235,14760237,14760239,14760241,14760243,14760247,14760249,14760260,14760262,14760264,14760266,14760298,14760300,14760306,14760308,14760310,14760319","103273797,103273799,103273932,103288255,103288704,103288922,103288956,103289172,103289173,103289205,103289272,103289367,103289416,103289419,103289448,103289449,103289602,103289619,103289620,103289621,103289630,103289631,103289657,103289660,103289681,103289682,103289683",1991,In vitro,P08246,Curation Efforts|Research and Development,2391692,0,10.1021/jm00171a029,3.4.21.37,P08246,NULL
156759,2,"Inhibition of porcine pepsin at pH 4.0 (time-dependent inhibition, T1/2>30 s)","Title: Inhibition of porcine pepsin by two substrate analogues containing statine. The effect of histidine at the P2 subsite on the inhibition of aspartic proteinases._|__|_Abstract: Two new inhibitors, 4 and 5, of the aspartic proteinase porcine pepsin were synthesized. These compounds, which span the P4-P'3 binding subsites of the enzyme, were derived by replacing the Nph-Phe dipeptidyl unit of a good pepsin substrate, H2N-Phe-Gly-His-Nph-Phe-Ala-Phe-OMe (3), with statine [(3S,4S)-4-amino-3-hydroxy-6-meth",43,ChEMBL,154013,20181012,194955,312364889,396892,NULL,P00791,Curation Efforts|Research and Development,3126296,0,10.1021/jm00398a022,3.4.23.1,P00791,NULL
224924,2,Compound was evaluated for the inhibition of porcine penicillopepsin; ( Value is time-dependent inhibition (TDI) with T1/2 > 30 s.),"Title: Inhibition of aspartic proteinases by peptides containing lysine and ornithine side-chain analogues of statine._|__|_Abstract: The synthesis of two new analogues of statine are reported corresponding to analogues with the lysine side chain and the ornithine side chain. These analogues were designed on the basis of substrate specificity and molecular modeling of three-dimensional structures of the penicillopepsin: Iva-Val-Sta-OEt crystal structure. 4,8-Diamino-3-hydroxyoctanoic acid [LySta] and 4,7-di",43,ChEMBL,222278,20181011,44317794,103282507,NULL,NULL,NULL,Curation Efforts|Research and Development,3100801,0,10.1021/jm00385a010,NULL,NULL,NULL
224926,2,Compound was evaluated for the inhibition of porcine penicillopepsin; ( Value is time-dependent inhibition (TDI) with T1/2 > 30 s.),"Title: Inhibition of aspartic proteinases by peptides containing lysine and ornithine side-chain analogues of statine._|__|_Abstract: The synthesis of two new analogues of statine are reported corresponding to analogues with the lysine side chain and the ornithine side chain. These analogues were designed on the basis of substrate specificity and molecular modeling of three-dimensional structures of the penicillopepsin: Iva-Val-Sta-OEt crystal structure. 4,8-Diamino-3-hydroxyoctanoic acid [LySta] and 4,7-di",43,ChEMBL,222280,20181011,44331185,103315958,NULL,NULL,NULL,Curation Efforts|Research and Development,3100801,0,10.1021/jm00385a010,NULL,NULL,NULL
224927,2,Compound was evaluated for the inhibition of porcine penicillopepsin; Value is time-dependent inhibition (TDI) with T1/2 > 30 s),"Title: Inhibition of aspartic proteinases by peptides containing lysine and ornithine side-chain analogues of statine._|__|_Abstract: The synthesis of two new analogues of statine are reported corresponding to analogues with the lysine side chain and the ornithine side chain. These analogues were designed on the basis of substrate specificity and molecular modeling of three-dimensional structures of the penicillopepsin: Iva-Val-Sta-OEt crystal structure. 4,8-Diamino-3-hydroxyoctanoic acid [LySta] and 4,7-di",43,ChEMBL,222281,20181011,49796464,103315233,NULL,NULL,NULL,Curation Efforts|Research and Development,3100801,0,10.1021/jm00385a010,NULL,NULL,NULL
444457,2,Inhibition of c-Met by HTRF assay,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595635,20180911,"24824705,24864821,24864825,24864993,24865175,25064072,25064073,25064510,25064730,25065131,45102733,45487862,45487864,45487870","103620793,103620861,103620862,103620914,103708688,103708689,103708700,103708726,103708727,103708732,103708738,103708750,103708758,103708764",4233,NULL,P08581,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,2.7.10.1,P08581,NULL
444458,2,Inhibition of HGF-mediated human c-Met autophosphorylation expressed in human PC3 cells after 1 hr by electrochemiluminescent immunoassay,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595636,20180911,"24864821,25064730,45102733,45487862,45487864,45487870","103620793,103708726,103708732,103708738,103708750,103708758",4233,NULL,P08581,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,2.7.10.1,P08581,NULL
444459,2,Inhibition of human CYP3A4,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595637,20180911,"24824705,24864821,24864825,24864993,24865175,25064072,25064073,25064510,25064730,25065131,45102733,45487862,45487864,45487870","103620793,103620861,103620862,103620914,103708688,103708689,103708700,103708726,103708727,103708732,103708738,103708750,103708758,103708764",1576,NULL,P08684,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
444460,2,Inhibition of human CYP3A4 in human liver microsomes preincubated with NADPH,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595638,20180911,"24824705,24864821,24864825,24864993,24865175,25064072,25064073,25064510,25064730,25065131,45102733,45487862,45487864,45487870","103620793,103620861,103620862,103620914,103708688,103708689,103708700,103708726,103708727,103708732,103708738,103708750,103708758,103708764",1576,NULL,P08684,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
444476,2,Inhibition of human ERG,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595654,20180911,"45102733,45487870","103708738,103708758",3757,NULL,Q12809,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,Q12809,NULL
444478,2,Inhibition of HGF-induced c-Met phosphorylation in BALB/c mouse liver after 6 hrs by electrochemiluminescent assay,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595656,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444479,2,Inhibition of HGF-induced c-Met phosphorylation in BALB/c mouse plasma after 6 hrs by electrochemiluminescent assay,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595657,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444480,100,"Inhibition of HGF-induced c-Met phosphorylation in BALB/c mouse liver at 30 mg/kg, po after 12 hrs by electrochemiluminescent assay","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595658,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
551520,2,Inhibition of rat liver cytosolic TrxR1 by spectrophotometry,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700048,20200626,"2950,6688,7018,10168,10207,10208,10639,171194,196979,9866696,10462387,137629134,137630055","103181305,103197137,103220054,103220499,103220535,103240009,103354777,103635304,103768141,123089869,124956021,124956022,174520441",58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551521,2,Inhibition of rat liver mitochondrial TrxR2 by spectrophotometry,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700049,20200626,"2950,6688,7018,10168,10207,10208,10639,171194,196979,9866696,10462387,137629134,137630055","103181305,103197137,103220054,103220499,103220535,103240009,103354777,103635304,103768141,123089869,124956021,124956022,174520441",50551,NULL,Q9Z0J5,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,Q9Z0J5,NULL
551522,2,Mixed-type inhibition of rat liver cytosolic TrxR1 by Lineweaver-Burk plot analysis,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700050,20200626,137630055,123089869,58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551523,2,Mixed-type inhibition of rat liver cytosolic TrxR1 at protein-substrate complex by Lineweaver-Burk plot analysis,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700051,20200626,137630055,123089869,58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551524,100,Inhibition of rat liver cytosolic TrxR1 at 50 to 100 uM by spectrophotometry in presence of 0.025 mM NADPH,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700052,20200626,137630055,123089869,58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551525,2,Inhibition of yeast glutathione reductase by spectrophotometry,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700053,20200626,"137629134,137630055","103197137,123089869",856014,NULL,P41921,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.7,P41921,NULL
551526,100,Inhibition of rat liver cytosolic TrxR1 at 20 uM after 1 hr by spectrophotometry,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700054,20200626,137629134,103197137,58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551527,100,Inhibition of rat liver cytosolic TrxR1 at 20 uM after 2 mins by spectrophotometry,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700055,20200626,137629134,103197137,58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551528,100,Inhibition of rat liver cytosolic TrxR1 at 5 uM after 2 mins by spectrophotometry,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700056,20200626,137630055,123089869,58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551529,100,Inhibition of rat liver cytosolic TrxR1 at 100 uM by spectrophotometry in presence of 0.25 mM NADPH,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700057,20200626,"137629134,137630055","103197137,123089869",58819,NULL,O89049,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,O89049,NULL
551530,100,Inhibition of rat liver mitochondrial TrxR2 at 100 uM by spectrophotometry in presence of 0.25 mM NADPH,Title: Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones._|__|_Abstract: Cytosolic (TrxR1) and mitochondrial (TrxR2) thioredoxin reductases experience pronounced concentration- and time-dependent inhibition when incubated with the two naphthodianthrones hypericin and pseudohypericin. Pseudohypericin turned out to be a quite strong inhibitor of TrxR1 (IC(50)=4.40&#x3BC;M) being far more effective than hypericin (I,43,ChEMBL,700058,20200626,"137629134,137630055","103197137,123089869",50551,NULL,Q9Z0J5,Curation Efforts|Research and Development,21106380,0,10.1016/j.bmc.2010.10.045,1.8.1.9,Q9Z0J5,NULL
614467,2,Competitive inhibition of Bacillus subtilis LuxS preincubated for 15 mins by UV-vis spectrophotometric analysis,"Title: Inhibition of LuxS by S-ribosylhomocysteine analogues containing a [4-aza]ribose ring._|__|_Abstract: LuxS (S-ribosylhomocysteinase) catalyzes the cleavage of the thioether linkage of S-ribosylhomocysteine (SRH) to produce homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), the precursor to a small signaling molecule that mediates interspecies bacterial communication called autoinducer 2 (AI-2). Inhibitors of LuxS should interfere with bacterial interspecies communication and potentially provide a",43,ChEMBL,764478,20200629,"53494996,56659894,56663353","134437346,134441261,134441262",937106,NULL,O34667,Curation Efforts|Research and Development,21855358,0,10.1016/j.bmc.2011.07.043,4.4.1.21,O34667,NULL
614468,100,Inhibition of Bacillus subtilis LuxS preincubated for 15 mins by UV-vis spectrophotometric analysis,"Title: Inhibition of LuxS by S-ribosylhomocysteine analogues containing a [4-aza]ribose ring._|__|_Abstract: LuxS (S-ribosylhomocysteinase) catalyzes the cleavage of the thioether linkage of S-ribosylhomocysteine (SRH) to produce homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), the precursor to a small signaling molecule that mediates interspecies bacterial communication called autoinducer 2 (AI-2). Inhibitors of LuxS should interfere with bacterial interspecies communication and potentially provide a",43,ChEMBL,764479,20200629,"56666786,56673001,56677051,56677052,56683712","134445014,134451425,134456622,134456623,134464254",937106,NULL,O34667,Curation Efforts|Research and Development,21855358,0,10.1016/j.bmc.2011.07.043,4.4.1.21,O34667,NULL
614469,100,Inhibition of Bacillus subtilis LuxS at 20 to 50 uM by UV-vis spectrophotometric analysis,"Title: Inhibition of LuxS by S-ribosylhomocysteine analogues containing a [4-aza]ribose ring._|__|_Abstract: LuxS (S-ribosylhomocysteinase) catalyzes the cleavage of the thioether linkage of S-ribosylhomocysteine (SRH) to produce homocysteine and 4,5-dihydroxy-2,3-pentanedione (DPD), the precursor to a small signaling molecule that mediates interspecies bacterial communication called autoinducer 2 (AI-2). Inhibitors of LuxS should interfere with bacterial interspecies communication and potentially provide a",43,ChEMBL,764480,20200629,53494996,134441262,937106,NULL,O34667,Curation Efforts|Research and Development,21855358,0,10.1016/j.bmc.2011.07.043,4.4.1.21,O34667,NULL
635251,100,Time dependent inhibition of human recombinant MAOA using kynuramine as substrate at 5.22 uM by fluorescence assay,"Title: Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase._|__|_Abstract: In a recent study it was shown that 8-benzyloxycaffeine analogues act as potent reversible inhibitors of human monoamine oxidase (MAO) A and B. Although the benzyloxy side chain appears to be particularly favorable for enhancing the MAO inhibition potency of caffeine, a variety of other C8 oxy substituents of caffeine also lead to potent MAO inhibition. In an attempt to discover additional C8 substituents of ca",43,ChEMBL,792699,20200626,56950927,136940973,4128,NULL,P21397,Curation Efforts|Research and Development,22055712,0,10.1016/j.bmc.2011.10.036,1.4.3.4,P21397,NULL
635252,100,Time dependent inhibition of human recombinant MAOB using kynuramine as substrate at 0.32 uM by fluorescence assay,"Title: Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase._|__|_Abstract: In a recent study it was shown that 8-benzyloxycaffeine analogues act as potent reversible inhibitors of human monoamine oxidase (MAO) A and B. Although the benzyloxy side chain appears to be particularly favorable for enhancing the MAO inhibition potency of caffeine, a variety of other C8 oxy substituents of caffeine also lead to potent MAO inhibition. In an attempt to discover additional C8 substituents of ca",43,ChEMBL,792700,20200626,56950927,136940973,4129,NULL,P27338,Curation Efforts|Research and Development,22055712,0,10.1016/j.bmc.2011.10.036,1.4.3.4,P27338,NULL
635253,100,Time dependent inhibition of human recombinant MAOA using kynuramine as substrate at 11.56 uM by fluorescence assay,"Title: Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase._|__|_Abstract: In a recent study it was shown that 8-benzyloxycaffeine analogues act as potent reversible inhibitors of human monoamine oxidase (MAO) A and B. Although the benzyloxy side chain appears to be particularly favorable for enhancing the MAO inhibition potency of caffeine, a variety of other C8 oxy substituents of caffeine also lead to potent MAO inhibition. In an attempt to discover additional C8 substituents of ca",43,ChEMBL,792701,20200626,57394022,136927835,4128,NULL,P21397,Curation Efforts|Research and Development,22055712,0,10.1016/j.bmc.2011.10.036,1.4.3.4,P21397,NULL
635254,100,Time dependent inhibition of human recombinant MAOB using kynuramine as substrate at 5.94 uM by fluorescence assay,"Title: Thio- and aminocaffeine analogues as inhibitors of human monoamine oxidase._|__|_Abstract: In a recent study it was shown that 8-benzyloxycaffeine analogues act as potent reversible inhibitors of human monoamine oxidase (MAO) A and B. Although the benzyloxy side chain appears to be particularly favorable for enhancing the MAO inhibition potency of caffeine, a variety of other C8 oxy substituents of caffeine also lead to potent MAO inhibition. In an attempt to discover additional C8 substituents of ca",43,ChEMBL,792702,20200626,57394023,136927837,4129,NULL,P27338,Curation Efforts|Research and Development,22055712,0,10.1016/j.bmc.2011.10.036,1.4.3.4,P27338,NULL
1210068,2,Non-competitive inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method and Dixon plot,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485700,20200625,"65999,941361","103199419,103271997",1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210069,2,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485701,20200625,"1983,2119,2165,2206,2333,2351,2520,2554,2726,2733,2756,2995,3033,3100,3348,3356,3386,3440,3559,3639,3672,3696,3825,3883,4044,4060,4171,4178,4474,4485,4497,4539,4594,4748,4754,4912,4932,4946,5039,5335,5339,5355,5472,5578,5743,5754,5755,12555,12560,31307,33613,39186,60663,65999,68617,71733,77993,156391,158781,202225,941361,5284596,5360696,5479530,54675783,54676228,54677971,135398513,135398737","103163909,103164240,103164420,103164453,103164817,103164821,103164872,103164922,103164951,103165167,103165561,103165562,103165728,103165765,103167216,103169156,103169389,103169414,103170037,103172857,103174500,103174787,103175312,103177753,103178542,103178971,103179006,103179008,103179087,103184643,103188539,103188808,103189031,103189227,103189265,103190631,103191369,103191448,103199419,103210646,103213015,103219164,103222919,103224438,103229908,103234890,103238871,103240795,103268010,103271997,103296891,10",1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210070,2,Inhibition of CYP2D6 in human liver microsomes using bufuralol substrate by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485702,20200625,"2165,2333,2351,2520,2726,3559,4171,4474,4485,4497,4539,4748,5472,31307,60663,65999,68617,941361,5479530,135398737","103163909,103164420,103165765,103167216,103169389,103179008,103190631,103199419,103213015,103219164,103229908,103240795,103268010,103271997,103504457,103513016,103520216,103545241,103557046,104234145",1565,NULL,P10635,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,1.14.14.-,P10635,NULL
1210071,2,Inhibition of CYP3A4 in human liver microsomes using testosterone substrate by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485703,20200625,"2165,2333,2351,2520,2726,3559,4171,4474,4485,4497,4539,4748,5472,31307,60663,65999,68617,941361,5479530,135398737","103163909,103164420,103165765,103167216,103169389,103179008,103190631,103199419,103213015,103219164,103229908,103240795,103268010,103271997,103504457,103513016,103520216,103545241,103557046,104234145",1576,NULL,P08684,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1210072,2,Inhibition of CYP2C9 in human liver microsomes using tolbutamide substrate by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485704,20200625,"2165,2333,2351,2520,2726,3559,4171,4474,4485,4497,4539,4748,5472,31307,60663,65999,68617,941361,5479530,135398737","103163909,103164420,103165765,103167216,103169389,103179008,103190631,103199419,103213015,103219164,103229908,103240795,103268010,103271997,103504457,103513016,103520216,103545241,103557046,104234145",1559,NULL,P11712,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1210073,2,Inhibition of CYP2C19 in human liver microsomes using omeprazole substrate by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485705,20200625,"2165,2333,2351,2520,2726,3559,4171,4474,4485,4497,4539,4748,5472,31307,60663,65999,68617,941361,5479530,135398737","103163909,103164420,103165765,103167216,103169389,103179008,103190631,103199419,103213015,103219164,103229908,103240795,103268010,103271997,103504457,103513016,103520216,103545241,103557046,104234145",1557,NULL,P33261,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1210074,2,Inhibition of CYP1A2 in human liver microsomes using phenacetin substrate by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485706,20200625,"2165,2333,2351,2520,2726,3559,4171,4474,4485,4497,4539,4748,5472,31307,60663,65999,68617,941361,5479530,135398737","103163909,103164420,103165765,103167216,103169389,103179008,103190631,103199419,103213015,103219164,103229908,103240795,103268010,103271997,103504457,103513016,103520216,103545241,103557046,104234145",1544,NULL,P05177,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.1,4.2.1.152",P05177,NULL
1210080,2,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation reduction in astemizole O-demethylation after 30 mins by LC-MS/MS method in absence of 1 mM NADPH,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1486448,20200625,"65999,941361","103199419,103271997",1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210081,2,Inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation after 30 mins by LC-MS/MS method in presence of 1 mM NADPH,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1486449,20200625,"65999,941361","103199419,103271997",1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210082,2,Mixed type inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1486450,20200625,65999,103271997,1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210083,2,Non-competitive inhibition of human recombinant CYP2J2 assessed as reduction in astemizole O-demethylation by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492092,20200625,941361,103199419,1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1238166,100,Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as residual enzyme activity using midazolam as substrate preincubated for 30 mins by fluorescence-based assay,"Title: Discovery of an 8-methoxytetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain without CYP inhibition liability._|__|_Abstract: In lead optimization efforts starting from the tetrahydroisoquinoline (S)-1, we identified 2-{[(2R)-2-hydroxypropyl]amino}-1-[(1S)-8-methoxy-1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl]ethanone ((1S)-8t) as a novel orally active small-molecule N-type calcium channel blocker without CYP inhibition liability. CYP3A4 inhibition p",43,ChEMBL,1508730,20181009,"25067546,25118805,25119161,25119164,25119856,59396167,59396176,59396210,59396217,59396246,59396249,59396273,59396275,59396281,59396283,59396290,59396298,59396356,59396371,59396429,59396449,59396534,59396538,59396548,59396605,59396609,59396624,59396631,122184610,122184611,122184743","312369992,312369996,318377858,318381590,318381591,318381592,318381593,318381594,318381595,318381596,318381597,318381598,318381858,318381859,318381860,318381861,318381862,318381863,318381864,318381865,318381866,318381867,318381868,318381869,318381870,318381871,318381872,318381873,318381979,318381980,318381981",1576,NULL,P08684,Curation Efforts|Research and Development,26078010,0,10.1016/j.bmc.2015.05.053,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1269171,100,Time dependent inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate assessed as second order rate constant measured every 30 secs by Morrison and Walsh plot analysis,"Title: Highly potent tyrosinase inhibitor, neorauflavane from Campylotropis hirtella and inhibitory mechanism with molecular docking._|__|_Abstract: Tyrosinase inhibition may be a means to alleviate not only skin hyperpigmentation but also neurodegeneration associated with Parkinson's disease. In the course of metabolite analysis from tyrosinase inhibitory methanol extract (80% inhibition at 20 &#x3BC;g/ml) of Campylotropis hirtella, we isolated fourteen phenolic compounds, among which neorauflavane 3 emerg",43,ChEMBL,1543866,20200623,"44227000,101643011","336887741,336888186",NULL,NULL,O42713,Curation Efforts|Research and Development,26706112,0,10.1016/j.bmc.2015.11.040,1.14.18.1,O42713,NULL
1269172,100,Time dependent inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate assessed as off rate constant measured every 30 secs by Morrison and Walsh plot analysis,"Title: Highly potent tyrosinase inhibitor, neorauflavane from Campylotropis hirtella and inhibitory mechanism with molecular docking._|__|_Abstract: Tyrosinase inhibition may be a means to alleviate not only skin hyperpigmentation but also neurodegeneration associated with Parkinson's disease. In the course of metabolite analysis from tyrosinase inhibitory methanol extract (80% inhibition at 20 &#x3BC;g/ml) of Campylotropis hirtella, we isolated fourteen phenolic compounds, among which neorauflavane 3 emerg",43,ChEMBL,1543867,20200623,"44227000,101643011","336887741,336888186",NULL,NULL,O42713,Curation Efforts|Research and Development,26706112,0,10.1016/j.bmc.2015.11.040,1.14.18.1,O42713,NULL
1269173,2,Time dependent inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate measured every 30 secs by Morrison and Walsh plot analysis,"Title: Highly potent tyrosinase inhibitor, neorauflavane from Campylotropis hirtella and inhibitory mechanism with molecular docking._|__|_Abstract: Tyrosinase inhibition may be a means to alleviate not only skin hyperpigmentation but also neurodegeneration associated with Parkinson's disease. In the course of metabolite analysis from tyrosinase inhibitory methanol extract (80% inhibition at 20 &#x3BC;g/ml) of Campylotropis hirtella, we isolated fourteen phenolic compounds, among which neorauflavane 3 emerg",43,ChEMBL,1543868,20200623,"44227000,101643011","336887741,336888186",NULL,NULL,O42713,Curation Efforts|Research and Development,26706112,0,10.1016/j.bmc.2015.11.040,1.14.18.1,O42713,NULL
1303836,2,Time-dependent inhibition of wild type Klebsiella pneumoniae 6xHis-tagged metallo-beta-lactamase NDM-1 expressed in Escherichia coli BL21 (DE3)pLysS assessed as inhibition constant for initial non-covalant complex,"Title: Discovery of a novel covalent non-&#xCE;&#xB2;-lactam inhibitor of the metallo-&#xCE;&#xB2;-lactamase NDM-1._|__|_Abstract: The inhibition of metallo-&#x3B2;-lactamases (MBL) can prevent the hydrolysis of &#x3B2;-lactam antibiotics and hence is a promising strategy for the treatment of antibiotic resistant infections. In this study, we present a novel reversible covalent inhibitor of the clinically relevant MBL New Delhi metallo-&#x3B2;-lactamase 1 (NDM-1). Electrospray ionization-mass spectrometry (",43,ChEMBL,1581522,20200624,87112,103291442,"11934636,13913959,13914060,13914125,13914405,14258327,14858116,15414734,17373266,18983573,20494087",NULL,C7C422,Curation Efforts|Research and Development,27184103,0,10.1016/j.bmc.2016.04.064,3.5.2.6,C7C422,NULL
1303837,100,Time-dependent inhibition of wild type Klebsiella pneumoniae 6xHis-tagged metallo-beta-lactamase NDM-1 expressed in Escherichia coli BL21 (DE3)pLysS assessed as rate constant for bond formation,"Title: Discovery of a novel covalent non-&#xCE;&#xB2;-lactam inhibitor of the metallo-&#xCE;&#xB2;-lactamase NDM-1._|__|_Abstract: The inhibition of metallo-&#x3B2;-lactamases (MBL) can prevent the hydrolysis of &#x3B2;-lactam antibiotics and hence is a promising strategy for the treatment of antibiotic resistant infections. In this study, we present a novel reversible covalent inhibitor of the clinically relevant MBL New Delhi metallo-&#x3B2;-lactamase 1 (NDM-1). Electrospray ionization-mass spectrometry (",43,ChEMBL,1581523,20200624,87112,103291442,"11934636,13913959,13914060,13914125,13914405,14258327,14858116,15414734,17373266,18983573,20494087",NULL,C7C422,Curation Efforts|Research and Development,27184103,0,10.1016/j.bmc.2016.04.064,3.5.2.6,C7C422,NULL
1303838,100,Time-dependent inhibition of wild type Klebsiella pneumoniae 6xHis-tagged metallo-beta-lactamase NDM-1 expressed in Escherichia coli BL21 (DE3)pLysS assessed as rate constant for bond breaking,"Title: Discovery of a novel covalent non-&#xCE;&#xB2;-lactam inhibitor of the metallo-&#xCE;&#xB2;-lactamase NDM-1._|__|_Abstract: The inhibition of metallo-&#x3B2;-lactamases (MBL) can prevent the hydrolysis of &#x3B2;-lactam antibiotics and hence is a promising strategy for the treatment of antibiotic resistant infections. In this study, we present a novel reversible covalent inhibitor of the clinically relevant MBL New Delhi metallo-&#x3B2;-lactamase 1 (NDM-1). Electrospray ionization-mass spectrometry (",43,ChEMBL,1581524,20200624,87112,103291442,"11934636,13913959,13914060,13914125,13914405,14258327,14858116,15414734,17373266,18983573,20494087",NULL,C7C422,Curation Efforts|Research and Development,27184103,0,10.1016/j.bmc.2016.04.064,3.5.2.6,C7C422,NULL
1303839,2,Time-dependent inhibition of wild type Klebsiella pneumoniae 6xHis-tagged metallo-beta-lactamase NDM-1 expressed in Escherichia coli BL21 (DE3)pLysS,"Title: Discovery of a novel covalent non-&#xCE;&#xB2;-lactam inhibitor of the metallo-&#xCE;&#xB2;-lactamase NDM-1._|__|_Abstract: The inhibition of metallo-&#x3B2;-lactamases (MBL) can prevent the hydrolysis of &#x3B2;-lactam antibiotics and hence is a promising strategy for the treatment of antibiotic resistant infections. In this study, we present a novel reversible covalent inhibitor of the clinically relevant MBL New Delhi metallo-&#x3B2;-lactamase 1 (NDM-1). Electrospray ionization-mass spectrometry (",43,ChEMBL,1581525,20200624,87112,103291442,"11934636,13913959,13914060,13914125,13914405,14258327,14858116,15414734,17373266,18983573,20494087",NULL,C7C422,Curation Efforts|Research and Development,27184103,0,10.1016/j.bmc.2016.04.064,3.5.2.6,C7C422,NULL
1327646,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as substrate AUC shift using testosterone as substrate,"Title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors._|__|_Abstract: NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moietie",43,ChEMBL,1624786,20180907,"56943206,66610067,66610926,68277248,68277935,71727805,71728054,90012001,134133237","174487940,174507096,174518843,174522249,174523921,312378117,374272599,374305744,374356038",1576,NULL,P08684,Curation Efforts|Research and Development,27541271,0,10.1021/acs.jmedchem.6b00697,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1327647,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as substrate AUC shift using midazolam as substrate,"Title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors._|__|_Abstract: NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moietie",43,ChEMBL,1624787,20180907,"56943206,66610067,66610926,68277248,68277935,71727805,71728054,90012001,134133237","174487940,174507096,174518843,174522249,174523921,312378117,374272599,374305744,374356038",1576,NULL,P08684,Curation Efforts|Research and Development,27541271,0,10.1021/acs.jmedchem.6b00697,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1327657,100,Time dependent inhibition of CYP2D6 in human liver microsomes assessed as substrate AUC shift,"Title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors._|__|_Abstract: NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moietie",43,ChEMBL,1624797,20180907,90012001,374305744,1565,NULL,P10635,Curation Efforts|Research and Development,27541271,0,10.1021/acs.jmedchem.6b00697,1.14.14.-,P10635,NULL
1327658,100,Time dependent inhibition of CYP1A2 in human liver microsomes assessed as substrate AUC shift,"Title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors._|__|_Abstract: NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moietie",43,ChEMBL,1624798,20200624,90012001,374305744,1544,NULL,P05177,Curation Efforts|Research and Development,27541271,0,10.1021/acs.jmedchem.6b00697,"1.14.14.1,4.2.1.152",P05177,NULL
1327659,100,Time dependent inhibition of CYP2C19 in human liver microsomes assessed as substrate AUC shift,"Title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors._|__|_Abstract: NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moietie",43,ChEMBL,1624799,20180907,90012001,374305744,1557,NULL,P33261,Curation Efforts|Research and Development,27541271,0,10.1021/acs.jmedchem.6b00697,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1327660,100,Time dependent inhibition of CYP2C9 in human liver microsomes assessed as substrate AUC shift,"Title: Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors._|__|_Abstract: NAMPT inhibitors may show potential as therapeutics for oncology. Throughout our NAMPT inhibitor program, we found that exposed pyridines or related heterocyclic systems in the left-hand portion of the inhibitors are necessary pharmacophores for potent cellular NAMPT inhibition. However, when combined with a benzyl group in the center of the inhibitors, such pyridine-like moietie",43,ChEMBL,1624800,20180907,90012001,374305744,1559,NULL,P11712,Curation Efforts|Research and Development,27541271,0,10.1021/acs.jmedchem.6b00697,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1383069,100,Ratio of IC50 for inhibition of human MAO-B expressed in baculovirus infected insect cell membranes without preincubation to IC50 for inhibition of human MAO-B expressed in baculovirus infected insect cell membranes with preincubation,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762512,20200618,"145971024,145974947","404683489,404689313",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
8443,100,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,5544,20181017,11119120,103293846,995,NULL,P30307,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30307,NULL
33675,2,Inhibition constant against Adenosine deaminase was determined from calf intestinal mucosa,"Title: Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides._|__|_Abstract: A series of nucleoside dialdehydes has been prepared as powders after treatment of hexofuranosyladenine nucleosides with paraperiodic acid; thus, periodate oxidation and purification of the products yielded dialdehydes derived from 9-(6-deoxy-beta-D-gulofuranosyl)adenine (1), 9-(6-deoxy-beta-L-gulofuranosyl)adenine (2), 9-(alpha-D-rhamnofuranosyl",43,ChEMBL,30804,20181001,"44354899,44378896,71457975,71458031,71719087","103369114,103421011,163329585,163329685,164141761",280712,NULL,P56658,Curation Efforts|Research and Development,6965728,0,10.1021/jm00175a008,3.5.4.4,P56658,NULL
33676,100,Inhibition constant against Adenosine deaminase was determined from calf intestinal mucosa; b = not an inhibitor,"Title: Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides._|__|_Abstract: A series of nucleoside dialdehydes has been prepared as powders after treatment of hexofuranosyladenine nucleosides with paraperiodic acid; thus, periodate oxidation and purification of the products yielded dialdehydes derived from 9-(6-deoxy-beta-D-gulofuranosyl)adenine (1), 9-(6-deoxy-beta-L-gulofuranosyl)adenine (2), 9-(alpha-D-rhamnofuranosyl",43,ChEMBL,30805,20181001,"44355064,44378896","103369530,103421011",280712,NULL,P56658,Curation Efforts|Research and Development,6965728,0,10.1021/jm00175a008,3.5.4.4,P56658,NULL
48404,2,Inhibition of Cathepsin K at pH 5.5,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45547,20181017,"73737,9812750,10198366,10198752,10313520","103167408,103167436,103167539,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
48405,2,Inhibition of Cathepsin K at pH 7,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45548,20181017,"73737,9812750,10198366,10198752,10313520","103167408,103167436,103167539,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
51190,100,Pre-steady-state kinetic parameter for inhibition of human cathepsin K,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,48334,20181017,"9816412,9964915,10198752,10313520","103167419,103167589,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
51191,100,Pre-steady-state kinetic parameter for inhibition of human cathepsin K,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,48335,20181017,"9816412,9964915,10198752,10313520","103167419,103167589,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
51732,2,Inhibitory constant of compound against Cell division cycle 25 was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,48877,20181017,10950602,103293898,995,NULL,P30307,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30307,NULL
51860,2,Eight point inhibitory concentration against Cell division cycle 25A was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49005,20181017,"381594,9840174,9843442,10069057,10881285,10950602,10979124,11024745,11089726,11109259,11110408,11119120,11132168,11141454,11173938,11727266,11810495,11824141,11833119,22066140","103293193,103293713,103293810,103293812,103293846,103293894,103293895,103293898,103293918,103293968,103293969,103293981,103294296,103294379,103294380,103294400,103294441,103294446,103294484,103364390",993,NULL,P30304,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30304,NULL
51867,100,Percent inhibition of cell division cycle 25A at 50 uM,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49012,20181017,"9840174,9843442,10859055,10881285,10891030,10891337,10901758,10913251,10913252,10914042,10924048,10934921,10946475,10950602,10956547,10957834,10978635,10979124,10989757,11046628,11068128,11076582,11089726,11108385,11109259,11110408,11119120,11121979,11131422,11132168,11141454,11173938,11185774,11255754,11380181,11727266,11809773,11810495,11822196,11824141,11833119,22066099,22066103,22066104,22066106,22066112,22066114,22066115,22066125,22066140","103293193,103293194,103293680,103293711,103293712,103293713,103293714,103293727,103293728,103293741,103293758,103293798,103293810,103293811,103293812,103293846,103293848,103293894,103293895,103293898,103293935,103293969,103293970,103293971,103293977,103293981,103293982,103294016,103294028,103294029,103294030,103294059,103294094,103294296,103294303,103294304,103294343,103294344,103294379,103294380,103294400,103294423,103294424,103294439,103294441,103294446,103294463,103294464,103294469,103294484",993,NULL,P30304,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30304,NULL
51878,2,Inhibitory constant of compound against Cdc25 phosphatase was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49023,20181017,44320813,103293730,NULL,NULL,NULL,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,NULL,NULL,NULL
51880,2,Eight point inhibitory concentration against Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49025,20181017,"381594,9840174,10069057,10881285,10950602,10979124,11024745,11089726,11109259,11141454,11173938,11727266,11810495,11824141,11833119,22066140","103293193,103293713,103293894,103293895,103293898,103293918,103293968,103293969,103293981,103294296,103294379,103294380,103294400,103294441,103294484,103364390",994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51884,2,Inhibitory concentration of compound against Cdc25B phosphatase was determined using CDK2-p-TpY/Cyclin A as a substrate,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49029,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51885,2,Inhibitory concentration of compound against Cell division cycle 25B was determined using CDK2-p-TpY/Cyclin A as a substrate,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49030,20181017,"9840174,10069057","103293918,103294379",994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51888,100,Percent inhibition of cell division cycle 25B at 50 uM,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49033,20181017,"9840174,9843442,10859055,10881285,10891030,10891337,10901758,10913251,10913252,10914042,10924048,10934921,10946475,10950602,10956547,10957834,10978635,10979124,10989757,11046628,11068128,11076582,11089726,11108385,11109259,11110408,11119120,11121979,11131422,11132168,11141454,11173938,11185774,11255754,11380181,11727266,11809773,11810495,11822196,11824141,11833119,22066099,22066103,22066104,22066106,22066112,22066114,22066115,22066125,22066140","103293193,103293194,103293680,103293711,103293712,103293713,103293714,103293727,103293728,103293741,103293758,103293798,103293810,103293811,103293812,103293846,103293848,103293894,103293895,103293898,103293935,103293969,103293970,103293971,103293977,103293981,103293982,103294016,103294028,103294029,103294030,103294059,103294094,103294296,103294303,103294304,103294343,103294344,103294379,103294380,103294400,103294423,103294424,103294439,103294441,103294446,103294463,103294464,103294469,103294484",994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51889,2,Inhibitory constant of compound against Cdc25B phosphatase was determined using mFP as a substrate,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49034,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51890,2,Inhibitory constant of compound against Cell division cycle 25B was determined using mFP as a substrate,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49035,20181017,"9840174,10069057","103293918,103294379",994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51891,100,Eight point inhibitory concentration of compound against Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49036,20181017,"11110408,11119120,11132168","103293810,103293812,103293846",994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51892,100,Eight point inhibitory concentration of compound against Cell division cycle 25B; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49037,20181017,9843442,103294446,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51896,2,Inhibitory concentration of compound against mutant E474Q of Cdc25B phosphatase was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49041,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51897,2,Inhibitory concentration of compound against mutant E474Q of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49042,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51898,2,Inhibitory concentration of compound against mutant E478Q of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49043,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
51899,2,Inhibitory concentration of compound against mutant F475A of Cdc25B phosphatase was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49044,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52027,2,Inhibitory concentration of compound against mutant F475A of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49172,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52028,2,Inhibitory concentration of compound against mutant M531A of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49173,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52029,2,Inhibitory concentration of compound against mutant M532A of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49174,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52030,2,Inhibitory concentration of compound against mutant R482L of Cdc25B phosphatase was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49175,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52031,2,Inhibitory concentration of compound against mutant R482L of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49176,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52032,2,Inhibitory concentration of compound against mutant R492L of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49177,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52033,2,Inhibitory concentration of compound against mutant R544L of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49178,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52034,2,Inhibitory concentration of compound against mutant WT of Cdc25B phosphatase was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49179,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52035,2,Inhibitory concentration of compound against mutant WT of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49180,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52036,2,Inhibitory concentration of compound against mutant Y528F of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49181,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52037,2,Inhibitory concentration of compound against truncated mutant of Cdc25B phosphatase was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49182,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52038,2,Inhibitory concentration of compound against truncated mutant of Cell division cycle 25B was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49183,20181017,9840174,103294379,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52039,100,Inhibitory concentration of compound against mutant E478Q of Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49184,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52040,100,Inhibitory concentration of compound against mutant M531A of Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49185,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52041,100,Inhibitory concentration of compound against mutant M532A of Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49186,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52042,100,Inhibitory concentration of compound against mutant R492L of Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49187,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52043,100,Inhibitory concentration of compound against mutant R544L of Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49188,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52044,100,Inhibitory concentration of compound against mutant Y528F of Cdc25B phosphatase; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49189,20181017,22066140,103294296,994,NULL,P30305,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30305,NULL
52045,2,Eight point inhibitory concentration against Cell division cycle 25 degree C was determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49190,20181017,"381594,9840174,9843442,10069057,10881285,10950602,10979124,11024745,11089726,11109259,11141454,11173938,11727266,11810495,11824141,11833119,22066140","103293193,103293713,103293894,103293895,103293898,103293918,103293968,103293969,103293981,103294296,103294379,103294380,103294400,103294441,103294446,103294484,103364390",995,NULL,P30307,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30307,NULL
52048,100,Percent inhibition of cell division cycle 25 degree C at 50 uM,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49193,20181017,"9840174,9843442,10859055,10881285,10891030,10891337,10901758,10913251,10913252,10914042,10924048,10934921,10946475,10950602,10956547,10957834,10978635,10979124,10989757,11046628,11068128,11076582,11089726,11108385,11109259,11110408,11121979,11131422,11132168,11141454,11173938,11185774,11255754,11380181,11727266,11809773,11810495,11822196,11824141,11833119,22066099,22066103,22066104,22066106,22066112,22066114,22066115,22066125,22066140","103293193,103293194,103293680,103293711,103293712,103293713,103293714,103293727,103293728,103293741,103293758,103293798,103293810,103293811,103293812,103293848,103293894,103293895,103293898,103293935,103293969,103293970,103293971,103293977,103293981,103293982,103294016,103294028,103294029,103294030,103294059,103294094,103294296,103294303,103294304,103294343,103294344,103294379,103294380,103294400,103294423,103294424,103294439,103294441,103294446,103294463,103294464,103294469,103294484",995,NULL,P30307,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30307,NULL
52049,100,Eight point inhibitory concentration of compound against Cell division cycle 25C; Not determined,"Title: Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones._|__|_Abstract: Overexpression of the Cdc25A and Cdc25B dual-specificity phosphatases correlates with a wide variety of cancers, making the Cdc25s attractive drug targets for anticancer therapies. However, the search for good lead molecules has been hampered by the reactivity of the active site thiolate anion and the flat solvent-exposed active site region. We describe here the indolyldihydroxyquinones, a new class of inhibitors of Cdc25 th",43,ChEMBL,49194,20181017,"11110408,11119120,11132168","103293810,103293812,103293846",995,NULL,P30307,Curation Efforts|Research and Development,12801222,0,10.1021/jm0300835,3.1.3.48,P30307,NULL
67471,100,"elastase inhibitory activity, evaluated for second order rate constant (time-dependent inhibition)","Title: Orally active beta-lactam inhibitors of human leukocyte elastase-1. Activity of 3,3-diethyl-2-azetidinones._|__|_Abstract: A thorough analysis of the mechanism of inhibition of human leukocyte elastase (HLE) by a monocyclic beta-lactam and the mechanism of beta-lactam hydrolysis led to the preparation of potent and highly stable inhibitors of HLE. This work led to the identification of 4-[(4-carboxyphenyl)-oxy]-3,3-diethyl-1- [[(phenylmethyl)amino]carbonyl]-2-azetidinone (2) as the first orally activ",43,ChEMBL,64633,20181013,"132583,9978461,9982871,10001169,10002464,10025815,10048765,10071820,10090038,10091533,10252685,10321344,10342296,10408795,10409290,10411650,10434010,10434016,10434107,10477441,10478735,10479667,44348245,44348456,44348471,44348472,44348473,44348517,44348518,44348545,44348546,44348557,44348558,44348566,44348569,44348570,44348586,44348597,44348599,44348608,44348617,44348639,44348644,44348708,44348709,44348724,44348751,44348752","103352815,103352816,103353261,103353263,103353311,103353343,103353344,103353368,103353383,103353428,103353429,103353430,103353456,103353550,103353551,103353651,103353652,103353693,103353694,103353714,103353718,103353719,103353753,103353756,103353776,103353778,103353789,103353795,103353796,103353815,103353816,103353828,103353830,103353902,103353906,103353928,103353938,103353943,103354098,103354131,103354132,103354133,103354192,103354193,103354194,103354219,103354258,103354265",1991,NULL,P08246,Curation Efforts|Research and Development,1433189,0,10.1021/jm00099a003,3.4.21.37,P08246,NULL
67982,2,Inhibition of endothelial isoform of nitric oxide synthase,"Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,65144,20181015,"10499986,10570902,10713929,15547277,49859953,49859954,49859955,49859956,49859957,52941715,52942950,52944144,54582038","103307706,103307739,103308580,103308698,104234604,104234605,104234606,104234607,104234608,104236908,104236910,104236911,131275997",287024,NULL,P29473,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,1.14.13.39,P29473,NULL
67986,100,selectivity index which is the ratio of the Ki or IC50 values of recombinant bovine eNOS (endothelial isoform) / recombinant murine iNOS(inducible isoform).,"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,65148,20200703,"49859950,49859960,49859961,49859962,49861985,49861988,49861993,52941715,70682895,70695506,71454527","104234601,104234611,104234612,104234613,104236907,104236908,104236909,104236912,160670727,160702983,163322995",NULL,NULL,NULL,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,NULL,NULL,NULL
67987,100,selectivity index which is the ratio of the Ki or IC50 values of recombinant bovine eNOS (endothelial isoform) and bovine brain nNOS(neuronal isoform).,"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,65149,20200703,"49859950,49859960,49859961,49859962,49861985,49861988,49861993,52941715,70682895,70695506,71454527","104234601,104234611,104234612,104234613,104236907,104236908,104236909,104236912,160670727,160702983,163322995",NULL,NULL,NULL,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,NULL,NULL,NULL
67988,100,Selectivity index which is the ratio of the Ki or IC50 values of recombinant bovine Endothelial nitric oxide synthase and bovine brain nNOS (Neuronal nitric oxide synthase),"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,65150,20200703,"1331,1433,1534,1893,2146,3311,5139,107968,107984,132862,440005,447180,447181,10220076,10632810,15887952,18356525,135409360","103171730,103326418,103326419,103326477,103326949,103326974,103327033,103327058,103327068,103327144,103327145,103327181,103327182,103327184,103513944,103515954,103549052,103562638",NULL,NULL,NULL,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,NULL,NULL,NULL
67989,100,Selectivity index which is the ratio of the Ki or IC50 values of recombinant bovine eNOS (Endothelial nitric oxide synthase) / recombinant murine iNOS (Inducible nitric oxide synthase),"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,65151,20200703,"1331,1433,1534,1893,2146,3311,5139,107968,107984,132862,440005,447180,447181,10220076,10632810,15887952,18356525,135409360","103171730,103326418,103326419,103326477,103326949,103326974,103327033,103327058,103327068,103327144,103327145,103327181,103327182,103327184,103513944,103515954,103549052,103562638",NULL,NULL,NULL,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,NULL,NULL,NULL
67990,2,Nitric Oxide Synthase Inhibitory activity tested against recombinant bovine eNOS (Endothelial nitric oxide synthase),"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,65152,20181016,"49859950,49859960,49859961,49859962,49861985,49861988,49861993,52941715,70682895,70695506,71454527","104234601,104234611,104234612,104234613,104236907,104236908,104236909,104236912,160670727,160702983,163322995",287024,NULL,P29473,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,1.14.13.39,P29473,NULL
73483,100,Compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase (GABA-AT),"Title: Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase._|__|_Abstract: Several cyclopentene GABA analogues were synthesized as conformationally rigid analogues of the epilepsy drug vigabatrin and tested as inhibitors and substrates of gamma-aminobutyric acid aminotransferase (GABA-AT). None of these compounds produced time-dependent inhibition. (1R, 4S)-(+)-4-Amino-2-cyclopentene-1-carboxylic acid ((+)-3), (4R)-(-)-4-amino-1-cycl",43,ChEMBL,70655,20181016,"119,2734525,10171262,12645059","103173784,103384222,103384256,103384258",397500,NULL,P80147,Curation Efforts|Research and Development,10579835,0,10.1021/jm990271o,"2.6.1.19,2.6.1.22",P80147,NULL
73486,2,Compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase (GABA-AT),"Title: Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase._|__|_Abstract: Several cyclopentene GABA analogues were synthesized as conformationally rigid analogues of the epilepsy drug vigabatrin and tested as inhibitors and substrates of gamma-aminobutyric acid aminotransferase (GABA-AT). None of these compounds produced time-dependent inhibition. (1R, 4S)-(+)-4-Amino-2-cyclopentene-1-carboxylic acid ((+)-3), (4R)-(-)-4-amino-1-cycl",43,ChEMBL,70658,20181016,"2734525,10034643,10171262,12645058,12645059,44361891","103384222,103384256,103384257,103384258,103385810,103385811",397500,NULL,P80147,Curation Efforts|Research and Development,10579835,0,10.1021/jm990271o,"2.6.1.19,2.6.1.22",P80147,NULL
73490,2,Compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase (GABA-AT),"Title: Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase._|__|_Abstract: Several cyclopentene GABA analogues were synthesized as conformationally rigid analogues of the epilepsy drug vigabatrin and tested as inhibitors and substrates of gamma-aminobutyric acid aminotransferase (GABA-AT). None of these compounds produced time-dependent inhibition. (1R, 4S)-(+)-4-Amino-2-cyclopentene-1-carboxylic acid ((+)-3), (4R)-(-)-4-amino-1-cycl",43,ChEMBL,70662,20181016,"119,2734525,10171262,12645059","103173784,103384222,103384256,103384258",397500,NULL,P80147,Curation Efforts|Research and Development,10579835,0,10.1021/jm990271o,"2.6.1.19,2.6.1.22",P80147,NULL
73491,100,Compound was tested for the inhibition of Gamma-amino-N-butyrate transaminase (GABA-AT); No turn over,"Title: Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase._|__|_Abstract: Several cyclopentene GABA analogues were synthesized as conformationally rigid analogues of the epilepsy drug vigabatrin and tested as inhibitors and substrates of gamma-aminobutyric acid aminotransferase (GABA-AT). None of these compounds produced time-dependent inhibition. (1R, 4S)-(+)-4-Amino-2-cyclopentene-1-carboxylic acid ((+)-3), (4R)-(-)-4-amino-1-cycl",43,ChEMBL,70663,20181016,"10034643,12645058,44361891","103384257,103385810,103385811",397500,NULL,P80147,Curation Efforts|Research and Development,10579835,0,10.1021/jm990271o,"2.6.1.19,2.6.1.22",P80147,NULL
75278,100,Inactivation of recombinant human Glutathione S-transferase P,"Title: Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors._|__|_Abstract: Overexpression of glutathione S-transferase (GST), particularly the GST-pi isozyme, has been proposed to be one of the biochemical mechanisms responsible for drug resistance in cancer chemotherapy, and inhibition of overexpressed GST has been suggested as an approach to combat GST-induced drug resistance. 3-Cinnamyl-5(E)-bromomethyliden",43,ChEMBL,72452,20200703,"10422367,10447087,11162586,11173026,11173341,11174546,11207868,11220573,11231708,11277486,11290736,11301128,11311888,11415028,11417106,11450130","103333965,103334039,103334040,103334041,103334066,103334067,103334068,103334073,103334182,103334183,103334210,103334211,103334226,103334745,103334746,103334780",2950,NULL,P09211,Curation Efforts|Research and Development,15163208,0,10.1021/jm0499615,2.5.1.18,P09211,NULL
75279,2,Inhibitory activity for human Glutathione S-transferase P was determined,"Title: Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors._|__|_Abstract: Overexpression of glutathione S-transferase (GST), particularly the GST-pi isozyme, has been proposed to be one of the biochemical mechanisms responsible for drug resistance in cancer chemotherapy, and inhibition of overexpressed GST has been suggested as an approach to combat GST-induced drug resistance. 3-Cinnamyl-5(E)-bromomethyliden",43,ChEMBL,72453,20181018,10447087,103334039,2950,NULL,P09211,Curation Efforts|Research and Development,15163208,0,10.1021/jm0499615,2.5.1.18,P09211,NULL
75280,2,Inhibitory activity for human glutathione S-transferase-pi isozyme was determined,"Title: Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors._|__|_Abstract: Overexpression of glutathione S-transferase (GST), particularly the GST-pi isozyme, has been proposed to be one of the biochemical mechanisms responsible for drug resistance in cancer chemotherapy, and inhibition of overexpressed GST has been suggested as an approach to combat GST-induced drug resistance. 3-Cinnamyl-5(E)-bromomethyliden",43,ChEMBL,72454,20181018,10422367,103334780,2950,NULL,P09211,Curation Efforts|Research and Development,15163208,0,10.1021/jm0499615,2.5.1.18,P09211,NULL
75281,100,Inhibitory activity for human Glutathione S-transferase P was determined,"Title: Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors._|__|_Abstract: Overexpression of glutathione S-transferase (GST), particularly the GST-pi isozyme, has been proposed to be one of the biochemical mechanisms responsible for drug resistance in cancer chemotherapy, and inhibition of overexpressed GST has been suggested as an approach to combat GST-induced drug resistance. 3-Cinnamyl-5(E)-bromomethyliden",43,ChEMBL,72455,20181018,10447087,103334039,2950,NULL,P09211,Curation Efforts|Research and Development,15163208,0,10.1021/jm0499615,2.5.1.18,P09211,NULL
75282,100,Inhibitory activity for human glutathione S-transferase-pi isozyme was determined,"Title: Design, synthesis, and structure-activity relationships of haloenol lactones: site-directed and isozyme-selective glutathione S-transferase inhibitors._|__|_Abstract: Overexpression of glutathione S-transferase (GST), particularly the GST-pi isozyme, has been proposed to be one of the biochemical mechanisms responsible for drug resistance in cancer chemotherapy, and inhibition of overexpressed GST has been suggested as an approach to combat GST-induced drug resistance. 3-Cinnamyl-5(E)-bromomethyliden",43,ChEMBL,72456,20181018,10422367,103334780,2950,NULL,P09211,Curation Efforts|Research and Development,15163208,0,10.1021/jm0499615,2.5.1.18,P09211,NULL
91988,2,Inhibition of inducible Nitric Oxide Synthase,"Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,89178,20181015,"10499986,10570902,10713929,15547277,49859953,49859954,49859955,49859956,49859957,52941715,52942950,52944144,54582038","103307706,103307739,103308580,103308698,104234604,104234605,104234606,104234607,104234608,104236908,104236910,104236911,131275997",18126,NULL,P29477,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,1.14.13.39,P29477,NULL
92179,2,Nitric Oxide Synthase Inhibitory activity tested against recombinant murine Inducible nitric oxide synthase (inducible isoform),"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,89369,20181016,"49859950,49859960,49859961,49859962,49861985,49861988,49861993,52941715,70682895,70695506,71454527","104234601,104234611,104234612,104234613,104236907,104236908,104236909,104236912,160670727,160702983,163322995",18126,NULL,P29477,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,1.14.13.39,P29477,NULL
146095,2,Compound was evaluated for the inhibition of Neuronal Nitric oxide synthase enzyme (nNOS).,"Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,143339,20181015,44327898,103308539,4842,NULL,P29475,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,1.14.13.39,P29475,NULL
146097,2,Compound was evaluated for the inhibition of Neuronal Nitric oxide synthase enzyme (nNOS).,"Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,143341,20181015,44327898,103308539,4842,NULL,P29475,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,1.14.13.39,P29475,NULL
146099,2,Inhibition of Neuronal Nitric oxide synthase enzyme (nNOS),"Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,143343,20181015,"10499986,10570902,10713929,15547277,49859953,49859954,49859955,49859956,49859957,52941715,52942950,52944144,54582038","103307706,103307739,103308580,103308698,104234604,104234605,104234606,104234607,104234608,104236908,104236910,104236911,131275997",4842,NULL,P29475,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,1.14.13.39,P29475,NULL
146101,2,Nitric Oxide Synthase Inhibitory activity tested against bovine brain nNOS (Neuronal nitric oxide synthase),"Title: N(omega)-Nitroarginine-containing dipeptide amides. Potent and highly selective inhibitors of neuronal nitric oxide synthase._|__|_Abstract: Selective inhibition of the isoforms of nitric oxide synthase (NOS) could be therapeutically useful in the treatment of certain disease states arising from the overproduction of nitric oxide (NO). Recently, we reported the dipeptide methyl ester, D-Phe-D-Arg(NO)()2-OMe (19), as a modest inhibitor of nNOS (K(i) = 2 microM), but with selectivity over iNOS as high ",43,ChEMBL,143345,20181016,"49859950,49859960,49859961,49859962,49861985,49861988,49861993,52941715,70682895,70695506,71454527","104234601,104234611,104234612,104234613,104236907,104236908,104236909,104236912,160670727,160702983,163322995",4842,NULL,P29475,Curation Efforts|Research and Development,10447959,0,10.1021/jm990111c,1.14.13.39,P29475,NULL
199145,100,Time dependent inhibition of S-Adenosyl-homocysteine hydrolase was determined by Kitz and Wilson method,Title: Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues._|__|_Abstract: Selectively protected adenine nucleosides were converted into 5'-carboxaldehyde analogues by Moffatt oxidation (dimethyl sulfoxide/dicyclohexylcarbodiimide/dichloroacetic acid) or with the Dess-Martin periodinane reagent. Hydrolysis of a 5'-fluoro-5'-S-methyl-5'-thio (alpha-fluoro thioether) arabinosyl deriv,43,ChEMBL,196419,20181015,443234,103277727,191,NULL,P23526,Curation Efforts|Research and Development,9171871,0,10.1021/jm960828p,3.3.1.1,P23526,NULL
199282,100,Time dependent inhibition of S-Adenosyl-homocysteine hydrolase was determined by Kitz and Wilson method,Title: Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues._|__|_Abstract: Selectively protected adenine nucleosides were converted into 5'-carboxaldehyde analogues by Moffatt oxidation (dimethyl sulfoxide/dicyclohexylcarbodiimide/dichloroacetic acid) or with the Dess-Martin periodinane reagent. Hydrolysis of a 5'-fluoro-5'-S-methyl-5'-thio (alpha-fluoro thioether) arabinosyl deriv,43,ChEMBL,196556,20181015,"515217,10061387,46874055,46874757,46874759,118718118","103276736,103730600,103731312,103731314,123090573,312364528",191,NULL,P23526,Curation Efforts|Research and Development,9171871,0,10.1021/jm960828p,3.3.1.1,P23526,NULL
227951,100,Compound was evaluated for kinetic constant Kcat/Km,"Title: Inhibition and substrate activity of conformationally rigid vigabatrin analogues with gamma-aminobutyric acid aminotransferase._|__|_Abstract: Several cyclopentene GABA analogues were synthesized as conformationally rigid analogues of the epilepsy drug vigabatrin and tested as inhibitors and substrates of gamma-aminobutyric acid aminotransferase (GABA-AT). None of these compounds produced time-dependent inhibition. (1R, 4S)-(+)-4-Amino-2-cyclopentene-1-carboxylic acid ((+)-3), (4R)-(-)-4-amino-1-cycl",43,ChEMBL,225308,20181016,"119,2734525,10171262,12645059","103173784,103384222,103384256,103384258",NULL,NULL,NULL,Curation Efforts|Research and Development,10579835,0,10.1021/jm990271o,NULL,NULL,NULL
231779,100,Ratio of concentration and time dependent inhibition of AdoHcy Hydrolase.,Title: Anticancer and antiviral effects and inactivation of S-adenosyl-L-homocysteine hydrolase with 5'-carboxaldehydes and oximes synthesized from adenosine and sugar-modified analogues._|__|_Abstract: Selectively protected adenine nucleosides were converted into 5'-carboxaldehyde analogues by Moffatt oxidation (dimethyl sulfoxide/dicyclohexylcarbodiimide/dichloroacetic acid) or with the Dess-Martin periodinane reagent. Hydrolysis of a 5'-fluoro-5'-S-methyl-5'-thio (alpha-fluoro thioether) arabinosyl deriv,43,ChEMBL,229136,20200704,"443234,515217,10061387,46874055,46874757,46874759,118718118","103276736,103277727,103730600,103731312,103731314,123090573,312364528",NULL,NULL,NULL,Curation Efforts|Research and Development,9171871,0,10.1021/jm960828p,NULL,NULL,NULL
234516,100,"Selectivity for iNOS and eNOS binding, ratio of Ki","Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,231873,20200704,"10499986,10570902,10713929,15547277,49859953,49859954,49859955,49859956,49859957,52941715,52942950,52944144,54582038","103307706,103307739,103308580,103308698,104234604,104234605,104234606,104234607,104234608,104236908,104236910,104236911,131275997",NULL,NULL,NULL,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,NULL,NULL,NULL
234517,100,"Selectivity for nNOS and eNOS, ratio of Ki","Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,231874,20200704,"10499986,10570902,10713929,15547277,49859953,49859954,49859955,49859956,49859957,52941715,52942950,52944144,54582038","103307706,103307739,103308580,103308698,104234604,104234605,104234606,104234607,104234608,104236908,104236910,104236911,131275997",NULL,NULL,NULL,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,NULL,NULL,NULL
234518,100,"Selectivity for nNOS and iNOS, ratio of Ki","Title: Selective inhibition of neuronal nitric oxide synthase by N omega-nitroarginine-and phenylalanine-containing dipeptides and dipeptide esters._|__|_Abstract: A series of N omega-nitroarginine (ArgNO2)- and phenylalanine-containing dipeptides and dipeptide esters were synthesized as potential selective inhibitors of neuronal nitric oxide synthase (nNOS). All of the dipeptides and dipeptide esters are competitive inhibitors of nNOS, macrophage nitric oxide synthase (iNOS), and endothelial nitric oxide s",43,ChEMBL,231875,20200704,"10499986,10570902,10713929,15547277,49859953,49859954,49859955,49859956,49859957,52941715,52942950,52944144,54582038","103307706,103307739,103308580,103308698,104234604,104234605,104234606,104234607,104234608,104236908,104236910,104236911,131275997",NULL,NULL,NULL,Curation Efforts|Research and Development,9288162,0,10.1021/jm970200u,NULL,NULL,NULL
267923,2,Agonist activity at human OTR expressed in CHO cells assessed as inhibition of oxytocin-induced calcium mobilization by FLIPR assay,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373748,20181020,11465834,103492803,5021,NULL,P30559,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P30559,NULL
267924,2,Inhibition of CYP450 1A2 transfected in human microsome,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373749,20200703,"11465834,11488952","103492327,103492803",1544,NULL,P05177,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,"1.14.14.1,4.2.1.152",P05177,NULL
267925,2,Inhibition of CYP450 2C9 transfected in human microsome,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373750,20181020,"11465834,11488952","103492327,103492803",1559,NULL,P11712,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
267926,2,Inhibition of CYP450 2C19 transfected in human microsome,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373751,20181020,"11465834,11488952","103492327,103492803",1557,NULL,P33261,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
267927,2,Inhibition of CYP450 3A4 transfected in human microsome using DEF fluorogenic substrate,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373752,20181020,"11465834,11488952","103492327,103492803",1576,NULL,P08684,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
267928,2,Inhibition of CYP450 3A4 transfected in human microsome using PPR fluorogenic substrate,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373753,20181020,"11465834,11488952","103492327,103492803",1576,NULL,P08684,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
267929,2,Inhibition of CYP450 2D6 transfected in human microsome using DEF fluorogenic substrate,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373754,20181020,"11465834,11488952","103492327,103492803",1565,NULL,P10635,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,1.14.14.-,P10635,NULL
277583,2,Inhibition of Plasmodium falciparum ENR,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425609,20181021,"65064,72277,107905,5280343,5281222","103167027,103215553,103226312,103226419,103359379",NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277584,2,Inhibition of Escherichia coli ENR,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425610,20181021,"65064,72277,107905,5280343,5281222","103167027,103215553,103226312,103226419,103359379",NULL,NULL,P0AEK4,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,1.3.1.9,P0AEK4,NULL
277585,2,Inhibition of Plasmodium falciparum ENR using NADH substrate,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425611,20181021,"65064,72277,107905,5280343,5281222","103167027,103215553,103226312,103226419,103359379",NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277586,2,Inhibition of Plasmodium falciparum ENR using crotonyl-CoA substrate,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425612,20181021,"65064,72277,107905,5280343,5281222","103167027,103215553,103226312,103226419,103359379",NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277587,2,Inhibition of Plasmodium falciparum ENR in presence of triclosan,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425613,20181021,"65064,72277,107905,5280343,5281222","103167027,103215553,103226312,103226419,103359379",NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277588,2,Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of EGCG,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425614,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277589,2,Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of ECG,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425615,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277590,2,Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of EGC,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425616,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277591,2,Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of quercetin,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425617,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277592,2,Inhibition of Plasmodium falciparum ENR by fluorescence quenching in presence of butein,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425618,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277593,2,Inhibition of Plasmodium falciparum ENR in presence of EGCG by dilution assay,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425619,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277594,2,Inhibition of Plasmodium falciparum ENR in presence of EGC by dilution assay,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425620,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277595,2,Inhibition of Plasmodium falciparum ENR in presence of ECG by dilution assay,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425621,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277596,2,Inhibition of Plasmodium falciparum ENR in presence of quercetin by dilution assay,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425622,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277597,2,Inhibition of Plasmodium falciparum ENR in presence of butein by dilution assay,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425623,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277598,2,Inhibition of Plasmodium falciparum ENR in presence of EGCG,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425624,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277599,2,Inhibition of Plasmodium falciparum ENR in presence of EGC,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425625,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277600,2,Inhibition of Plasmodium falciparum ENR in presence of ECG,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425626,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277601,2,Inhibition of Plasmodium falciparum ENR in presence of quercetin,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425627,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
277602,2,Inhibition of Plasmodium falciparum ENR in presence of butein,"Title: Green tea catechins potentiate triclosan binding to enoyl-ACP reductase from Plasmodium falciparum (PfENR)._|__|_Abstract: We have investigated the mechanism of inhibition of enoyl-acyl carrier protein reductase of Plasmodium falciparum (PfENR) by triclosan in the presence of a few important catechins and related plant polyphenols. The examined flavonoids inhibited PfENR reversibly with Ki values in the nanomolar range, EGCG being the best with 79 +/- 2.67 nM. The steady-state kinetics revealed time ",43,ChEMBL,425628,20181021,5564,103222736,NULL,NULL,Q965D5,Curation Efforts|Research and Development,17263522,0,10.1021/jm061154d,NULL,Q965D5,NULL
301712,2,Inhibition of soybean recombinant SMT expressed in Escherichia coli,Title: Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26._|__|_Abstract: The enzymatic C-methylation reaction catalyzed by the Glycine max sterol 24-C-methyltransferase was studied with substrate analogs containing a cycloartenol nucleus (CA) and a double bond (8) or triple bond (14) attached to C26. The production of the corresponding C24(28)-methylene olefin and time-dependent inhibition kinetics of k(inact) 0.24 min(-1) (CA-8) or 0.06 min(-1) (CA-14) indicates a,43,ChEMBL,449738,20181022,"44434251,44434252,44434253,44434254","103538157,103538158,103538159,103538160",NULL,NULL,Q43445,Curation Efforts|Research and Development,17851075,0,10.1016/j.bmcl.2007.07.096,NULL,Q43445,NULL
301715,100,Inhibition of soybean recombinant SMT expressed in Escherichia coli assessed as C-methylation in presence of 50 uM cycloartenol substrate,Title: Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26._|__|_Abstract: The enzymatic C-methylation reaction catalyzed by the Glycine max sterol 24-C-methyltransferase was studied with substrate analogs containing a cycloartenol nucleus (CA) and a double bond (8) or triple bond (14) attached to C26. The production of the corresponding C24(28)-methylene olefin and time-dependent inhibition kinetics of k(inact) 0.24 min(-1) (CA-8) or 0.06 min(-1) (CA-14) indicates a,43,ChEMBL,449741,20181022,44434251,103538157,NULL,NULL,Q43445,Curation Efforts|Research and Development,17851075,0,10.1016/j.bmcl.2007.07.096,NULL,Q43445,NULL
301716,100,Inhibition of soybean recombinant SMT expressed in Escherichia coli assessed as C-methylation in presence of 100 uM cycloartenol substrate,Title: Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26._|__|_Abstract: The enzymatic C-methylation reaction catalyzed by the Glycine max sterol 24-C-methyltransferase was studied with substrate analogs containing a cycloartenol nucleus (CA) and a double bond (8) or triple bond (14) attached to C26. The production of the corresponding C24(28)-methylene olefin and time-dependent inhibition kinetics of k(inact) 0.24 min(-1) (CA-8) or 0.06 min(-1) (CA-14) indicates a,43,ChEMBL,449742,20181022,44434251,103538157,NULL,NULL,Q43445,Curation Efforts|Research and Development,17851075,0,10.1016/j.bmcl.2007.07.096,NULL,Q43445,NULL
327798,2,Inhibition of SARS-CoV 3CL protease,"Title: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease._|__|_Abstract: A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enz",43,ChEMBL,475824,20181023,"10601389,44452180,44452182,44452183,44452184,44452208,44452209,73350244","103569656,103569658,103569659,103569660,103569693,103569694,103569695,174500515",NULL,NULL,NULL,Curation Efforts|Research and Development,18329272,0,10.1016/j.bmc.2008.02.040,NULL,NULL,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
327799,2,Inhibition of SARS-CoV 3CL protease after 10 mins,"Title: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease._|__|_Abstract: A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enz",43,ChEMBL,475825,20181023,73350244,174500515,NULL,NULL,NULL,Curation Efforts|Research and Development,18329272,0,10.1016/j.bmc.2008.02.040,NULL,NULL,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
327800,2,Inhibition of SARS-CoV 3CL protease after 30 mins,"Title: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease._|__|_Abstract: A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enz",43,ChEMBL,475826,20181023,73350244,174500515,NULL,NULL,NULL,Curation Efforts|Research and Development,18329272,0,10.1016/j.bmc.2008.02.040,NULL,NULL,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
327801,2,Inhibition of SARS-CoV 3CL protease after 1 hr,"Title: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease._|__|_Abstract: A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enz",43,ChEMBL,475827,20181023,73350244,174500515,NULL,NULL,NULL,Curation Efforts|Research and Development,18329272,0,10.1016/j.bmc.2008.02.040,NULL,NULL,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
327802,2,Inhibition of SARS-CoV 3CL protease after 2 hrs,"Title: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease._|__|_Abstract: A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enz",43,ChEMBL,475828,20181023,73350244,174500515,NULL,NULL,NULL,Curation Efforts|Research and Development,18329272,0,10.1016/j.bmc.2008.02.040,NULL,NULL,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
327803,2,Inhibition of SARS-CoV 3CL protease after 4 hrs,"Title: Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease._|__|_Abstract: A series of trifluoromethyl ketones as SARS-CoV 3CL protease inhibitors was developed. The inhibitors were synthesized in four steps from commercially available compounds. Three different amino acids were explored in the P1-position and in the P2-P4 positions varying amino acids and long alkyl chain were incorporated. All inhibitors were evaluated in an in vitro assay using purified enz",43,ChEMBL,475829,20181023,73350244,174500515,NULL,NULL,NULL,Curation Efforts|Research and Development,18329272,0,10.1016/j.bmc.2008.02.040,NULL,NULL,"COVID-19, COVID19, Coronavirus, Corona-virus, SARS, SARS2, SARS-CoV, SARS-CoV-2 [as per BioAssay]"
347510,2,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 0 to 5 mins by time dependent inhibition assay,"Title: Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate._|__|_Abstract: N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist ",43,ChEMBL,495539,20181026,"12560,16040587","103175312,103590712",1576,NULL,P08684,Curation Efforts|Research and Development,19191554,0,10.1021/jm801332q,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
347511,2,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate measured in 25 to 30 mins by time dependent inhibition assay,"Title: Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate._|__|_Abstract: N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist ",43,ChEMBL,495540,20181026,"12560,16040587","103175312,103590712",1576,NULL,P08684,Curation Efforts|Research and Development,19191554,0,10.1021/jm801332q,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
347513,2,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate by time dependent inhibition assay,"Title: Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate._|__|_Abstract: N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist ",43,ChEMBL,495542,20181026,"15604512,15984134,15984238,15984240,15984241,15984242,15984318,15984937,15984938,15984939","103590713,103590714,103590715,103590791,103590962,103590963,103590964,103590965,103591039,103591040",1576,NULL,P08684,Curation Efforts|Research and Development,19191554,0,10.1021/jm801332q,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
347514,2,Inhibition of human CYP3A4 expressed in Escherichia coli using 7BQ substrate by time dependent inhibition assay,"Title: Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate._|__|_Abstract: N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist ",43,ChEMBL,495543,20181026,"15604512,15984134,15984238,15984240,15984241,15984242,15984318,15984937,15984938,15984939","103590713,103590714,103590715,103590791,103590962,103590963,103590964,103590965,103591039,103591040",1576,NULL,P08684,Curation Efforts|Research and Development,19191554,0,10.1021/jm801332q,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
347515,100,Inhibition of human CYP3A4 expressed in Escherichia coli using diethoxyfluorescein substrate assessed as decrease in enzyme activity by time dependent inhibition assay,"Title: Discovery of N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine (GSK962040), the first small molecule motilin receptor agonist clinical candidate._|__|_Abstract: N-(3-fluorophenyl)-1-[(4-([(3S)-3-methyl-1-piperazinyl]methyl)phenyl)acetyl]-4-piperidinamine 12 (GSK962040) is a novel small molecule motilin receptor agonist. It possesses excellent activity at the recombinant human motilin receptor and also at the native rabbit motilin receptor where its agonist ",43,ChEMBL,495544,20200703,"15604512,15984134,15984238,15984240,15984241,15984242,15984318,15984937,15984938,15984939","103590713,103590714,103590715,103590791,103590962,103590963,103590964,103590965,103591039,103591040",1576,NULL,P08684,Curation Efforts|Research and Development,19191554,0,10.1021/jm801332q,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
428223,100,Inhibition of CYP3A4 by time-dependent inhibition assay,"Title: Synthesis, structure-activity relationships, and biological profiles of a dihydrobenzoxathiin class of histamine H(3) receptor inverse agonists._|__|_Abstract: A series of novel dihydrobenzoxathiin derivatives was synthesized and evaluated as potent human histamine H(3) receptor inverse agonists. After systematic modification of lead 1a, the potent and selective histamine H(3) inverse agonist 1-(3-{4-[(2S,3S)-8-methoxy-3-methyl-4,4-dioxido-2,3-dihydro-1,4-benzoxathiin-2-yl]phenoxy}propyl)pyrrolidine ",43,ChEMBL,579567,20180910,44250288,103684802,1576,NULL,P08684,Curation Efforts|Research and Development,19520574,0,10.1016/j.bmcl.2009.05.101,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
444455,100,"AUC (0 to 24 hrs) in mouse at ED50, po","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595633,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444456,100,"AUC (0 to 24 hrs) in mouse at ED90, po","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595634,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444461,100,Selective ratio of human CYP3A4 IC50 to human CYP3A4 IC50 with pre-incubation,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595639,20200702,"24824705,24864821,24864825,24864993,24865175,25064072,25064073,25064510,25064730,25065131,45102733,45487862,45487864,45487870","103620793,103620861,103620862,103620914,103708688,103708689,103708700,103708726,103708727,103708732,103708738,103708750,103708758,103708764",1576,NULL,P08684,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
444462,100,Intrinsic clearance in rat liver microsomes,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595640,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444463,100,Intrinsic clearance in mouse liver microsomes,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595641,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444464,100,Intrinsic clearance in human liver microsomes,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595642,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444465,100,Plasma protein binding in rat at 5 ug/ml,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595643,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444466,100,Plasma protein binding in mouse at 5 ug/ml,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595644,20180911,45102733,103708738,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444467,100,Plasma protein binding in human at 5 ug/ml,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595645,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444468,100,"Clearance in Sprague-Dawley rat at 0.25 mg/kg, iv in DMSO vehicle","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595646,20180911,45102733,103708738,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444469,100,"Clearance in Sprague-Dawley rat at 0.25 mg/kg, iv in 20% hydroxypropyl beta-cyclodextrin in water pH 3.5 w/MSA vehicle","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595647,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444470,100,"Volume of distribution at steady state in Sprague-Dawley rat at 0.25 mg/kg, iv in DMSO vehicle","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595648,20180911,45102733,103708738,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444471,100,"Volume of distribution at steady state in Sprague-Dawley rat at 0.25 mg/kg, iv in 20% hydroxypropyl beta-cyclodextrin in water pH 3.5 w/MSA vehicle","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595649,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444472,100,"Half life in Sprague-Dawley rat at 0.25 mg/kg, iv in DMSO vehicle","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595650,20180911,45102733,103708738,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444473,100,"Half life in Sprague-Dawley rat at 0.25 mg/kg, iv in 20% hydroxypropyl beta-cyclodextrin in water pH 3.5 w/MSA vehicle","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595651,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444474,100,"AUC (0 to infinity) in Sprague-Dawley rat at 2 mg/kg, po","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595652,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444475,100,Oral bioavailability in Sprague-Dawley rat at 2 mg/kg,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595653,20180911,"45102733,45487870","103708738,103708758",NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444477,100,Cardiotoxicity in rabbit heart assessed as electrocardiographic parameters up to 3 uM,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595655,20180911,45487870,103708758,NULL,Toxicity,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444481,100,Antitumor activity against TPR-Met expressing NIH/3T3 xenografted in mouse dosed po over 22 days q.d,"Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595659,20180911,45487870,103708758,NULL,NULL,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
444482,100,"Toxicity in mouse xenografted with TPR-Met expressing NIH/3T3 up to 100 mg/kg, po over 22 days q.d","Title: Discovery and optimization of potent and selective triazolopyridazine series of c-Met inhibitors._|__|_Abstract: Deregulation of the receptor tyrosine kinase c-Met has been implicated in several human cancers and is an attractive target for small molecule drug discovery. We previously showed that O-linked triazolopyridazines can be potent inhibitors of c-Met. Herein, we report the discovery of a related series of N-linked triazolopyridazines which demonstrate nanomolar inhibition of c-Met kinase acti",43,ChEMBL,595660,20180911,45487870,103708758,NULL,Toxicity,NULL,Curation Efforts|Research and Development,19819693,0,10.1016/j.bmcl.2009.09.096,NULL,NULL,NULL
457066,2,Inhibition of human VLA4,Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608124,20180912,"45485800,45485803,45485807,46229904,46229905,46229906,46229907,46229908,46229909,46229910,46229911,46229912,46229913,46229914,46229915,46229916,46229917,46229918,46229919","103704720,103704723,103704727,103724604,103724605,103724606,103724607,103724608,103724609,103724610,103724611,103724612,103724613,103724614,103724615,103724616,103724617,103724618,103724619",3676,NULL,P13612,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,P13612,NULL
457072,2,Inhibition of human VLA4 in presence of 90% human plasma,Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608130,20180912,"45485800,45485803,45485807,46229904,46229908,46229909,46229910,46229911,46229912,46229913,46229914,46229915,46229916,46229917,46229918,46229919","103704720,103704723,103704727,103724604,103724608,103724609,103724610,103724611,103724612,103724613,103724614,103724615,103724616,103724617,103724618,103724619",3676,NULL,P13612,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,P13612,NULL
457073,100,Inhibition of human VLA4 in presence of 90% human plasma at 100 nM,Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608131,20180912,"46229905,46229907","103724605,103724607",3676,NULL,P13612,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,P13612,NULL
457074,100,Inhibition of human VLA4 in presence of 90% human plasma at 62.5 nM,Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608132,20180912,46229906,103724606,3676,NULL,P13612,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,P13612,NULL
489767,100,Inhibition of CYP3A4 in human liver microsomes assessed as time dependent inhibition at 12 mins,"Title: 2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression._|__|_Abstract: Recently a class of compounds known as triple reuptake inhibitors has emerged as a new strategy for the treatment of depression. These compounds work by simultaneously inhibiting the synaptic reuptake of serotonin, norepinephrine and dopamine. In this Letter we describe the optimization of a novel series of 2-substituted N-aryl piperazine based triple reuptake inhibitors.",43,ChEMBL,640169,20180913,"24782486,44188689,44188691,49798218,49798242,49798243","103766800,103766831,103766832,103766833,103766862,103766865",1576,NULL,P08684,Curation Efforts|Research and Development,20570146,0,10.1016/j.bmcl.2010.05.008,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
494757,100,Cytotoxicity against human A549 cells at 10 uM after 48 hrs by SRB assay,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644797,20180914,46919421,104238032,NULL,Toxicity,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494758,100,Cytotoxicity against human A549 cells at 20 uM after 48 hrs by SRB assay,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644798,20180914,46919421,104238032,NULL,Toxicity,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494759,100,Cytotoxicity against human A549 cells at 40 uM after 48 hrs by SRB assay,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644799,20180914,46919421,104238032,NULL,Toxicity,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494760,2,Cytotoxicity against human A549 cells after 48 hrs by SRB assay,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644800,20180914,"46919421,49862764,49862765,49862766,49862767,49862832,49862833,49862834,49862835","104237952,104237953,104237954,104237955,104238032,104238033,104238034,104238035,104238036",NULL,Toxicity,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494761,100,Cytotoxicity against human A549 cells at 10 to 40 uM by SRB assay,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644801,20180914,"46919421,49862764,49862765,49862766,49862767,49862832,49862833,49862834,49862835","104237952,104237953,104237954,104237955,104238032,104238033,104238034,104238035,104238036",NULL,Toxicity,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494762,100,Induction of apoptosis in human A549 cells assessed as occurrence of nuclear granulation at 10 to 40 uM after 48 hrs by Hoechst 33258 staining-based fluorescence microscopy,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644802,20180914,"46919421,49862764,49862765,49862766,49862767,49862832","104237952,104237953,104237954,104237955,104238032,104238033",NULL,NULL,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494763,100,Induction of necrosis in human A549 cells assessed as LDH release at 40 uM after 48 hrs,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644803,20180914,"46919421,49862764,49862765,49862766,49862767,49862832,49862833,49862834,49862835","104237952,104237953,104237954,104237955,104238032,104238033,104238034,104238035,104238036",NULL,NULL,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494764,100,Anticancer activity against human A549 cells assessed as occurrence of autophagy at 10 to 40 uM after 48 hrs by acridine orange staining-based fluorescence microscopy,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644804,20180914,"46919421,49862765,49862767,49862832,49862834,49862835","104237953,104237955,104238032,104238033,104238035,104238036",NULL,NULL,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494765,100,Anticancer activity against human A549 cells assessed as increase in autophagosome level at 20 uM after 24 hrs by Western blot analysis,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644805,20180914,"46919421,49862767","104237955,104238032",NULL,NULL,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
494766,100,Anticancer activity against human A549 cells assessed as increase in autophagosome level at 40 uM after 24 hrs by Western blot analysis,"Title: Synthesis of novel oxime-containing pyrazole derivatives and discovery of regulators for apoptosis and autophagy in A549 lung cancer cells._|__|_Abstract: A series of novel oxime-containing pyrazole derivatives were synthesized by the reaction of ethyl 3-phenyl-1H-pyrazole-5-carboxylate derivatives and 2-bromo-1-phenylethanone followed by the reaction with hydroxylamine hydrochloride. The structures were determined by IR, (1)H NMR, HRMS, and X-ray analysis. A dose- and time-dependent inhibition of pr",43,ChEMBL,644806,20180914,"49862765,49862832,49862833,49862834,49862835","104237953,104238033,104238034,104238035,104238036",NULL,NULL,NULL,Curation Efforts|Research and Development,20637610,0,10.1016/j.bmcl.2010.06.121,NULL,NULL,NULL
541241,100,Inhibition of CYP3A4 in human liver microsomes assessed as time dependent inhibition using nifedipine as probe,"Title: Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist._|__|_Abstract: In an effort to identify selective drug like pan-antagonists of the 5-HT1 autoreceptors, studies were conducted to elaborate a previously reported dual acting 5-HT1 antagonist/SSRI structure. A novel series of compounds was identified showing low intrinsic activities and potent affinities across the 5-HT1A, 5-H",43,ChEMBL,689767,20180916,11292933,124970505,1576,NULL,P08684,Curation Efforts|Research and Development,21053897,0,10.1021/jm100714c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
541242,100,Inhibition of CYP3A4 in human liver microsomes assessed as time dependent inhibition using atorvastatin as probe,"Title: Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist._|__|_Abstract: In an effort to identify selective drug like pan-antagonists of the 5-HT1 autoreceptors, studies were conducted to elaborate a previously reported dual acting 5-HT1 antagonist/SSRI structure. A novel series of compounds was identified showing low intrinsic activities and potent affinities across the 5-HT1A, 5-H",43,ChEMBL,689768,20180916,11292933,124970505,1576,NULL,P08684,Curation Efforts|Research and Development,21053897,0,10.1021/jm100714c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
541243,100,Inhibition of CYP3A4 in human liver microsomes assessed as time dependent inhibition using midazolam as probe,"Title: Discovery of 1-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-2-imidazolidinone (GSK163090), a Potent, selective, and orally active 5-HT1A/B/D receptor antagonist._|__|_Abstract: In an effort to identify selective drug like pan-antagonists of the 5-HT1 autoreceptors, studies were conducted to elaborate a previously reported dual acting 5-HT1 antagonist/SSRI structure. A novel series of compounds was identified showing low intrinsic activities and potent affinities across the 5-HT1A, 5-H",43,ChEMBL,689769,20180916,11292933,124970505,1576,NULL,P08684,Curation Efforts|Research and Development,21053897,0,10.1021/jm100714c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
568414,2,Inhibition of human CYP3A4 by time-dependent inhibition assay,"Title: Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist._|__|_Abstract: Compound 21 (AM432) was identified as a potent and selective antagonist of the DP(2) receptor (CRTH2). Modification of a bi-aryl core identified a series of tri-aryl antagonists of which compound 21 proved a viable clinical candidate. AM432 shows excellent potency in a human whole blood eosinophil shape cha",43,ChEMBL,716954,20180917,50901657,124961155,1576,NULL,P08684,Curation Efforts|Research and Development,21211969,0,10.1016/j.bmcl.2010.12.016,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
577783,100,Inhibition of STAT3 dimerization in v-Src transformed mouse NIH3T3 cells assessed as suppression of STAT3-DNA binding activity in nucleus at 100 uM after 24 hrs by electrophoretic mobility shift assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726323,20200626,"51351545,51351546,53319710,53319711","124962272,124962273,124967792,124975440",20848,NULL,P42227,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,P42227,NULL
577784,100,Inhibition of STAT3 dimerization in v-Src transformed mouse NIH3T3 cells assessed as suppression of STAT3-DNA binding activity in nucleus at 100 uM after 6 hrs by electrophoretic mobility shift assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726324,20200626,"51351545,51351546,53319710,53319711","124962272,124962273,124967792,124975440",20848,NULL,P42227,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,P42227,NULL
577787,2,Inhibition of STAT3 dimerization in mouse NIH3T3 cells expressing v-Src assessed as disruption of STAT3-STAT3: DNA complexation in nucleus after 30 mins by electrophoretic mobility shift assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726327,20200626,"51351545,51351546,53318375,53318376,53318509,53319710,53319711,53319712,53319837,53322458,53324283,53324977,53325554,53326387","124959666,124959667,124959886,124962272,124962273,124962274,124962502,124967792,124967793,124971285,124972826,124973826,124975440,124975641",20848,NULL,P42227,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,P42227,NULL
577790,2,Inhibition of mouse recombinant SH2 domain of His-tagged full-length STAT3 by surface plasmon resonance assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726330,20200626,"51351545,51351546,53319710,53319711,73352819","124962272,124962273,124967792,124975440,174510323",20848,NULL,P42227,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,P42227,NULL
590889,2,Inhibition of human recombinant renin in human citreated-plasma,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741040,20180918,"24953169,24953170,24953519,25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580283,54581286,54584273,54587171,54587173","131272660,131272662,131274612,131274613,131274698,131276682,131276683,131276685,131278661,131278662,131280715,131280716,131280717,131280782,131286722,131286724,131286725",5972,NULL,P00797,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,3.4.23.15,P00797,NULL
590891,2,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry in absence of NADPH,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741042,20180918,"24953169,24953170,24953519,25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580283,54581286,54584273,54587171,54587173","131272660,131272662,131274612,131274613,131274698,131276682,131276683,131276685,131278661,131278662,131280715,131280716,131280717,131280782,131286722,131286724,131286725",1576,NULL,P08684,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
590892,2,Inhibition of human CYP3A4 in human liver microsomes assessed as formation of 6beta-hydroxy-testosterone using testosterone as substrate by high throughput mass spectrometry preincubated for 30 mins in presence of NADPH,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741043,20180918,"24953169,24953170,24953519,25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580283,54581286,54584273,54587171,54587173","131272660,131272662,131274612,131274613,131274698,131276682,131276683,131276685,131278661,131278662,131280715,131280716,131280717,131280782,131286722,131286724,131286725",1576,NULL,P08684,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
590895,2,Inhibition of human recombinant renin in PBS buffer using tetradecapeptide at pH 7.4,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741046,20180918,"24953169,24953170,24953519,25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580283,54581286,54584273,54587171,54587173","131272660,131272662,131274612,131274613,131274698,131276682,131276683,131276685,131278661,131278662,131280715,131280716,131280717,131280782,131286722,131286724,131286725",5972,NULL,P00797,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,3.4.23.15,P00797,NULL
604218,2,Time dependent inhibition of CYP1A2,Title: Selective non zinc binding inhibitors of MMP13._|__|_Abstract: Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates an interesting mode of inhibition without interaction with the catalytic zinc atom.,43,ChEMBL,754228,20200629,53311230,134460062,1544,NULL,P05177,Curation Efforts|Research and Development,21669521,0,10.1016/j.bmcl.2011.05.075,"1.14.14.1,4.2.1.152",P05177,NULL
604243,2,Time dependent inhibition of CYP2C9,Title: Selective non zinc binding inhibitors of MMP13._|__|_Abstract: Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates an interesting mode of inhibition without interaction with the catalytic zinc atom.,43,ChEMBL,754253,20180919,53311230,134460062,1559,NULL,P11712,Curation Efforts|Research and Development,21669521,0,10.1016/j.bmcl.2011.05.075,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
604244,2,Time dependent inhibition of CYP2C19,Title: Selective non zinc binding inhibitors of MMP13._|__|_Abstract: Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates an interesting mode of inhibition without interaction with the catalytic zinc atom.,43,ChEMBL,754254,20180919,53311230,134460062,1557,NULL,P33261,Curation Efforts|Research and Development,21669521,0,10.1016/j.bmcl.2011.05.075,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
604245,2,Time dependent inhibition of CYP2D6,Title: Selective non zinc binding inhibitors of MMP13._|__|_Abstract: Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates an interesting mode of inhibition without interaction with the catalytic zinc atom.,43,ChEMBL,754255,20180919,53311230,134460062,1565,NULL,P10635,Curation Efforts|Research and Development,21669521,0,10.1016/j.bmcl.2011.05.075,1.14.14.-,P10635,NULL
604246,2,Time dependent inhibition of CYP3A4,Title: Selective non zinc binding inhibitors of MMP13._|__|_Abstract: Directed screening has identified a novel series of MMP13 inhibitors that possess good levels of activity whilst possessing excellent selectivity over related MMPs. The binding mode of the series has been solved by co-crystallisation and demonstrates an interesting mode of inhibition without interaction with the catalytic zinc atom.,43,ChEMBL,754256,20180919,53311230,134460062,1576,NULL,P08684,Curation Efforts|Research and Development,21669521,0,10.1016/j.bmcl.2011.05.075,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
612392,100,Time dependent inhibition of human recombinant MAOA expressed in insect cells at 13.42 uM preincubated 0 to 60 mins before kynuramine substrate addition by fluorescence spectroscopy,"Title: Inhibition of monoamine oxidase by C5-substituted phthalimide analogues._|__|_Abstract: Literature reports that isatin as well as C5- and C6-substituted isatin analogues are reversible inhibitors of human monoamine oxidase (MAO) A and B. In general, C5- and C6-substitution of isatin leads to enhanced binding affinity to both MAO isozymes compared to isatin and in most instances result in selective binding to the MAO-B isoform. Crystallographic and modeling studies suggest that the isatin ring binds t",43,ChEMBL,762403,20200629,834420,134459389,4128,NULL,P21397,Curation Efforts|Research and Development,21778064,0,10.1016/j.bmc.2011.06.070,1.4.3.4,P21397,NULL
612393,100,Time dependent inhibition of human recombinant MAOB expressed in insect cells at 5 uM preincubated 0 to 60 mins before kynuramine substrate addition by fluorescence spectroscopy,"Title: Inhibition of monoamine oxidase by C5-substituted phthalimide analogues._|__|_Abstract: Literature reports that isatin as well as C5- and C6-substituted isatin analogues are reversible inhibitors of human monoamine oxidase (MAO) A and B. In general, C5- and C6-substitution of isatin leads to enhanced binding affinity to both MAO isozymes compared to isatin and in most instances result in selective binding to the MAO-B isoform. Crystallographic and modeling studies suggest that the isatin ring binds t",43,ChEMBL,762404,20200629,834420,134459389,4129,NULL,P27338,Curation Efforts|Research and Development,21778064,0,10.1016/j.bmc.2011.06.070,1.4.3.4,P27338,NULL
619347,100,Time dependent inhibition of human recombinant MAO-B assessed as oxidation of kynuramine to 4-hydroxyquinoline at IC50 after 15 to 60 mins,"Title: Monoamine oxidase inhibition by selected anilide derivatives._|__|_Abstract: A series of anilide derivatives were synthesized and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The most potent inhibitors among the derivatives that were initially evaluated were (2E)-N-(3-chlorophenyl)-3-phenylprop-2-enamide (2c) and (2E)-N-(3-bromophenyl)-3-phenylprop-2-enamide (2d) with IC(50) values of 0.53 &#x3BC;M and 0.45 &#x3BC;M, respectively. These derivatives exhibited reversibl",43,ChEMBL,769358,20200629,"690158,54753443","134453078,134456882",4129,NULL,P27338,Curation Efforts|Research and Development,21899930,0,10.1016/j.ejmech.2011.08.036,1.4.3.4,P27338,NULL
622602,2,Time dependent inhibition of CYP1A2,"Title: Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders._|__|_Abstract: To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.",43,ChEMBL,772613,20200629,"1684,54752774","103200390,134450767",1544,NULL,P05177,Curation Efforts|Research and Development,21907579,0,10.1016/j.bmcl.2011.08.083,"1.14.14.1,4.2.1.152",P05177,NULL
622603,2,Time dependent inhibition of CYP2C9,"Title: Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders._|__|_Abstract: To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.",43,ChEMBL,772614,20180919,"1684,54752774","103200390,134450767",1559,NULL,P11712,Curation Efforts|Research and Development,21907579,0,10.1016/j.bmcl.2011.08.083,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
622604,2,Time dependent inhibition of CYP2C19,"Title: Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders._|__|_Abstract: To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.",43,ChEMBL,772615,20180919,"1684,54752774","103200390,134450767",1557,NULL,P33261,Curation Efforts|Research and Development,21907579,0,10.1016/j.bmcl.2011.08.083,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
622605,2,Time dependent inhibition of CYP2D6,"Title: Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders._|__|_Abstract: To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.",43,ChEMBL,772616,20180919,"1684,54752774","103200390,134450767",1565,NULL,P10635,Curation Efforts|Research and Development,21907579,0,10.1016/j.bmcl.2011.08.083,1.14.14.-,P10635,NULL
622606,2,Time dependent inhibition of CYP3A4,"Title: Effect of lipophilicity modulation on inhibition of human rhinovirus capsid binders._|__|_Abstract: To try and generate broad spectrum human rhinovirus VP1 inhibitors with more attractive physicochemical, DMPK and safety profiles, we explored the current SAR of known VP1 compounds. This lead to the identification of specific structural regions where reduction in polarity can be achieved, so guiding chemistry to analogues with significantly superior profiles to previously reported inhibitors.",43,ChEMBL,772617,20180919,"1684,54752774","103200390,134450767",1576,NULL,P08684,Curation Efforts|Research and Development,21907579,0,10.1016/j.bmcl.2011.08.083,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
632188,100,Time-dependent inhibition of CYP3A4 at 10 uM,"Title: 5-Lipoxygenase-activating protein (FLAP) inhibitors. Part 4: development of 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid (AM803), a potent, oral, once daily FLAP inhibitor._|__|_Abstract: The potent 5-lipoxygenase-activating protein (FLAP) inhibitor 3-[3-tert-butylsulfanyl-1-[4-(6-ethoxypyridin-3-yl)benzyl]-5-(5-methylpyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethylpropionic acid 11cc is described (AM803, now GSK2",43,ChEMBL,789636,20180920,44473151,136926348,1576,NULL,P08684,Curation Efforts|Research and Development,22059882,0,10.1021/jm2008369,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
644759,100,Time dependent inhibition of recombinant human monoamine oxidase A at 0.190 uM preincubated for 15 to 60 mins before kynuramine substrate addition measured after 15 mins by fluorescence spectrophotometry,"Title: Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives._|__|_Abstract: Chromone has been reported to be a useful scaffold for the design of monoamine oxidase (MAO) inhibitors. In an attempt to discover highly potent MAO inhibitors and to contribute to the known structure-activity relationships (SAR) of MAO inhibition by chromones, in the present study, we have synthesized a series of chromone derivatives substituted at C6 with a variety of alkyloxy substituents, and evaluated",43,ChEMBL,802207,20180921,57379977,136933010,4128,NULL,P21397,Curation Efforts|Research and Development,22309913,0,10.1016/j.ejmech.2012.01.037,1.4.3.4,P21397,NULL
644760,100,Time dependent inhibition of recombinant human monoamine oxidase B at 0.064 uM preincubated for 15 to 60 mins before kynuramine substrate addition measured after 15 mins by fluorescence spectrophotometry,"Title: Inhibition of monoamine oxidase by selected C6-substituted chromone derivatives._|__|_Abstract: Chromone has been reported to be a useful scaffold for the design of monoamine oxidase (MAO) inhibitors. In an attempt to discover highly potent MAO inhibitors and to contribute to the known structure-activity relationships (SAR) of MAO inhibition by chromones, in the present study, we have synthesized a series of chromone derivatives substituted at C6 with a variety of alkyloxy substituents, and evaluated",43,ChEMBL,802208,20180921,57379977,136933010,4129,NULL,P27338,Curation Efforts|Research and Development,22309913,0,10.1016/j.ejmech.2012.01.037,1.4.3.4,P27338,NULL
657368,2,Inhibition of cytosolic human carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814440,20200626,"5056,10680,11349,5281607,5281894,7463363,7463364,7463369,7463376,12420669,13803658,14435742,16450309,45029305,45029333,56921864,70681295,70685487,70687643,70689703,70689704,70691832,70691833,70693894","103180236,103180356,103180510,103243469,160667305,160667306,160677937,160677938,160683303,160683304,160683305,160683306,160688651,160688652,160688653,160694135,160694136,160694137,160694138,160694139,160699478,160699479,160704800,160704801",759,NULL,P00915,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P00915,NULL
657369,2,Inhibition of cytosolic human carbonic anhydrase 1 preincubated for 12 hrs by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814441,20200626,"10680,11349,5281607,5281894","103180236,103180356,103180510,103243469",759,NULL,P00915,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P00915,NULL
657370,2,Inhibition of cytosolic human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814442,20200626,"5056,10680,11349,5281607,5281894,7463363,7463364,7463369,7463376,12420669,13803658,14435742,16450309,45029305,45029333,56921864,70681295,70685487,70687643,70689703,70689704,70691832,70691833,70693894","103180236,103180356,103180510,103243469,160667305,160667306,160677937,160677938,160683303,160683304,160683305,160683306,160688651,160688652,160688653,160694135,160694136,160694137,160694138,160694139,160699478,160699479,160704800,160704801",760,NULL,P00918,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P00918,NULL
657371,2,Inhibition of cytosolic human carbonic anhydrase 2 preincubated for 12 hrs by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814443,20200626,"10680,11349,5281607,5281894","103180236,103180356,103180510,103243469",760,NULL,P00918,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P00918,NULL
657372,2,Inhibition of transmembrane tumor-associated human carbonic anhydrase 9 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814444,20200626,"5056,10680,11349,5281607,5281894,7463376,56921864","103180236,103180356,103180510,103243469,160683306,160694135,160704801",768,NULL,Q16790,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,Q16790,NULL
657373,2,Inhibition of transmembrane tumor-associated human carbonic anhydrase 9 preincubated for 12 hrs by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814445,20200626,"10680,11349,5281607,5281894","103180236,103180356,103180510,103243469",768,NULL,Q16790,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,Q16790,NULL
657374,2,Inhibition of transmembrane tumor-associated human carbonic anhydrase 12 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814446,20200626,"5056,10680,11349,5281607,5281894,7463376,56921864","103180236,103180356,103180510,103243469,160683306,160694135,160704801",771,NULL,O43570,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,O43570,NULL
657375,2,Inhibition of transmembrane tumor-associated human carbonic anhydrase 12 preincubated for 12 hrs by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814447,20200626,"10680,11349,5281607,5281894","103180236,103180356,103180510,103243469",771,NULL,O43570,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,O43570,NULL
657376,2,Inhibition of human carbonic anhydrase 3 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814448,20200626,"5056,7463376,56921864","160683306,160694135,160704801",761,NULL,P07451,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P07451,NULL
657377,2,Inhibition of human carbonic anhydrase 4 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814449,20200626,"5056,7463376,56921864","160683306,160694135,160704801",762,NULL,P22748,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P22748,NULL
657378,2,Inhibition of human carbonic anhydrase 5b preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814450,20200626,"5056,7463376,56921864","160683306,160694135,160704801",11238,NULL,Q9Y2D0,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,Q9Y2D0,NULL
657379,2,Inhibition of human carbonic anhydrase 6 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814451,20200626,"5056,7463376,56921864","160683306,160694135,160704801",765,NULL,P23280,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P23280,NULL
657380,2,Inhibition of human carbonic anhydrase 7 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814452,20200626,"5056,7463376,56921864","160683306,160694135,160704801",766,NULL,P43166,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P43166,NULL
657381,2,Inhibition of human carbonic anhydrase 13 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814453,20200626,"5056,7463376,56921864","160683306,160694135,160704801",377677,NULL,Q8N1Q1,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,Q8N1Q1,NULL
657382,2,Inhibition of human carbonic anhydrase 14 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814454,20200626,"5056,7463376,56921864","160683306,160694135,160704801",23632,NULL,Q9ULX7,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,Q9ULX7,NULL
657383,2,Inhibition of mouse carbonic anhydrase 15 preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814455,20200626,"5056,7463376,56921864","160683306,160694135,160704801",80733,NULL,Q99N23,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,Q99N23,NULL
657384,2,Inhibition of human carbonic anhydrase 5a preincubated for 15 mins by stopped flow CO2 hydration assay,"Title: Flavones and structurally related 4-chromenones inhibit carbonic anhydrases by a different mechanism of action compared to coumarins._|__|_Abstract: An inhibition study of several carbonic anhydrase (CA, EC 4.2.1.1) isoforms with flavones and aminoflavones, compounds possessing a rather similar scaffold with the coumarins, recently discovered inhibitors of this enzyme, is reported. The natural product flavone and some of its hydroxylated derivatives did not show time-dependent inhibition of the CAs, ",43,ChEMBL,814456,20200626,"5056,7463376,56921864","160683306,160694135,160704801",763,NULL,P35218,Curation Efforts|Research and Development,22487176,0,10.1016/j.bmcl.2012.03.071,4.2.1.1,P35218,NULL
663238,100,Time dependent inhibition of electric eel acetylcholine esterase using acetylcholine chloride as substrate incubated for 5 mins prior to substrate addition measured for 2 to 40 mins by Ellman's assay,"Title: Multifunctional mercapto-tacrine derivatives for treatment of age-related neurodegenerative diseases._|__|_Abstract: Cooperating mercapto groups with tacrine in a single molecular, novel multifunctional compounds have been designed and synthesized. These mercapto-tacrine derivatives displayed a synergistic pharmacological profile of long-term potentiation enhancement, cholinesterase inhibition, neuroprotection, and less hepatotoxicity, emerging as promising molecules for the therapy of age-related ne",43,ChEMBL,820327,20180921,57386592,160684278,113580815,NULL,O42275,Curation Efforts|Research and Development,22420827,0,10.1021/jm300124p,3.1.1.7,O42275,NULL
665481,100,Time dependent inhibition of TrxR,"Title: Inhibition of thioredoxin reductase by a novel series of bis-1,2-benzisoselenazol-3(2H)-ones: Organoselenium compounds for cancer therapy._|__|_Abstract: Thioredoxin reductase (TrxR) is critical for cellular redox regulation and is involved in tumor proliferation, apoptosis and metastasis. Its C-terminal redox-active center contains a cysteine (Cys497) and a unique selenocysteine (Sec498), which are exposed to solvent and easily accessible. Thus, it is becoming an important target for anticancer drug",43,ChEMBL,822570,20180922,46911404,160668149,NULL,NULL,NULL,Curation Efforts|Research and Development,22579620,0,10.1016/j.bmc.2012.04.033,NULL,NULL,NULL
671189,100,Reversible inhibition of His-tagged PRMT1 expressed in Escherichia coli BL21(DE3) cells in time dependent inhibition protocol using [14C]-S-adenosyl-L-methionine and histone H4 peptide by scintillation counting,Title: Synthesis and evaluation of carbocyanine dyes as PRMT inhibitors and imaging agents._|__|_Abstract: Protein arginine methylation regulates multiple biological processes. Deregulation of protein arginine methyltransferase (PRMT) activities has been observed in many disease phenotypes. Small molecule probes that target PRMTs with strong affinity and selectivity can be used as valuable tools to dissect biological mechanisms of arginine methylation and establish the role of PRMT proteins in a disease pro,43,ChEMBL,828312,20180922,70686225,160679550,3276,NULL,Q99873,Curation Efforts|Research and Development,22749641,0,10.1016/j.ejmech.2012.06.017,2.1.1.319,Q99873,NULL
672021,2,Inhibition of human recombinant HDAC1 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 5 mins measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829144,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3065,NULL,Q13547,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q13547,NULL
672022,2,Inhibition of human recombinant HDAC1 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 3 hrs measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829145,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3065,NULL,Q13547,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q13547,NULL
672023,2,Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 5 mins measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829146,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672024,2,Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 3 hrs measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829147,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672025,2,Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 24 hrs measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829148,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672026,100,Inhibition of human recombinant HDAC3 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 5 mins at 10 uM measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829149,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",8841,NULL,O15379,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,O15379,NULL
672027,100,Inhibition of human recombinant HDAC3 using Boc-L-Lys (Ac)-AMC as substrate preincubated with compound for 3 hrs at 10 uM measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829150,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",8841,NULL,O15379,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,O15379,NULL
672028,100,Inhibition of human recombinant HDAC8 expressed in Escherichia coli using BML-KI-178 as substrate preincubated with compound for 5 mins at 10 uM measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829151,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",55869,NULL,Q9BY41,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q9BY41,NULL
672029,100,Inhibition of human recombinant HDAC8 expressed in Escherichia coli using BML-KI-178 as substrate preincubated with compound for 3 hrs at 10 uM measured after 35 mins by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829152,20180922,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",55869,NULL,Q9BY41,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q9BY41,NULL
672035,100,Ratio of inhibition of human HDAC3 at 10 uM preincubated for 3 hrs to inhibition of human HDAC3 at 10 uM preincubated for 5 mins,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829158,20200627,"5311,25155955,44454143,62706003,62706004,62706005,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160701401,160701402,160706679",8841,NULL,O15379,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,O15379,NULL
672040,100,Inhibition of human recombinant HDAC2 using Boc-L-Lys (Ac)-AMC as substrate by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829163,20180922,"25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672042,100,Inhibition of HDAC1 in human MDA-MB-231 cells assessed as inhibition of H4 deacetylation at 50 uM after 24 hrs by Western blot analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829165,20180922,"62706003,62706004,62706005,62706006,62706167,62706168,62706170,62706171,62706321","160669203,160669204,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3065,NULL,Q13547,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q13547,NULL
672043,100,Inhibition of HDAC2 in human MDA-MB-231 cells assessed as inhibition of H4 deacetylation at 50 uM after 24 hrs by Western blot analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829166,20180922,"62706003,62706004,62706005,62706006,62706167,62706168,62706170,62706171,62706321","160669203,160669204,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672044,100,Inhibition of human recombinant HDAC1 using Boc-L-Lys (Ac)-AMC as substrate by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829167,20180922,"25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3065,NULL,Q13547,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q13547,NULL
672045,100,Inhibition of human recombinant HDAC3 using Boc-L-Lys (Ac)-AMC as substrate at 10 uM by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829168,20180922,"25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",8841,NULL,O15379,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,O15379,NULL
672046,100,Inhibition of human recombinant HDAC8 using BML-KI-178 as substrate at 10 uM by spectrofluorometric analysis,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829169,20180922,"25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",55869,NULL,Q9BY41,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q9BY41,NULL
677036,100,Time dependent inhibition of human recombinant CYP3A4 coexpressed in Escherichia coli at 50 uM using midazolam as probe,"Title: Oxadiazoles in medicinal chemistry._|__|_Abstract: Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZene",43,ChEMBL,834175,20180922,"863679,877119,5299617,5300578,8902499,22431956,22520172,70682487,70695067","160669918,160669919,160675217,160675218,160691399,160696831,160702151,160702152,160707403",1576,NULL,P08684,Curation Efforts|Research and Development,22185670,0,10.1021/jm2013248,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
677037,100,Time dependent inhibition of human recombinant CYP2D6 coexpressed in Escherichia coli at 50 uM using bufuralol as probe,"Title: Oxadiazoles in medicinal chemistry._|__|_Abstract: Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZene",43,ChEMBL,834176,20180922,"863679,877119,5299617,5300578,8902499,22431956,22520172,70682487,70695067","160669918,160669919,160675217,160675218,160691399,160696831,160702151,160702152,160707403",1565,NULL,P10635,Curation Efforts|Research and Development,22185670,0,10.1021/jm2013248,1.14.14.-,P10635,NULL
677038,100,Time dependent inhibition of human recombinant CYP2C8 coexpressed in Escherichia coli at 50 uM using amodiaquine as probe,"Title: Oxadiazoles in medicinal chemistry._|__|_Abstract: Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZene",43,ChEMBL,834177,20180922,"863679,877119,5299617,5300578,8902499,22431956,22520172,70682487,70695067","160669918,160669919,160675217,160675218,160691399,160696831,160702151,160702152,160707403",1558,NULL,P10632,Curation Efforts|Research and Development,22185670,0,10.1021/jm2013248,1.14.14.1,P10632,NULL
677039,100,Time dependent inhibition of human recombinant CYP2C9 coexpressed in Escherichia coli at 50 uM using diclofenac as probe,"Title: Oxadiazoles in medicinal chemistry._|__|_Abstract: Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZene",43,ChEMBL,834178,20180922,"863679,877119,5299617,5300578,8902499,22431956,22520172,70682487,70695067","160669918,160669919,160675217,160675218,160691399,160696831,160702151,160702152,160707403",1559,NULL,P11712,Curation Efforts|Research and Development,22185670,0,10.1021/jm2013248,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
677040,100,Time dependent inhibition of human recombinant CYP2C19 coexpressed in Escherichia coli at 50 uM using mephenytoin as probe,"Title: Oxadiazoles in medicinal chemistry._|__|_Abstract: Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZene",43,ChEMBL,834179,20180922,"863679,877119,5299617,5300578,8902499,22431956,22520172,70682487,70695067","160669918,160669919,160675217,160675218,160691399,160696831,160702151,160702152,160707403",1557,NULL,P33261,Curation Efforts|Research and Development,22185670,0,10.1021/jm2013248,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
677041,100,Time dependent inhibition of human recombinant CYP1A2 coexpressed in Escherichia coli at 50 uM using phenacetin as probe,"Title: Oxadiazoles in medicinal chemistry._|__|_Abstract: Oxadiazoles are five-membered heteroaromatic rings containing two carbons, two nitrogens, and one oxygen atom, and they exist in different regioisomeric forms. Oxadiazoles are frequently occurring motifs in druglike molecules, and they are often used with the intention of being bioisosteric replacements for ester and amide functionalities. The current study presents a systematic comparison of 1,2,4- and 1,3,4-oxadiazole matched pairs in the AstraZene",43,ChEMBL,834180,20200630,"863679,877119,5299617,5300578,8902499,22431956,22520172,70682487,70695067","160669918,160669919,160675217,160675218,160691399,160696831,160702151,160702152,160707403",1544,NULL,P05177,Curation Efforts|Research and Development,22185670,0,10.1021/jm2013248,"1.14.14.1,4.2.1.152",P05177,NULL
683793,100,Time dependent inhibition of human recombinant MAO-A expressed in baculovirus infected insect cells using kynuramine as substrate at 9.7 uM by fluorescence spectrophotometry,"Title: Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives._|__|_Abstract: A recent study has reported that a series of 8-benzyloxycaffeines are potent and reversible inhibitors of both human monoamine oxidase (MAO) isoforms, MAO-A and -B. In an attempt to discover additional caffeine derivatives with potent MAO inhibitory activities, and to contribute to the known structure-activity relationships of MAO inhibition by caffeine derived compounds, the present study investigates the MAO inhi",43,ChEMBL,840940,20200630,70689078,160686455,4128,NULL,P21397,Curation Efforts|Research and Development,22705191,0,10.1016/j.bmc.2012.05.048,1.4.3.4,P21397,NULL
683794,100,Time dependent inhibition of human recombinant MAO-A expressed in baculovirus infected insect cells using kynuramine as substrate at 0.3 uM by fluorescence spectrophotometry,"Title: Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives._|__|_Abstract: A recent study has reported that a series of 8-benzyloxycaffeines are potent and reversible inhibitors of both human monoamine oxidase (MAO) isoforms, MAO-A and -B. In an attempt to discover additional caffeine derivatives with potent MAO inhibitory activities, and to contribute to the known structure-activity relationships of MAO inhibition by caffeine derived compounds, the present study investigates the MAO inhi",43,ChEMBL,840941,20200630,70689077,160686454,4128,NULL,P21397,Curation Efforts|Research and Development,22705191,0,10.1016/j.bmc.2012.05.048,1.4.3.4,P21397,NULL
683797,100,Time dependent inhibition of human recombinant MAO-B expressed in baculovirus infected insect cells using kynuramine as substrate at 9.7 uM by fluorescence spectrophotometry,"Title: Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives._|__|_Abstract: A recent study has reported that a series of 8-benzyloxycaffeines are potent and reversible inhibitors of both human monoamine oxidase (MAO) isoforms, MAO-A and -B. In an attempt to discover additional caffeine derivatives with potent MAO inhibitory activities, and to contribute to the known structure-activity relationships of MAO inhibition by caffeine derived compounds, the present study investigates the MAO inhi",43,ChEMBL,840944,20200630,70689078,160686455,4129,NULL,P27338,Curation Efforts|Research and Development,22705191,0,10.1016/j.bmc.2012.05.048,1.4.3.4,P27338,NULL
683798,100,Time dependent inhibition of human recombinant MAO-B expressed in baculovirus infected insect cells using kynuramine as substrate at 0.3 uM by fluorescence spectrophotometry,"Title: Inhibition of monoamine oxidase by 8-phenoxymethylcaffeine derivatives._|__|_Abstract: A recent study has reported that a series of 8-benzyloxycaffeines are potent and reversible inhibitors of both human monoamine oxidase (MAO) isoforms, MAO-A and -B. In an attempt to discover additional caffeine derivatives with potent MAO inhibitory activities, and to contribute to the known structure-activity relationships of MAO inhibition by caffeine derived compounds, the present study investigates the MAO inhi",43,ChEMBL,840945,20200630,70689077,160686454,4129,NULL,P27338,Curation Efforts|Research and Development,22705191,0,10.1016/j.bmc.2012.05.048,1.4.3.4,P27338,NULL
703360,100,Time dependent inhibition of CYP2D6,"Title: Potent and highly selective benzimidazole inhibitors of PI3-kinase delta._|__|_Abstract: Inhibition of PI3K&#x3B4; is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3K&#x3B4;. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3K&#x3B4; inhibi",43,ChEMBL,864104,20200625,"49834576,59606138","163314243,163338412",1565,NULL,P10635,Curation Efforts|Research and Development,22877085,0,10.1021/jm300717c,1.14.14.-,P10635,NULL
703361,100,Time dependent inhibition of CYP2C9,"Title: Potent and highly selective benzimidazole inhibitors of PI3-kinase delta._|__|_Abstract: Inhibition of PI3K&#x3B4; is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3K&#x3B4;. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3K&#x3B4; inhibi",43,ChEMBL,864105,20200625,"49834576,59606138","163314243,163338412",1559,NULL,P11712,Curation Efforts|Research and Development,22877085,0,10.1021/jm300717c,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
703362,100,Time dependent inhibition of CYP2C19,"Title: Potent and highly selective benzimidazole inhibitors of PI3-kinase delta._|__|_Abstract: Inhibition of PI3K&#x3B4; is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3K&#x3B4;. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3K&#x3B4; inhibi",43,ChEMBL,864106,20200625,"49834576,59606138","163314243,163338412",1557,NULL,P33261,Curation Efforts|Research and Development,22877085,0,10.1021/jm300717c,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
703363,100,Time dependent inhibition of CYP3A4,"Title: Potent and highly selective benzimidazole inhibitors of PI3-kinase delta._|__|_Abstract: Inhibition of PI3K&#x3B4; is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3K&#x3B4;. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3K&#x3B4; inhibi",43,ChEMBL,864107,20200625,"49834576,59606138","163314243,163338412",1576,NULL,P08684,Curation Efforts|Research and Development,22877085,0,10.1021/jm300717c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
703364,100,Time dependent inhibition of CYP1A2,"Title: Potent and highly selective benzimidazole inhibitors of PI3-kinase delta._|__|_Abstract: Inhibition of PI3K&#x3B4; is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3K&#x3B4;. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3K&#x3B4; inhibi",43,ChEMBL,864108,20200625,"49834576,59606138","163314243,163338412",1544,NULL,P05177,Curation Efforts|Research and Development,22877085,0,10.1021/jm300717c,"1.14.14.1,4.2.1.152",P05177,NULL
707016,100,Time dependent inhibition of CYP1A2,"Title: Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors._|__|_Abstract: There is a high demand for potent, selective, and brain-penetrant small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) to test whether inhibition of LRRK2 kinase activity is a potentially viable treatment option for Parkinson's disease patients. Herein we disclose the use of property and structure-based drug design for the optimization of highly ligan",43,ChEMBL,874759,20200625,"58539301,71460830","163331277,163335220",1544,NULL,P05177,Curation Efforts|Research and Development,22985112,0,10.1021/jm301020q,"1.14.14.1,4.2.1.152",P05177,NULL
718023,100,Time dependent inhibition of human recombinant MAO-B expressed in insect cell microsome assessed as 4-hydroxyquinoline formation using kynuramine as substrate preincubated for 15 to 60 mins at 2 times IC50 measured after 15 mins following twofold compound,"Title: Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues._|__|_Abstract: In a previous study we have investigated the monoamine oxidase (MAO) inhibitory properties of a series of 8-sulfanylcaffeine analogues. Among the compounds studied, 8-[(phenylethyl)sulfanyl]caffeine (IC(50) = 0.223 &#x3BC;M) was found to be a particularly potent inhibitor of the type B MAO isoform. In an attempt to discover potent MAO inhibitors and to further examine the structure-activity relationships (S",43,ChEMBL,885766,20200625,71461376,163336054,4129,NULL,P27338,Curation Efforts|Research and Development,23122934,0,10.1016/j.bmc.2012.10.005,1.4.3.4,P27338,NULL
718024,100,Time dependent inhibition of human recombinant MAO-A expressed in insect cell microsome assessed as 4-hydroxyquinoline formation using kynuramine as substrate preincubated for 15 to 60 mins at 2 times IC50 measured after 15 mins following twofold compound,"Title: Inhibition of monoamine oxidase by 8-[(phenylethyl)sulfanyl]caffeine analogues._|__|_Abstract: In a previous study we have investigated the monoamine oxidase (MAO) inhibitory properties of a series of 8-sulfanylcaffeine analogues. Among the compounds studied, 8-[(phenylethyl)sulfanyl]caffeine (IC(50) = 0.223 &#x3BC;M) was found to be a particularly potent inhibitor of the type B MAO isoform. In an attempt to discover potent MAO inhibitors and to further examine the structure-activity relationships (S",43,ChEMBL,885767,20200625,71461376,163336054,4128,NULL,P21397,Curation Efforts|Research and Development,23122934,0,10.1016/j.bmc.2012.10.005,1.4.3.4,P21397,NULL
727552,100,Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate at 10 x IC50 after 30 mins,"Title: Discovery of a Highly Selective, Brain-Penetrant Aminopyrazole LRRK2 Inhibitor._|__|_Abstract: The modulation of LRRK2 kinase activity by a selective small molecule inhibitor has been proposed as a potentially viable treatment for Parkinson's disease. By using aminopyrazoles as aniline bioisosteres, we discovered a novel series of LRRK2 inhibitors. Herein, we describe our optimization effort that resulted in the identification of a highly potent, brain-penetrant aminopyrazole LRRK2 inhibitor (18) tha",43,ChEMBL,940118,20200626,"67814206,67817055,67818467,67988921,69081998,69085771,69093006,69093123,69281457,69281523,69281529,69281543,69281678,69281708","164129002,164129003,164131843,164134684,164137536,164137537,164140330,164143100,164145859,164145860,164148698,164148699,164148700,164148701",1544,NULL,P05177,Curation Efforts|Research and Development,24900567,0,10.1021/ml3003007,"1.14.14.1,4.2.1.152",P05177,NULL
727904,100,Ratio of IC50 for in vivo inhibition of c-MET in human GTL16 cells xenografted in mouse to IC50 for c-MET (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940470,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727905,100,Toxicity in CD1 nu/nu mouse xenografted with human GLT16 cells assessed as change in body weight relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940471,20180925,45142457,164148325,NULL,Toxicity,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727906,2,Inhibition of c-MET (unknown origin) in presence of 10 % FBS,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940472,20180925,45142457,164148325,4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
727907,100,"Antitumor activity against human GTL16 cells expressing c-MET xenografted in CD1 nu/nu mouse assessed as tumor growth inhibition at 100 mg/kg, po qd for 21 days","Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940473,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727908,100,"Antitumor activity against human GTL16 cells expressing c-MET xenografted in CD1 nu/nu mouse assessed as tumor growth inhibition at 100 mg/kg, po bid for 21 days relative to control","Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940474,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727909,100,"Antitumor activity against human GTL16 cells expressing c-MET xenografted in CD1 nu/nu mouse assessed as tumor growth inhibition at 30 mg/kg, po bid for 21 days relative to control","Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940475,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727910,100,"Antitumor activity against human GTL16 cells expressing c-MET xenografted in CD1 nu/nu mouse assessed as tumor growth inhibition at 10 mg/kg, po bid for 21 days relative to control","Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940476,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727911,100,"Antitumor activity against human GTL16 cells expressing c-MET xenografted in CD1 nu/nu mouse assessed as tumor growth inhibition at 3 mg/kg, po bid for 21 days relative to control","Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940477,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727912,100,Antitumor activity against human GTL16 cells expressing c-MET xenografted in po dosed CD1 nu/nu mouse assessed as tumor growth inhibition administered bid for 21 days,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940478,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727913,2,In vivo inhibition of c-MET phosphorylation at tyrosine Y1349 in human GTL16 cells xenografted in po dosed mouse after 8 hrs by Western blotting analysis,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940479,20180925,45142457,164148325,NULL,In vivo,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727914,2,In vivo inhibition of c-MET phosphorylation at tyrosine Y1349 in human GTL16 cells xenografted in po dosed mouse after 1 hr by Western blotting analysis,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940480,20180925,45142457,164148325,NULL,In vivo,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727915,100,"In vivo inhibition of c-MET phosphorylation at tyrosine Y1349 in human GTL16 cells xenografted in mouse at 100 mg/kg, po after 1 hr by Western blotting analysis","Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940481,20180925,45142457,164148325,NULL,In vivo,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
727916,2,Inhibition of c-MET activation (unknown origin) expressed in human HCT116 cells,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940482,20180925,45142457,164148325,4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728047,100,Inhibition of FLT4 (unknown origin) relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940613,20180925,45142457,164148325,2324,NULL,P35916,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P35916,NULL
728048,100,Inhibition of MER (unknown origin) relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940614,20180925,45142457,164148325,10461,NULL,Q12866,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,Q12866,NULL
728049,100,Inhibition of FES (unknown origin) relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940615,20180925,45142457,164148325,2242,NULL,P07332,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.2,P07332,NULL
728050,100,Inhibition of FGFR3 (unknown origin) relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940616,20180925,45142457,164148325,2261,NULL,P22607,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P22607,NULL
728051,100,Inhibition of RON (unknown origin) at 1 uM by TR-FRET assay relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940617,20180925,45142457,164148325,4486,NULL,Q04912,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,Q04912,NULL
728052,100,Inhibition of c-MET (unknown origin)-catalyzed N-biotinylated EQEDEPEGDYFEWLECONH2 phosphorylation at 1 uM by TR-FRET assay relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940618,20180925,45142457,164148325,4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728053,2,Inhibition of c-MET M1250T mutant (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940619,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728054,2,Inhibition of c-MET Y1235D mutant (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940620,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728055,2,Inhibition of c-MET Y1230H mutant (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940621,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728056,2,Inhibition of c-MET Y1230C mutant (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940622,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728057,2,Inhibition of c-MET N1100Y mutant (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940623,20200626,45142457,164148325,NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728058,100,Selectivity ratio of Kd for phosphorylated c-MET kinase domain (unknown origin) to unphosphorylated c-MET kinase domain (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940624,20200626,45142457,164148325,4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728059,2,Binding affinity to unphosphorylated c-MET kinase domain (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940625,20180925,45142457,164148325,4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728060,2,Binding affinity to phosphorylated c-MET kinase domain (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940626,20180925,45142457,164148325,4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728061,2,Inhibition of CYP2D6 (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940627,20180925,45142457,164148325,1565,NULL,P10635,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,1.14.14.-,P10635,NULL
728063,2,Inhibition of CYP2C9 (unknown origin),"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940629,20180925,45142457,164148325,1559,NULL,P11712,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
728064,2,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC-MS-MS analysis,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940630,20180925,45142457,164148325,1576,NULL,P08684,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
728065,100,Inhibition of CYP3A4 in human liver microsomes using testosterone as substrate at 10 uM by LC-MS-MS analysis relative to control,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940631,20180925,"23653618,25012550,25013520,25013521,25013522,25013523,25013686,25013841,25013847,25014027,25014029,25014237,45142457,57541250,57541253,57541255,71601934,71601935,71602068,71602069,71602070,71602071","164128628,164128629,164128630,164128678,164128679,164128680,164128681,164131477,164131478,164134364,164137205,164142732,164142774,164142775,164145506,164145507,164145508,164145547,164145548,164148324,164148325,164148368",1576,NULL,P08684,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
728067,100,Inhibition of human ERG,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940633,20180925,16222392,134448021,3757,NULL,Q12809,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,Q12809,NULL
728068,100,Oral bioavailability in dog,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940634,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728069,100,Half life in dog,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940635,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728070,100,Plasma clearance in dog,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940636,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728071,100,Volume of distribution at steady state in dog,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940637,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728072,100,Oral bioavailability in rat,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940638,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728073,100,Half life in rat,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940639,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728074,100,Volume of distribution at steady state in rat,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940640,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728075,100,Plasma clearance in rat,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940641,20180925,"16222392,45142457","134448021,164148325",NULL,NULL,NULL,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,NULL,NULL,NULL
728078,2,Inhibition of c-MET (unknown origin) expressed in human GTL16 cells assessed as inhibition of cell proliferation,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940644,20180925,"16222392,45142457","134448021,164148325",4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728079,2,Inhibition of HGF-stimulated c-MET (unknown origin) autophosphorylation at tyrosine 1349 expressed in human GTL16 cells after 2 hrs by Western blotting analysis,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940645,20180925,"16222392,45142457","134448021,164148325",4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728080,2,Inhibition of c-MET (unknown origin)-catalyzed N-biotinylated EQEDEPEGDYFEWLECONH2 phosphorylation by TR-FRET assay,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940646,20180925,"16222392,23653618,25012550,25013520,25013521,25013522,25013523,25013686,25013841,25013847,25014027,25014029,25014237,44137946,45142457,49837887,56593141,57541250,57541253,57541255,71601341,71601483,71601485,71601486,71601487,71601488,71601634,71601635,71601636,71601639,71601790,71601934,71601935,71602068,71602069,71602070,71602071,71717471,71720501","123085297,134434312,134440321,134448021,164128628,164128629,164128630,164128678,164128679,164128680,164128681,164128682,164131477,164131478,164134308,164134363,164134364,164137169,164137204,164137205,164139979,164142732,164142773,164142774,164142775,164145506,164145507,164145508,164145546,164145547,164145548,164145549,164148324,164148325,164148326,164148327,164148328,164148367,164148368",4233,NULL,P08581,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,P08581,NULL
728081,2,Inhibition of RON (unknown origin) by TR-FRET assay,"Title: Discovery of 1-[3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo[4,5]cyclohepta[1,2-b]pyridin-7-yl]-N-(pyridin-2-ylmethyl)methanesulfonamide (MK-8033): A Specific c-Met/Ron dual kinase inhibitor with preferential affinity for the activated state of c-Met._|__|_Abstract: This report documents the first example of a specific inhibitor of protein kinases with preferential binding to the activated kinase conformation: 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one 11r (MK-8033), a dual c-Met/Ron inhibitor under ",43,ChEMBL,940647,20180925,"16222392,45142457,71601485,71601486,71601487,71601488,71601634,71601635,71601636,71601639,71601790","134448021,164128682,164134363,164137169,164137204,164139979,164142773,164145546,164145549,164148325,164148367",4486,NULL,Q04912,Curation Efforts|Research and Development,23379595,0,10.1021/jm301619u,2.7.10.1,Q04912,NULL
728356,100,Time dependent inhibition of CYP3A4-mediated midazolam metabolism in human liver microsomes at 10 uM by liquid chromatography-tandem mass spectrometry,Title: Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity._|__|_Abstract: ATR is an attractive new anticancer drug target whose inhibitors have potential as chemo- or radiation sensitizers or as monotherapy in tumors addicted to particular DNA-repair pathways. We describe the discovery and synthesis of a series of sulfonylmorpholinopyrimidines tha,43,ChEMBL,940922,20180925,46244454,164142958,1576,NULL,P08684,Curation Efforts|Research and Development,23394205,0,10.1021/jm301859s,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
730816,100,Inhibition of PI3Kdelta (unknown origin) at 1 uM,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943384,20180926,71720046,164146268,5293,NULL,O00329,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,2.7.1.153,O00329,NULL
730817,100,"Inhibition of mTORC2-mediated AKT phosphorylation in human PC3 cells xenografted in NCR mouse up to 5 mg/kg, po measured at 6 hrs","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943385,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730818,100,"Inhibition of mTORC1-mediated S6RP phosphorylation in human PC3 cells xenografted in NCR mouse up to 5 mg/kg, po measured at 6 hrs","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943386,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730826,100,"Inhibition of mTORC2-mediated AKT phosphorylation in human NCI-PC3 cells xenografted in NCR nude mouse at 50 to 100 mg/kg, po after 6 to 10 hrs","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943394,20180926,71604742,164137989,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730827,100,"Inhibition of mTORC1-mediated S6RP phosphorylation in human NCI-PC3 cells xenografted in NCR nude mouse at 50 to 100 mg/kg, po after 6 to 10 hrs","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943395,20180926,71604742,164137989,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730828,100,Inhibition of mTORC2-mediated AKT phosphorylation in human NCI-PC3 cells xenografted in po dosed NCR nude mouse after 1 to 10 hrs,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943396,20180926,71604742,164137989,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730829,100,Inhibition of mTORC1-mediated S6RP phosphorylation in human NCI-PC3 cells xenografted in po dosed NCR nude mouse after 1 to 10 hrs,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943397,20180926,71604742,164137989,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730845,2,Inhibition of mTORC2 in human NCI-PC3 cells assessed as inhibition of AKT phosphorylation,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943413,20180926,"71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149156,164149157,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730846,2,Inhibition of mTORC1 in human NCI-PC3 cells assessed as inhibition of p70S6K phosphorylation,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943414,20200626,"71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149156,164149157,164149158","2280,2475",NULL,"P42345,P62942",Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,"2.7.11.1,5.2.1.8","P42345,P62942",NULL
730849,2,Inhibition of human recombinant mTOR expressed in insect cells assessed as inhibition of phosphorylation of (GFP)-4-EBP1 protein after 30 mins by fluorescence resonance energy transfer assay,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943417,20180926,"59239374,71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164129458,164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149156,164149157,164149158",2475,NULL,P42345,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,2.7.11.1,P42345,NULL
741582,100,Inhibition of human recombinant AChE by time-dependent inhibition assay,"Title: Synthesis and anti-acetylcholinesterase properties of novel &#xCE;&#xB2;- and &#xCE;&#xB3;-substituted alkoxy organophosphonates._|__|_Abstract: Activated organophosphate (OP) insecticides and chemical agents inhibit acetylcholinesterase (AChE) to form OP-AChE adducts. Whereas the structure of the OP correlates with the rate of inhibition, the structure of the OP-AChE adduct influences the rate at which post-inhibitory reactivation or aging phenomena occurs. In this report, we prepared a panel of &#x",43,ChEMBL,954150,20200626,"71579905,71579906,71579998,71580005","164130179,164133025,164135835,164144252",43,NULL,P22303,Curation Efforts|Research and Development,23453838,0,10.1016/j.bmcl.2013.02.010,3.1.1.7,P22303,NULL
741583,100,Inhibition of rat brain AChE by time-dependent inhibition assay,"Title: Synthesis and anti-acetylcholinesterase properties of novel &#xCE;&#xB2;- and &#xCE;&#xB3;-substituted alkoxy organophosphonates._|__|_Abstract: Activated organophosphate (OP) insecticides and chemical agents inhibit acetylcholinesterase (AChE) to form OP-AChE adducts. Whereas the structure of the OP correlates with the rate of inhibition, the structure of the OP-AChE adduct influences the rate at which post-inhibitory reactivation or aging phenomena occurs. In this report, we prepared a panel of &#x",43,ChEMBL,954151,20200626,"9395,71579905,71579906,71579998,71580005","103191824,164130179,164133025,164135835,164144252",83817,NULL,P37136,Curation Efforts|Research and Development,23453838,0,10.1016/j.bmcl.2013.02.010,3.1.1.7,P37136,NULL
741585,100,Inhibition of electric eel AChE by time-dependent inhibition assay,"Title: Synthesis and anti-acetylcholinesterase properties of novel &#xCE;&#xB2;- and &#xCE;&#xB3;-substituted alkoxy organophosphonates._|__|_Abstract: Activated organophosphate (OP) insecticides and chemical agents inhibit acetylcholinesterase (AChE) to form OP-AChE adducts. Whereas the structure of the OP correlates with the rate of inhibition, the structure of the OP-AChE adduct influences the rate at which post-inhibitory reactivation or aging phenomena occurs. In this report, we prepared a panel of &#x",43,ChEMBL,954153,20200626,"71579905,71579906,71579998,71580005","164130179,164133025,164135835,164144252",113580815,NULL,O42275,Curation Efforts|Research and Development,23453838,0,10.1016/j.bmcl.2013.02.010,3.1.1.7,O42275,NULL
745085,100,Time dependent inhibition of CYP450 (unknown origin),"Title: Identification and design of a novel series of MGAT2 inhibitors._|__|_Abstract: [Acyl CoA]monoacylglycerol acyltransferase 2 (MGAT2) is of interest as a target for therapeutic treatment of diabetes, obesity and other diseases which together constitute the metabolic syndrome. In this Letter we report our discovery and optimisation of a novel series of MGAT2 inhibitors. The development of the SAR of the series and a detailed discussion around some key parameters monitored and addressed during the lead ",43,ChEMBL,957847,20200629,"71571356,71602372,71602433,71602434,71603028,71603093,71603095,71603097,71603210,71603211,71603212","174490536,174490537,174495571,174495573,174500787,174500788,174500789,174505986,174521370,174521371,174521375",NULL,NULL,NULL,Curation Efforts|Research and Development,23541669,0,10.1016/j.bmcl.2013.02.084,NULL,NULL,NULL
746240,2,Time dependent inhibition of human EL (19 to 500) expressed in HEK293 cells using PED-A1 as substrate by spectrophotometry,"Title: A thiocarbamate inhibitor of endothelial lipase raises HDL cholesterol levels in mice._|__|_Abstract: By screening directed libraries of serine hydrolase inhibitors using the cell surface form of endothelial lipase (EL), we identified a series of carbamate-derived (EL) inhibitors. Compound 3 raised plasma HDL-C levels in the mouse, and a correlation was found between HDL-C and plasma compound levels. Spectroscopic and kinetic studies support a covalent mechanism of inhibition. Our findings represent ",43,ChEMBL,959272,20180926,"71744953,73351940","174506290,174506291",9388,NULL,Q9Y5X9,Curation Efforts|Research and Development,23528297,0,10.1016/j.bmcl.2013.02.113,"3.1.1.3,3.1.1.32",Q9Y5X9,NULL
746250,100,Time dependent inhibition of human recombinant CYP3A4 using BFC as substrate incubated for 30 mins prior to substrate addition,"Title: Discovery, synthesis, selectivity modulation and DMPK characterization of 5-azaspiro[2.4]heptanes as potent orexin receptor antagonists._|__|_Abstract: Starting from a orexin 1 receptor selective antagonist 4,4-disubstituted piperidine series a novel potent 5-azaspiro[2.4]heptane dual orexin 1 and orexin 2 receptor antagonist class has been discovered. SAR and Pharmacokinetic optimization of this series is herein disclosed. Lead compound 15 exhibits potent activity against orexin 1 and orexin 2 recep",43,ChEMBL,959459,20180926,"71602354,71603188,71603190,71603193","174495844,174501076,174506293,174511421",1576,NULL,P08684,Curation Efforts|Research and Development,23535328,0,10.1016/j.bmcl.2013.02.093,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
759610,100,Time dependent inhibition of human CYP3A4 at 10 uM,"Title: 2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)octahydro-2H-isoindol-2-yl]-1,3-oxazol-4(5H)-one: a potent human NK1 receptor antagonist with multiple clearance pathways._|__|_Abstract: Hydroisoindoline 2 has been previously identified as a potent, brain-penetrant NK1 receptor antagonist with a long duration of action and improved profile of CYP3A4 inhibition and induction compared to aprepitant. However, compound 2 is predicted, based on data in precl",43,ChEMBL,969689,20180927,25028925,174522911,1576,NULL,P08684,Curation Efforts|Research and Development,23808489,0,10.1021/jm400751p,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
766392,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as AUC shift of inhibition at 0.1 to 10 uM,"Title: Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)._|__|_Abstract: Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea an",43,ChEMBL,977563,20180927,"56943206,71727461,71727930,71727932,71817351,71817500","174487944,174503351,174508540,174513665,174518703,174523921",1576,NULL,P08684,Curation Efforts|Research and Development,23899614,0,10.1016/j.bmcl.2013.06.090,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
766393,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as AUC shift of inhibition at 0.1 to 10 uM,"Title: Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)._|__|_Abstract: Potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitors containing 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas were identified using structure-based design techniques. The new compounds displayed improved aqueous solubilities, determined using a high-throughput solubility assessment, relative to previously disclosed urea an",43,ChEMBL,977564,20180927,"56943206,71727461,71727930,71727932,71817351,71817500","174487944,174503351,174508540,174513665,174518703,174523921",1576,NULL,P08684,Curation Efforts|Research and Development,23899614,0,10.1016/j.bmcl.2013.06.090,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1054095,100,Time dependent inhibition of human recombinant UP1 expressed in Escherichia coli Rosetta (DE3) using URD and inorganic phosphate as substrate at 1 uM by spectrophotometric analysis,"Title: Design of novel potent inhibitors of human uridine phosphorylase-1: synthesis, inhibition studies, thermodynamics, and in vitro influence on 5-fluorouracil cytotoxicity._|__|_Abstract: Uridine (Urd) is a promising biochemical modulator to reduce host toxicity caused by 5-fluorouracil (5-FU) without impairing its antitumor activity. Elevated doses of Urd are required to achieve a protective effect against 5-FU toxicity, but exogenous administration of Urd is not well-tolerated. Selective inhibitors of",43,ChEMBL,1275635,20180928,"79516,100608,13115629,72711417,72711418,72711419","194138048,194145067,194165845,194172571,194172707,194186253",7378,NULL,Q16831,Curation Efforts|Research and Development,24131420,0,10.1021/jm401389u,2.4.2.3,Q16831,NULL
1071269,100,Time dependent inhibition of CYP in human liver microsomes by HPLC-MS analysis,"Title: Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors._|__|_Abstract: Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinson's disease therapy. Herein, we disclose structurally diverse small molecule inhibitors suitable for assessing the implications of sustained in vivo LRRK2 ",43,ChEMBL,1291747,20180929,"69093113,76328936","194153984,194174690",NULL,NULL,NULL,Curation Efforts|Research and Development,24354345,0,10.1021/jm401654j,NULL,NULL,NULL
1071278,2,Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate by HPLC-MS analysis,"Title: Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors._|__|_Abstract: Leucine-rich repeat kinase 2 (LRRK2) has drawn significant interest in the neuroscience research community because it is one of the most compelling targets for a potential disease-modifying Parkinson's disease therapy. Herein, we disclose structurally diverse small molecule inhibitors suitable for assessing the implications of sustained in vivo LRRK2 ",43,ChEMBL,1291756,20200620,"69093374,69281569,69281703","194147116,194160977,194167893",1544,NULL,P05177,Curation Efforts|Research and Development,24354345,0,10.1021/jm401654j,"1.14.14.1,4.2.1.152",P05177,NULL
1141025,100,Time-dependent inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate at 10 uM,"Title: Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization._|__|_Abstract: Heat shock protein 90 (HSP90) is a molecular chaperone to fold and maintain the proper conformation of many signaling proteins, especially some oncogenic proteins and mutated unstable proteins. Inhibition of HSP90 was recognized as an effective approach to simultaneously suppress several aberrant signaling pathways, and therefore it was considered as a novel target f",43,ChEMBL,1350245,20181003,"86294728,86294734,86294735,86294736,86294737,86294738,90656486,90656487","242633684,242633690,242633691,242633694,242633695,242633696,242633697,242633698",1557,NULL,P33261,Curation Efforts|Research and Development,24751441,0,10.1016/j.bmcl.2014.03.100,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1151121,100,Time dependent inhibition of FLAG-tagged full-length human recombinant HDAC1 expressed in HEK293F cells using acetyl-lysine containing peptide as substrate by fluorescence assay,"Title: Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor._|__|_Abstract: The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described. Kinetic analysis indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 preparations. Delayed histone hyperacetylation and gene expression changes were also observed in cell culture, and histone acetylation was observed in vivo beyond disappearance of drug from plasma. I",43,ChEMBL,1362746,20181004,24744325,242645507,3065,NULL,Q13547,Curation Efforts|Research and Development,24900838,0,10.1021/ml4004233,3.5.1.98,Q13547,NULL
1151122,100,Time dependent inhibition of FLAG-tagged full-length human recombinant HDAC2 expressed in baculovirus infected Sf9 cells using acetyl-lysine containing peptide as substrate by fluorescence assay,"Title: Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor._|__|_Abstract: The identification and in vitro and in vivo characterization of a potent SHI-1:2 are described. Kinetic analysis indicated that biaryl inhibitors exhibit slow binding kinetics in isolated HDAC1 and HDAC2 preparations. Delayed histone hyperacetylation and gene expression changes were also observed in cell culture, and histone acetylation was observed in vivo beyond disappearance of drug from plasma. I",43,ChEMBL,1362747,20181004,24744325,242645507,3066,NULL,Q92769,Curation Efforts|Research and Development,24900838,0,10.1021/ml4004233,3.5.1.98,Q92769,NULL
1153727,2,Inhibition of human recombinant PDE10A expressed in Sf9 insect cell system assessed as inhibition of cAMP hydrolysis preincubated for 30 mins before substrate addition measured after 60 mins by HTRF assay,"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361474,20181004,"74049853,74049854,90644304,90644305,90644306,90644307,90644308,90644309,90644310,90644311,90644312,90644313,90644314,90644315,90644316,90644317,90644318,90644319","242647200,242647201,242647202,242647203,242647204,242647205,242647206,242647207,242647208,242647209,242647210,242647211,242647212,242647213,242647214,242647215,242647216,242647217",10846,NULL,Q9Y233,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,"3.1.4.17,3.1.4.35",Q9Y233,NULL
1153731,100,Inhibition of CYP1A2 (unknown origin),"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361478,20200618,90644318,242647216,1544,NULL,P05177,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,"1.14.14.1,4.2.1.152",P05177,NULL
1153732,100,Inhibition of CYP2C9 (unknown origin),"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361479,20181004,90644318,242647216,1559,NULL,P11712,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1153733,100,Inhibition of CYP2C19 (unknown origin),"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361480,20181004,90644318,242647216,1557,NULL,P33261,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1153734,100,Inhibition of CYP2D6 (unknown origin),"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361481,20181004,90644318,242647216,1565,NULL,P10635,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,1.14.14.-,P10635,NULL
1165821,2,"Antagonist activity at human OX2R expressed in CHO cells assessed as inhibition of Ala-6,12-orexinA-induced effect after 5 mins by FLIPR assay","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433181,20181005,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,58394291,71555054,118715606,118715607,118715608,118715609,118715610,118715611,118715612,118715613","312360586,312360588,312360589,312360590,312360591,312360592,312360593,312360594,312360595,312360596,312360597,312360598,312360599,312360600,312360601,312360602,312360603,312360604,312360605",3062,NULL,O43614,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,O43614,NULL
1165822,2,"Antagonist activity at human OX1R I408V mutant expressed in CHO cells assessed as inhibition of Ala-6,12-orexinA-induced effect after 5 mins by FLIPR assay","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433182,20181005,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,58394291,71555054,118715606,118715607,118715608,118715609,118715610,118715611,118715612,118715613","312360586,312360588,312360589,312360590,312360591,312360592,312360593,312360594,312360595,312360596,312360597,312360598,312360599,312360600,312360601,312360602,312360603,312360604,312360605",3061,NULL,O43613,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,O43613,NULL
1165834,2,Reversible inhibition of CYP3A4 (unknown origin),"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433194,20181005,46190695,312360605,1576,NULL,P08684,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1165835,2,Reversible inhibition of CYP2C9 (unknown origin),"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433195,20181005,46190695,312360605,1559,NULL,P11712,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1165836,2,Reversible inhibition of CYP2D6 (unknown origin),"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433196,20181005,46190695,312360605,1565,NULL,P10635,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,1.14.14.-,P10635,NULL
1165998,100,Time-dependent inhibition of human recombinant CYP3A4 expressed in Escherichia coli bactosomes using diethoxyfluorescein as substrate by fluorescence assay,"Title: The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor._|__|_Abstract: Through their function as epigenetic readers of the histone code, the BET family of bromodomain-containing proteins regulate expression of multiple genes of therapeutic relevance, including those involved in tumor cell growth and inflammation. BET bromodomain inhibitors have profound antiproliferative and anti-inflammatory effects which translate into effica",43,ChEMBL,1434769,20181005,52912222,163317830,1576,NULL,P08684,Curation Efforts|Research and Development,25249180,0,10.1021/jm5010539,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1168828,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition._|__|_Abstract: Nonimmunosuppressive cyclophilin inhibitors have demonstrated efficacy for the treatment of hepatitis C infection (HCV). However, alisporivir, cyclosporin A, and most other cyclosporins are potent inhibitors of OATP1B1, MRP2, MDR1, and other important drug transporters. Reduction of the side chain hydrophobicity of the P4 residue preserves cyclophilin binding",43,ChEMBL,1436356,20181005,"90142631,118213818","312363830,312363831",1576,NULL,P08684,Curation Efforts|Research and Development,25310383,0,10.1021/jm500862r,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1169206,100,Time-dependent inhibition of CYP3A4 in human liver microsomes,"Title: Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors._|__|_Abstract: HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)",43,ChEMBL,1440843,20200625,"135539077,135566860,136266500","103556527,312362066,312362081",1576,NULL,P08684,Curation Efforts|Research and Development,25313505,0,10.1016/j.ejmech.2014.09.065,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1169207,100,Time-dependent inhibition of CYP2D6 in human liver microsomes,"Title: Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors._|__|_Abstract: HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)",43,ChEMBL,1440844,20200625,"135539077,135566860,136266500","103556527,312362066,312362081",1565,NULL,P10635,Curation Efforts|Research and Development,25313505,0,10.1016/j.ejmech.2014.09.065,1.14.14.-,P10635,NULL
1169208,100,Time-dependent inhibition of CYP2C9 in human liver microsomes,"Title: Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors._|__|_Abstract: HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)",43,ChEMBL,1440845,20200625,"135539077,135566860,136266500","103556527,312362066,312362081",1559,NULL,P11712,Curation Efforts|Research and Development,25313505,0,10.1016/j.ejmech.2014.09.065,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1169209,100,Time-dependent inhibition of CYP1A2 in human liver microsomes,"Title: Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors._|__|_Abstract: HSP90 is ubiquitously overexpressed in a broad spectrum of human cancers and has been recognized as an attractive target for cancer treatment. Here, we described the fragment screening, synthesis and structure-activity relationship studies of small molecule inhibitors with 4,5-diarylisoxazole scaffold targeting HSP90. Among them, the compound N-(3-(2,4-dihydroxy-5-isopropylphenyl)-4-(4-((4-morpholinopiperidin-1-yl)methyl)",43,ChEMBL,1440846,20200625,"135539077,135566860,136266500","103556527,312362066,312362081",1544,NULL,P05177,Curation Efforts|Research and Development,25313505,0,10.1016/j.ejmech.2014.09.065,"1.14.14.1,4.2.1.152",P05177,NULL
1177211,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate,"Title: Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors._|__|_Abstract: Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causa",43,ChEMBL,1445012,20181005,"118720885,118720886,118720887","312369212,312369213,312369214",1576,NULL,P08684,Curation Efforts|Research and Development,25589928,0,10.1021/ml500352s,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1177212,100,Time dependent inhibition of CYP2D6 in human liver microsomes,"Title: Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors._|__|_Abstract: Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causa",43,ChEMBL,1445013,20181005,118720885,312369212,1565,NULL,P10635,Curation Efforts|Research and Development,25589928,0,10.1021/ml500352s,1.14.14.-,P10635,NULL
1177213,100,Time dependent inhibition of CYP2C9 in human liver microsomes,"Title: Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors._|__|_Abstract: Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causa",43,ChEMBL,1445014,20181005,118720885,312369212,1559,NULL,P11712,Curation Efforts|Research and Development,25589928,0,10.1021/ml500352s,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1177214,100,Time dependent inhibition of CYP1A2 in human liver microsomes,"Title: Structure-Based Drug Design of Novel, Potent, and Selective Azabenzimidazoles (ABI) as ATR Inhibitors._|__|_Abstract: Compound 13 was discovered through morphing of the ATR biochemical HTS hit 1. The ABI series was potent and selective for ATR. Incorporation of a 6-azaindole afforded a marked increase in cellular potency but was associated with poor PK and hERG ion channel inhibition. DMPK experiments established that CYP P450 and AO metabolism in conjunction with Pgp and BCRP efflux were major causa",43,ChEMBL,1445015,20200625,118720885,312369212,1544,NULL,P05177,Curation Efforts|Research and Development,25589928,0,10.1021/ml500352s,"1.14.14.1,4.2.1.152",P05177,NULL
1181941,100,Time dependent inhibition of recombinant Clostridium botulinum neurotoxin serotype A light chain assessed as Kinact to KI ratio at 200 uM by SNAPtide FRET based assay,"Title: Benzoquinones as inhibitors of botulinum neurotoxin serotype A._|__|_Abstract: Although botulinum neurotoxin serotype A (BoNT/A) is known for its use in cosmetics, it causes a potentially fatal illness, botulism, and can be used as a bioterror weapon. Many compounds have been developed that inhibit the BoNTA zinc-metalloprotease light chain (LC), however, none of these inhibitors have advanced to clinical trials. In this study, a fragment-based approach was implemented to develop novel covalent inhib",43,ChEMBL,1448544,20200623,3806,103222861,NULL,NULL,P10845,Curation Efforts|Research and Development,24984937,0,10.1016/j.bmc.2014.06.004,3.4.24.69,P0DPI0,NULL
1181942,100,Time dependent inhibition of recombinant Clostridium botulinum neurotoxin serotype A light chain assessed as Kinact to KI ratio after 1.5 hrs by SNAPtide FRET based assay,"Title: Benzoquinones as inhibitors of botulinum neurotoxin serotype A._|__|_Abstract: Although botulinum neurotoxin serotype A (BoNT/A) is known for its use in cosmetics, it causes a potentially fatal illness, botulism, and can be used as a bioterror weapon. Many compounds have been developed that inhibit the BoNTA zinc-metalloprotease light chain (LC), however, none of these inhibitors have advanced to clinical trials. In this study, a fragment-based approach was implemented to develop novel covalent inhib",43,ChEMBL,1448545,20200623,4650,103167124,NULL,NULL,P10845,Curation Efforts|Research and Development,24984937,0,10.1016/j.bmc.2014.06.004,3.4.24.69,P0DPI0,NULL
1185427,100,Time dependent inhibition of equine serum BChE at 5 to 100 nM,"Title: Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase._|__|_Abstract: A series of cyclic acyl guanidine with carbamate moieties have been synthesized and evaluated in vitro for their AChE and BChE inhibitory activities. Structure-activity relationships identified compound 23 as a nanomolar and selective BChE inhibitor, while compound 32 exhibited nanomolar and selective AChE inhibition, selectivity depending o",43,ChEMBL,1458516,20181006,101903036,312353313,100033901,NULL,P81908,Curation Efforts|Research and Development,25059502,0,10.1016/j.bmc.2014.06.010,3.1.1.8,P81908,NULL
1185428,100,Time dependent inhibition of equine serum BChE at 25 to 250 nM,"Title: Cyclic acyl guanidines bearing carbamate moieties allow potent and dirigible cholinesterase inhibition of either acetyl- or butyrylcholinesterase._|__|_Abstract: A series of cyclic acyl guanidine with carbamate moieties have been synthesized and evaluated in vitro for their AChE and BChE inhibitory activities. Structure-activity relationships identified compound 23 as a nanomolar and selective BChE inhibitor, while compound 32 exhibited nanomolar and selective AChE inhibition, selectivity depending o",43,ChEMBL,1458517,20181006,101903040,312353321,100033901,NULL,P81908,Curation Efforts|Research and Development,25059502,0,10.1016/j.bmc.2014.06.010,3.1.1.8,P81908,NULL
1200651,100,Time dependent inhibition of wild-type KRas (unknown origin) assessed as SOS-mediated MANT-dGDP displacement at 200 uM by microplate reader analysis,"Title: Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation._|__|_Abstract: Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compou",43,ChEMBL,1470592,20181006,118732785,312387437,3845,NULL,P01116,Curation Efforts|Research and Development,25695162,0,10.1021/jm501660t,NULL,P01116,NULL
1200652,100,Time dependent inhibition of KRas G12V mutant (unknown origin) assessed as SOS-mediated MANT-dGDP displacement at 200 uM by microplate reader analysis,"Title: Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation._|__|_Abstract: Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compou",43,ChEMBL,1470593,20200625,118732785,312387437,NULL,NULL,NULL,Curation Efforts|Research and Development,25695162,0,10.1021/jm501660t,NULL,NULL,NULL
1200653,100,Time dependent inhibition of KRas G12C mutant (unknown origin) assessed as SOS-mediated MANT-dGDP displacement at 200 uM by microplate reader analysis,"Title: Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation._|__|_Abstract: Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compou",43,ChEMBL,1470594,20200625,118732785,312387437,NULL,NULL,NULL,Curation Efforts|Research and Development,25695162,0,10.1021/jm501660t,NULL,NULL,NULL
1210075,100,Ratio of IC50 for human recombinant CYP2J2 in absence of 1 mM NADPH to IC50 for human recombinant CYP2J2 in absence of 1 mM NADPH,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485707,20200625,"65999,941361","103199419,103271997",1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210076,100,Drug metabolism assessed as human recombinant CYP2J2-mediated intrinsic clearance assessed per pmol protein after 30 mins,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1485708,20200625,2247,103224052,1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210077,2,Activity of human recombinant CYP2J2 assessed as compound O-demethylation,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1486445,20200625,2247,103224052,1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210078,100,Activity of human recombinant CYP2J2 assessed as compound O-demethylation assessed per nmol protein,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1486446,20200625,2247,103224052,1573,NULL,P51589,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,"1.14.14.-,1.14.14.73,1.14.14.74,5.4.4.7",P51589,NULL
1210079,100,Metabolic stability in human liver microsomes at 1 uM after 30 mins by LC-MS/MS method,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1486447,20200625,"65999,941361","103199419,103271997",NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1210084,100,"Selectivity index, ratio of IC50 for CYP21A2 in human liver microsomes to IC50 for human recombinant CYP2J2","Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492093,20200625,"65999,941361","103199419,103271997",NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1210085,100,"Selectivity index, ratio of IC50 for CYP3A4 in human liver microsomes to IC50 for human recombinant CYP2J2","Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492094,20200625,"65999,941361","103199419,103271997",NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1210086,100,"Selectivity index, ratio of IC50 for CYP2D6 in human liver microsomes to IC50 for human recombinant CYP2J2","Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492095,20200625,"65999,941361","103199419,103271997",NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1210087,100,"Selectivity index, ratio of IC50 for CYP2C9 in human liver microsomes to IC50 for human recombinant CYP2J2","Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492096,20200625,"65999,941361","103199419,103271997",NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1210088,100,"Selectivity index, ratio of IC50 for CYP2C19 in human liver microsomes to IC50 for human recombinant CYP2J2","Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492097,20200625,"65999,941361","103199419,103271997",NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1210089,100,Tmax in human,"Title: Discovery and characterization of novel, potent, and selective cytochrome P450 2J2 inhibitors._|__|_Abstract: Cytochrome P450 (CYP) 2J2 is one of the human CYPs involved in phase I xenobiotics metabolism. It is mainly expressed in extrahepatic tissues, including intestine and cardiovascular systems. The general role of CYP2J2 in drug metabolism is not yet fully understood, and the recent discovery that CYP2J2 can metabolize a wide range of structurally diverse drugs and its primary distribution in th",43,ChEMBL,1492098,20200625,941361,103199419,NULL,NULL,NULL,Curation Efforts|Research and Development,23033255,0,10.1124/dmd.112.048264,NULL,NULL,NULL
1212117,100,Induction of MRP2 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488018,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212118,100,Induction of CYP2A6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488019,20200624,135398735,136926966,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212119,100,Induction of CYP1A2 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488020,20200624,135398735,136926966,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212120,2,Induction of CYP2B6 in human hepatocytes after 72 hrs relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488021,20200624,9838675,174510203,1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212121,2,Cytotoxicity against human hepatocytes assessed as cell viability relative to control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488022,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212122,100,Chemical stability of the compound in human hepatocyte culture medium assessed as compound remaining at 1 to 50 uM after 24 hrs,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488796,20200624,"9838675,10221470","174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212123,100,Induction of CYP3A4 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488797,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212124,2,Induction of CYP3A4 in human hepatocytes after 72 hrs relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488914,20200624,9838675,174510203,1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212125,2,Total Cmax in human,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488915,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212126,2,Unbound Cmax in human,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488916,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212127,2,Competitive inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488917,20200624,9838675,174510203,1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212128,100,Induction of MDR1 mRNA expression in human hepatocytes at 300 uM after 48 hrs by RT-PCR analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488918,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212129,2,Induction of CYP1A2 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488919,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212130,2,Induction of CYP2A6 mRNA expression in human hepatocytes after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1488920,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212131,2,Activation of human PXR expressed in human LS174T cells,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492951,20200624,9838675,174510203,8856,NULL,O75469,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,O75469,NULL
1212132,100,Activation of CAR (unknown origin) expressed in HEK293 cells at 10 uM,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492952,20200624,9838675,174510203,9970,NULL,Q14994,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,Q14994,NULL
1212133,2,Inhibition of CYP2B6 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 10 mins by LC-MS analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492953,20200624,"9838675,10221470","174484575,174510203",1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212134,2,Inhibition of recombinant CYP2B6 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 10 mins by LC-MS analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492954,20200624,"9838675,10221470","174484575,174510203",1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212135,2,Competitive reversible inhibition of CYP2B6 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 10 mins by Dixon plot analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492955,20200624,9838675,174510203,1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212136,2,Activity of CYP2B6 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 10 mins by Dixon plot analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492956,20200624,9838675,174510203,1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212137,2,Inhibition of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492957,20200624,"9838675,10221470","174484575,174510203",1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212138,2,Inhibition of recombinant CYP3A4 (unknown origin) incubated for 3 mins prior to NADPH addition measured after 3 mins by LC-MS analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492958,20200624,"9838675,10221470","174484575,174510203",1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212139,2,Activity of CYP3A4 in human liver microsomes incubated for 3 mins prior to NADPH addition measured after 3 mins by Dixon plot analysis,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492959,20200624,9838675,174510203,1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212142,100,Chemical stability of the compound in PBS buffer assessed as compound remaining at pH 7.4 after 10 mins,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492962,20200624,9838675,174510203,NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212143,100,Induction of CYP2B6 in human hepatocytes at 10 uM after 72 hrs relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492963,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",1555,NULL,P20813,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,1.14.13.-,P20813,NULL
1212144,100,Induction of CYP3A4 in human hepatocytes at 10 uM after 72 hrs relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492964,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",1576,NULL,P08684,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1212145,100,Induction of CYP2C9 in human hepatocytes at 10 uM after 72 hrs relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492965,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",1559,NULL,P11712,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1212146,100,Induction of CYP2B6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492966,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212147,100,Induction of CYP3A4 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492967,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212148,100,Induction of CYP2C9 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492968,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212149,100,Induction of CYP1A2 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492969,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212150,100,Induction of CYP2A6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492970,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212151,100,Induction of CYP2C8 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492971,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212152,100,Induction of CYP2C19 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492972,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212153,100,Induction of CYP3A5 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492973,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212154,100,Induction of CYP2D6 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492974,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212155,100,Induction of CYP2E1 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492975,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212156,100,Induction of UGT1A9 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492976,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212157,100,Induction of UGT2B7 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492977,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212158,100,Induction of MDR1 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492978,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1212159,100,Induction of MRP1 mRNA expression in human hepatocytes at 10 uM after 72 hrs by RT-PCR analysis relative to vehicle-treated control,"Title: Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes._|__|_Abstract: Artemisinin drugs have become the first-line antimalarials in areas of multidrug resistance. However, monotherapy with artemisinin drugs results in comparatively high recrudescence rates. Autoinduction of cytochrome P450 (P450)-mediated metabolism, resulting in reduced exposure, has been supposed to be the underlying mechanism. To better understand the autoi",43,ChEMBL,1492979,20200624,"9838675,10221470,135398735","136926966,174484575,174510203",NULL,NULL,NULL,Curation Efforts|Research and Development,22679214,0,10.1124/dmd.112.045765,NULL,NULL,NULL
1219186,2,Inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486159,20200624,11556711,103652542,1544,NULL,P05177,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,4.2.1.152",P05177,NULL
1219187,2,Inhibition of CYP2C8 in human liver microsomes using amodiaquine as substrate after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486160,20181007,11556711,103652542,1558,NULL,P10632,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,1.14.14.1,P10632,NULL
1219188,2,Inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486161,20181007,11556711,103652542,1559,NULL,P11712,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1219189,2,Inhibition of CYP2C19 in human liver microsomes using S-mephenytoin as substrate after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486162,20181007,11556711,103652542,1557,NULL,P33261,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1219214,2,Inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487837,20181007,11556711,103652542,1565,NULL,P10635,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,1.14.14.-,P10635,NULL
1219229,2,Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using midazolam as substrate preincubated with microsomes for 30 mins prior to substrate addition measured after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488627,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219230,2,Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using testosterone as substrate preincubated with microsomes for 30 mins prior to substrate addition measured after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488628,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219241,100,Inhibition of CYP3A in human liver microsomes treated with carfilzomib up to 30 uM by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489451,20181007,"90092286,118753380","312467140,312467258",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219243,2,Inhibition of CYP3A in human liver microsomes treated with carfilzomib by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489453,20181007,118753464,312467259,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219249,2,Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using midazolam as substrate measured after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1490256,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219250,2,Inhibition of CYP3A in human liver microsomes assessed as substrate metabolite formation using testosterone as substrate measured after 5 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1490257,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1227038,2,Reversible-time dependent inhibition of human wild type HDAC8 by Fluor-de-Lys activity assay,"Title: Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release._|__|_Abstract: Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies, including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described. Although hydroxamic acids are utilized universally in the development of metalloenzyme inhibitors, they are considered to be poor pharmacophores wit",43,ChEMBL,1496074,20181008,122177622,318371440,55869,NULL,Q9BY41,Curation Efforts|Research and Development,25974739,0,10.1021/acs.jmedchem.5b00539,3.5.1.98,Q9BY41,NULL
1227041,2,Reversible-time dependent inhibition of human wild type HDAC8 assessed as rate constant by Fluor-de-Lys activity assay,"Title: Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release._|__|_Abstract: Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies, including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described. Although hydroxamic acids are utilized universally in the development of metalloenzyme inhibitors, they are considered to be poor pharmacophores wit",43,ChEMBL,1496077,20181008,122177622,318371440,55869,NULL,Q9BY41,Curation Efforts|Research and Development,25974739,0,10.1021/acs.jmedchem.5b00539,3.5.1.98,Q9BY41,NULL
1227042,100,Time-dependent inhibition of human HDAC8 C153A mutant by Fluor-de-Lys activity assay,"Title: Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release._|__|_Abstract: Histone deacetylase inhibitors (HDACi) target abnormal epigenetic states associated with a variety of pathologies, including cancer. Here, the development of a prodrug of the canonical broad-spectrum HDACi suberoylanilide hydroxamic acid (SAHA) is described. Although hydroxamic acids are utilized universally in the development of metalloenzyme inhibitors, they are considered to be poor pharmacophores wit",43,ChEMBL,1496078,20181008,122177622,318371440,55869,NULL,Q9BY41,Curation Efforts|Research and Development,25974739,0,10.1021/acs.jmedchem.5b00539,3.5.1.98,Q9BY41,NULL
1234572,100,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as residual activity at 5 uM preincubated for 30 mins followed by substrate addition measured after 20 mins by LC-MS/MS analysis relative to vehicle-treate,"Title: Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain._|__|_Abstract: N-type calcium channel blockade is a promising therapeutic approach for the treatment of neuropathic pain. Starting from lead compound (S)-1, we focused our optimization efforts on potency for N-type calcium channel inhibition and improvement of CYP inhibition profile. 2-{[(1-Hydroxycyclohexyl)methyl]amino}-(1R)-(1-isopropyl-6-methoxy-3,4-dihydroisoquinol",43,ChEMBL,1505191,20181008,"25118804,25119513,25119857,25119860,59396246,59396249,59396250,59396293,59396342,59396348,59396577,59396619,67538612,70923016,122181896,122181897,122181898,122181899,122181900,122181901,122181902,122181903,122182156","312369992,318377852,318377853,318377854,318377855,318377856,318377857,318377858,318377859,318377860,318377861,318377862,318377863,318377864,318377865,318377866,318377867,318377868,318378181,318378182,318378183,318378184,318378185",1576,NULL,P08684,Curation Efforts|Research and Development,26071371,0,10.1016/j.bmc.2015.05.030,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1234583,2,Time-dependent inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate assessed as residual activity preincubated for 30 mins followed by substrate addition measured after 20 mins by LC-MS/MS analysis,"Title: Discovery of a 1-isopropyltetrahydroisoquinoline derivative as an orally active N-type calcium channel blocker for neuropathic pain._|__|_Abstract: N-type calcium channel blockade is a promising therapeutic approach for the treatment of neuropathic pain. Starting from lead compound (S)-1, we focused our optimization efforts on potency for N-type calcium channel inhibition and improvement of CYP inhibition profile. 2-{[(1-Hydroxycyclohexyl)methyl]amino}-(1R)-(1-isopropyl-6-methoxy-3,4-dihydroisoquinol",43,ChEMBL,1505202,20181008,122182156,318378184,1565,NULL,P10635,Curation Efforts|Research and Development,26071371,0,10.1016/j.bmc.2015.05.030,1.14.14.-,P10635,NULL
1238421,100,Time dependent inhibition of CYP3A4 (unknown origin) at 25 uM after 30 mins,"Title: Design, synthesis and evaluation of MCH receptor 1 antagonists--Part III: Discovery of pre-clinical development candidate BI 186908._|__|_Abstract: Although overweight and obesity are highly prevalent conditions, options to treat them are still very limited. As part of our search for safe and effective MCH-R1 antagonists for the treatment of obesity, two series of pyridones and pyridazinones were evaluated. Optimization was aimed at improving DMPK properties by increasing metabolic stability and impr",43,ChEMBL,1509177,20181009,71714121,318382098,1576,NULL,P08684,Curation Efforts|Research and Development,26105194,0,10.1016/j.bmcl.2015.05.065,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1251714,100,Time dependent inhibition of CYP3A4 (unknown origin),Title: Discovery of 2-Pyridinone Aminals: A Prodrug Strategy to Advance a Second Generation of HIV-1 Integrase Strand Transfer Inhibitors._|__|_Abstract: The search for new molecular constructs that resemble the critical two-metal binding pharmacophore required for HIV integrase strand transfer inhibition represents a vibrant area of research within drug discovery. Here we present the discovery of a new class of HIV integrase strand transfer inhibitors based on the 2-pyridinone core of MK-0536. These effort,43,ChEMBL,1518940,20181009,"86577515,86577668","318393329,318393330",1576,NULL,P08684,Curation Efforts|Research and Development,26397965,0,10.1021/acs.jmedchem.5b01037,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1298614,2,Inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 using D-AMC substrate measured over 40 mins by fluorescence based assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573063,20180906,"1383884,10427006,53251433,53251434,67235559,127045757,127045758,127045759,127045760,127045761,127045984,127046052,127046192,127046193,127046194,127046387,127046635,127046636,127046637,127046638,127046788,127046789,127046790,127046791,127047497,127047498,127047499,127047500,127047501,127047752","103439500,103455066,336897709,336897710,336897711,336897712,336897713,336897998,336898094,336898273,336898274,336898275,336898276,336898545,336898546,336898899,336898900,336898901,336898902,336899116,336899117,336899118,336899119,336900162,336900163,336900164,336900165,336900166,336900167,336900503",2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298615,100,Inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 assessed as enzyme inactivation rate constant using D-AMC substrate incubated for 2 hrs by fluorescence based assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573064,20180906,"25154867,53251433,67235559,127045984,127046192,127046791,127047497","124971390,336897998,336898273,336898274,336899119,336900162,336900163",2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298616,2,Inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 assessed as enzyme inactivation using D-AMC substrate incubated for 2 hrs by fluorescence based assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573065,20180906,"53251433,67235559,127045984,127046192,127046791,127047497","336897998,336898273,336898274,336899119,336900162,336900163",2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298617,100,Ratio of Kinact to Ki for inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 using D-AMC substrate incubated for 2 hrs by fluorescence based assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573066,20180906,"53251433,67235559,127045984,127046192,127046791,127047497","336897998,336898273,336898274,336899119,336900162,336900163",2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298618,100,Reversible inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 assessed as enzyme activity recovery rate using D-AMC substrate measured 24 to 144 hrs after exhaustive dialysis by f,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573067,20180906,"2809273,67235559,127047497","103586821,336900162,336900163",2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298619,100,Reversible inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 assessed as enzyme activity recovery rate using D-AMC substrate measured at 144 hrs after exhaustive dialysis by fluo,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573068,20180906,53251433,336898273,2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298621,100,Inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 assessed as formation of phenol in reaction mix using D-AMC substrate by LC/APCI-MS method based single turnover assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573070,20180906,53251433,336898273,2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298622,100,Inhibition of MBP-fused human recombinant FAAH with truncated N-terminal transmembrane domain expressed in Escherichia coli T7 assessed as formation of aniline in reaction mix using D-AMC substrate by LC/APCI-MS method based single turnover assay,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573071,20180906,67235559,336900162,2166,NULL,O00519,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.1.1.-,3.5.1.99",O00519,NULL
1298623,100,Inhibition of porcine pancreatic elastase at 10 uM using N-Succinyl-ala-ala-ala-p-nitroanilide substrate assessed as reduction in p-nitroaniline release measured over 5 mins,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573072,20180906,"53251433,53251434,67235559,127045758,127046194,127046791","336897710,336898273,336898276,336898546,336899119,336900162","396766,397197",NULL,"P00772,P08419",Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,"3.4.21.36,3.4.21.71","P00772,P08419",NULL
1298624,2,Inhibition of porcine liver esterase using 4-nitrophenyl butyrate substrate assessed as reduction in p-nitrophenol release measured over 5 mins,"Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573073,20180906,"53251433,53251434,67235559,127045758,127046194,127046791","336897710,336898273,336898276,336898546,336899119,336900162",397478,NULL,Q29550,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,3.1.1.1,Q29550,NULL
1300121,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as ratio of inhibition from 30 mins to 5 mins using BFC as substrate,"Title: Discovery and Preclinical Evaluation of BMS-955829, a Potent Positive Allosteric Modulator of mGluR5._|__|_Abstract: Positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 5 (mGluR5) are of interest due to their potential therapeutic utility in schizophrenia and other cognitive disorders. Herein we describe the discovery and optimization of a novel oxazolidinone-based chemotype to identify BMS-955829 (4), a compound with high functional PAM potency, excellent mGluR5 bind",43,ChEMBL,1578237,20200624,"57330204,69081596,69083336,69083418,69084420,69086317","336901544,336901545,336901964,336903733,336903734,336903735",1576,NULL,P08684,Curation Efforts|Research and Development,26985317,0,10.1021/acsmedchemlett.5b00450,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1300223,100,"Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of MK-801-induced hyperlocomotive activity at 10 mg/kg, treated for 30 mins followed by MK-801 challenge measured over 90 mins relative to vehicle control","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576650,20180906,127052897,336907555,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300227,100,Inhibition of CYP3A4 in human liver microsomes at 10 uM,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576654,20180906,"71128783,71479388,127052897","336907555,336907556,336907557",1576,NULL,P08684,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1300229,100,"Antipsychotic activity in Sprague-Dawley rat assessed as inhibition of MK-801-induced hyperlocomotive activity at 30 mg/kg, treated for 30 mins followed by MK-801 challenge measured over 90 mins relative to vehicle control","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576656,20180906,"71479388,127052897","336907555,336907557",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1310176,100,"Time dependent inhibition of C-terminal His-tagged full length human SRC expressed in insect cells preincubated for 20 mins using poly[Glu,Tyr]4:1 as substrate measured every 10 mins for 120 mins in presence of [gamma-33P]ATP",Title: Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase._|__|_Abstract: Novel pyrazolopyrimidines displaying high potency and selectivity toward SRC family kinases have been developed by combining ligand-based design and phenotypic screening in an iterative manner. Compounds were derived from the promiscuous kinase inhibitor PP1 to search for analogs that could p,43,ChEMBL,1587986,20180906,121231408,336904683,6714,NULL,P12931,Curation Efforts|Research and Development,27115835,0,10.1021/acs.jmedchem.6b00065,2.7.10.2,P12931,NULL
1321015,100,Time-dependent inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate at 10 to 100 uM by fluorescence assay,"Title: Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening._|__|_Abstract: Noncovalent proteasome inhibitors introduce an alternative mechanism of inhibition to that of covalent inhibitors, e.g. carfilzomib, used in cancer therapy. A multistep hierarchical structure-based virtual screening (SBVS) of the 65,375 NCI lead-like compound library led to the identification of two compounds (9 and 28) which noncova",43,ChEMBL,1618122,20200624,"21140132,86290925,134139145,134155499","318386941,318386942,374294270,374352617",5693,NULL,P28074,Curation Efforts|Research and Development,27318981,0,10.1016/j.ejmech.2016.05.049,3.4.25.1,P28074,NULL
1325502,2,Inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli using Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622625,20180907,"104934,9828058,14585243,134134572,134135432,134136688,134138690,134145896,134147411,134148745,134149983,134151245,134152014,134153309,134156687","242220079,374275733,374277539,374280654,374282134,374285342,374292683,374318695,374324090,374328889,374333378,374337727,374340463,374344820,374357001",834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1325503,2,Inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-4 expressed in Escherichia coli using Ac-LEVD-AMC as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622626,20200624,"104934,9828058,14585243,134134572,134135432,134136688,134138690,134145896,134147411,134148745,134149983,134151245,134152014,134153309,134156687","242220079,374275733,374277539,374280654,374282134,374285342,374292683,374318695,374324090,374328889,374333378,374337727,374340463,374344820,374357001",837,NULL,P49662,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.57,P49662,NULL
1325504,2,Inhibition of human recombinant DTT-activated caspase-5 expressed in Escherichia coli using Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622627,20180907,"104934,9828058,14585243,134134572,134135432,134136688,134138690,134145896,134147411,134148745,134149983,134151245,134152014,134153309,134156687","242220079,374275733,374277539,374280654,374282134,374285342,374292683,374318695,374324090,374328889,374333378,374337727,374340463,374344820,374357001",838,NULL,P51878,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.58,P51878,NULL
1325509,2,Inhibition of human recombinant DTT-activated caspase-5 expressed in Escherichia coli using Ac-WEHD-AMC as substrate preincubated for 15 mins followed by substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622632,20180907,134136688,374285342,838,NULL,P51878,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.58,P51878,NULL
1325510,2,Inhibition of human recombinant DTT-activated caspase-5 expressed in Escherichia coli using Ac-WEHD-AMC as substrate preincubated for 45 mins followed by substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622633,20180907,134136688,374285342,838,NULL,P51878,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.58,P51878,NULL
1325513,100,Non-competitive inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli assessed as enzyme Vmax at 50 nM using Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by Michaeli,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622636,20180907,134147411,374324090,834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1325514,100,Non-competitive inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli assessed as enzyme Vmax at 500 nM using Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by Michael,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622637,20180907,134147411,374324090,834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1325515,2,Non-competitive inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli assessed as enzyme Km at 50 nM using Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by Michaelis-,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622638,20180907,134147411,374324090,834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1325516,2,Non-competitive inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli assessed as enzyme Km at 500 nM using Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by Michaelis,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622639,20180907,134147411,374324090,834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1325517,100,Non-competitive inhibition of human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli using 5 to 50 uM Ac-WEHD-AMC as substrate preincubated for 30 mins followed by substrate addition by Michaelis-Menten plot analysis,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622640,20180907,134147411,374324090,834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1325518,100,Inhibition of full-length human calpain-1 assessed as residual activity at 5 uM preincubated for 10 mins followed by Suc-LLVY-AMC substrate addition by fluorescence assay relative to control,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622641,20180907,9828058,374275733,823,NULL,P07384,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.52,P07384,NULL
1325519,100,Inhibition of human recombinant cathepsin-K assessed as residual activity at 5 uM preincubated for 10 mins followed by Z-FR-AMC substrate addition by fluorescence assay relative to control,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622642,20180907,134148745,374328889,1513,NULL,P43235,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.38,P43235,NULL
1325520,100,Inhibition of human recombinant cathepsin-B at 5 uM preincubated for 10 mins followed by Z-FR-AMC substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622643,20180907,"9828058,134136688,134147411,134148745","374275733,374285342,374324090,374328889",1508,NULL,P07858,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.1,P07858,NULL
1325521,100,Inhibition of papaya papain at 5 uM preincubated for 10 mins followed by Suc-LLVY-AMC substrate addition by fluorescence assay relative to control,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622644,20180907,"9828058,134136688,134147411,134148745","374275733,374285342,374324090,374328889",110813108,NULL,P00784,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.2,P00784,NULL
1325522,100,Inhibition of full-length human calpain-1 at 5 uM preincubated for 10 mins followed by Suc-LLVY-AMC substrate addition by fluorescence assay relative to control,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622645,20180907,"134136688,134147411,134148745","374285342,374324090,374328889",823,NULL,P07384,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.52,P07384,NULL
1325523,100,Inhibition of human recombinant cathepsin-K at 5 uM preincubated for 10 mins followed by Z-FR-AMC substrate addition by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622646,20180907,"9828058,134136688,134147411","374275733,374285342,374324090",1513,NULL,P43235,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.38,P43235,NULL
1325524,2,Inhibition of human recombinant DTT-activated caspase-1 expressed in Escherichia coli using WEHD-AMC as substrate after 30 mins by fluorescence assay,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622647,20180907,"104934,9828058","242220079,374275733",834,NULL,P29466,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.36,P29466,NULL
1332155,100,Time-dependent inhibition of human recombinant microsomal MAO-B expressed in baculovirus-infected insect cells preincubated for 5 to 30 mins by IC50 shift assay,"Title: N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents._|__|_Abstract: In the brains of patients with Alzheimer's disease, the enzymatic activities of butyrylcholinesterase (BChE) and monoamine oxidase B (MAO-B) are increased. While BChE is a viable therapeutic target for alleviation of symptoms caused by cholinergic hypofunction, MAO-B is a potential therapeutic target for prevention of neurodegeneration in Alzhe",43,ChEMBL,1629369,20200624,132495360,374284075,4129,NULL,P27338,Curation Efforts|Research and Development,27908752,0,10.1016/j.bmc.2016.11.032,1.4.3.4,P27338,NULL
1354964,100,Time dependent inhibition of CYP1A2 in human liver microsomes,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734325,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1354965,100,Time dependent inhibition of CYP3A4 in human liver microsomes using BFC/BZR as substrate,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734326,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1355026,100,Time dependent inhibition of CYP2B6 in human liver microsomes,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734387,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1355027,100,Time dependent inhibition of CYP2C8 in human liver microsomes,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734388,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1355028,100,Time dependent inhibition of CYP2C9 in human liver microsomes,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734389,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1355029,100,Time dependent inhibition of CYP2C19 in human liver microsomes,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734390,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1355030,100,Time dependent inhibition of CYP2D6 in human liver microsomes,"Title: BMS-986163, a Negative Allosteric Modulator of GluN2B with Potential Utility in Major Depressive Disorder._|__|_Abstract: There is a significant unmet medical need for more efficacious and rapidly acting antidepressants. Toward this end, negative allosteric modulators of the N-methyl-d-aspartate receptor subtype GluN2B have demonstrated encouraging therapeutic potential. We report herein the discovery and preclinical profile of a water-soluble intravenous prodrug BMS-986163 (6) and its active parent ",43,ChEMBL,1734391,20200618,91820646,374287233,NULL,NULL,NULL,Curation Efforts|Research and Development,29795762,0,10.1021/acsmedchemlett.8b00080,NULL,NULL,NULL
1363909,2,Time dependent inhibition of recombinant human NAAA expressed in HEK293 cell membranes using [14C]-PEA as substrate by liquid scintillation counting method,"Title: Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors._|__|_Abstract: Fatty acid ethanolamides (FAEs) and endocannabinoids (ECs) have been shown to alleviate pain and inflammation, regulate motility and appetite, and produce anticancer, anxiolytic, and neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2) or via peroxisome proliferator-activated receptor &#x3B1; (PPAR-&#x3B1;) stimulation. FAEs and ECs a",43,ChEMBL,1743297,20200618,26248,103220500,NULL,NULL,NULL,Curation Efforts|Research and Development,27766867,0,10.1021/acs.jmedchem.6b00538,NULL,NULL,NULL
1363910,2,Time dependent inhibition of recombinant human NAAA expressed in HEK293 cells by liquid scintillation counting method,"Title: Therapeutic Potential of Fatty Acid Amide Hydrolase, Monoacylglycerol Lipase, and N-Acylethanolamine Acid Amidase Inhibitors._|__|_Abstract: Fatty acid ethanolamides (FAEs) and endocannabinoids (ECs) have been shown to alleviate pain and inflammation, regulate motility and appetite, and produce anticancer, anxiolytic, and neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2) or via peroxisome proliferator-activated receptor &#x3B1; (PPAR-&#x3B1;) stimulation. FAEs and ECs a",43,ChEMBL,1743298,20200618,26248,103220500,NULL,NULL,NULL,Curation Efforts|Research and Development,27766867,0,10.1021/acs.jmedchem.6b00538,NULL,NULL,NULL
1364075,100,Time-dependent inhibition of CYP1A2 (unknown origin),"Title: Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)._|__|_Abstract: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthesis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel heteroaryldihydropyrimidine (HAP) inhibitors of H",43,ChEMBL,1743463,20200618,25144422,336889586,NULL,NULL,NULL,Curation Efforts|Research and Development,28082068,0,10.1016/j.bmc.2016.12.017,NULL,NULL,NULL
1364076,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)._|__|_Abstract: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthesis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel heteroaryldihydropyrimidine (HAP) inhibitors of H",43,ChEMBL,1743464,20200618,25144422,336889586,NULL,NULL,NULL,Curation Efforts|Research and Development,28082068,0,10.1016/j.bmc.2016.12.017,NULL,NULL,NULL
1364077,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)._|__|_Abstract: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthesis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel heteroaryldihydropyrimidine (HAP) inhibitors of H",43,ChEMBL,1743465,20200618,25144422,336889586,NULL,NULL,NULL,Curation Efforts|Research and Development,28082068,0,10.1016/j.bmc.2016.12.017,NULL,NULL,NULL
1364078,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)._|__|_Abstract: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthesis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel heteroaryldihydropyrimidine (HAP) inhibitors of H",43,ChEMBL,1743466,20200618,25144422,336889586,NULL,NULL,NULL,Curation Efforts|Research and Development,28082068,0,10.1016/j.bmc.2016.12.017,NULL,NULL,NULL
1364079,100,Time-dependent inhibition of CYP2E1 (unknown origin),"Title: Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)._|__|_Abstract: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthesis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel heteroaryldihydropyrimidine (HAP) inhibitors of H",43,ChEMBL,1743467,20200618,25144422,336889586,NULL,NULL,NULL,Curation Efforts|Research and Development,28082068,0,10.1016/j.bmc.2016.12.017,NULL,NULL,NULL
1364080,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of hepatitis B virus capsid assembly inhibitors leading to a heteroaryldihydropyrimidine based clinical candidate (GLS4)._|__|_Abstract: Inhibition of hepatitis B virus (HBV) capsid assembly is a novel strategy for the development of chronic hepatitis B (CHB) therapeutics. Herein we described our lead optimization studies including the synthesis, molecular docking studies and structure-activity relationship (SAR) studies of a series of novel heteroaryldihydropyrimidine (HAP) inhibitors of H",43,ChEMBL,1743468,20200618,25144422,336889586,NULL,NULL,NULL,Curation Efforts|Research and Development,28082068,0,10.1016/j.bmc.2016.12.017,NULL,NULL,NULL
1368067,100,Time-dependent inhibition of human CYP1A1 expressed in yeast microsomal membranes using 7-ethoxyresorufin as substrate,"Title: (E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent._|__|_Abstract: The overexpression of CYP1 family of enzymes is reported to be associated with development of human carcinomas. It has been well reported that CYP1A1 specific inhibitors prevents carcinogenesis. Herein, thirteen pyridine-4-yl series of chalcones were synthesized and screened for inhibition of CYP1 isoforms 1A1, 1B1 and 1A2 ",43,ChEMBL,1747455,20200618,10379988,404683130,NULL,NULL,NULL,Curation Efforts|Research and Development,29138024,0,10.1016/j.bmcl.2017.11.009,NULL,NULL,NULL
1368068,100,Time-dependent inhibition of recombinant human CYP1A1 expressed in HEK293 cells using 7-ethoxyresorufin as substrate,"Title: (E)-3-(3,4,5-Trimethoxyphenyl)-1-(pyridin-4-yl)prop-2-en-1-one, a heterocyclic chalcone is a potent and selective CYP1A1 inhibitor and cancer chemopreventive agent._|__|_Abstract: The overexpression of CYP1 family of enzymes is reported to be associated with development of human carcinomas. It has been well reported that CYP1A1 specific inhibitors prevents carcinogenesis. Herein, thirteen pyridine-4-yl series of chalcones were synthesized and screened for inhibition of CYP1 isoforms 1A1, 1B1 and 1A2 ",43,ChEMBL,1747456,20200618,10379988,404683130,NULL,NULL,NULL,Curation Efforts|Research and Development,29138024,0,10.1016/j.bmcl.2017.11.009,NULL,NULL,NULL
1373675,100,Time dependent inhibition of human recombinant MAOA using kynuramine as substrate preincubated for up to 30 mins followed by substrate addition,"Title: Selective inhibition of monoamine oxidase A by hispidol._|__|_Abstract: Hispidol, an aurone, isolated from Glycine max Merrill, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A), with an IC50 value of 0.26&#x202F;&#xB5;M, and to inhibit MAO-B, but with lower potency (IC50&#x202F;=&#x202F;2.45&#x202F;&#xB5;M). Hispidol reversibly and competitively inhibited MAO-A with a Ki value of 0.10&#x202F;&#xB5;M with a potency much greater than toloxatone (",43,ChEMBL,1753082,20200618,"5281254,5281295","103476444,103597598",NULL,NULL,NULL,Curation Efforts|Research and Development,29395970,0,10.1016/j.bmcl.2018.01.049,NULL,NULL,NULL
1374347,100,Time-dependent inhibition of recombinant His-tagged MIF tautomerase activity (unknown origin) using 4-HPP as substrate,"Title: Discovery of chromenes as inhibitors of macrophage migration inhibitory factor._|__|_Abstract: Macrophage migration inhibitory factor (MIF) is an essential signaling cytokine with a key role in the immune system. Binding of MIF to its molecular targets such as, among others, the cluster of differentiation 74 (CD74) receptor plays a key role in inflammatory diseases and cancer. Therefore, the identification of MIF binding compounds gained importance in drug discovery. In this study, we aimed to discov",43,ChEMBL,1753754,20200618,"71299360,71299377","404691596,404695074",NULL,NULL,NULL,Curation Efforts|Research and Development,29428527,0,10.1016/j.bmc.2017.12.032,NULL,NULL,NULL
1375884,100,Time-dependent inhibition of human CYP3A4 using midazolam as substrate,"Title: Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity._|__|_Abstract: Aldehyde dehydrogenases (ALDHs) are responsible for the metabolism of aldehydes (exogenous and endogenous) and possess vital physiological and toxicological functions in areas such as CNS, inflammation, metabolic disorders, and cancers. Overexpression of certain ALDHs (e.g., ALDH1A1) is an important biomarker in cancers and cancer stem cells (CSCs) indicating",43,ChEMBL,1755291,20200618,"134821685,137628670","404691511,404691920",NULL,NULL,NULL,Curation Efforts|Research and Development,29767973,0,10.1021/acs.jmedchem.8b00270,NULL,NULL,NULL
1375885,100,Time-dependent inhibition of human CYP2C9,"Title: Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity._|__|_Abstract: Aldehyde dehydrogenases (ALDHs) are responsible for the metabolism of aldehydes (exogenous and endogenous) and possess vital physiological and toxicological functions in areas such as CNS, inflammation, metabolic disorders, and cancers. Overexpression of certain ALDHs (e.g., ALDH1A1) is an important biomarker in cancers and cancer stem cells (CSCs) indicating",43,ChEMBL,1755292,20200618,"134821685,137628670","404691511,404691920",NULL,NULL,NULL,Curation Efforts|Research and Development,29767973,0,10.1021/acs.jmedchem.8b00270,NULL,NULL,NULL
1375886,100,Time-dependent inhibition of human CYP2D6,"Title: Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity._|__|_Abstract: Aldehyde dehydrogenases (ALDHs) are responsible for the metabolism of aldehydes (exogenous and endogenous) and possess vital physiological and toxicological functions in areas such as CNS, inflammation, metabolic disorders, and cancers. Overexpression of certain ALDHs (e.g., ALDH1A1) is an important biomarker in cancers and cancer stem cells (CSCs) indicating",43,ChEMBL,1755293,20200618,"134821685,137628670","404691511,404691920",NULL,NULL,NULL,Curation Efforts|Research and Development,29767973,0,10.1021/acs.jmedchem.8b00270,NULL,NULL,NULL
1383054,2,Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate up to 30 mins by spectrophotometric method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762497,20200618,6422124,103177393,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383055,2,Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes using kynuramine as substrate up to 30 mins by spectrophotometric method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762498,20200618,6422124,103177393,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383056,2,Binding affinity to human H3R,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762499,20200618,6422124,103177393,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383057,2,Displacement of [125I]iodoproxyfan from human H3R expressed in CHOK1 cell membranes after 60 mins by gamma counting method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762500,20200618,9838864,194137603,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383058,100,Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes at 10 uM using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method relative to control,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762501,20200618,"12214367,12214369,44072806,69744095,145964274,145967442,145971024,145971387,145973881,145973963,145975223,145977335","404672892,404673435,404675169,404678218,404683489,404684012,404687730,404687852,404688815,404689725,404692912,404693235",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383059,100,Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes at 2 uM using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method relative to control,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762502,20200618,145974947,404689313,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383060,100,Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes at 5 uM using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method relative to control,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762503,20200618,145977624,404693331,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383061,100,Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes at 10 uM using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method relative to control,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762504,20200618,"12214367,12214369,44072806,69744095,145964274,145967442,145971024,145971387,145973881,145973963,145975223,145977335","404672892,404673435,404675169,404678218,404683489,404684012,404687730,404687852,404688815,404689725,404692912,404693235",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383062,100,Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes at 2 uM using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method relative to control,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762505,20200618,145974947,404689313,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383063,100,Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes at 5 uM using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method relative to control,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762506,20200618,145977624,404693331,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383064,2,Displacement of [3H]-N-alpha-methylhistamine from human H3R expressed in HEK293 cell membranes after 90 mins by liquid scintillation counting method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762507,20200618,"9838864,12214367,12214369,44072806,69744095,145964274,145967442,145971024,145971387,145973881,145973963,145974947,145975223,145977335,145977624","194137603,404672892,404673435,404675169,404678218,404683489,404684012,404687730,404687852,404688815,404689313,404689725,404692912,404693235,404693331",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383065,2,Inhibition of human MAO-A expressed in baculovirus infected insect cell membranes using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762508,20200618,"26757,131682,9838864,145971024,145974947,145977624","103252336,103526952,194137603,404683489,404689313,404693331",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383066,2,Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate preincubated for 30 mins followed by substrate addition measured after 15 to 20 mins by discontinuous fluorimetric method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762509,20200618,"26757,131682,145971024,145974947,145977624","103252336,103526952,404683489,404689313,404693331",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383067,2,Inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using kynuramine as substrate after 15 to 20 mins by discontinuous fluorimetric method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762510,20200618,"26757,131682,9838864,145971024,145974947,145977624","103252336,103526952,194137603,404683489,404689313,404693331",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383068,100,"Selectivity index, ratio of IC50 for human MAO-A expressed in baculovirus infected insect cell membranes without preincubation with enzyme to IC50 for human MAO-B expressed in baculovirus infected insect cell membranes without preincubation with enzyme","Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762511,20200618,"26757,131682,9838864,145971024,145974947,145977624","103252336,103526952,194137603,404683489,404689313,404693331",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383070,100,Reversible inhibition of human MAO-B expressed in baculovirus infected insect cell membranes using excess of kynuramine substrate preincubated for 30 to 60 mins followed by 50 fold compound dilution by fluorimetric method,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762513,20200618,"145971024,145974947,145977624","404683489,404689313,404693331",NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383071,100,Thiol reactivity of the compound assessed as cysteine adduct formation at 4 ug/ml up to 3 days in presence of N-Acetylcysteine by ESI-MS analysis,"Title: Novel indanone derivatives as MAO B/H3R dual-targeting ligands for treatment of Parkinson's disease._|__|_Abstract: The design of multi-targeting ligands was developed in the last decades as an innovative therapeutic concept for Parkinson's disease (PD) and other neurodegenerative disorders. As the monoamine oxidase B (MAO B) and the histamine H3 receptor (H3R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the",43,ChEMBL,1762514,20200618,145971024,404683489,NULL,NULL,NULL,Curation Efforts|Research and Development,29477889,0,10.1016/j.ejmech.2018.02.015,NULL,NULL,NULL
1383791,100,Time-dependent inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam as substrate preincubated for 5 to 30 mins followed by NADPH addition measured after 10 mins,"Title: Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups._|__|_Abstract: Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1-BRD4 dual inhibitor BI-2536, we discovered a new series of dihydroquinoxalin-2(1H)-one with aniline and indoline WPF binders as selective BRD4 inhibitors. They showed better BRD4-BD1 potency and negl",43,ChEMBL,1763234,20200618,"142296515,142296521,142296525,142296533,142296540,142296546,142296552,142296555,142296557,142296562,142296567,142296570,142296573,142296575,142296581,142296582,142296589,142296592,142296595,142296607","404673551,404673625,404673632,404673968,404674096,404674374,404675070,404676660,404681443,404685032,404685503,404686128,404689422,404689787,404689932,404691400,404691995,404692714,404694532,404694667",NULL,NULL,NULL,Curation Efforts|Research and Development,29525435,0,10.1016/j.ejmech.2018.02.070,NULL,NULL,NULL
1383792,100,Time-dependent inhibition of CYP3A4 in human liver microsomes at 10 uM using testosterone as substrate preincubated for 5 to 30 mins followed by NADPH addition measured after 10 mins,"Title: Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups._|__|_Abstract: Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1-BRD4 dual inhibitor BI-2536, we discovered a new series of dihydroquinoxalin-2(1H)-one with aniline and indoline WPF binders as selective BRD4 inhibitors. They showed better BRD4-BD1 potency and negl",43,ChEMBL,1763235,20200618,"142296515,142296521,142296525,142296533,142296540,142296546,142296552,142296555,142296557,142296562,142296567,142296570,142296573,142296575,142296581,142296582,142296589,142296592,142296595,142296607","404673551,404673625,404673632,404673968,404674096,404674374,404675070,404676660,404681443,404685032,404685503,404686128,404689422,404689787,404689932,404691400,404691995,404692714,404694532,404694667",NULL,NULL,NULL,Curation Efforts|Research and Development,29525435,0,10.1016/j.ejmech.2018.02.070,NULL,NULL,NULL
1383793,100,Time-dependent inhibition of CYP2D6 in human liver microsomes at 10 uM using dextromethorphan as substrate preincubated for 5 to 30 mins followed by NADPH addition measured after 10 mins,"Title: Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups._|__|_Abstract: Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1-BRD4 dual inhibitor BI-2536, we discovered a new series of dihydroquinoxalin-2(1H)-one with aniline and indoline WPF binders as selective BRD4 inhibitors. They showed better BRD4-BD1 potency and negl",43,ChEMBL,1763236,20200618,"142296515,142296521,142296525,142296533,142296540,142296546,142296552,142296555,142296557,142296562,142296567,142296570,142296573,142296575,142296581,142296582,142296589,142296592,142296595,142296607","404673551,404673625,404673632,404673968,404674096,404674374,404675070,404676660,404681443,404685032,404685503,404686128,404689422,404689787,404689932,404691400,404691995,404692714,404694532,404694667",NULL,NULL,NULL,Curation Efforts|Research and Development,29525435,0,10.1016/j.ejmech.2018.02.070,NULL,NULL,NULL
1383794,100,Time-dependent inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac as substrate preincubated for 5 to 30 mins followed by NADPH addition measured after 10 mins,"Title: Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups._|__|_Abstract: Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1-BRD4 dual inhibitor BI-2536, we discovered a new series of dihydroquinoxalin-2(1H)-one with aniline and indoline WPF binders as selective BRD4 inhibitors. They showed better BRD4-BD1 potency and negl",43,ChEMBL,1763237,20200618,"142296515,142296521,142296525,142296533,142296540,142296546,142296552,142296555,142296557,142296562,142296567,142296570,142296573,142296575,142296581,142296582,142296589,142296592,142296595,142296607","404673551,404673625,404673632,404673968,404674096,404674374,404675070,404676660,404681443,404685032,404685503,404686128,404689422,404689787,404689932,404691400,404691995,404692714,404694532,404694667",NULL,NULL,NULL,Curation Efforts|Research and Development,29525435,0,10.1016/j.ejmech.2018.02.070,NULL,NULL,NULL
1383795,100,Time-dependent inhibition of CYP1A2 in human liver microsomes at 10 uM using phenacetin as substrate preincubated for 5 to 30 mins followed by NADPH addition measured after 10 mins,"Title: Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups._|__|_Abstract: Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1-BRD4 dual inhibitor BI-2536, we discovered a new series of dihydroquinoxalin-2(1H)-one with aniline and indoline WPF binders as selective BRD4 inhibitors. They showed better BRD4-BD1 potency and negl",43,ChEMBL,1763238,20200618,"142296515,142296521,142296525,142296533,142296540,142296546,142296552,142296555,142296557,142296562,142296567,142296570,142296573,142296575,142296581,142296582,142296589,142296592,142296595,142296607","404673551,404673625,404673632,404673968,404674096,404674374,404675070,404676660,404681443,404685032,404685503,404686128,404689422,404689787,404689932,404691400,404691995,404692714,404694532,404694667",NULL,NULL,NULL,Curation Efforts|Research and Development,29525435,0,10.1016/j.ejmech.2018.02.070,NULL,NULL,NULL
1383796,100,Time-dependent inhibition of CYP2C19 in human liver microsomes at 10 uM using mephenytoin as substrate preincubated for 5 to 30 mins followed by NADPH addition measured after 10 mins,"Title: Structure-based optimization of a series of selective BET inhibitors containing aniline or indoline groups._|__|_Abstract: Recently, several kinase inhibitors were found to also inhibit bromodomains, providing a new strategy for the discovery of bromodomain inhibitors. Along this line, starting from PLK1-BRD4 dual inhibitor BI-2536, we discovered a new series of dihydroquinoxalin-2(1H)-one with aniline and indoline WPF binders as selective BRD4 inhibitors. They showed better BRD4-BD1 potency and negl",43,ChEMBL,1763239,20200618,"142296515,142296521,142296525,142296533,142296540,142296546,142296552,142296555,142296557,142296562,142296567,142296570,142296573,142296575,142296581,142296582,142296589,142296592,142296595,142296607","404673551,404673625,404673632,404673968,404674096,404674374,404675070,404676660,404681443,404685032,404685503,404686128,404689422,404689787,404689932,404691400,404691995,404692714,404694532,404694667",NULL,NULL,NULL,Curation Efforts|Research and Development,29525435,0,10.1016/j.ejmech.2018.02.070,NULL,NULL,NULL
1385208,100,Time dependent inhibition of CYP3A4 (unknown origin) at 33 uM measured over 15 mins relative to control,"Title: Reverse Hydroxamate Inhibitors of Bone Morphogenetic Protein 1._|__|_Abstract: Bone Morphogenetic Protein 1 (BMP1) inhibition is a potential method for treating fibrosis because BMP1, a member of the zinc metalloprotease family, is required to convert pro-collagen to collagen. A novel class of reverse hydroxamate BMP1 inhibitors was discovered, and cocrystal structures with BMP1 were obtained. The observed binding mode is unique in that the small molecule occupies the nonprime side of the metalloprot",43,ChEMBL,1764651,20200618,118225789,404693793,NULL,NULL,NULL,Curation Efforts|Research and Development,30034610,0,10.1021/acsmedchemlett.8b00173,NULL,NULL,NULL
1387475,100,Time dependent inhibition of His-tagged human MAGL expressed in Escherichia coli BL21(DE3) assessed as reduction in arachidonic acid production from 2-arachidonoylglycerol,"Title: Design, Synthesis, and Evaluation of Piperazinyl Pyrrolidin-2-ones as a Novel Series of Reversible Monoacylglycerol Lipase Inhibitors._|__|_Abstract: Monoacylglycerol lipase (MAGL) is a major serine hydrolase that hydrolyzes 2-arachidonoylglycerol (2-AG) to arachidonic acid (AA) and glycerol in the brain. Because 2-AG and AA are endogenous biologically active ligands in the brain, inhibition of MAGL is an attractive therapeutic target for CNS disorders, particularly neurodegenerative diseases. In thi",43,ChEMBL,1766918,20200618,18184754,163321129,NULL,NULL,NULL,Curation Efforts|Research and Development,30251836,0,10.1021/acs.jmedchem.8b00824,NULL,NULL,NULL
1391263,2,Inhibition of human N-terminal His6-tagged Pin1 PPIase activity expressed in Escherichia coli BL21 using Suc-Ala-Glu-cis-Pro-Phe-4-nitroanilide as substrate preincubated for 10 mins followed by substrate addition monitored for 90 secs by protease enzyme c,"Title: Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors._|__|_Abstract: Pin1 (Protein interacting with NIMA1) is a cis-trans isomerase and promotes the amide bond rotation of phosphoSer/Thr-Pro motifs in its substrates. Inhibition of Pin1 might be a novel strategy for developing anticancer agents. Herein, a series of pyrimidine derivatives were synthesized and their Pin1 inhibitory activities were evaluated. Among them, four compounds (2a, 2f, 2h and 2l) displayed",43,ChEMBL,1770714,20200619,"3806,444795,7147232,7147236,7147253,11418384,11689343,12875050,58243056,59868882,71364521,86731374,89486397,108137459,108137463,108137632,108137725,108137732,114044218,114044219,114044230,145967653,145967916,145967923,145968164,145968301,145968650,145968765,145968864,145969010,145969015,145969074,145969565,145969756,145970008,145970114,145970180,145970188,145970386,145970621,145971036,145971130,145971175,145986584,145987041,145988830,145989474","103165713,103222861,103706774,123092512,312352154,404678477,404678533,404678828,404678845,404678940,404678949,404679301,404679508,404679517,404680014,404680174,404680313,404680532,404680538,404680630,404681023,404681147,404681351,404681492,404681656,404682019,404682165,404682242,404682262,404682275,404682576,404682907,404682932,404683200,404683226,404683236,404683252,404683322,404683509,404683649,404683708,404706657,404707356,404708433,404708436,404710155,404711169",NULL,NULL,NULL,Curation Efforts|Research and Development,29576270,0,10.1016/j.bmc.2018.03.024,NULL,NULL,NULL
1391264,100,Inhibition of human N-terminal His6-tagged Pin1 PPIase activity expressed in Escherichia coli BL21 using Suc-Ala-Glu-cis-Pro-Phe-4-nitroanilide as substrate by beckman coulter-paradigm assay,"Title: Synthesis and biological evaluation of pyrimidine derivatives as novel human Pin1 inhibitors._|__|_Abstract: Pin1 (Protein interacting with NIMA1) is a cis-trans isomerase and promotes the amide bond rotation of phosphoSer/Thr-Pro motifs in its substrates. Inhibition of Pin1 might be a novel strategy for developing anticancer agents. Herein, a series of pyrimidine derivatives were synthesized and their Pin1 inhibitory activities were evaluated. Among them, four compounds (2a, 2f, 2h and 2l) displayed",43,ChEMBL,1770715,20200619,"58243056,86731374,145967916,145969015","404678940,404680538,404681492,404683252",NULL,NULL,NULL,Curation Efforts|Research and Development,29576270,0,10.1016/j.bmc.2018.03.024,NULL,NULL,NULL
1406228,100,Inhibition of Leishmania mexicana cathepsin L-like protease CPB2.8 assessed as second order inactivation rate constant using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801037,20200619,"145981911,145994261","404699941,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406232,2,Inhibition of Leishmania major MHOM/IL/81/FE/BNI His6-tagged CPC expressed in Pichia pastoris using Cbz-Phe-Arg-AMC as substrate by fluorescence spectrometric method,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801041,20200619,145980966,404698495,NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406233,2,Inhibition of human cathepsin-L using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801042,20200619,"11599792,44411027,44411237,145990306,145994261","103487457,103487719,103487850,404712482,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406234,2,Inhibition of human cathepsin-B using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801043,20200619,11599792,103487850,NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406235,2,Inhibition of Leishmania mexicana cathepsin L-like protease CPB2.8 using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801044,20200619,"11599792,11859052,44411027,44411149,44411237,145979229,145980577,145980966,145981911,145984909,145986467,145987523,145989942,145990306,145990424,145990979,145994261","103487457,103487618,103487719,103487850,103488025,404695828,404697878,404698495,404699941,404704255,404706494,404708114,404711878,404712482,404712663,404713523,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406236,2,Inhibition of Trypanosoma brucei rhodesiense rhodesain using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801045,20200619,"11599792,11859052,44411027,44411149,44411237,145980966,145981911,145987523,145990306,145994261","103487457,103487618,103487719,103487850,103488025,404698495,404699941,404708114,404712482,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406237,2,Inhibition of Trypanosoma cruzi cruzain using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801046,20200619,"11599792,11859052,44411027,44411149,44411237,145986467,145987523,145990306,145990424,145990979,145994261","103487457,103487618,103487719,103487850,103488025,404706494,404708114,404712482,404712663,404713523,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406238,2,Inhibition of Plasmodium falciparum falcipain 2 using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801047,20200619,"11599792,44411027,44411237,145981911,145987330,145990306,145994261","103487457,103487719,103487850,404699941,404707797,404712482,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406240,100,Inhibition of human cathepsin-L at 20 uM using Z-Phe-Arg-AMC as substrate by fluorometric assay relative to control,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801049,20200619,"11859052,44411149,145979229,145980577,145980631,145980966,145981911,145984909,145986467,145987330,145987523,145988247,145989607,145989942,145990306,145990424,145990979,145993415,145994261","103487618,103488025,404695828,404697878,404697971,404698495,404699941,404704255,404706494,404707797,404708114,404709262,404711358,404711878,404712482,404712663,404713523,404717315,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406241,100,Inhibition of human cathepsin-B at 20 uM using Z-Phe-Arg-AMC as substrate by fluorometric assay relative to control,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801050,20200619,"11859052,44411027,44411149,44411237,145979229,145980577,145980631,145980966,145981911,145984909,145986467,145987330,145987523,145988247,145989607,145989942,145990306,145990424,145990979,145993415,145994261","103487457,103487618,103487719,103488025,404695828,404697878,404697971,404698495,404699941,404704255,404706494,404707797,404708114,404709262,404711358,404711878,404712482,404712663,404713523,404717315,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406242,100,Inhibition of Leishmania mexicana cathepsin L-like protease CPB2.8 at 20 uM using Z-Phe-Arg-AMC as substrate by fluorometric assay relative to control,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801051,20200619,"145979229,145980577,145980631,145981911,145984909,145986467,145987330,145988247,145989607,145989942,145990306,145990424,145990979,145993415,145994261","404695828,404697878,404697971,404699941,404704255,404706494,404707797,404709262,404711358,404711878,404712482,404712663,404713523,404717315,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406243,100,Inhibition of Trypanosoma brucei rhodesiense rhodesain at 20 uM using Z-Phe-Arg-AMC as substrate by fluorometric assay relative to control,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801052,20200619,"145979229,145980577,145980631,145981911,145984909,145986467,145987330,145988247,145989607,145989942,145990306,145990424,145990979,145993415,145994261","404695828,404697878,404697971,404699941,404704255,404706494,404707797,404709262,404711358,404711878,404712482,404712663,404713523,404717315,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406244,100,Inhibition of Trypanosoma cruzi cruzain at 20 uM using Z-Phe-Arg-AMC as substrate by fluorometric assay relative to control,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801053,20200619,"145979229,145980577,145980631,145980966,145981911,145984909,145986467,145987330,145988247,145989607,145989942,145990306,145990424,145990979,145993415,145994261","404695828,404697878,404697971,404698495,404699941,404704255,404706494,404707797,404709262,404711358,404711878,404712482,404712663,404713523,404717315,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406245,100,Inhibition of Plasmodium falciparum falcipain 2 at 20 uM using Z-Phe-Arg-AMC as substrate by fluorometric assay relative to control,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801054,20200619,"11859052,44411149,145979229,145980577,145980631,145980966,145981911,145984909,145986467,145987330,145987523,145988247,145989607,145989942,145990306,145990424,145990979,145993415,145994261","103487618,103488025,404695828,404697878,404697971,404698495,404699941,404704255,404706494,404707797,404708114,404709262,404711358,404711878,404712482,404712663,404713523,404717315,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406246,100,Inhibition of Trypanosoma cruzi cruzain assessed as second order inactivation rate constant using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801055,20200619,145994261,404718788,NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406247,100,Inhibition of Trypanosoma brucei rhodesiense rhodesain assessed as second order inactivation rate constant using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801056,20200619,"145981911,145994261","404699941,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406248,100,Inhibition of Plasmodium falciparum falcipain 2 assessed as second order inactivation rate constant using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801057,20200619,"145981911,145987330,145994261","404699941,404707797,404718788",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406249,100,Inhibition of human cathepsin-L assessed as second order inactivation rate constant using Z-Phe-Arg-AMC as substrate by fluorometric assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801058,20200619,145994261,404718788,NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1423055,2,Inhibition of ATR in human HeLa cell nuclear extract using GST-fused p53N66 as substrate preincubated for 10 mins followed by ATP addition and measured after 1 hr by ELISA,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797560,20200619,"46244173,46244258,46244454,46244883,54761305,54761306,54761473,54761474,54761648,71584283,71584419,117906028,145979565,145979907,145980103,145980208,145980501,145981271,145981505,145983402,145986333,145987142,145987199,145987381,145989852,145990007,145990234,145991167,145991457,145991697,145992074,145992301,145992816,145993592","164128834,164128876,164140186,164142958,164142959,164148581,318406763,318406764,404673549,404696336,404696851,404697159,404697311,404697765,404698969,404699329,404699733,404702154,404706296,404707511,404707592,404707882,404711740,404711995,404712361,404713809,404714267,404714628,404715209,404715558,404716372,404716419,404717608,404718021",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423056,2,Inhibition of ATR in human HT29 cells after 60 mins by Hoechst 33258 staining-based assay,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797561,20200619,"46244173,46244258,46244454,46244883,54761305,54761306,54761473,54761474,54761648,71584283,71584419,117906028,145979565,145979907,145980103,145980208,145980501,145981271,145981505,145983402,145986333,145987142,145987199,145987381,145989852,145990007,145990234,145991167,145991457,145991697,145992074,145992301,145992816,145993592","164128834,164128876,164140186,164142958,164142959,164148581,318406763,318406764,404673549,404696336,404696851,404697159,404697311,404697765,404698969,404699329,404699733,404702154,404706296,404707511,404707592,404707882,404711740,404711995,404712361,404713809,404714267,404714628,404715209,404715558,404716372,404716419,404717608,404718021",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423057,100,"Octanol-phosphate buffer partition co-efficient, log D of the compound at 10 uM at pH 7.4 after 3 hrs by shake flask method","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797562,20200619,"46244173,46244258,46244454,46244883,54761305,54761306,54761473,54761474,54761648,71584283,71584419,117906028,145980501,145981271,145981505,145983402,145986333,145987142,145987381,145989852,145990234,145991457,145992074,145992301,145992816","164128834,164128876,164140186,164142958,164142959,164148581,318406763,318406764,404673549,404697765,404698969,404699329,404699733,404702154,404706296,404707511,404707882,404711740,404712361,404714267,404715209,404715558,404716372,404716419,404718021",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423059,2,Aqueous solubility in pH 7.4 phosphate buffer after 24 hrs by LC-UV-MS analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797564,20200619,"46244454,54761305,54761306,54761473,54761474,54761648,117906028,145980501,145981271,145983402,145986333,145987142,145989852,145990234,145991457,145992074,145992816","164142958,318406763,318406764,404673549,404697765,404698969,404699733,404702154,404706296,404707511,404711740,404712361,404714267,404715209,404716372,404716419,404718021",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423060,2,Inhibition of PI3Kalpha (unknown origin),"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797565,20200619,"145987381,145992074","404707882,404715209",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423061,100,Fraction unbound in mouse 10% plasma,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797566,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423062,100,Fraction unbound in human 10% plasma,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797567,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423063,2,Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797568,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423064,2,Inhibition of CYP1A2 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797569,20200619,"46244173,46244258,46244454,46244883,54761306,54761473,71584283,71584419,145981271,145981505,145987142,145987381,145992301","164128834,164128876,164140186,164142958,164142959,164148581,318406764,404698969,404699329,404707511,404707882,404715558,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423065,2,Inhibition of CYP2C19 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797570,20200619,"46244173,46244258,46244454,46244883,54761306,54761473,71584283,71584419,145981271,145981505,145987142,145987381,145992301","164128834,164128876,164140186,164142958,164142959,164148581,318406764,404698969,404699329,404707511,404707882,404715558,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423066,2,Inhibition of CYP2C9 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797571,20200619,"46244173,46244258,46244454,46244883,54761306,54761473,71584283,71584419,145981271,145981505,145987142,145987381,145992301","164128834,164128876,164140186,164142958,164142959,164148581,318406764,404698969,404699329,404707511,404707882,404715558,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423067,2,Inhibition of CYP2D6 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by substrate addition and measured after 30 mins in presence of NADPH by LC-MS analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797572,20200619,"46244173,46244258,46244454,46244883,54761306,54761473,71584283,71584419,145981271,145981505,145987142,145987381,145992301","164128834,164128876,164140186,164142958,164142959,164148581,318406764,404698969,404699329,404707511,404707882,404715558,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423068,2,Inhibition of human ERG by whole cell electrophysiology analysis,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797573,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423069,100,Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM at pH 6.5,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797574,20200619,"46244454,54761306,145981271","164142958,404698969,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423070,100,Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM at pH 7.4,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797575,20200619,"46244454,54761306,54761473,145987142","164142958,318406764,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423071,100,Intrinsic clearance in rat hepatocytes at 1 uM assessed per 10'6 cells,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797576,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423072,100,Intrinsic clearance in human hepatocytes at 1 uM assessed per 10'6 cells,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797577,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423073,100,"Dose normalized AUC in Han-Wistar rat at 4 umol/kg, po","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797578,20200619,"46244454,145981271","164142958,404698969",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423074,100,"Dose normalized AUC in Han-Wistar rat at 10 umol/kg, po","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797579,20200619,"54761306,54761473,145987142","318406764,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423075,100,Inhibition of full length recombinant human GST-tagged CLK4 expressed in baculovirus expression system at 1 uM by Lanthascreen assay relative to control,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797580,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423076,100,Inhibition of recombinant human GST-tagged PIK3C2G (468 to 1203 residues) expressed in insect cells at 1 uM by ADAPTA assay relative to control,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797581,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423077,2,Inhibition of mTOR (unknown origin),"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797582,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423078,2,Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in AKT phosphorylation at S473 residue,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797583,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423079,2,Inhibition of mTOR in human MDA-MB-468 cells assessed as decrease in 70S6K S235/236 phosphorylation,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797584,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423080,2,Inhibition of PI3Kalpha in human BT-474 cells assessed as decrease in AKT phosphorylation at T308 residue,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797585,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423081,2,Inhibition of ATM phosphorylation at Ser1981 residue in human HT-29 cells using ionizing radiation,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797586,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423082,2,Inhibition of DNA-PK phosphorylation at Ser2056 residue in human HT-29 cells using ionizing radiation,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797587,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423083,2,Cytotoxicity against human LoVo cells after 72 hrs by MTS assay,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797588,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423084,2,Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797589,20200619,"46244454,54761306,54761473,145981271,145987142","164142958,318406764,404698969,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423085,100,"Toxicity in Swiss nu/nu mouse xenografted with human LoVo cells assessed as drug tolerability at 25 mg/kg, po qd administered via gavage","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797590,20200619,"145981271,145987142","404698969,404707511",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423086,100,"Toxicity in Swiss nu/nu mouse xenografted with human LoVo cells assessed as drug tolerability at 50 mg/kg, po qd administered via gavage","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797591,20200619,"46244454,54761306,54761473","164142958,318406764,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423087,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 20 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797592,20200619,46244454,164142958,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423088,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 14 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797593,20200619,"46244454,54761306,54761473","164142958,318406764,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423089,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 13 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797594,20200619,"46244454,54761306","164142958,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423090,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 25 mg/kg, po bid for 13 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797595,20200619,"46244454,54761306","164142958,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423091,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 75 mg/kg, po qd for 11 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797596,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423092,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 50 mg/kg, po qd for 15 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797597,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423093,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 25 mg/kg, po qd for 15 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797598,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423094,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 25 mg/kg, po qd for 11 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797599,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423095,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 10 mg/kg, po qd for 15 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797600,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423096,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 12.5 mg/kg, po bid for 11 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797601,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423097,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 25 mg/kg, po qd for 20 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797602,20200619,"145981271,145987142","404698969,404707511",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423098,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 25 mg/kg, po qd for 13 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797603,20200619,145981271,404698969,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423099,100,"Antitumor activity against human LoVo cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 12.5 mg/kg, po bid for 13 days and measured on day 22","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797604,20200619,145981271,404698969,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423100,2,"Plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 50 mg/kg, po qd after 8 hrs","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797605,20200619,"46244454,54761306,54761473","164142958,318406764,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423101,2,"Plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 25 mg/kg, po bid after 8 hrs","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797606,20200619,"46244454,54761306,145987142","164142958,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423102,2,"Plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 75 mg/kg, po qd after 8 hrs","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797607,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423103,2,"Plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 25 mg/kg, po qd after 8 hrs","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797608,20200619,145981271,404698969,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423104,2,"Plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 12.5 mg/kg, po bid after 8 hrs","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797609,20200619,145981271,404698969,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423105,100,"Ratio of free plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 50 mg/kg, po qd to in vitro GI50 for human LoVo cells","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797610,20200619,"46244454,54761306,145987142","164142958,404707511,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423106,100,"Ratio of free plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 25 mg/kg, po bid to in vitro GI50 for human LoVo cells","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797611,20200619,"46244454,54761306,54761473","164142958,318406764,404716419",NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423107,100,"Ratio of free plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 75 mg/kg, po qd to in vitro GI50 for human LoVo cells","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797612,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423108,100,"Ratio of free plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 25 mg/kg, po qd to in vitro GI50 for human LoVo cells","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797613,20200619,145981271,404698969,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423109,100,"Ratio of free plasma concentration in Swiss nu/nu mouse xenografted with human LoVo cells at 12.5 mg/kg, po bid to in vitro GI50 for human LoVo cells","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797614,20200619,145981271,404698969,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423110,100,"Clearance in Han Wistar rat at 8.55 umol/kg, iv or 20.3 umol/kg, po relative to liver blood flow","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797615,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423111,100,"Volume of distribution at steady state in Han Wistar rat at 8.55 umol/kg, iv or 20.3 umol/kg, po","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797616,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423112,100,Oral bioavailability in Han Wistar rat at 20.3 umol/kg,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797617,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423113,100,"Clearance in Beagle dog at 10.5 umol/kg, iv or 15.1 umol/kg, po relative to liver blood flow","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797618,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423114,100,"Volume of distribution at steady state in Beagle dog at 10.5 umol/kg, iv or 15.1 umol/kg, po","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797619,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423115,100,Oral bioavailability in Beagle dog at 15.1 umol/kg,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797620,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423116,100,Intrinsic clearance in human hepatocytes assessed as per million cells at 1 uM,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797621,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423117,100,Solubility in SGF at pH 2.5,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797622,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423118,100,Solubility in FaSSIF at pH 6.5,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797623,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423119,100,"Antitumor activity against human HT-29 cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 25 mg/kg, po bid measured on day 27","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797624,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423120,100,"Antitumor activity against human HT-29 cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 50 mg/kg, po qd measured on day 27","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797625,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423121,100,"Antitumor activity against human HT-29 cells xenografted in Swiss nu/nu mouse assessed as tumor growth inhibition at 75 mg/kg, po qd measured on day 27","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797626,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423122,100,"Toxicity in Swiss nu/nu mouse xenografted with human LoVo cells assessed as drug tolerability at 75 mg/kg, po qd administered via gavage","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797627,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423123,100,Induction of DNA damage in human LoVo cells xenografted in Swiss nu/nu mouse assessed as increase in gammaH2AX levels administered as po qd for 4 consecutive days and measured at 8 to 24 hrs post last dose on day 4 by immunohistochemistry staining-based a,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797628,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423124,100,Tmax in human,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797629,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423125,100,Elimination half life in human,"Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797630,20200619,54761306,404716419,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1423126,100,"Octanol-buffer partition co-efficient, log D of the compound at pH 7.4 by shake flask method","Title: Discovery and Characterization of AZD6738, a Potent Inhibitor of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Kinase with Application as an Anticancer Agent._|__|_Abstract: The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DNA double-strand breaks. Inhibition of repair pathways mediated by ATR in a",43,ChEMBL,1797631,20200619,46244454,164142958,NULL,NULL,NULL,Curation Efforts|Research and Development,30346772,0,10.1021/acs.jmedchem.8b01187,NULL,NULL,NULL
1429939,100,Time-dependent inhibition of human liver cathepsin-L up to 20 uM using Z-FR-AMC as substrate preincubated with enzyme followed by substrate addition by fluorometric method,"Title: Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L._|__|_Abstract: The magnitude of expression of cathepsin L, often upregulated in the tumor microenvironment, correlates with the invasive and metastatic nature of certain tumors. Inhibition of cathepsin L represents an emerging strategy for the treatment of metastatic cancer. A potent, small-molecule inhibitor (referred to as KGP94) of cathepsin L, and new K",43,ChEMBL,1647856,20200620,126610782,381856938,NULL,NULL,NULL,Curation Efforts|Research and Development,28117205,0,10.1016/j.bmcl.2016.12.039,NULL,NULL,NULL
1429954,100,Time-dependent inhibition of human liver cathepsin-L assessed as association constant up to 20 uM using 10 uM Z-FR-AMC as substrate preincubated with enzyme followed by substrate addition by fluorometric method,"Title: Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L._|__|_Abstract: The magnitude of expression of cathepsin L, often upregulated in the tumor microenvironment, correlates with the invasive and metastatic nature of certain tumors. Inhibition of cathepsin L represents an emerging strategy for the treatment of metastatic cancer. A potent, small-molecule inhibitor (referred to as KGP94) of cathepsin L, and new K",43,ChEMBL,1647871,20200620,126610782,381856938,NULL,NULL,NULL,Curation Efforts|Research and Development,28117205,0,10.1016/j.bmcl.2016.12.039,NULL,NULL,NULL
1429955,100,Time-dependent inhibition of human liver cathepsin-L assessed as dissociation constant up to 20 uM using 10 uM Z-FR-AMC as substrate preincubated with enzyme followed by substrate addition by fluorometric method,"Title: Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L._|__|_Abstract: The magnitude of expression of cathepsin L, often upregulated in the tumor microenvironment, correlates with the invasive and metastatic nature of certain tumors. Inhibition of cathepsin L represents an emerging strategy for the treatment of metastatic cancer. A potent, small-molecule inhibitor (referred to as KGP94) of cathepsin L, and new K",43,ChEMBL,1647872,20200620,126610782,381856938,NULL,NULL,NULL,Curation Efforts|Research and Development,28117205,0,10.1016/j.bmcl.2016.12.039,NULL,NULL,NULL
1429956,100,Time-dependent inhibition of human liver cathepsin-L assessed as association constant up to 20 uM using 5 uM Z-FR-AMC as substrate preincubated with enzyme followed by substrate addition by fluorometric method,"Title: Synthesis and biological evaluation of a water-soluble phosphate prodrug salt and structural analogues of KGP94, a lead inhibitor of cathepsin L._|__|_Abstract: The magnitude of expression of cathepsin L, often upregulated in the tumor microenvironment, correlates with the invasive and metastatic nature of certain tumors. Inhibition of cathepsin L represents an emerging strategy for the treatment of metastatic cancer. A potent, small-molecule inhibitor (referred to as KGP94) of cathepsin L, and new K",43,ChEMBL,1647873,20200620,126610782,381856938,NULL,NULL,NULL,Curation Efforts|Research and Development,28117205,0,10.1016/j.bmcl.2016.12.039,NULL,NULL,NULL
1432433,100,Time-dependent inhibition of recombinant human MAO-A preincubated up to 30 mins followed by addition of 0.2 mM of kynuramine as substrate,"Title: Selective inhibition of monoamine oxidase A by purpurin, an anthraquinone._|__|_Abstract: Monoamine oxidase (MAO) catalyzes the oxidation of monoamines that act as neurotransmitters. During a target-based screening of natural products using two isoforms of recombinant human MAO-A and MAO-B, purpurin (an anthraquinone derivative) was found to potently and selectively inhibit MAO-A, with an IC50 value of 2.50&#x3BC;M, and not to inhibit MAO-B. Alizarin (also an anthraquinone) inhibited MAO-A less poten",43,ChEMBL,1650369,20200620,6683,103246639,NULL,NULL,NULL,Curation Efforts|Research and Development,28188065,0,10.1016/j.bmcl.2017.01.085,NULL,NULL,NULL
1442536,100,Time dependent inhibition of human CYP3A4,"Title: Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity._|__|_Abstract: Leucine-rich repeat kinase 2 (LRRK2) is a large, multidomain protein which contains a kinase domain and GTPase domain among other regions. Individuals possessing gain of function mutations in the kinase domain such as the most prevalent G2019S mutation have been associated with an increased risk for the development of Pa",43,ChEMBL,1660521,20200620,78319901,381885815,NULL,NULL,NULL,Curation Efforts|Research and Development,28245354,0,10.1021/acs.jmedchem.7b00045,NULL,NULL,NULL
1446201,100,Time dependent inhibition of human FGFR1 using 5-FAM-KKKKEEIYFFF-NH2 as substrate preincubated with enzyme followed by peptide substrate addition by caliper capillary electrophoresis method,"Title: Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors._|__|_Abstract: Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to de",43,ChEMBL,1664209,20200620,118295624,381838803,NULL,NULL,NULL,Curation Efforts|Research and Development,28665128,0,10.1021/acs.jmedchem.7b00360,NULL,NULL,NULL
1446202,100,Time dependent inhibition of human FGFR2 preincubated with enzyme followed by peptide substrate addition by caliper capillary electrophoresis method,"Title: Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors._|__|_Abstract: Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to de",43,ChEMBL,1664210,20200620,118295624,381838803,NULL,NULL,NULL,Curation Efforts|Research and Development,28665128,0,10.1021/acs.jmedchem.7b00360,NULL,NULL,NULL
1446203,100,Time dependent inhibition of human FGFR3 preincubated with enzyme followed by peptide substrate addition by caliper capillary electrophoresis method,"Title: Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors._|__|_Abstract: Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to de",43,ChEMBL,1664211,20200620,118295624,381838803,NULL,NULL,NULL,Curation Efforts|Research and Development,28665128,0,10.1021/acs.jmedchem.7b00360,NULL,NULL,NULL
1446204,100,Time dependent inhibition of human FGFR4 preincubated with enzyme followed by peptide substrate addition by caliper capillary electrophoresis method,"Title: Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors._|__|_Abstract: Aberrant signaling of the FGF/FGFR pathway occurs frequently in cancers and is an oncogenic driver in many solid tumors. Clinical validation of FGFR as a therapeutic target has been demonstrated in bladder, liver, lung, breast, and gastric cancers. Our goal was to de",43,ChEMBL,1664212,20200620,118295624,381838803,NULL,NULL,NULL,Curation Efforts|Research and Development,28665128,0,10.1021/acs.jmedchem.7b00360,NULL,NULL,NULL
1458600,100,Time dependent inhibition of human CYP19 at 10 uM,"Title: Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides._|__|_Abstract: Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and ",43,ChEMBL,1690466,20200621,"66720098,66720197","381842778,381870597",NULL,NULL,NULL,Curation Efforts|Research and Development,28759231,0,10.1021/acs.jmedchem.7b00731,NULL,NULL,NULL
1458601,100,Time dependent inhibition of human CYP1A2 at 10 uM,"Title: Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides._|__|_Abstract: Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and ",43,ChEMBL,1690467,20200621,"66720098,66720197","381842778,381870597",NULL,NULL,NULL,Curation Efforts|Research and Development,28759231,0,10.1021/acs.jmedchem.7b00731,NULL,NULL,NULL
1458602,100,Time dependent inhibition of human CYP2C19 at 10 uM,"Title: Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides._|__|_Abstract: Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and ",43,ChEMBL,1690468,20200621,"66720098,66720197","381842778,381870597",NULL,NULL,NULL,Curation Efforts|Research and Development,28759231,0,10.1021/acs.jmedchem.7b00731,NULL,NULL,NULL
1458603,100,Time dependent inhibition of human CYP2C9 at 10 uM,"Title: Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides._|__|_Abstract: Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and ",43,ChEMBL,1690469,20200621,"66720098,66720197","381842778,381870597",NULL,NULL,NULL,Curation Efforts|Research and Development,28759231,0,10.1021/acs.jmedchem.7b00731,NULL,NULL,NULL
1458604,100,Time dependent inhibition of human CYP2D6 at 10 uM,"Title: Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides._|__|_Abstract: Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and ",43,ChEMBL,1690470,20200621,"66720098,66720197","381842778,381870597",NULL,NULL,NULL,Curation Efforts|Research and Development,28759231,0,10.1021/acs.jmedchem.7b00731,NULL,NULL,NULL
1458605,100,Time dependent inhibition of human CYP3A4 at 10 uM,"Title: Discovery of Novel and Highly Selective Inhibitors of Calpain for the Treatment of Alzheimer's Disease: 2-(3-Phenyl-1H-pyrazol-1-yl)-nicotinamides._|__|_Abstract: Calpain overactivation has been implicated in a variety of pathological disorders including ischemia/reperfusion injury, cataract formation, and neurodegenerative diseases such as Alzheimer's disease (AD). Herein we describe our efforts leading to the identification of ketoamide-based 2-(3-phenyl-1H-pyrazol-1-yl)nicotinamides as potent and ",43,ChEMBL,1690471,20200621,"66720098,66720197","381842778,381870597",NULL,NULL,NULL,Curation Efforts|Research and Development,28759231,0,10.1021/acs.jmedchem.7b00731,NULL,NULL,NULL
1459589,100,Time-dependent inhibition of recombinant human MAO-A assessed as reduction in 4-hydroxyquinoline formation at 0.5 uM using kynuramine as substrate preincubated up to 15 mins followed by substrate addition by fluorometric assay,"Title: Isolation of Acacetin from Calea urticifolia with Inhibitory Properties against Human Monoamine Oxidase-A and -B._|__|_Abstract: Calea urticifolia (Asteraceae: Asteroideae) has long been used as a traditional medicine in El Salvador to treat arthritis and fever, among other illnesses. The chloroform extract of the leaves of C. urticifolia showed potent inhibition of recombinant human monoamine oxidases (MAO-A and -B). Further bioassay-guided fractionation led to the isolation of a flavonoid, acacetin",43,ChEMBL,1691472,20200621,5280442,103528478,NULL,NULL,NULL,Curation Efforts|Research and Development,27754693,0,10.1021/acs.jnatprod.6b00440,NULL,NULL,NULL
1459590,100,Time-dependent inhibition of recombinant human MAO-B assessed as reduction in 4-hydroxyquinoline formation at 0.2 uM using kynuramine as substrate preincubated up to 15 mins followed by substrate addition by fluorometric assay,"Title: Isolation of Acacetin from Calea urticifolia with Inhibitory Properties against Human Monoamine Oxidase-A and -B._|__|_Abstract: Calea urticifolia (Asteraceae: Asteroideae) has long been used as a traditional medicine in El Salvador to treat arthritis and fever, among other illnesses. The chloroform extract of the leaves of C. urticifolia showed potent inhibition of recombinant human monoamine oxidases (MAO-A and -B). Further bioassay-guided fractionation led to the isolation of a flavonoid, acacetin",43,ChEMBL,1691473,20200621,5280442,103528478,NULL,NULL,NULL,Curation Efforts|Research and Development,27754693,0,10.1021/acs.jnatprod.6b00440,NULL,NULL,NULL
1464934,2,Antagonist activity at human histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced intracellular calcium mobilization at 100 nM pretreated for 30 mins followed by histamine addition measured for 1 min by Fluo-4-AM dye ba,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696841,20200622,"2267,25164128,25189510,25190195,25190435,131728656,131728658,137631458,137632738,137633326,137634700,137637727,137643918,137646827,137646948,137647842,137651292,137653149,137659034,137661121,137662184","103188977,381836615,381838540,381839444,381841487,381842408,381845324,381846040,381853272,381854860,381855232,381858451,381859521,381859706,381860953,381860993,381866098,381868886,381883040,381886127,381887703",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464937,100,Antagonist activity at human histamine H1 receptor expressed in CHO cells assessed as inhibition of histamine-induced intracellular calcium mobilization pretreated for 30 mins followed by compound washout and subsequent histamine addition at 90 and 270 mi,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696844,20200622,"25164128,25190195,137632738,137651292,137653149,137661121,137662184","381838540,381854860,381858451,381866098,381868886,381886127,381887703",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464972,2,Inhibition of human CYP1A2,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696883,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464973,2,Inhibition of human CYP2C9,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696884,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464974,2,Inhibition of human CYP2C19,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696885,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464975,2,Inhibition of human CYP2D6,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696886,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464976,2,Inhibition of human CYP3A4,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696887,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1482772,2,Inhibition of human ATX using LPC (16:0) as substrate after 30 mins by horseradish peroxidase/choline oxidase coupled enzyme based spectrophotometric analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700905,20200622,"78426574,78427773,90420193,90420346,90420407,90420624,90420765,117762542,117763631,117763635,117764297","336895202,381837450,381841832,381842801,381845037,381852982,381858777,381865495,381868165,381873039,381886864",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482773,2,Inhibition of human ERG by automated patch clamp assay,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700906,20200622,"90420193,90420346,90420407,90420765","336895202,381845037,381858777,381886864",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482775,2,Inhibition of ATX in mouse plasma assessed as reduction in LPA 18:2 production after 2 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700908,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482776,2,Inhibition of ATX in rat plasma assessed as reduction in LPA 18:2 production after 2 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700909,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482777,2,Inhibition of ATX in human plasma assessed as reduction in LPA 18:2 production after 2 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700910,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482778,100,Protein binding to human plasma,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700911,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482779,100,Protein binding to dog plasma,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700912,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482780,100,Protein binding to rat plasma,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700913,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482781,100,Protein binding to mouse plasma,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700914,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482782,100,"Plasma clearance in mouse at 1 mg/kg, iv","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700915,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482783,100,Oral bioavailability in mouse at 5 mg/kg,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700916,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482784,100,"Plasma clearance in rat at 1 mg/kg, iv","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700917,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482785,100,Oral bioavailability in rat at 5 mg/kg,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700918,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482786,100,"Plasma clearance in dog at 1 mg/kg, iv","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700919,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482787,100,Oral bioavailability in dog at 1 mg/kg,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700920,20200622,"90420193,90420407","336895202,381845037",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482788,2,Inhibition of human ERG by manual patch clamp assay,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700921,20200622,"78426574,90420193","336895202,381842801",NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482789,100,Cmax in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700922,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482790,100,Dose normalized Cmax in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700923,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482791,100,AUC (0 to 24 hrs) in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700924,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482792,100,Dose normalized AUC (0 to 24 hrs) in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700925,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482793,100,Plasma concentration in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage after 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700926,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482794,100,Apparent elimination half life in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700927,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482795,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as reduction in LPA 18:2 level in plasma at 3 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700928,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482796,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as reduction in LPA 18:2 level in plasma at 10 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700929,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482797,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as reduction in LPA 18:2 level in plasma at 30 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700930,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482799,100,Tmax in C57BL/6Rj mouse at 3 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700932,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482800,100,Cmax in C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700933,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482801,100,Dose normalized Cmax in C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700934,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482802,100,AUC (0 to 24 hrs) in C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700935,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482803,100,Dose normalized AUC (0 to 24 hrs) in C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700936,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482804,100,Tmax in C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700937,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482805,100,Plasma concentration C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage after 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700938,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482806,100,Apparent terminal half life in C57BL/6Rj mouse at 10 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700939,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482807,100,Cmax in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700940,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482808,100,Dose normalized Cmax in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700941,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482809,100,Tmax in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700942,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482810,100,AUC (0 to 24 hrs) in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700943,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482811,100,Dose normalized AUC (0 to 24 hrs) in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700944,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482812,100,Plasma concentration in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage after 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700945,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482813,100,Apparent terminal half life in C57BL/6Rj mouse at 30 mg/kg administered as single dose via oral gavage up to 24 hrs by LC-MS/MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700946,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482814,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in fibrotic thickening of aveolar/bronchial walls at 50 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative to control","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700947,20200622,40632,123092043,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482815,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in fibrotic thickening of aveolar/bronchial walls at 10 to 30 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative to contr","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700948,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482816,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as lung weight at 10 to 30 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative to control","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700949,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482817,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in LAP 18:2 content in BALF at 30 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days measured 2 hrs post last dose on day 21 by LC","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700950,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482818,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in fibrous area with severe distortion of lung structure at 50 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative to cont","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700951,20200622,40632,123092043,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482822,100,In vivo inhibition of ATX in C57BL/6Rj mouse assessed as reduction in LPA 18:2 production at 3 mg/kg administered as single dose via oral gavage after 6 hrs by LC-MS/MS analysis relative to control,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700955,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482823,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in fibrosis with damage of pulmonary structure at 50 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative to control","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700956,20200622,40632,123092043,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482824,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in fibrosis with damage of pulmonary structure at 10 to 30 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative to control","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700957,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482825,100,"Anti-fibrotic activity in BML-induced pulmonary fibrosis C57BL/6 mouse model assessed as reduction in fibrous area with severe distortion of lung structure at 10 to 30 mg/kg, po administered bid with 7.5 hrs interval between 2 doses for 21 days relative t","Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700958,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482826,100,Chemical stability of the compound in DMSO by 1H NMR analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700959,20200622,117763631,381865495,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482827,100,Chemical stability of the compound in DMSO by LC-MS analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700960,20200622,117763631,381865495,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1482828,2,Competitive inhibition of human ATX using LPC (16:0) as substrate after 30 mins by Michaelis-Menten plot analysis,"Title: Discovery of 2-[[2-Ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]methylamino]-4-(4-fluorophenyl)thiazole-5-carbonitrile (GLPG1690), a First-in-Class Autotaxin Inhibitor Undergoing Clinical Evaluation for the Treatment of Idiopathic Pulmonary Fibrosis._|__|_Abstract: Autotaxin is a circulating enzyme with a major role in the production of lysophosphatic acid (LPA) species in blood. A role for the autotaxin/LPA axis has been suggested in many disea",43,ChEMBL,1700961,20200622,90420193,336895202,NULL,NULL,NULL,Curation Efforts|Research and Development,28414242,0,10.1021/acs.jmedchem.7b00032,NULL,NULL,NULL
1498468,100,Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as residual activity at 5 uM using midazolam as substrate by LC-MS/MS analysis relative to control,"Title: Design, synthesis, and biological evaluation of novel biphenyl-4-carboxamide derivatives as orally available TRPV1 antagonists._|__|_Abstract: A new series of transient receptor potential vanilloid type 1 (TRPV1) antagonists were designed and synthesized from N-(3-hydroxyphenyl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide hydrochloride (8). SAR studies identified (R)-N-(1-methyl-2-oxo-1,2,3,4-tetrahydro-7-quinolyl)-2-[(2-methylpyrrolidin-1-yl)methyl]biphenyl-4-carboxamide hydrochloride (ASP8370, 7",43,ChEMBL,1715154,20200623,"23112208,57927125,145952872,145953312,145953315,145953318,145954238,145954944,145954951,145955162,145955415,145955646,145960771,145960890,145961025,145962051,145962156,145962213,145962782,145962832,145962994,145963166,145963177,145963228,145963457","404656834,404657484,404657488,404657493,404658813,404659840,404659848,404660171,404660511,404660849,404668255,404668427,404668628,404669687,404670129,404670299,404670378,404670548,404671192,404671271,404671495,404671758,404671775,404671852,404672200",NULL,NULL,NULL,Curation Efforts|Research and Development,29887511,0,10.1016/j.bmc.2018.06.001,NULL,NULL,NULL
1503604,100,Time-dependent inhibition of electric eel AChE at 300 nM using acetylthiocholine iodide as substrate,Title: New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation._|__|_Abstract: A new series of pyridine derivatives with carbamic or amidic function has been designed and synthesized to act as cholinesterase inhibitors. The synthesized compounds were tested toward EeAChE and hAChE and toward eqBChE and hBChE. The carbamate 8 was the most potent hAChE inhibitor (IC50 = 0.153 &#xB1; 0.016 &#x3BC;M) while the carbamate 11 was the most potent inhibitor of hBChE (IC50 = 0.828 &#xB1,43,ChEMBL,1720302,20200623,"145950308,145951391,145953230,145956699,145958077,145959287","404653147,404654695,404657367,404662359,404664355,404666094",NULL,NULL,NULL,Curation Efforts|Research and Development,29031067,0,10.1016/j.ejmech.2017.09.022,NULL,NULL,NULL
1503618,100,Time-dependent inhibition of electric eel AChE at 1 uM using acetylthiocholine iodide as substrate,Title: New pyridine derivatives as inhibitors of acetylcholinesterase and amyloid aggregation._|__|_Abstract: A new series of pyridine derivatives with carbamic or amidic function has been designed and synthesized to act as cholinesterase inhibitors. The synthesized compounds were tested toward EeAChE and hAChE and toward eqBChE and hBChE. The carbamate 8 was the most potent hAChE inhibitor (IC50 = 0.153 &#xB1; 0.016 &#x3BC;M) while the carbamate 11 was the most potent inhibitor of hBChE (IC50 = 0.828 &#xB1,43,ChEMBL,1720316,20200623,6129,103224448,NULL,NULL,NULL,Curation Efforts|Research and Development,29031067,0,10.1016/j.ejmech.2017.09.022,NULL,NULL,NULL
1505338,100,Time dependent inhibition of recombinant human CYP3A4 by fluorescence-based assay,"Title: Optimization of 1,4-Oxazine &#xCE;&#xB2;-Secretase 1 (BACE1) Inhibitors Toward a Clinical Candidate._|__|_Abstract: In previous studies, the introduction of electron withdrawing groups to 1,4-oxazine BACE1 inhibitors reduced the p Ka of the amidine group, resulting in compound 2 that showed excellent in vivo efficacy, lowering A&#x3B2; levels in brain and CSF. However, a suboptimal cardiovascular safety margin, based on QTc prolongation, prevented further progression. Further optimization resulted in",43,ChEMBL,1722036,20200623,127255875,404670771,NULL,NULL,NULL,Curation Efforts|Research and Development,29809004,0,10.1021/acs.jmedchem.8b00304,NULL,NULL,NULL
1507301,100,Time-dependent inhibition of full length C-terminal FLAG tagged human SMS2 expressed in HEK293 cell membranes using DMPC-d72 and C17-ceramide as substrate preincubated with enzyme followed by substrate addition by RapidFire/mass spectrometry assay,"Title: Discovery and characterization of selective human sphingomyelin synthase 2 inhibitors._|__|_Abstract: Sphingomyelin synthase (SMS) is a membrane enzyme that catalyzes the synthesis of sphingomyelin, is required for the maintenance of plasma membrane microdomain fluidity, and has two isoforms: SMS1 and SMS2. Although these isoforms exhibit the same SMS activity, they are different enzymes with distinguishable subcellular localizations. It was reported that SMS2 KO mice displayed lower inflammatory res",43,ChEMBL,1724017,20200623,145960205,404667422,NULL,NULL,NULL,Curation Efforts|Research and Development,28505533,0,10.1016/j.ejmech.2017.04.067,NULL,NULL,NULL
18083,2,Kinetic Constant (Km) against Adenosine Aminohydrolase was determined from calf intestinal mucosa,"Title: Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides._|__|_Abstract: A series of nucleoside dialdehydes has been prepared as powders after treatment of hexofuranosyladenine nucleosides with paraperiodic acid; thus, periodate oxidation and purification of the products yielded dialdehydes derived from 9-(6-deoxy-beta-D-gulofuranosyl)adenine (1), 9-(6-deoxy-beta-L-gulofuranosyl)adenine (2), 9-(alpha-D-rhamnofuranosyl",43,ChEMBL,15204,20181001,"44354899,44378896,71719087","103369114,103421011,164141761",NULL,NULL,NULL,Curation Efforts|Research and Development,6965728,0,10.1021/jm00175a008,NULL,NULL,NULL
18084,100,Kinetic Constant (Km) against Adenosine Aminohydrolase was determined from calf intestinal mucosa; a = not a substrate,"Title: Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides._|__|_Abstract: A series of nucleoside dialdehydes has been prepared as powders after treatment of hexofuranosyladenine nucleosides with paraperiodic acid; thus, periodate oxidation and purification of the products yielded dialdehydes derived from 9-(6-deoxy-beta-D-gulofuranosyl)adenine (1), 9-(6-deoxy-beta-L-gulofuranosyl)adenine (2), 9-(alpha-D-rhamnofuranosyl",43,ChEMBL,15205,20181001,"44355064,44378896,71457975,71458031","103369530,103421011,163329585,163329685",NULL,NULL,NULL,Curation Efforts|Research and Development,6965728,0,10.1021/jm00175a008,NULL,NULL,NULL
22606,100,Kinetic constant (Vmax) against Adenosine Aminohydrolase was determined from calf intestinal mucosa,"Title: Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides._|__|_Abstract: A series of nucleoside dialdehydes has been prepared as powders after treatment of hexofuranosyladenine nucleosides with paraperiodic acid; thus, periodate oxidation and purification of the products yielded dialdehydes derived from 9-(6-deoxy-beta-D-gulofuranosyl)adenine (1), 9-(6-deoxy-beta-L-gulofuranosyl)adenine (2), 9-(alpha-D-rhamnofuranosyl",43,ChEMBL,19727,20181001,"44354899,44378896,71719087","103369114,103421011,164141761",NULL,NULL,NULL,Curation Efforts|Research and Development,6965728,0,10.1021/jm00175a008,NULL,NULL,NULL
22607,100,Kinetic constant (Vmax) against Adenosine Aminohydrolase was determined from calf intestinal mucosa; a = not a substrate,"Title: Binding specificities of adenosine aminohydrolase from calf intestinal mucosa with dialdehydes derived from hexofuranosyladenine nucleosides._|__|_Abstract: A series of nucleoside dialdehydes has been prepared as powders after treatment of hexofuranosyladenine nucleosides with paraperiodic acid; thus, periodate oxidation and purification of the products yielded dialdehydes derived from 9-(6-deoxy-beta-D-gulofuranosyl)adenine (1), 9-(6-deoxy-beta-L-gulofuranosyl)adenine (2), 9-(alpha-D-rhamnofuranosyl",43,ChEMBL,19728,20181001,"44355064,44378896,71457975,71458031","103369530,103421011,163329585,163329685",NULL,NULL,NULL,Curation Efforts|Research and Development,6965728,0,10.1021/jm00175a008,NULL,NULL,NULL
22943,100,The times of half-inactivation constant (T50) was determined for ODC; No time-dependent inhibition,"Title: alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase._|__|_Abstract: (E)-Dehydro analogues of alpha-(fluoromethyl)putrescine and -ornithine derivatives were synthesized and evaluated in vitro as irreversible inhibitors of a preparation of ornithine decarboxylase (ODC, EC 4.1.1.17) obtained from rat liver. The key step in the synthesis of (E)-alpha-(fluoromethyl)dehydroornithine (17) and -putrescine (14) was the ",43,ChEMBL,20064,20181002,2113,103217184,NULL,NULL,NULL,Curation Efforts|Research and Development,6631913,0,10.1021/jm00365a002,NULL,NULL,NULL
22944,100,The times of half-inactivation constant (T50) was determined for ODC; No time-dependent inhibition.,"Title: alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase._|__|_Abstract: (E)-Dehydro analogues of alpha-(fluoromethyl)putrescine and -ornithine derivatives were synthesized and evaluated in vitro as irreversible inhibitors of a preparation of ornithine decarboxylase (ODC, EC 4.1.1.17) obtained from rat liver. The key step in the synthesis of (E)-alpha-(fluoromethyl)dehydroornithine (17) and -putrescine (14) was the ",43,ChEMBL,20065,20181002,44286520,103217183,NULL,NULL,NULL,Curation Efforts|Research and Development,6631913,0,10.1021/jm00365a002,NULL,NULL,NULL
23590,100,Pharmacokinetic parameter half life was determined; No time-dependent inhibition,"Title: alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase._|__|_Abstract: (E)-Dehydro analogues of alpha-(fluoromethyl)putrescine and -ornithine derivatives were synthesized and evaluated in vitro as irreversible inhibitors of a preparation of ornithine decarboxylase (ODC, EC 4.1.1.17) obtained from rat liver. The key step in the synthesis of (E)-alpha-(fluoromethyl)dehydroornithine (17) and -putrescine (14) was the ",43,ChEMBL,20711,20181002,2113,103217184,NULL,NULL,NULL,Curation Efforts|Research and Development,6631913,0,10.1021/jm00365a002,NULL,NULL,NULL
23591,100,Pharmacokinetic parameter half life was determined; No time-dependent inhibition.,"Title: alpha-(Fluoromethyl)dehydroornithine and alpha-(fluoromethyl)dehydroputrescine analogues as irreversible inhibitors of ornithine decarboxylase._|__|_Abstract: (E)-Dehydro analogues of alpha-(fluoromethyl)putrescine and -ornithine derivatives were synthesized and evaluated in vitro as irreversible inhibitors of a preparation of ornithine decarboxylase (ODC, EC 4.1.1.17) obtained from rat liver. The key step in the synthesis of (E)-alpha-(fluoromethyl)dehydroornithine (17) and -putrescine (14) was the ",43,ChEMBL,20712,20181002,44286520,103217183,NULL,NULL,NULL,Curation Efforts|Research and Development,6631913,0,10.1021/jm00365a002,NULL,NULL,NULL
27219,100,Half life period in rat after (iv) administration,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,24342,20181017,9816412,103167589,NULL,NULL,NULL,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,NULL,NULL,NULL
29464,100,Bioavailability after oral administration of 20 mg/kg in rat,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,26593,20181017,9816412,103167589,NULL,NULL,NULL,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,NULL,NULL,NULL
48398,2,"Effect of 10 mM of GSH on the inhibitory activity of compound against Cathepsin K, at pH 5.5","Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45541,20181017,"73737,9812750,10198366,10198752,10313520","103167408,103167436,103167539,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
48399,2,"Effect of 10 mM of GSH on the inhibitory activity against Cathepsin K, at pH 7","Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45542,20181017,"73737,9812750,10198366,10198752,10313520","103167408,103167436,103167539,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
48409,2,Inhibitory activity tested against Human Cathepsin K receptor using bone resorption assay,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45552,20181017,"9816412,10198752","103167589,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
48410,2,Inhibitory activity tested against Human Cathepsin K receptor using gelatinase assay,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45553,20181017,"9816412,10198366,10198752,10313520","103167408,103167589,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
48411,2,Inhibitory activity tested against Human Cathepsin K using Z-Phe-Arg-pNA as substrate,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45554,20181017,"12050,73737,9812750,9813935,9816412,9834360,9835685,9855884,9877581,9877623,9899272,9920989,9964915,10198366,10198752,10313520,10515827","103167408,103167419,103167420,103167436,103167482,103167504,103167530,103167531,103167538,103167539,103167565,103167589,103167608,103167609,103167610,103167617,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
48414,2,Inhibitory constant against human cathepsin K,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,45557,20181017,"9816412,9964915,10198752,10313520","103167419,103167589,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
50270,2,Inhibitory activity tested against Human Cathepsin B using Z-Phe-Arg-pNA as substrate,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,47414,20181017,"12050,73737,9812750,9816412,9834360,9835685,9855884,9877581,9877623,9899272,9920989,9964915,10198366,10198752,10313520,10515827","103167408,103167419,103167420,103167436,103167482,103167504,103167530,103167538,103167539,103167565,103167589,103167608,103167609,103167610,103167617,103167618",1508,NULL,P07858,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.1,P07858,NULL
51180,2,Inhibitory constant against human cathepsin K,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,48324,20181017,"9816412,9964915,10198752,10313520","103167419,103167589,103167610,103167618",1513,NULL,P43235,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.38,P43235,NULL
51224,2,Inhibitory activity tested against Human Cathepsin L using Z-Phe-Arg-pNA as substrate,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,48368,20181017,"12050,73737,9812750,9813935,9816412,9834360,9835685,9855884,9877581,9877623,9899272,9920989,9964915,10198366,10198752,10313520,10515827","103167408,103167419,103167420,103167436,103167482,103167504,103167530,103167531,103167538,103167539,103167565,103167589,103167608,103167609,103167610,103167617,103167618",1514,NULL,P07711,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.15,P07711,NULL
125206,100,Kinetic parameter for the time dependent inhibition of Bovine liver Monoamine Oxidase B at 25 degrees C (pH= 7.4).,"Title: Stereoisomers of allenic amines as inactivators of monoamine oxidase type B. Stereochemical probes of the active site._|__|_Abstract: The kinetics of inactivation of mitochondrial monoamine oxidase type B (MAO-B) by a series of 18 stereoisomers of tertiary alpha-allenic amines have been investigated in detail. The chirality of the allene group in N-methyl-N-aralkylpenta-2,3-dienamines was found to have a profound effect on the inactivation rate, with the (R)-allenes being up to 200-fold more potent t",43,ChEMBL,122438,20181012,"328859,14142528,14142538,14142539,14142543,14142545,14142546,70684955,118718807,118719076","103217422,103734972,160670753,160676059,160689036,163316208,163326461,174499615,312365724,312366171",338445,NULL,P56560,Curation Efforts|Research and Development,3397993,0,10.1021/jm00403a012,1.4.3.4,P56560,NULL
145969,2,Time dependent inhibition against neuronal Nitric Oxide Synthase(nNOS),"Title: 1H-pyrazole-1-carboxamidines: new inhibitors of nitric oxide synthase._|__|_Abstract: 1H-Pyrazole-1-carboxamidines were prepared as potential inhibitors of the three isozymes of nitric oxide synthase. All of the compounds were found to be competitive inhibitors of all three isoforms. The most selective compound prepared was 1H-pyrazole-N-(3-aminomethylanilino)-1-carboxamidine (14), which is 100-fold selective for nNOS over eNOS with a Ki value of 2 microM.",43,ChEMBL,143213,20180929,45264946,103677959,24598,NULL,P29476,Curation Efforts|Research and Development,11133088,0,10.1016/s0960-894x(00)00573-4,1.14.13.39,P29476,NULL
145970,100,Time dependent inhibition against neuronal Nitric Oxide Synthase(nNOS),"Title: 1H-pyrazole-1-carboxamidines: new inhibitors of nitric oxide synthase._|__|_Abstract: 1H-Pyrazole-1-carboxamidines were prepared as potential inhibitors of the three isozymes of nitric oxide synthase. All of the compounds were found to be competitive inhibitors of all three isoforms. The most selective compound prepared was 1H-pyrazole-N-(3-aminomethylanilino)-1-carboxamidine (14), which is 100-fold selective for nNOS over eNOS with a Ki value of 2 microM.",43,ChEMBL,143214,20180929,45264946,103677959,24598,NULL,P29476,Curation Efforts|Research and Development,11133088,0,10.1016/s0960-894x(00)00573-4,1.14.13.39,P29476,NULL
154309,2,Time dependent inhibition of hydrolysis of nitrocefin after 5 min pre-incubation with P99 beta-lactamases (class C),Title: Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics._|__|_Abstract: Anti-Bredt bridged bicyclo[3.2.1] gamma-lactams were designed as inhibitors of penicillin binding proteins (PBPs). The compounds were prepared by a carbenoid insertion into a lactam N-H bond. Their weak antibacterial activity could either be explained by a poor chemical stability or by unfavorable steric interactions of the methylene bridge of the gamma-lactam with the targeted enzymes.,43,ChEMBL,151559,20181001,44462185,103287512,NULL,NULL,P00811,Curation Efforts|Research and Development,15109638,0,10.1016/j.bmcl.2004.03.004,3.5.2.6,P00811,NULL
195382,100,Effect of compound on AFB1-induced micronuclei formation in rat bone marrow cells (Activity: Micronucleated cells/1000 cells),"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192656,20200630,"14005,390798,5280343","103167027,103183744,103292922",NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
195383,100,Effect of compound on AFB1-induced micronuclei formation in rat bone marrow cells in the presence of AFB1 (Activity: Micronucleated cells/1000 cells),"Title: Comparison of the prevention of aflatoxin b(1)-induced genotoxicity by quercetin and quercetin pentaacetate._|__|_Abstract: Earlier work carried out in our laboratory highlighted the mode of action of acetoxy 4-methylcoumarins in preventing the genotoxicity of aflatoxin B(1) (AFB(1)). We have in this report extended the observations to quercetin pentaacetate (QPA), which unlike quercetin (Q) has demonstrated time-dependent inhibition of liver microsome catalysed AFB(1) epoxidation as measured by AFB(",43,ChEMBL,192657,20200630,"14005,390798,5280343","103167027,103183744,103292922",NULL,NULL,NULL,Curation Efforts|Research and Development,12182864,0,10.1016/s0960-894x(02)00478-x,NULL,NULL,NULL
209010,2,Time dependent inhibition of hydrolysis of nitrocefin after 5 min pre-incubation with TEM-1 beta-lactamase (class 1),Title: Design and synthesis of bridged gamma-lactams as analogues of beta-lactam antibiotics._|__|_Abstract: Anti-Bredt bridged bicyclo[3.2.1] gamma-lactams were designed as inhibitors of penicillin binding proteins (PBPs). The compounds were prepared by a carbenoid insertion into a lactam N-H bond. Their weak antibacterial activity could either be explained by a poor chemical stability or by unfavorable steric interactions of the methylene bridge of the gamma-lactam with the targeted enzymes.,43,ChEMBL,206312,20181001,"5280980,44462153,44462185","103205106,103287436,103287512",NULL,NULL,NULL,Curation Efforts|Research and Development,15109638,0,10.1016/j.bmcl.2004.03.004,NULL,NULL,NULL
224909,2,Inhibitory activity tested against papain at a pH 5.5,"Title: Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L._|__|_Abstract: Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC(50) values of 0. 37 and 0.45 M, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found ",43,ChEMBL,222263,20181017,9816412,103167589,110813108,NULL,P00784,Curation Efforts|Research and Development,11141092,0,10.1021/jm0003440,3.4.22.2,P00784,NULL
267904,2,Displacement of [3H]oxytocin from human OTR,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373729,20181020,"5311010,6918854,11295207,11341369,11465834,11488952,11495934,11569527,11569672,11570523,11590596,11590614,11598736,11634960,11662784,11685100,44413575","103470536,103470634,103492327,103492764,103492802,103492803,103492828,103492871,103492896,103492929,103492953,103492974,103493016,103493017,103493043,103493130,160703997",5021,NULL,P30559,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P30559,NULL
267905,100,Clearance in rat,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373730,20181020,"6918854,11295207,11341369,11465834,11488952,11569527,11569672,11570523,11590596,11590614,11598736,11634960,11662784,11685100,44413575","103470536,103470634,103492327,103492764,103492802,103492803,103492828,103492871,103492896,103492929,103492953,103492974,103493016,103493017,103493130",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267906,100,Oral bioavailability in rat,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373731,20181020,"6918854,11295207,11341369,11465834,11488952,11569527,11569672,11570523,11590596,11590614,11598736,11634960,11662784,11685100,44413575","103470536,103470634,103492327,103492764,103492802,103492803,103492828,103492871,103492896,103492929,103492953,103492974,103493016,103493017,103493130",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267907,100,Clearance in dog,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373732,20181020,"6918854,11341369,11465834,11488952,11569527,11569672,11570523,11590614,11598736,11634960,11662784,11685100,44413575","103470536,103470634,103492327,103492802,103492803,103492828,103492871,103492896,103492929,103492953,103492974,103493017,103493130",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267908,100,Oral bioavailability in dog,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373733,20181020,"6918854,11341369,11465834,11488952,11569527,11569672,11570523,11590614,11598736,11634960,11662784,11685100,44413575","103470536,103470634,103492327,103492802,103492803,103492828,103492871,103492896,103492929,103492953,103492974,103493017,103493130",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267909,100,"Lipophilicity, log D by CHI method","Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373734,20200703,"6918854,11295207,11341369,11375822,11465834,11511019,11519541,11569194,11569527,11569672,11570523,11590596,11590614,11592699,11598736,11598897,11606383,11634960,11662784,11678031,11685100,11719971,44413575","103470536,103470605,103470634,103492442,103492704,103492725,103492763,103492764,103492802,103492803,103492828,103492871,103492896,103492929,103492953,103492974,103493016,103493017,103493042,103493068,103493096,103493130,103493131",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267910,100,AUC in rat,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373735,20181020,"6918854,11295207,11465834,11495934,11569527,11590596,11590614,11598736,11662784,11685100","103470536,103492764,103492802,103492803,103492929,103492953,103492974,103493016,103493017,103493043",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267911,100,AUC in dog,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373736,20181020,"6918854,11465834,11569527,11590614,11598736,11662784,11685100","103470536,103492802,103492803,103492929,103492953,103492974,103493017",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267912,100,Solubility of the compound,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373737,20181020,"6918854,11295207,11465834,11569527,11590596,11590614,11598736,11662784","103470536,103492764,103492802,103492803,103492929,103492974,103493016,103493017",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267913,2,Antagonist activity against human OTR expressed in CHO cells measured as calcium influx by FLIPR assay,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373738,20181020,"11465834,11488952","103492327,103492803",5021,NULL,P30559,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P30559,NULL
267914,2,Displacement of vasopressin from human V1aR,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373739,20181020,"11465834,11488952","103492327,103492803",552,NULL,P37288,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P37288,NULL
267915,2,Displacement of vasopressin from human V1bR,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373740,20181020,"11465834,11488952","103492327,103492803",553,NULL,P47901,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P47901,NULL
267916,2,Displacement of vasopressin from human V2R,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373741,20181020,"11465834,11488952","103492327,103492803",554,NULL,P30518,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P30518,NULL
267917,100,Selectivity for human OTR over V1aR,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373742,20200703,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267918,100,Selectivity for human OTR over V1bR,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373743,20200703,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267919,100,Selectivity for human OTR over V2R,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373744,20200703,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267920,2,Reduction in oxytocin-induced uterine contraction in iv dosed anaesthetized rat,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373745,20181020,"5311010,11465834,11488952","103492327,103492803,160703997",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267921,2,Displacement of [3H]oxytocin from rat OTR,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373746,20181020,"5311010,11465834,11488952","103492327,103492803,160703997",25342,NULL,P70536,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P70536,NULL
267922,100,Ratio of displacement of [3H]oxytocin from human OTR in presence and absence of 50 mg/ml human serum albumin,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373747,20200703,"11465834,11488952","103492327,103492803",5021,NULL,P30559,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,P30559,NULL
267930,100,Half life in rat,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373755,20181020,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267931,100,Volume of distribution in rat,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373756,20181020,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267932,100,Half life in dog,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373757,20181020,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
267933,100,Volume of distribution in dog,"Title: 2,5-diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potency._|__|_Abstract: A short, efficient, and highly stereoselective synthesis of a series of (3R,6R,7R)-2,5-diketopiperazine oxytocin antagonists and their pharmacokinetics in rat and dog is described. Prediction of the estimated human oral absorption (EHOA) using measured lipophilicity (CHI log D) and calculated size (cMR) has allowed us to rank various 2,5-diketop",43,ChEMBL,373758,20181020,"11465834,11488952","103492327,103492803",NULL,NULL,NULL,Curation Efforts|Research and Development,16821776,0,10.1021/jm060073e,NULL,NULL,NULL
301713,2,Activity of soybean recombinant SMT expressed in Escherichia coli,Title: Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26._|__|_Abstract: The enzymatic C-methylation reaction catalyzed by the Glycine max sterol 24-C-methyltransferase was studied with substrate analogs containing a cycloartenol nucleus (CA) and a double bond (8) or triple bond (14) attached to C26. The production of the corresponding C24(28)-methylene olefin and time-dependent inhibition kinetics of k(inact) 0.24 min(-1) (CA-8) or 0.06 min(-1) (CA-14) indicates a,43,ChEMBL,449739,20181022,"44434251,44434252","103538157,103538158",NULL,NULL,Q43445,Curation Efforts|Research and Development,17851075,0,10.1016/j.bmcl.2007.07.096,NULL,Q43445,NULL
301714,100,Ratio of Kcat to Kinact for soybean recombinant SMT expressed in Escherichia coli,Title: Inactivation of soybean sterol 24-C-methyltransferase by elongated sterol side chains at C26._|__|_Abstract: The enzymatic C-methylation reaction catalyzed by the Glycine max sterol 24-C-methyltransferase was studied with substrate analogs containing a cycloartenol nucleus (CA) and a double bond (8) or triple bond (14) attached to C26. The production of the corresponding C24(28)-methylene olefin and time-dependent inhibition kinetics of k(inact) 0.24 min(-1) (CA-8) or 0.06 min(-1) (CA-14) indicates a,43,ChEMBL,449740,20200704,"44434251,44434252","103538157,103538158",NULL,NULL,Q43445,Curation Efforts|Research and Development,17851075,0,10.1016/j.bmcl.2007.07.096,NULL,Q43445,NULL
457067,100,"Ex vivo receptor occupancy for VLA4 in rat at 5 mg/kg, po after 1 hr",Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608125,20180912,42633319,103614211,NULL,NULL,NULL,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,NULL,NULL
457068,100,"Ex vivo receptor occupancy for VLA4 in rat at 5 mg/kg, po after 12 hr",Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608126,20180912,"42633319,46229920","103614211,103724620",NULL,NULL,NULL,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,NULL,NULL
457070,2,"Cmax in rat at 5 mg/kg, po",Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608128,20180912,"45485807,46229920","103704727,103724620",NULL,NULL,NULL,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,NULL,NULL
457071,2,"Cmax in rat portal vein at 5 mg/kg, po",Title: Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists._|__|_Abstract: A variety of N-linked tertiary amines and heteroarylamines were examined at the 4-position of sulfonylated proline dipeptides in order to improve VLA-4 receptor off-rates and overcome the issue of CYP3A4 time-dependent inhibition of ester prodrugs. A tight-binding inhibitor 5j with a long off-rate provided sustained receptor occupancy despite poor oral pharmacokinetics.,43,ChEMBL,608129,20180912,"45485807,46229920","103704727,103724620",NULL,NULL,NULL,Curation Efforts|Research and Development,20022493,0,10.1016/j.bmcl.2009.12.009,NULL,NULL,NULL
502280,100,Time dependent inhibition of cathepsin L by Dixon plot analysis,"Title: Allicin and derivates are cysteine protease inhibitors with antiparasitic activity._|__|_Abstract: Allicin and derivatives thereof inhibit the CAC1 cysteine proteases falcipain 2, rhodesain, cathepsin B and L in the low micromolar range. The structure-activity relationship revealed that only derivatives with primary carbon atom in vicinity to the thiosulfinate sulfur atom attacked by the active-site Cys residue are active against the target enzymes. Some compounds also show potent antiparasitic activ",43,ChEMBL,652320,20180914,74761,104244947,1514,NULL,P07711,Curation Efforts|Research and Development,20692829,0,10.1016/j.bmcl.2010.07.062,3.4.22.15,P07711,NULL
502286,100,Time dependent inhibition of Plasmodium falciparum falcipain-2 by Dixon plot analysis,"Title: Allicin and derivates are cysteine protease inhibitors with antiparasitic activity._|__|_Abstract: Allicin and derivatives thereof inhibit the CAC1 cysteine proteases falcipain 2, rhodesain, cathepsin B and L in the low micromolar range. The structure-activity relationship revealed that only derivatives with primary carbon atom in vicinity to the thiosulfinate sulfur atom attacked by the active-site Cys residue are active against the target enzymes. Some compounds also show potent antiparasitic activ",43,ChEMBL,652326,20180914,"74761,10244468,14849212","104244947,104244948,104244952",NULL,NULL,NULL,Curation Efforts|Research and Development,20692829,0,10.1016/j.bmcl.2010.07.062,NULL,NULL,NULL
502287,100,Time dependent inhibition of Trypanosoma brucei rhodesiense rhodesain by Dixon plot analysis,"Title: Allicin and derivates are cysteine protease inhibitors with antiparasitic activity._|__|_Abstract: Allicin and derivatives thereof inhibit the CAC1 cysteine proteases falcipain 2, rhodesain, cathepsin B and L in the low micromolar range. The structure-activity relationship revealed that only derivatives with primary carbon atom in vicinity to the thiosulfinate sulfur atom attacked by the active-site Cys residue are active against the target enzymes. Some compounds also show potent antiparasitic activ",43,ChEMBL,652327,20180914,"74761,10244468,14849212","104244947,104244948,104244952",NULL,NULL,Q95PM0,Curation Efforts|Research and Development,20692829,0,10.1016/j.bmcl.2010.07.062,NULL,Q95PM0,NULL
552905,100,Time dependent inhibition of CYP3A4 up to 50 uM,"Title: Discovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymerase._|__|_Abstract: Infections caused by hepatitis C virus (HCV) are a significant world health problem for which novel therapies are in urgent demand. The polymerase of HCV is responsible for the replication of viral genome and has been a prime target for drug",43,ChEMBL,701433,20180916,49800096,104249692,1576,NULL,P08684,Curation Efforts|Research and Development,21141896,0,10.1021/jm1013105,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
577781,100,Antiproliferative activity against mouse NIH/3T3 cells assessed as suppression of cell viability at 50 uM after 24 hrs by CyQuant cell viability assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726321,20200626,51351545,124975440,NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
577782,2,Antiproliferative activity against human HL60 cells assessed as suppression of cell viability after 24 hrs by CyQuant cell viability assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726322,20200626,51351545,124975440,NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
577785,2,Displacement of 5-carboxyfluorescein-GpYDKPHVL-NH2 from mouse recombinant His-tagged STAT1-SH2 domain expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726325,20200626,"51351545,51351546","124967792,124975440",20846,NULL,P42225,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,P42225,NULL
577786,2,Displacement of 5-carboxyfluorescein-GpYLPQTV-NH2 from mouse recombinant His-tagged STAT3-SH2 domain expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726326,20200626,"51351545,51351546,53318375,53318376,53318509,53319712,53319837,53322458,53324283,53324977,53325554,53326387","124959666,124959667,124959886,124962274,124962502,124967792,124967793,124971285,124972826,124973826,124975440,124975641",20848,NULL,P42227,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,P42227,NULL
577788,100,Metabolic stability in human Caco2 cells at 10 uM at pH 7.4 after 90 mins by LC/MS analysis,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726328,20200626,"53319710,53319711","124962272,124962273",NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
577789,100,Apparent permeability across apical to basolateral side in human Caco2 cells at 10 uM at pH 7.4 after 90 mins by LC/MS analysis,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726329,20200626,"51351545,51351546,53319710,53319711","124962272,124962273,124967792,124975440",NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
577791,100,Antiproliferative activity against human MDA-MB-231 cells assessed as suppression of cell viability at 50 uM after 24 hrs by CyQuant cell viability assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726331,20200626,51351545,124975440,NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
577792,100,Antiproliferative activity against human PANC1 cells assessed as suppression of cell viability at 50 uM after 24 hrs by CyQuant cell viability assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726332,20200626,51351545,124975440,NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
577793,100,Antiproliferative activity against human DU145 cells assessed as suppression of cell viability at 50 uM after 24 hrs by CyQuant cell viability assay,"Title: Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein._|__|_Abstract: Aberrant activation of oncogenic signal transducer and activator of transcription 3 (STAT3) protein signaling pathways has been extensively implicated in human cancers. Given STAT3's prominent dysregulatory role in malignant transformation and tumorigenesis, there has been a significant effort to discover STAT3-specific inhibitors as chemical probes for defining the aberrant STA",43,ChEMBL,726333,20200626,51351545,124975440,NULL,NULL,NULL,Curation Efforts|Research and Development,21216604,0,10.1016/j.bmc.2010.12.010,NULL,NULL,NULL
590883,100,"Metabolic stability in rhesus monkey whole blood assessed as conversion to (1R,2R)-2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylic ","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741034,20180918,25122184,131276682,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590884,100,"Metabolic stability in Sprague-Dawley rat whole blood assessed as conversion to (1R,2R)-2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarbox","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741035,20180918,"25122184,54580284,54582303,54585211,54587172","131272661,131276682,131276684,131282691,131286723",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590885,100,"Metabolic stability in human whole blood assessed as conversion to (1R,2R)-2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylic acid aft","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741036,20180918,"25122184,54580284,54582303,54585211,54587172","131272661,131276682,131276684,131282691,131286723",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590886,100,"Metabolic stability in Sprague-Dawley rat liver S9 fraction assessed as conversion to (1R,2R)-2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropane","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741037,20180918,"25122184,54580284,54582303,54585211,54587172","131272661,131276682,131276684,131282691,131286723",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590887,100,"Metabolic stability in human liver S9 fraction assessed as conversion to (1R,2R)-2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylic ac","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741038,20180918,"25122184,54580284,54585211,54587172","131272661,131276682,131282691,131286723",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590888,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 20 mg/kg, po as 0.5% methocel suspension","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741039,20180918,54587172,131286723,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590890,2,Binding affinity to human ERG,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741041,20180918,"24953169,24953170,24953519,25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580283,54580284,54581286,54582303,54584273,54587171,54587172,54587173","131272660,131272661,131272662,131274612,131274613,131274698,131276682,131276683,131276684,131276685,131278661,131278662,131280715,131280716,131280717,131280782,131286722,131286723,131286724,131286725",3757,NULL,Q12809,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,Q12809,NULL
590893,100,Ratio of IC50 for human CYP3A4 in absence of NADPH to IC50 for human CYP3A4 preincubated for 30 mins in presence of NADPH,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741044,20200629,"24953169,24953170,24953519,25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580283,54581286,54584273,54587171,54587173","131272660,131272662,131274612,131274613,131274698,131276682,131276683,131276685,131278661,131278662,131280715,131280716,131280717,131280782,131286722,131286724,131286725",1576,NULL,P08684,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
590894,100,"Metabolic stability in dog whole blood assessed as conversion to (1R,2R)-2-((3-(((3R,4S)-N-cyclopropyl-4-(4-(2-(2,6-dichloro-4-methylphenoxy)ethoxy)phenyl)piperidine-3-carboxamido)methyl)-5-(3-methoxypropyl)phenoxy)methyl)cyclopropanecarboxylic acid after","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741045,20180918,25122184,131276682,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590896,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg as 0.5% methocel suspension,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741047,20180918,"25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54584273,54587173","131272662,131274698,131276682,131276683,131276685,131278662,131280716,131280717,131280782,131286724,131286725",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590897,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po as 0.5% methocel suspension","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741048,20180918,"25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,25122184,54580284,54582303,54584273,54585211,54587173","131272661,131272662,131274698,131276682,131276683,131276684,131276685,131278662,131280716,131280717,131280782,131282691,131286724,131286725",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590898,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg in 60% PEG 200,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741049,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590899,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po in 60% PEG 200","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741050,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590900,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg in 60% PEG 200 at PH 2.5,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741051,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590901,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po in 60% PEG 200 at PH 2.5","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741052,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590902,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg in peanut oil,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741053,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590903,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po in peanut oil","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741054,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590904,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg in lyposin 2,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741055,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590905,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po in lyposin 2","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741056,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590906,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg in Na salt in 0.5% methocel,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741057,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590907,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po in Na salt in 0.5% methocel","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741058,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590908,100,Oral bioavailability in Sprague-Dawley rat at 30 mg/kg in Ca salt in 0.5% methocel,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741059,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590909,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 30 mg/kg, po in Ca salt in 0.5% methocel","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741060,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590910,100,"Bioavailability in Sprague-Dawley rat at 20 mg/kg, intra-duodenum in 5% dextrose","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741061,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590911,100,"AUC (0 to 24 hrs) in Sprague-Dawley rat at 20 mg/kg, intra-duodenum in 5% dextrose","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741062,20180918,25122183,131276683,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590912,100,Oral bioavailability in Beagle dog at at 3 mg/kg in 0.5% methocel,"Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741063,20180918,25122184,131276682,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590913,100,"AUC (0 to 24 hrs) in Beagle dog at at 3 mg/kg, po in 0.5% methocel","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741064,20180918,25122184,131276682,NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
590914,100,"Clearance in Sprague-Dawley rat at 30 mg/kg, po in 5% dextrose and 3 to 5 mg/kg, iv in 60% PEG 200","Title: The discovery and synthesis of potent zwitterionic inhibitors of renin._|__|_Abstract: The incorporation of a carboxylic acid within in a series of 3-amido-4-aryl substituted piperidines (represented by general structure 32) led to the discovery of potent, zwitterionic, renin inhibitors with improved off-target profiles (CYP3A4 time-dependent inhibition and hERG affinity) relative to analogous non-zwitterionic inhibitors of the past (i.e., 3). Strategies to address the oral absorption of these zwitte",43,ChEMBL,741065,20180918,"25118294,25119356,25119357,25119716,25120419,25121114,25121469,25122183,54584273,54587173","131272662,131274698,131276683,131276685,131278662,131280716,131280717,131280782,131286724,131286725",NULL,NULL,NULL,Curation Efforts|Research and Development,21429746,0,10.1016/j.bmcl.2011.02.067,NULL,NULL,NULL
591573,100,Time dependent inhibition of CYP3A4,"Title: The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis._|__|_Abstract: A series of potent phthalazinone-based human H(1) and H(3) bivalent histamine receptor antagonists, suitable for intranasal administration for the potential treatment of allergic rhinitis, were identified. Blockade of H(3) receptors is thought to improve efficacy on nasal congestion, a symptom of allergic rhinitis that is currentl",43,ChEMBL,741724,20180918,17747460,131286315,1576,NULL,P08684,Curation Efforts|Research and Development,21381763,0,10.1021/jm1013874,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
591574,100,Time dependent inhibition of CYP2D6,"Title: The discovery of phthalazinone-based human H1 and H3 single-ligand antagonists suitable for intranasal administration for the treatment of allergic rhinitis._|__|_Abstract: A series of potent phthalazinone-based human H(1) and H(3) bivalent histamine receptor antagonists, suitable for intranasal administration for the potential treatment of allergic rhinitis, were identified. Blockade of H(3) receptors is thought to improve efficacy on nasal congestion, a symptom of allergic rhinitis that is currentl",43,ChEMBL,741725,20180918,17747460,131286315,1565,NULL,P10635,Curation Efforts|Research and Development,21381763,0,10.1021/jm1013874,1.14.14.-,P10635,NULL
626942,100,Time dependent inhibition of CYP3A4 assessed as conversion of testosterone to 6-beta-hydroxytestosterone at 10 uM after 30 mins relative to control,"Title: Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of tertiary alcohol-bearing piperidines._|__|_Abstract: The design and optimization of a novel series of renin inhibitor is described herein. Strategically, by committing the necessary resources to the development of synthetic sequences and scaffolds that were most amenable for late stage structural diversification, even as the focus of the SAR campaign moved from one end of the molecule to another, highly p",43,ChEMBL,776448,20180919,"42642010,53307874,57392012,57393726,57393727,57397294,57397297,57398992","136924038,136927268,136927269,136933968,136933971,136937097,136937120,136940319",1576,NULL,P08684,Curation Efforts|Research and Development,21641209,0,10.1016/j.bmcl.2011.05.014,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
635881,100,Time-dependent inhibition of rat liver mitochondrial MAO-A using 5-hydroxytryptamine at 6 nM by scintillation counting,"Title: Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease._|__|_Abstract: A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized. Novel compounds (3-9) have been de",43,ChEMBL,793329,20200626,53378764,136928086,29253,NULL,P21396,Curation Efforts|Research and Development,22023459,0,10.1021/jm200853t,1.4.3.4,P21396,NULL
635883,100,Time-dependent inhibition of rat liver mitochondrial MAO-B using phenylethylamine at 45 nM,"Title: Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease._|__|_Abstract: A new family of multitarget molecules able to interact with acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE), as well as with monoamino oxidase (MAO) A and B, has been synthesized. Novel compounds (3-9) have been de",43,ChEMBL,793331,20200626,53378764,136928086,25750,NULL,P19643,Curation Efforts|Research and Development,22023459,0,10.1021/jm200853t,1.4.3.4,P19643,NULL
639075,2,Time dependent inhibition of CYP,Title: Lead optimisation of pyrazoles as novel FPR1 antagonists._|__|_Abstract: Optimisation of a series of pyrazole inhibitors of the human FPR1 receptor has been achieved. The use of an in vitro media loss assay was utilised to identify sub-series with more robust DMPK profiles. These were subsequently improved to generate analogues with attractive overall profiles.,43,ChEMBL,796523,20180920,"56949822,56949966","136925338,136928541",NULL,NULL,NULL,Curation Efforts|Research and Development,22094028,0,10.1016/j.bmcl.2011.10.090,NULL,NULL,NULL
646520,100,Time-dependent inhibition of rat glutaryl-co A dehydrogenase after 30 mins by spectrophotometry,"Title: Functional characterization of rat glutaryl-CoA dehydrogenase and its comparison with straight-chain acyl-CoA dehydrogenase._|__|_Abstract: Glutaryl-CoA dehydrogenase catalyzes the oxidative decarboxylation of the &#x3B3;-carboxylate of the substrate, glutaryl-CoA, to yield crotonyl-CoA and CO(2). The enzyme is a member of the acyl-CoA dehydrogenase (ACD) family of flavoproteins. In the present study, the catalytic properties of this enzyme, including its substrate specificity, isomerase activity, an",43,ChEMBL,803968,20200626,57396811,136932948,NULL,NULL,NULL,Curation Efforts|Research and Development,21974953,0,10.1016/j.bmcl.2011.09.062,NULL,NULL,NULL
646523,100,Time-dependent inhibition of rat glutaryl-co A dehydrogenase after 160 mins by spectrophotometry,"Title: Functional characterization of rat glutaryl-CoA dehydrogenase and its comparison with straight-chain acyl-CoA dehydrogenase._|__|_Abstract: Glutaryl-CoA dehydrogenase catalyzes the oxidative decarboxylation of the &#x3B3;-carboxylate of the substrate, glutaryl-CoA, to yield crotonyl-CoA and CO(2). The enzyme is a member of the acyl-CoA dehydrogenase (ACD) family of flavoproteins. In the present study, the catalytic properties of this enzyme, including its substrate specificity, isomerase activity, an",43,ChEMBL,803971,20200626,57393329,136926502,NULL,NULL,NULL,Curation Efforts|Research and Development,21974953,0,10.1016/j.bmcl.2011.09.062,NULL,NULL,NULL
647375,2,Time dependent inhibition of CYP3A4,"Title: Pyrazoloquinolines as PDE10A inhibitors: discovery of a tool compound._|__|_Abstract: A series of pyrazoloquinolines, possessing (hetero)arylhydroxymethyl substituents at the quinoline C-4 position were evaluated as PDE10A inhibitors. Among these, methylpyrimidyl analogue 15 was identified as having good rodent and monkey exposure, and a MED of 10 mg/kg in an in vivo model.",43,ChEMBL,804823,20180921,"57334262,57391165,57391166,57392932,57396432,57396433,57396434,57396814,57398224,57398573,57398574,57399874,57400235,57402038,57403377,57403378,57403379,57403779,57403780","136922570,136922571,136925802,136932271,136932272,136932273,136932954,136935729,136936343,136936344,136938853,136939477,136942689,136945224,136945225,136945226,136945227,136945923,136945924",1576,NULL,P08684,Curation Efforts|Research and Development,22227212,0,10.1016/j.bmcl.2011.12.080,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
650573,100,Time dependent inhibition of CYP3A4 using testosterone as substrate at 10 uM for 30 mins,"Title: 3,4-Diarylpiperidines as potent renin inhibitors._|__|_Abstract: The discovery and SAR of a series of potent renin inhibitors possessing a novel 3,4-diarylpiperidine scaffold are described herein. The resulting compound 38 exhibit low nanomolar plasma renin IC(50), had a clean CYP 3A4 profile and displayed micromolar affinity for the hERG channel. Furthermore, it was found to be efficacious in the double transgenic rat hypertension model and show good to moderate oral bioavailability in two animal sp",43,ChEMBL,808021,20180921,"46912235,46931619,46931735,46931848,46931852,46931947,46931948,46932796,52934690,52934924,56962365,57401859","136922876,136926215,136929334,136929335,136929336,136929337,136932599,136936011,136936068,136942375,136945539,136945540",1576,NULL,P08684,Curation Efforts|Research and Development,22325946,0,10.1016/j.bmcl.2012.01.044,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
659354,100,Time dependent inhibition of CYP3A4 up to 10 uM,"Title: Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families._|__|_Abstract: In an effort to identify multi-targeted kinase inhibitors with a novel spectrum of kinase activity, a screen of Abbott proprietary KDR inhibitors against a broad panel of kinases was conducted and revealed a series of thienopyridine ureas with promising activity against the Aurora kinases. Modification of the diphenyl urea and C7 moiety of these compounds provided potent inhibitors with good pharmacokinetic",43,ChEMBL,816426,20180921,46207586,160682653,1576,NULL,P08684,Curation Efforts|Research and Development,22465635,0,10.1016/j.bmcl.2012.03.035,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
659837,100,Time-dependent inhibition of human recombinant PNP using MSEG as substrate by HPLC analysis,"Title: N-phosphonocarbonylpyrrolidine derivatives of guanine: a new class of bi-substrate inhibitors of human purine nucleoside phosphorylase._|__|_Abstract: A complete series of pyrrolidine nucleotides, (3R)- and (3S)-3-(guanin-9-yl)pyrrolidin-1-N-ylcarbonylphosphonic acids and (3S,4R)-, (3R,4S)-, (3S,4S)-, and (3R,4R)-4-(guanin-9-yl)-3-hydroxypyrrolidin-1-N-ylcarbonylphosphonic acids, were synthesized and evaluated as potential inhibitors of purine nucleoside phosphorylase (PNP) isolated from peripheral b",43,ChEMBL,816909,20200626,136020077,160667567,4860,NULL,P00491,Curation Efforts|Research and Development,22264015,0,10.1021/jm201409u,2.4.2.1,P00491,NULL
662750,100,Time dependent inhibition of human SSAO/VAP1 measuring H2O2 production by Resorufin/Amplex Red assay,"Title: The discovery and development of selective 3-fluoro-4-aryloxyallylamine inhibitors of the amine oxidase activity of semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1)._|__|_Abstract: A new class of 3-fluoroallyl amine-based SSAO/VAP-1 inhibitors is reported. These compounds have excellent selectivity over diamine oxidase, MAO-A and MAO-B. Synthesis and SAR studies leading to compound 28 (PXS-4159A) are reported. The pharmacokinetic profile of 28 in the rat, together with a",43,ChEMBL,819839,20180921,42623269,160689103,8639,NULL,Q16853,Curation Efforts|Research and Development,22595173,0,10.1016/j.bmcl.2012.04.111,1.4.3.21,Q16853,NULL
668990,100,Time-dependent inhibition of cytochrome P450,Title: Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties._|__|_Abstract: Recent clinical data provided proof-of-concept for selective B-Raf inhibitors in treatment of B-Raf(V600E) mutant melanoma. Pyrazolopyridine-type B-Raf inhibitors previously described by the authors are potent and selective but exhibit low solubility requiring the use of amorphous dispersion-based formulation for achieving efficacious drug exposures. Through struct,43,ChEMBL,826113,20180922,57343225,160706409,NULL,NULL,NULL,Curation Efforts|Research and Development,22335519,0,10.1021/jm300016v,NULL,NULL,NULL
670266,100,Time dependent inhibition of Mycobacterium tuberculosis CYP124A1 at 50 uM incubated up to 3 hrs by HPLC,"Title: Substrate analog studies of the &#xCF;&#x2030;-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1._|__|_Abstract: We report the synthesis and evaluation of a series of cholesterol side-chain analogs as mechanistic probes of three important Mycobacterium tuberculosis cytochrome P450 enzymes that selectively oxidize the &#x3C9;-position of the methyl-branched cholesterol side-chain. To probe the structural requirements for the",43,ChEMBL,827389,20200627,70690407,160690409,NULL,NULL,NULL,Curation Efforts|Research and Development,22647881,0,10.1016/j.bmc.2012.05.003,NULL,NULL,NULL
670267,100,Time dependent inhibition of Mycobacterium tuberculosis CYP125A1 at 50 uM incubated up to 3 hrs by HPLC,"Title: Substrate analog studies of the &#xCF;&#x2030;-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1._|__|_Abstract: We report the synthesis and evaluation of a series of cholesterol side-chain analogs as mechanistic probes of three important Mycobacterium tuberculosis cytochrome P450 enzymes that selectively oxidize the &#x3C9;-position of the methyl-branched cholesterol side-chain. To probe the structural requirements for the",43,ChEMBL,827390,20200627,70690407,160690409,887782,NULL,P9WPP1,Curation Efforts|Research and Development,22647881,0,10.1016/j.bmc.2012.05.003,1.14.15.29,P9WPP1,NULL
670268,100,Time dependent inhibition of Mycobacterium tuberculosis CYP142A1 at 50 uM incubated up to 3 hrs by HPLC,"Title: Substrate analog studies of the &#xCF;&#x2030;-regiospecificity of Mycobacterium tuberculosis cholesterol metabolizing cytochrome P450 enzymes CYP124A1, CYP125A1 and CYP142A1._|__|_Abstract: We report the synthesis and evaluation of a series of cholesterol side-chain analogs as mechanistic probes of three important Mycobacterium tuberculosis cytochrome P450 enzymes that selectively oxidize the &#x3C9;-position of the methyl-branched cholesterol side-chain. To probe the structural requirements for the",43,ChEMBL,827391,20200627,70690407,160690409,NULL,NULL,NULL,Curation Efforts|Research and Development,22647881,0,10.1016/j.bmc.2012.05.003,NULL,NULL,NULL
672030,100,Selectivity ratio of IC50 for human HDAC2 preincubated with compound for 3 hrs to IC50 for human HDAC1 preincubated with compound for 3 hrs,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829153,20200627,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",NULL,NULL,NULL,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,NULL,NULL,NULL
672031,100,Selectivity ratio of IC50 for human HDAC2 preincubated with compound for 24 hrs to IC50 for human HDAC1 preincubated with compound for 3 hrs,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829154,20200627,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",NULL,NULL,NULL,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,NULL,NULL,NULL
672032,100,Ratio of IC50 for human HDAC1 preincubated for 3 hrs to IC50 for human HDAC1 preincubated for 5 mins,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829155,20200627,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3065,NULL,Q13547,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q13547,NULL
672033,100,Ratio of IC50 for human HDAC2 preincubated for 3 hrs to IC50 for human HDAC2 preincubated for 5 mins,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829156,20200627,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672034,100,Ratio of IC50 for human HDAC2 preincubated for 24 hrs to IC50 for human HDAC2 preincubated for 5 mins,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829157,20200627,"5311,25155955,44454143,62706003,62706004,62706005,62706006,62706167,62706168,62706169,62706170,62706171,62706321","103174146,103560740,103572507,160669203,160669204,160669205,160674527,160674528,160685209,160690654,160701401,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672036,100,Selectivity for human HDAC1 over human HDAC3,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829159,20200627,"62706004,62706171,62706321","160674527,160685209,160706679",NULL,NULL,NULL,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,NULL,NULL,NULL
672037,100,Selectivity for human HDAC1 over human HDAC8,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829160,20200627,"62706004,62706171,62706321","160674527,160685209,160706679",NULL,NULL,NULL,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,NULL,NULL,NULL
672038,100,Selectivity for human HDAC2 over human HDAC3,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829161,20200627,"62706004,62706171,62706321","160674527,160685209,160706679",NULL,NULL,NULL,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,NULL,NULL,NULL
672039,100,Selectivity for human HDAC2 over human HDAC8,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829162,20200627,"62706004,62706171,62706321","160674527,160685209,160706679",NULL,NULL,NULL,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,NULL,NULL,NULL
672041,100,Binding affinity to His-tagged human HDAC2 assessed as decrease in biotinylation of HDAC2 at 25 uM preincubated for 24 hrs measured after 1 hr by Western blot analysis in presence of five-fold molar excess of Trichostatin A,"Title: Design, synthesis, modeling, biological evaluation and photoaffinity labeling studies of novel series of photoreactive benzamide probes for histone deacetylase 2._|__|_Abstract: The design, modeling, synthesis, biological evaluation of a novel series of photoreactive benzamide probes for class I HDAC isoforms is reported. The probes are potent and selective for HDAC1 and 2 and are efficient in crosslinking to HDAC2 as demonstrated by photolabeling experiments. The probes exhibit a time-dependent inhi",43,ChEMBL,829164,20180922,"62706005,62706006,62706167,62706168,62706169,62706171,62706321","160669204,160669205,160674527,160674528,160690654,160701402,160706679",3066,NULL,Q92769,Curation Efforts|Research and Development,22771007,0,10.1016/j.bmcl.2012.06.017,3.5.1.98,Q92769,NULL
672099,100,Time dependent inhibition of CYP3A4 at 10 and 50 uM,"Title: (1aR,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans._|__|_Abstract: G-protein coupled receptor (GPCR) GPR109a is a molecular target for nicotinic acid and is expressed in adipocytes, spleen, and immune cells. Nicotinic acid has long been used for the treatment of dyslipidemia due to its capacity to positively affect serum lipids to a greater extent than other currently marketed drugs. We report ",43,ChEMBL,829222,20180922,"49763030,57413367","160669177,160685186",1576,NULL,P08684,Curation Efforts|Research and Development,22435740,0,10.1021/jm2010964,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
677771,2,Time-dependent inhibition of CYP1A2,"Title: Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors._|__|_Abstract: An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position ",43,ChEMBL,834910,20200630,"70686766,70695115,70697151","160680642,160702202,160707438",1544,NULL,P05177,Curation Efforts|Research and Development,22853997,0,10.1016/j.bmcl.2012.06.087,"1.14.14.1,4.2.1.152",P05177,NULL
677773,2,Time-dependent inhibition of CYP2C9,"Title: Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors._|__|_Abstract: An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position ",43,ChEMBL,834912,20180922,"70686766,70695115,70697151","160680642,160702202,160707438",1559,NULL,P11712,Curation Efforts|Research and Development,22853997,0,10.1016/j.bmcl.2012.06.087,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
677775,2,Time-dependent inhibition of CYP2C19,"Title: Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors._|__|_Abstract: An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position ",43,ChEMBL,834914,20180922,"70686766,70695115,70697151","160680642,160702202,160707438",1557,NULL,P33261,Curation Efforts|Research and Development,22853997,0,10.1016/j.bmcl.2012.06.087,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
677777,2,Time-dependent inhibition of CYP2D6,"Title: Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors._|__|_Abstract: An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position ",43,ChEMBL,834916,20180922,"70686766,70695115,70697151","160680642,160702202,160707438",1565,NULL,P10635,Curation Efforts|Research and Development,22853997,0,10.1016/j.bmcl.2012.06.087,1.14.14.-,P10635,NULL
677779,100,Time-dependent inhibition of CYP3A4 at 5 uM,"Title: Orally available pyridinylpyrimidine derivatives as novel RANKL-induced osteoclastogenesis inhibitors._|__|_Abstract: An HTS campaign led to the identification of 4-pyrroldino-2-(pyridin-2-yl)pyrimidine compound 1 as an RANKL-induced osteoclastogenesis inhibitor. The compound 1 showed high clearance values in microsomes, however. Modification of the pyrrolidino group to a benzylamino group improved human microsomal stability with a slight loss of in vitro activity. Substitution at the ortho position ",43,ChEMBL,834918,20180922,"70686766,70695115,70697151","160680642,160702202,160707438",1576,NULL,P08684,Curation Efforts|Research and Development,22853997,0,10.1016/j.bmcl.2012.06.087,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
688945,100,Time-dependent inhibition of human CYP3A4,"Title: Discovery of BIIB042, a Potent, Selective, and Orally Bioavailable &#xCE;&#xB3;-Secretase Modulator._|__|_Abstract: We have investigated a novel series of acid-derived &#x3B3;-secretase modulators as a potential treatment of Alzheimer's disease. Optimization based on cellular potency and brain pharmacodynamics after oral dosing led to the discovery of 10a (BIIB042). Compound 10a is a potent &#x3B3;-secretase modulator, which lowered A&#x3B2;42, increased A&#x3B2;38, but had little to no effect on A&#",43,ChEMBL,849689,20200625,53493001,163326581,1576,NULL,P08684,Curation Efforts|Research and Development,24900267,0,10.1021/ml200175q,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
692827,2,Time dependent inhibition of Electric eel AChE assessed as stability constants of inhibitor-enzyme complex using acetylthiocholine as substrate after 60 mins,Title: Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer._|__|_Abstract: Tri- and tetracyclic nitrogen-bridgehead compounds were designed and synthesized to yield micromolar cholinesterase (ChE) inhibitors. Structure-activity relationships identified potent compounds with butyrylcholinesterase selectivity. These compounds were selected as starting points for the design and synthesis of carbamate-based (pseudo)irreversible inhibitors. Compounds with ,43,ChEMBL,853571,20180923,"5983,71453073","103172254,163320117",113580815,NULL,O42275,Curation Efforts|Research and Development,24900407,0,10.1021/ml3001825,3.1.1.7,O42275,NULL
692828,100,Time dependent inhibition of Electric eel AChE assessed as stability constants of inhibitor-enzyme complex using acetylthiocholine as substrate at 10 to 50 nM after 60 mins,Title: Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer._|__|_Abstract: Tri- and tetracyclic nitrogen-bridgehead compounds were designed and synthesized to yield micromolar cholinesterase (ChE) inhibitors. Structure-activity relationships identified potent compounds with butyrylcholinesterase selectivity. These compounds were selected as starting points for the design and synthesis of carbamate-based (pseudo)irreversible inhibitors. Compounds with ,43,ChEMBL,853572,20180923,60165327,163316640,113580815,NULL,O42275,Curation Efforts|Research and Development,24900407,0,10.1021/ml3001825,3.1.1.7,O42275,NULL
692829,2,Time dependent inhibition of equine serum BChE assessed as stability constants of inhibitor-enzyme complex using acetylthiocholine as substrate after 60 mins,Title: Neuroprotective Tri- and Tetracyclic BChE Inhibitors Releasing Reversible Inhibitors upon Carbamate Transfer._|__|_Abstract: Tri- and tetracyclic nitrogen-bridgehead compounds were designed and synthesized to yield micromolar cholinesterase (ChE) inhibitors. Structure-activity relationships identified potent compounds with butyrylcholinesterase selectivity. These compounds were selected as starting points for the design and synthesis of carbamate-based (pseudo)irreversible inhibitors. Compounds with ,43,ChEMBL,853573,20180923,"5983,60165327,71453073","103172254,163316640,163320117",100033901,NULL,P81908,Curation Efforts|Research and Development,24900407,0,10.1021/ml3001825,3.1.1.8,P81908,NULL
696292,100,Time dependent inhibition of CYP3A4 using testosterone as substrate,Title: Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2._|__|_Abstract: Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 se,43,ChEMBL,857036,20180923,56929216,163320443,1576,NULL,P08684,Curation Efforts|Research and Development,22698084,0,10.1021/jm300628c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
696293,100,Time dependent inhibition of CYP3A4 using midazolam as substrate,Title: Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2._|__|_Abstract: Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 se,43,ChEMBL,857037,20180923,56929216,163320443,1576,NULL,P08684,Curation Efforts|Research and Development,22698084,0,10.1021/jm300628c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
696294,100,Time dependent inhibition of CYP2C9 using warfarin as substrate,Title: Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2._|__|_Abstract: Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 se,43,ChEMBL,857038,20180923,56929216,163320443,1559,NULL,P11712,Curation Efforts|Research and Development,22698084,0,10.1021/jm300628c,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
696295,100,Time dependent inhibition of CYP2D6 using dextromethorphan as substrate,Title: Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2._|__|_Abstract: Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 se,43,ChEMBL,857039,20180923,56929216,163320443,1565,NULL,P10635,Curation Efforts|Research and Development,22698084,0,10.1021/jm300628c,1.14.14.-,P10635,NULL
696296,100,Time dependent inhibition of CYP2C19 using mephenytoin as substrate,Title: Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2._|__|_Abstract: Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 se,43,ChEMBL,857040,20180923,56929216,163320443,1557,NULL,P33261,Curation Efforts|Research and Development,22698084,0,10.1021/jm300628c,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
696297,100,Time dependent inhibition of CYP21A2 using phenacetin as substrate,Title: Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2._|__|_Abstract: Herein we report the discovery of the C-2 methyl substituted imidazopyrrolopyridine series and its optimization to provide potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2. The C-2 methyl substituted inhibitor 4 exhibited not only improved JAK1 potency relative to unsubstituted compound 3 but also notable JAK1 vs JAK2 se,43,ChEMBL,857041,20200625,56929216,163320443,1544,NULL,P05177,Curation Efforts|Research and Development,22698084,0,10.1021/jm300628c,"1.14.14.1,4.2.1.152",P05177,NULL
698001,100,Time dependent inhibition of CYP3A4 at 10 uM,"Title: Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients._|__|_Abstract: Glucokinase (GK) activation as a potential strategy to treat type 2 diabetes (T2D) is well recognized. Compound 1, a glucokinase activator (GKA) lead that we have previously disclosed, caused reversible hepatic lipidosis in repeat-dose toxicology studies. We hypothesized that the hepatic lipidosis was due to the structure-based toxicity and later established that it was due to the formation of a ",43,ChEMBL,858745,20200625,59086459,163334586,1576,NULL,P08684,Curation Efforts|Research and Development,22809456,0,10.1021/jm3008689,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
701642,100,Time dependent inhibition of CYP3A4 in human liver microsomes at up to 50 uM up to 20 mins,"Title: Identification of a potent sodium hydrogen exchanger isoform 1 (NHE1) inhibitor with a suitable profile for chronic dosing and demonstrated cardioprotective effects in a preclinical model of myocardial infarction in the rat._|__|_Abstract: Sodium-hydrogen exchanger isoform 1 (NHE1) is a ubiquitously expressed transmembrane ion channel responsible for intracellular pH regulation. During myocardial ischemia, low pH activates NHE1 and causes increased intracellular calcium levels and aberrant cellular p",43,ChEMBL,862386,20180923,51031001,163338225,1576,NULL,P08684,Curation Efforts|Research and Development,22803959,0,10.1021/jm300601d,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
705583,2,Time dependent inhibition of CYP2B6 in human liver microsomes,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873326,20180923,60606,103724173,1555,NULL,P20813,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,1.14.13.-,P20813,NULL
705592,2,Time dependent inhibition of CYP3A4,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873335,20180923,"4449,60663,176870,10304547","103177459,103188221,103229908,103457381",1576,NULL,P08684,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
705593,2,Time dependent inhibition of CYP3A4 in human liver microsomes,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873336,20180923,"4449,3062316,11713159","103188221,103501621,103756518",1576,NULL,P08684,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
705597,2,Time dependent inhibition of CYP3A4-mediated testosterone-6-beta hydroxylation in human liver microsome,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873340,20180923,"64143,65016,92727,392622,441243","103179606,103179760,103198077,103244854,104234156",1576,NULL,P08684,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
705604,2,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as quasi-irreversible complex formation,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873347,20180923,208908,103177479,1576,NULL,P08684,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
705605,2,Time dependent inhibition of CYP2C19,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873348,20180923,"5472,60606","103219164,103724173",1557,NULL,P33261,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
705608,2,Time dependent inhibition of CYP2C8 in human liver microsomes,Title: Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks._|_,43,ChEMBL,873351,20180923,88127,163318381,1558,NULL,P10632,Curation Efforts|Research and Development,22409598,0,10.1021/jm300065h,1.14.14.1,P10632,NULL
705610,100,Time dependent inhibition of CYP2D6,"Title: Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)._|__|_Abstract: A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine i",43,ChEMBL,873353,20180923,52912189,160683043,1565,NULL,P10635,Curation Efforts|Research and Development,22437115,0,10.1016/j.bmcl.2012.02.041,1.14.14.-,P10635,NULL
705649,100,Time dependent inhibition of CYP3A4 using diethoxyfluoresin as substrate,"Title: Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)._|__|_Abstract: A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine i",43,ChEMBL,873392,20180923,"52912189,70681173","160667084,160683043",1576,NULL,P08684,Curation Efforts|Research and Development,22437115,0,10.1016/j.bmcl.2012.02.041,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
705650,100,Time dependent inhibition of CYP2C19,"Title: Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)._|__|_Abstract: A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine i",43,ChEMBL,873393,20180923,"52912189,70681173","160667084,160683043",1557,NULL,P33261,Curation Efforts|Research and Development,22437115,0,10.1016/j.bmcl.2012.02.041,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
705651,100,Time dependent inhibition of CYP2C9,"Title: Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A)._|__|_Abstract: A novel series of quinoline isoxazole BET family bromodomain inhibitors are discussed. Crystallography is used to illustrate binding modes and rationalize their SAR. One member, I-BET151 (GSK1210151A), shows good oral bioavailability in both the rat and minipig as well as demonstrating efficient suppression of bacterial induced inflammation and sepsis in a murine i",43,ChEMBL,873394,20180923,"52912189,70681173","160667084,160683043",1559,NULL,P11712,Curation Efforts|Research and Development,22437115,0,10.1016/j.bmcl.2012.02.041,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
706614,100,Time dependent inhibition of human CYP3A4 assessed as residual activity at 10 uM after 15 mins relative to control,"Title: Structure-based design of novel inhibitors of the MDM2-p53 interaction._|__|_Abstract: Structure-based rational design led to the discovery of novel inhibitors of the MDM2-p53 protein-protein interaction. The affinity of these compounds for MDM2 was improved through conformational control of both the piperidinone ring and the appended N-alkyl substituent. Optimization afforded 29 (AM-8553), a potent and selective MDM2 inhibitor with excellent pharmacokinetic properties and in vivo efficacy.",43,ChEMBL,874357,20180923,"56591154,56965957,67998380","160690851,160701617,163331640",1576,NULL,P08684,Curation Efforts|Research and Development,22524527,0,10.1021/jm300354j,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
719396,100,Time dependent inhibition of CYP2D6,Title: Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2._|__|_Abstract: Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939). Efforts to improve cellular potency by reducing the polarity of the inhibitors are also detailed. The X-ray crystal structure,43,ChEMBL,887139,20180924,66557868,163339465,1565,NULL,P10635,Curation Efforts|Research and Development,23107482,0,10.1016/j.bmcl.2012.10.008,1.14.14.-,P10635,NULL
719397,100,Time dependent inhibition of CYP2C9,Title: Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2._|__|_Abstract: Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939). Efforts to improve cellular potency by reducing the polarity of the inhibitors are also detailed. The X-ray crystal structure,43,ChEMBL,887140,20180924,66557868,163339465,1559,NULL,P11712,Curation Efforts|Research and Development,23107482,0,10.1016/j.bmcl.2012.10.008,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
719398,100,Time dependent inhibition of CYP2C19,Title: Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2._|__|_Abstract: Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939). Efforts to improve cellular potency by reducing the polarity of the inhibitors are also detailed. The X-ray crystal structure,43,ChEMBL,887141,20180924,66557868,163339465,1557,NULL,P33261,Curation Efforts|Research and Development,23107482,0,10.1016/j.bmcl.2012.10.008,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
719399,100,Time dependent inhibition of CYP1A2,Title: Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2._|__|_Abstract: Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939). Efforts to improve cellular potency by reducing the polarity of the inhibitors are also detailed. The X-ray crystal structure,43,ChEMBL,887142,20200625,66557868,163339465,1544,NULL,P05177,Curation Efforts|Research and Development,23107482,0,10.1016/j.bmcl.2012.10.008,"1.14.14.1,4.2.1.152",P05177,NULL
719400,100,Time dependent inhibition of CYP3A4,Title: Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2._|__|_Abstract: Herein we describe our successful efforts in obtaining C-2 substituted imidazo-pyrrolopyridines with improved JAK1 selectivity relative to JAK2 by targeting an amino acid residue that differs between the two isoforms (JAK1: E966; JAK2: D939). Efforts to improve cellular potency by reducing the polarity of the inhibitors are also detailed. The X-ray crystal structure,43,ChEMBL,887143,20180924,66557868,163339465,1576,NULL,P08684,Curation Efforts|Research and Development,23107482,0,10.1016/j.bmcl.2012.10.008,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
724809,100,Time dependent inhibition of human RAD51 binding to single stranded DNA at 59 uM by fluorescence polarization based assay,Title: An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity._|__|_Abstract: Homologous recombination (HR) is an essential process in cells that provides repair of DNA double-strand breaks and lesions that block DNA replication. RAD51 is an evolutionarily conserved protein that is central to HR. Overexpression of RAD51 protein is common in cancer cells and represents a potential therapeutic target in oncology. We previously described a chemical inh,43,ChEMBL,937375,20180925,71547138,164139685,5888,NULL,Q06609,Curation Efforts|Research and Development,23231413,0,10.1021/jm301565b,NULL,Q06609,NULL
725314,100,Time dependent inhibition of pig brain GABA-AT using GABA as substrate at 5 mM up to 150 mins,"Title: Probing the steric requirements of the &#xCE;&#xB3;-aminobutyric acid aminotransferase active site with fluorinated analogues of vigabatrin._|__|_Abstract: We have synthesized three analogues of 4-amino-5-fluorohexanoic acids as potential inactivators of &#x3B3;-aminobutyric acid aminotransferase (GABA-AT), which were designed to combine the potency of their shorter chain analogue, 4-amino-5-fluoropentanoic acid (AFPA), with the greater enzyme selectivity of the antiepileptic vigabatrin (Sabril&#xAE;",43,ChEMBL,937880,20200626,"5665,71524820,71524821,71524822","103295174,164133443,164144698,164147439",397500,NULL,P80147,Curation Efforts|Research and Development,23306054,0,10.1016/j.bmc.2012.12.009,"2.6.1.19,2.6.1.22",P80147,NULL
727304,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore._|__|_Abstract: A small library of fragments comprising putative recognition motifs for the catalytic dyad of aspartic proteases was generated by in silico similarity searches within the corporate compound deck based on rh-renin active site docking and scoring filters. Subsequent screening by NMR identified the low-affinity hits 3 and 4 as competitive active site binders,",43,ChEMBL,939870,20180925,11963435,164145338,1576,NULL,P08684,Curation Efforts|Research and Development,23360239,0,10.1021/jm301706j,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
727732,100,Time dependent inhibition of human EGFR T790M/L858R mutant expressed in Sf9 cells using [gamma32P]-ATP up to 1 hr by scintillation counting,"Title: Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors._|__|_Abstract: The epidermal growth factor receptor (EGFR) family plays a critical role in vital cellular processes and in various cancers. Known EGFR inhibitors exhibit distinct antitumor responses against the various EGFR mutants associated with nonsmall-cell lung cancer. The L858R mutation enhances clinical sensitivity to gefitinib and erlotinib as compared with wild type and reduces th",43,ChEMBL,940298,20180925,71720447,164148138,"1956,2064,2065,2066",NULL,"P00533,P04626,P21860,Q15303",Curation Efforts|Research and Development,24900643,0,10.1021/ml300327z,2.7.10.1,"P00533,P04626,P21860,Q15303",NULL
730811,2,"Unbound plasma concentration in NCR nude mouse xenografted with human PC3 cells at 50 to 100 mg/kg, po measured at 6 to 10 hrs","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943379,20180926,71604742,164137989,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730812,2,"Plasma concentration in NCR nude mouse xenografted with human PC3 cells at 50 to 100 mg/kg, po measured at 6 to 10 hrs","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943380,20180926,71604742,164137989,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730813,100,Unbound blood clearance in iv dosed dog,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943381,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730814,100,"Antitumor activity against human MCF7-neo/Her2 xenografted in nude mouse at 37 mg/kg, qd measured after 14 days","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943382,20200626,59239165,164148754,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730815,100,"Antitumor activity against human MCF7-neo/Her2 xenografted in nude mouse at 12.5 mg/kg, qd measured after 14 days","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943383,20200626,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730819,100,Half life in iv dosed dog,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943387,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730820,100,Volume of distribution at steady state in iv dosed dog,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943388,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730821,100,Blood clearance in iv dosed dog,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943389,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730822,100,Clearance in dog liver microsomes,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943390,20180926,71720046,164146268,NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730830,100,Plasma protein binding in mouse at 5 uM after 4 hrs by rapid equilibrium dialysis,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943398,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730831,100,Plasma protein binding in human at 5 uM after 4 hrs by rapid equilibrium dialysis,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943399,20180926,"71604742,71604893,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730832,100,Plasma protein binding in rat at 5 uM after 4 hrs by rapid equilibrium dialysis,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943400,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730833,100,"Half life in mouse at 1 mg/kg, iv","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943401,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730834,100,Oral bioavailability in mouse at 5 mg/kg,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943402,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730835,100,"Volume of distribution at steady state in mouse at 1 mg/kg, iv","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943403,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730836,100,"Clearance in mouse at 1 mg/kg, iv","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943404,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730837,100,"Unbound clearance in mouse at 1 mg/kg, iv","Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943405,20180926,"59239165,71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164148754,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730838,100,Clearance in mouse liver microsomes,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943406,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730839,100,Clearance in rat liver microsomes,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943407,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730840,100,Clearance in human liver microsomes,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943408,20180926,"71604742,71604893,71605057,71717638,71717639,71720046,71720047","164135102,164135103,164137989,164146267,164146268,164146269,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730841,2,Kinetic solubility of the compound,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943409,20180926,"59239374,71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164129458,164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149156,164149157,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730843,2,Cytotoxicity against human MCF7 neo/Her2 cells after 3 days by CellTiter-Glo assay,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943411,20200626,"59239165,59239374,71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164129458,164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164148754,164149156,164149157,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730844,2,Cytotoxicity against human PC3 cells after 4 days by CellTiter-Glo assay,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943412,20180926,"59239165,59239374,71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164129458,164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164148754,164149156,164149157,164149158",NULL,Toxicity,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730847,100,Selectivity ratio of Ki for P13Kdelta (unknown origin) to Ki for human recombinant mTOR,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943415,20200626,"71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149156,164149157,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
730848,100,Selectivity ratio of Ki for P13Kalpha (unknown origin) to Ki for human recombinant mTOR,"Title: Pyrimidoaminotropanes as potent, selective, and efficacious small molecule kinase inhibitors of the mammalian target of rapamycin (mTOR)._|__|_Abstract: We have recently reported a series of tetrahydroquinazoline (THQ) mTOR inhibitors that produced a clinical candidate 1 (GDC-0349). Through insightful design, we hoped to discover and synthesize a new series of small molecule inhibitors that could attenuate CYP3A4 time-dependent inhibition commonly observed with the THQ scaffold, maintain or improve a",43,ChEMBL,943416,20200626,"71604742,71604893,71604894,71604895,71604896,71604897,71605054,71605056,71605057,71717638,71717639,71719453,71720046,71720047","164135102,164135103,164137989,164137990,164140757,164140758,164140759,164143535,164146267,164146268,164146269,164149156,164149157,164149158",NULL,NULL,NULL,Curation Efforts|Research and Development,23473235,0,10.1021/jm400194n,NULL,NULL,NULL
734329,100,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate at 10 uM incubated for 3 to 24 mins prior to substrate addition measured after 10 mins by LC-MS/MS analysis in presence of NADPH,"Title: Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes._|__|_Abstract: To resolve the metabolite redox cycling associated with our earlier clinical compound 2, we carried out lead optimization of lead molecule 1. Compound 4 showed improved lipophilic ligand efficiency and demonstrated robust glucose lowering in diet-induced obese mice without a liability in predictive preclinical drug safety studies. Thus, it was selected as a clinical candidat",43,ChEMBL,946897,20180926,"9982406,9983024,10007234,10051679,10073306,10074262,10074618,10096248,10323620,10366670,10411992,10413475,10482286,11754355,21958981,21959013,59086459,71625733,135474732,135487691,135507290","163334586,164129849,164129850,164129910,164132686,164132687,164132688,164132689,164135490,164135491,164135492,164138385,164138386,164138387,164138388,164143993,164146715,164149599,164149600,164149641,164149642",1576,NULL,P08684,Curation Efforts|Research and Development,24900686,0,10.1021/ml400027y,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
746327,2,Time-dependent inhibition of CYP2C9 in human liver microsomes using tolbutamide as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis,Title: Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors._|__|_Abstract: Drug design efforts in the emerging 2-aminothiazole-4-carboxamide class of CHK1 inhibitors have uncovered specific combinations of key substructures within the molecule; resulting in significant improvements in cell-based activity while retaining a greater than one hundred-fold selectivity against CDK2. The X-ray crystal structure of a complex between compound 39 and the CHK1 pro,43,ChEMBL,959656,20180926,24951610,174501078,1559,NULL,P11712,Curation Efforts|Research and Development,23535330,0,10.1016/j.bmcl.2013.02.108,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
746328,2,Time-dependent inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis,Title: Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors._|__|_Abstract: Drug design efforts in the emerging 2-aminothiazole-4-carboxamide class of CHK1 inhibitors have uncovered specific combinations of key substructures within the molecule; resulting in significant improvements in cell-based activity while retaining a greater than one hundred-fold selectivity against CDK2. The X-ray crystal structure of a complex between compound 39 and the CHK1 pro,43,ChEMBL,959657,20180926,24951610,174501078,1565,NULL,P10635,Curation Efforts|Research and Development,23535330,0,10.1016/j.bmcl.2013.02.108,1.14.14.-,P10635,NULL
746329,2,Time-dependent inhibition of CYP3A4 in human liver microsomes using 6beta-hydroxylase as substrate incubated for 30 mins prior to substrate addition measured after 30 mins by LC-MS/MS analysis,Title: Structure-based design and optimization of 2-aminothiazole-4-carboxamide as a new class of CHK1 inhibitors._|__|_Abstract: Drug design efforts in the emerging 2-aminothiazole-4-carboxamide class of CHK1 inhibitors have uncovered specific combinations of key substructures within the molecule; resulting in significant improvements in cell-based activity while retaining a greater than one hundred-fold selectivity against CDK2. The X-ray crystal structure of a complex between compound 39 and the CHK1 pro,43,ChEMBL,959658,20180926,24951610,174501078,1576,NULL,P08684,Curation Efforts|Research and Development,23535330,0,10.1016/j.bmcl.2013.02.108,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
748443,100,Time-dependent inhibition of CYP3A4/5 in human liver microsomes using midazolam as substrate at 0.14 to 100 uM incubated for 30 mins prior to substrate addition,"Title: Metabolically Stable tert-Butyl Replacement._|__|_Abstract: Susceptibility to metabolism is a common issue with the tert-butyl group on compounds of medicinal interest. We demonstrate an approach of removing all the fully sp(3) C-Hs from a tert-butyl group: replacing some C-Hs with C-Fs and increasing the s-character of the remaining C-Hs. This approach gave a trifluoromethylcyclopropyl group, which increased metabolic stability. Trifluoromethylcyclopropyl-containing analogues had consistently higher",43,ChEMBL,961331,20180926,"71817009,71817013,71817014,71817052,71817054,71817055,71817090,71817091","174486103,174496151,174501381,174506614,174511746,174516812,174516813,174521998","1576,1577",NULL,"P08684,P20815",Curation Efforts|Research and Development,24900702,0,10.1021/ml400045j,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73","P08684,P20815",NULL
748994,100,Time-dependent inhibition of recombinant NDM-1 C108D mutant (unknown origin) expressed in Escherichia coli BL21 (DE3) at 100 uM,"Title: An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening._|__|_Abstract: Due to the global threat of antibiotic resistance mediated by New Delhi metallo-beta-lactamase-1 (NDM-1) and the lack of structurally diverse inhibitors reported for this enzyme, we developed screening and counter-screening assays for manual and automated formats. The manual assay is a trans-well absorbance-based endpoint assay",43,ChEMBL,961409,20200629,NULL,103695334,NULL,NULL,NULL,Curation Efforts|Research and Development,23591260,0,10.1016/j.bmc.2013.03.031,NULL,NULL,NULL
748995,100,Time-dependent inhibition of wild type NDM-1 (unknown origin) expressed in Escherichia coli BL21 (DE3) at 100 uM,"Title: An altered zinc-binding site confers resistance to a covalent inactivator of New Delhi metallo-beta-lactamase-1 (NDM-1) discovered by high-throughput screening._|__|_Abstract: Due to the global threat of antibiotic resistance mediated by New Delhi metallo-beta-lactamase-1 (NDM-1) and the lack of structurally diverse inhibitors reported for this enzyme, we developed screening and counter-screening assays for manual and automated formats. The manual assay is a trans-well absorbance-based endpoint assay",43,ChEMBL,961410,20200629,NULL,103695334,NULL,NULL,NULL,Curation Efforts|Research and Development,23591260,0,10.1016/j.bmc.2013.03.031,NULL,NULL,NULL
750034,100,Time dependent inhibition of human liver cathepsin B using Z-RR-para-nitroanilide as substrate,"Title: Development of cell-active non-peptidyl inhibitors of cysteine cathepsins._|__|_Abstract: Cysteine cathepsins are an important class of enzymes that coordinate a variety of important cellular processes, and are implicated in various types of human diseases. However, small molecule inhibitors that are cell-permeable and non-peptidyl in nature are scarcely available. Herein the synthesis and development of sulfonyloxiranes as covalent inhibitors of cysteine cathepsins are reported. From a library of co",43,ChEMBL,961534,20180926,71659902,174486289,1508,NULL,P07858,Curation Efforts|Research and Development,23623677,0,10.1016/j.bmc.2013.03.062,3.4.22.1,P07858,NULL
750035,100,Time dependent inhibition of human liver cathepsin B using Z-RR-para-nitroanilide as substrate at 500 uM,"Title: Development of cell-active non-peptidyl inhibitors of cysteine cathepsins._|__|_Abstract: Cysteine cathepsins are an important class of enzymes that coordinate a variety of important cellular processes, and are implicated in various types of human diseases. However, small molecule inhibitors that are cell-permeable and non-peptidyl in nature are scarcely available. Herein the synthesis and development of sulfonyloxiranes as covalent inhibitors of cysteine cathepsins are reported. From a library of co",43,ChEMBL,961535,20180926,"11356071,14532897,15921047,71659901,71659902,71659903,71659904,71659905,71659906,71659907,71659908,73345888,73347392","174486287,174486288,174486289,174491286,174491287,174491288,174496341,174506796,174511924,174511925,174516987,174516988,174516989",1508,NULL,P07858,Curation Efforts|Research and Development,23623677,0,10.1016/j.bmc.2013.03.062,3.4.22.1,P07858,NULL
750396,100,Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate by LC/MS/MS analysis,Title: Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2._|__|_Abstract: Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein i,43,ChEMBL,962439,20200629,"9926791,58394783,58394837,58395078,58395283,67345882,71230234","103506979,174491173,174491174,174496220,174501443,174501445,174516870",1544,NULL,P05177,Curation Efforts|Research and Development,23659214,0,10.1021/jm4004895,"1.14.14.1,4.2.1.152",P05177,NULL
750397,100,Time dependent inhibition of CYP2C19 in human liver microsomes using mephenytoin as substrate by LC/MS/MS analysis,Title: Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2._|__|_Abstract: Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein i,43,ChEMBL,962440,20180926,"9926791,58394783,58394837,58395078,58395283,67345882,71230234","103506979,174491173,174491174,174496220,174501443,174501445,174516870",1557,NULL,P33261,Curation Efforts|Research and Development,23659214,0,10.1021/jm4004895,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
750398,100,Time dependent inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate by LC/MS/MS analysis,Title: Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2._|__|_Abstract: Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein i,43,ChEMBL,962441,20180926,"9926791,58394783,58394837,58395078,58395283,67345882,71230234","103506979,174491173,174491174,174496220,174501443,174501445,174516870",1565,NULL,P10635,Curation Efforts|Research and Development,23659214,0,10.1021/jm4004895,1.14.14.-,P10635,NULL
750399,100,Time dependent inhibition of CYP2C9 in human liver microsomes using warfarin as substrate by LC/MS/MS analysis,Title: Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2._|__|_Abstract: Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein i,43,ChEMBL,962442,20180926,"9926791,58394783,58394837,58395078,58395283,67345882,71230234","103506979,174491173,174491174,174496220,174501443,174501445,174516870",1559,NULL,P11712,Curation Efforts|Research and Development,23659214,0,10.1021/jm4004895,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
750400,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate by LC/MS/MS analysis,Title: Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2._|__|_Abstract: Herein we report on the structure-based discovery of a C-2 hydroxyethyl moiety which provided consistently high levels of selectivity for JAK1 over JAK2 to the imidazopyrrolopyridine series of JAK1 inhibitors. X-ray structures of a C-2 hydroxyethyl analogue in complex with both JAK1 and JAK2 revealed differential ligand/protein i,43,ChEMBL,962443,20180926,"9926791,58394783,58394837,58395078,58395283,67345882,71230234","103506979,174491173,174491174,174496220,174501443,174501445,174516870",1576,NULL,P08684,Curation Efforts|Research and Development,23659214,0,10.1021/jm4004895,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
759936,100,Time dependent inhibition of CYP3A4 (unknown origin),Title: Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744)._|__|_Abstract: We report herein the discovery of the human immunodeficiency virus type-1 (HIV-1) integrase inhibitors dolutegravir (S/GSK1349572) (3) and S/GSK1265744 (4). These drugs stem from a series of carbamoyl pyridone analogues designed using a two-metal chelation model of the integrase catalytic active site.,43,ChEMBL,969817,20180927,"46216142,54713659","104239334,174502414",1576,NULL,P08684,Curation Efforts|Research and Development,23845180,0,10.1021/jm400645w,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
760139,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate at 10 uM after 10 mins,"Title: Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis._|__|_Abstract: A set of fourteen imidazo[1,2-a]pyridine-3-carboxamides was synthesized and screened against Mycobacterium tuberculosis H37Rv. The minimum inhibitory concentrations of twelve of these agents were &#x2264; 1 &#x3BC;M against replicating bacteria and five compounds (9, 12, 16, 17 and 18) had MIC values &#x2264; 0.006 &#x3BC;M. Compounds 13 and 18 were screened ",43,ChEMBL,972192,20200629,"52935296,52935300","174517928,174523157",1559,NULL,P11712,Curation Efforts|Research and Development,23930153,0,10.1021/ml400088y,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
761887,100,Time dependent inhibition of human CYP3A4 at 50 uM,"Title: Hydantoin based inhibitors of MMP13--discovery of AZD6605._|__|_Abstract: Piperidine ether and aryl piperazine hydantoins are reported as potent inhibitors of MMP13. A medicinal chemistry campaign focused on replacing the reverse hydroxamate zinc binding group associated with historical inhibitors with a hydantoin zinc binding group then optimising MMP13 potency, solubility and DMPK properties whilst maintaining good selectivity over MMP14. A number of high quality candidates were progressed and foll",43,ChEMBL,973401,20180927,73349098,174497576,1576,NULL,P08684,Curation Efforts|Research and Development,23810497,0,10.1016/j.bmcl.2013.05.089,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
764738,100,Time dependent inhibition of CYP450 (unknown origin),"Title: 2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors._|__|_Abstract: The advancement of a series of ligand efficient 2-amino-[1,2,4]triazolo[1,5-a]pyridines, initially identified from high-throughput screening, to a JAK2 inhibitor with pharmacodynamic activity in a mouse xenograft model is disclosed.",43,ChEMBL,976178,20180927,44555004,174503048,NULL,NULL,NULL,Curation Efforts|Research and Development,23870430,0,10.1016/j.bmcl.2013.06.008,NULL,NULL,NULL
773624,100,Time-dependent inhibition of human CYP2D6,"Title: Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains._|__|_Abstract: The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, ",43,ChEMBL,985040,20180928,46943432,104248639,1565,NULL,P10635,Curation Efforts|Research and Development,24015967,0,10.1021/jm401088k,1.14.14.-,P10635,NULL
773625,100,Time-dependent inhibition of human CYP3A4,"Title: Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains._|__|_Abstract: The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, ",43,ChEMBL,985041,20180928,46943432,104248639,1576,NULL,P08684,Curation Efforts|Research and Development,24015967,0,10.1021/jm401088k,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
774235,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain._|__|_Abstract: XIAP is a key regulator of apoptosis, and its overexpression in cancer cells may contribute to their survival. The antiapoptotic function of XIAP derives from its BIR domains, which bind to and inhibit pro-apoptotic caspases. Most known IAP inhibitors are selective for the BIR3 domain and bind to cIAP1 and cIAP2 as well as XIAP. Pat",43,ChEMBL,985186,20180928,73053618,174519360,1576,NULL,P08684,Curation Efforts|Research and Development,24083782,0,10.1021/jm400731m,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
776354,100,Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation at 10 to 50 uM by LC-MS/MS analysis,Title: Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain._|__|_Abstract: The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of the BIR domains to the pro-apoptotic caspases. The BIR3 domain of XIAP binds and in,43,ChEMBL,988984,20200630,72712126,174519564,1576,NULL,P08684,Curation Efforts|Research and Development,24093940,0,10.1021/jm400732v,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
776358,2,Time-dependent inhibition of CYP3A4 in human liver microsomes assessed as midazolam hydroxylation by LC-MS/MS analysis,Title: Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain._|__|_Abstract: The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of the BIR domains to the pro-apoptotic caspases. The BIR3 domain of XIAP binds and in,43,ChEMBL,988988,20200630,"72712130,72712132,72712343,72712345,72712569,72712571,72713171,72714053,72714057,73352496","174488810,174493851,174499010,174504258,174504259,174509375,174509376,174519565,174519566,174524850",1576,NULL,P08684,Curation Efforts|Research and Development,24093940,0,10.1021/jm400732v,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1058534,100,"Reduction in ionized calcium level in blood of nephrectomized Sprague-Dawley rat model of kidney failure at 6 mg/kg, po measured at 8 hrs post administration relative to vehicle-treated control","Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277634,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058535,100,"Reduction in PTH level in nephrectomized Sprague-Dawley rat model of kidney failure at 6 mg/kg, po measured at 8 hrs post administration relative to vehicle-treated control","Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277635,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058536,100,Effect on carbonic anhydrase 2 (unknown origin),"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277636,20180928,72725441,194186698,760,NULL,P00918,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,4.2.1.1,P00918,NULL
1058537,100,Effect on guanylate cyclase (unknown origin),"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277637,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058538,100,Effect on adenosine transporter (unknown origin),"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277638,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058539,100,Solubility of the compound in phosphate buffered saline,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277639,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058540,100,Solubility of the compound in simulated intestinal fluid,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277640,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058541,100,Solubility of the compound in 0.01 N HCl,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277641,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058542,100,Oral bioavailability in beagle dog,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277642,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058543,100,Half life in beagle dog,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277643,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058545,100,Clearance in beagle dog,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277645,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058546,100,Volume of distribution at steady state in beagle dog,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277646,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058547,100,Oral bioavailability in monkey,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277647,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058548,100,Half life in monkey,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277648,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058549,100,Volume of distribution at steady state in monkey,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277649,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058551,100,Clearance in monkey,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277651,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058552,100,"Half life in Sprague-Dawley rat at 0.5 mg/kg, iv and 2 mg/kg, po","Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277652,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058554,100,"Volume of distribution at steady state in Sprague-Dawley rat at 0.5 mg/kg, iv and 2 mg/kg, po","Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277654,20180928,72725441,194186698,NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058555,100,Oral bioavailability in Sprague-Dawley rat at 2 mg/kg,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277655,20180928,"72725274,72725275,72725276,72725336,72725337,72725391,72725392,72725393,72725441","194138498,194145425,194152266,194152268,194159219,194159220,194166215,194173046,194186698",NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058556,100,"Clearance in Sprague-Dawley rat at 0.5 mg/kg, iv and 2 mg/kg, po","Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277656,20180928,"11955290,72725274,72725275,72725276,72725336,72725337,72725391,72725392,72725393,72725441","194138498,194145425,194152263,194152266,194152268,194159219,194159220,194166215,194173046,194186698",NULL,NULL,NULL,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,NULL,NULL
1058558,2,Activation of human CaSR,"Title: Metabolism-guided discovery of a potent and orally bioavailable urea-based calcimimetic for the treatment of secondary hyperparathyroidism._|__|_Abstract: A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized by the use of metabolite identification (ID) and measurement of time dependent inhibition (TDI) of CYP3A4, were essenti",43,ChEMBL,1277658,20180928,"11955209,11955290,58938049,58938102,72725152,72725153,72725211,72725212,72725272,72725273,72725274,72725275,72725276,72725335,72725336,72725337,72725338,72725391,72725392,72725393,72725441","194138497,194138498,194145423,194145424,194145425,194152263,194152264,194152265,194152266,194152267,194152268,194159218,194159219,194159220,194166213,194166214,194166215,194173045,194173046,194179931,194186698",846,NULL,P41180,Curation Efforts|Research and Development,24215889,0,10.1016/j.bmcl.2013.10.050,NULL,P41180,NULL
1059534,2,Time dependent inhibition of CYP450 (unknown origin),Title: Identification of clinical candidates from the benzazepine class of histamine H3 receptor antagonists._|__|_Abstract: This Letter describes the discovery of GSK189254 and GSK239512 that were progressed as clinical candidates to explore the potential of H3 receptor antagonists as novel therapies for the treatment of Alzheimer's disease and other dementias. By carefully controlling the physicochemical properties of the benzazepine series and through the implementation of an aggressive and innovative sc,43,ChEMBL,1277724,20180928,"9798547,9976892,10473209","103590505,131279142,194145322",NULL,NULL,NULL,Curation Efforts|Research and Development,24269482,0,10.1016/j.bmcl.2013.09.090,NULL,NULL,NULL
1070631,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease._|__|_Abstract: HCV serine protease NS3 represents an attractive drug target because it is not only essential for viral replication but also implicated in the viral evasion of the host immune response pathway through direct cleavage of key proteins in the human innate immune system. Through structure-based drug design and optimization, macrocyclic peptidomimetic molecules beari",43,ChEMBL,1292622,20180929,11285588,103568158,1576,NULL,P08684,Curation Efforts|Research and Development,23672640,0,10.1021/jm400164c,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1072708,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Novel spiroketal pyrrolidine GSK2336805 potently inhibits key hepatitis C virus genotype 1b mutants: from lead to clinical compound._|__|_Abstract: Rapid clinical progress of hepatitis C virus (HCV) replication inhibitors, including these selecting for resistance in the NS5A region (NS5A inhibitors), promises to revolutionize HCV treatment. Herein, we describe our explorations of diverse spiropyrrolidine motifs in novel NS5A inhibitors and a proposed interaction model. We discovered that the 1,4-diox",43,ChEMBL,1293192,20180929,57339460,194153965,1576,NULL,P08684,Curation Efforts|Research and Development,24568313,0,10.1021/jm4013104,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1074214,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate assessed as AUC shift by LC-MS/MS analysis relative to control,"Title: Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)._|__|_Abstract: Potent, trans-2-(pyridin-3-yl)cyclopropanecarboxamide-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques. Multiple crystal structures were obtained of initial fragment leads, and this st",43,ChEMBL,1296354,20200620,"71720911,73890932,76071764,76072411,76311092,76311096,76314702,76321979,76325597,76329164,76332826,76336447","194140614,194140618,194147455,194154329,194161312,194161313,194168219,194168221,194175046,194175048,194181906,194188748",1576,NULL,P08684,Curation Efforts|Research and Development,24405419,0,10.1021/jm4015108,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1074216,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as AUC shift by LC-MS/MS analysis relative to control,"Title: Fragment-based identification of amides derived from trans-2-(pyridin-3-yl)cyclopropanecarboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)._|__|_Abstract: Potent, trans-2-(pyridin-3-yl)cyclopropanecarboxamide-containing inhibitors of the human nicotinamide phosphoribosyltransferase (NAMPT) enzyme were identified using fragment-based screening and structure-based design techniques. Multiple crystal structures were obtained of initial fragment leads, and this st",43,ChEMBL,1296356,20200620,"71720911,73890932,76071764,76072411,76311092,76311096,76314702,76321979,76325597,76329164,76332826,76336447","194140614,194140618,194147455,194154329,194161312,194161313,194168219,194168221,194175046,194175048,194181906,194188748",1576,NULL,P08684,Curation Efforts|Research and Development,24405419,0,10.1021/jm4015108,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1075189,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development._|__|_Abstract: We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Continued research investigation of the N-alkyl substituent of this series, focused in particular on a previously underutilized interaction in a shallow cleft on the MDM2 surface, led to the discovery of a one-carbon tethered sulfone which gave rise to ",43,ChEMBL,1296782,20180929,"58573469,58573858,68000593","194154105,194161063,194188518",1576,NULL,P08684,Curation Efforts|Research and Development,24456472,0,10.1021/jm401753e,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1076180,100,Time-dependent inhibition of recombinant his6-tagged DPP4 (unknown origin) expressed in baculovirus expression system at 0.01 uM,"Title: Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors._|__|_Abstract: A series of novel hetero-aromatic moieties substituted &#x3B1;-amino pyrrole-2-carbonitrile derivatives was designed and synthesized based on structure-activity relationships (SARs) of pyrrole-2-carbonitrile inhibitors. All compounds demonstrated good dipeptidyl peptidase IV (DPP4) inhibitory activities (IC50 = 0.004-113.6 &#x3BC;",43,ChEMBL,1294182,20200620,76325645,194168276,1803,NULL,P27487,Curation Efforts|Research and Development,24531224,0,10.1016/j.ejmech.2014.01.021,3.4.14.5,P27487,NULL
1076181,100,Time-dependent inhibition of recombinant his6-tagged DPP4 (unknown origin) expressed in baculovirus expression system at 0.004 uM,"Title: Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors._|__|_Abstract: A series of novel hetero-aromatic moieties substituted &#x3B1;-amino pyrrole-2-carbonitrile derivatives was designed and synthesized based on structure-activity relationships (SARs) of pyrrole-2-carbonitrile inhibitors. All compounds demonstrated good dipeptidyl peptidase IV (DPP4) inhibitory activities (IC50 = 0.004-113.6 &#x3BC;",43,ChEMBL,1294183,20200620,76318342,194154403,1803,NULL,P27487,Curation Efforts|Research and Development,24531224,0,10.1016/j.ejmech.2014.01.021,3.4.14.5,P27487,NULL
1119187,2,Time-dependent inhibition of recombinant LSD1 catalytic domain (178 to 831 amino acids) (unknown origin) expressed in baculovirus infected insect Sf9 cells,"Title: Polyamine-based small molecule epigenetic modulators._|__|_Abstract: Chromatin remodelling enzymes such as the histone deacetylases (HDACs) and histone demethylases such as lysine-specific demethylase 1 (LSD1) have been validated as targets for cancer drug discovery. Although a number of HDAC inhibitors have been marketed or are in human clinical trials, the search for isoform-specific HDAC inhibitors is an ongoing effort. In addition, the discovery and development of compounds targeting histone deme",43,ChEMBL,1331154,20181002,16155491,103756866,23028,NULL,O60341,Curation Efforts|Research and Development,23293738,0,10.1039/c1md00220a,1.14.99.66,O60341,NULL
1124781,100,Time-dependent inhibition of CYP3A4 (unknown origin) assessed as IC50 shift ratio,Title: Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant._|__|_Abstract: Analogs of the dual orexin receptor antagonist filorexant were prepared. Replacement of the ether linkage proved highly sensitive toward modification with an acetylene linkage providing compounds with the best in vitro and in vivo potency profiles.,43,ChEMBL,1337255,20200619,71522361,242622029,1576,NULL,P08684,Curation Efforts|Research and Development,24630562,0,10.1016/j.bmcl.2014.02.026,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1124782,100,Time-dependent inhibition of CYP3A4 (unknown origin),Title: Synthesis and evaluation of carbon-linked analogs of dual orexin receptor antagonist filorexant._|__|_Abstract: Analogs of the dual orexin receptor antagonist filorexant were prepared. Replacement of the ether linkage proved highly sensitive toward modification with an acetylene linkage providing compounds with the best in vitro and in vivo potency profiles.,43,ChEMBL,1337256,20181002,71522361,242622029,1576,NULL,P08684,Curation Efforts|Research and Development,24630562,0,10.1016/j.bmcl.2014.02.026,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1128416,100,Time dependent inhibition of CYP3A4 (unknown origin) assessed as remaining activity at 10 uM after 30 mins relative to rifampin,"Title: Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction._|__|_Abstract: We previously reported the discovery of AMG 232, a highly potent and selective piperidinone inhibitor of the MDM2-p53 interaction. Our continued search for potent and diverse analogues led to the discovery of novel morpholinone MDM2 inhibitors. This change to a morpholinone core has a significant impact on both potency and metabolic stability compared to the piperidinone series. Within this morpho",43,ChEMBL,1339584,20181003,"73386674,89478498,89478524,90342080,90347747","242619878,242619882,242619883,242619884,242619885",1576,NULL,P08684,Curation Efforts|Research and Development,24548297,0,10.1021/jm401767k,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1129069,100,Time dependent inhibition of CYP2C8 in human liver microsomes,"Title: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus._|__|_Abstract: Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylpheno",43,ChEMBL,1339220,20181003,77107273,242621939,1558,NULL,P10632,Curation Efforts|Research and Development,24588963,0,10.1016/j.bmc.2014.02.009,1.14.14.1,P10632,NULL
1129070,100,Time dependent inhibition of CYP2C19 in human liver microsomes,"Title: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus._|__|_Abstract: Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylpheno",43,ChEMBL,1339221,20181003,77107273,242621939,1557,NULL,P33261,Curation Efforts|Research and Development,24588963,0,10.1016/j.bmc.2014.02.009,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1129071,100,Time dependent inhibition of CYP2D6 in human liver microsomes,"Title: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus._|__|_Abstract: Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylpheno",43,ChEMBL,1339222,20181003,77107273,242621939,1565,NULL,P10635,Curation Efforts|Research and Development,24588963,0,10.1016/j.bmc.2014.02.009,1.14.14.-,P10635,NULL
1129077,100,Time dependent inhibition of CYP3A in human liver microsomes,"Title: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus._|__|_Abstract: Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylpheno",43,ChEMBL,1339228,20181003,77107273,242621939,NULL,NULL,NULL,Curation Efforts|Research and Development,24588963,0,10.1016/j.bmc.2014.02.009,NULL,NULL,NULL
1129079,100,Time dependent inhibition of CYP2B6 in human liver microsomes,"Title: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus._|__|_Abstract: Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylpheno",43,ChEMBL,1339230,20181003,77107273,242621939,1555,NULL,P20813,Curation Efforts|Research and Development,24588963,0,10.1016/j.bmc.2014.02.009,1.14.13.-,P20813,NULL
1129080,100,Time dependent inhibition of CYP1A2 in human liver microsomes,"Title: Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus._|__|_Abstract: Novel heteroaryl-containing benzamide derivatives were synthesized and screened using an in vitro assay measuring increases in glucose uptake and glucokinase activity stimulated by 10mM glucose in rat hepatocytes. From a library of synthesized compounds, 3-(4-methanesulfonylpheno",43,ChEMBL,1339231,20200619,77107273,242621939,1544,NULL,P05177,Curation Efforts|Research and Development,24588963,0,10.1016/j.bmc.2014.02.009,"1.14.14.1,4.2.1.152",P05177,NULL
1129367,100,Time dependent inhibition of CYP3A4 (unknown origin) at 10 uM after 30 mins relative to rifampin,Title: Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres._|__|_Abstract: We previously reported the discovery of potent and selective morpholinone and piperidinone inhibitors of the MDM2-p53 interaction. These inhibitors have in common a carboxylic acid moiety that engages in an electrostatic interaction with MDM2-His96. Our continued search for potent and diverse inhibitors led to the discovery of novel replacements for these acids uncovering new in,43,ChEMBL,1336779,20181003,"73386675,73386677,90655372,90655373,90655386,90655387,90655388,90655389,90655390,90655391,90655392,90655393,90655394,90655396,90655397,90655398,90655399,90655400,90655402,90655403,90655404,90655405,90655406,90655407,90655408","242623143,242623144,242623429,242623430,242623431,242623432,242623433,242623434,242623435,242623436,242623437,242623438,242623439,242623441,242623442,242623443,242623445,242623446,242623448,242623449,242623450,242623451,242623452,242623453,242623454",1576,NULL,P08684,Curation Efforts|Research and Development,24601644,0,10.1021/jm401911v,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1139999,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor &#xCE;&#xB2; agonist in clinical trials for the treatment of dyslipidemia._|__|_Abstract: The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor &#x3B2; (THR-&#x3B2;) in the liver, while adverse effects, including cardiac effects, ",43,ChEMBL,1351973,20200619,15981237,242634543,1576,NULL,P08684,Curation Efforts|Research and Development,24712661,0,10.1021/jm4019299,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1140000,100,Time-dependent inhibition of CYP3A5 (unknown origin),"Title: Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor &#xCE;&#xB2; agonist in clinical trials for the treatment of dyslipidemia._|__|_Abstract: The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor &#x3B2; (THR-&#x3B2;) in the liver, while adverse effects, including cardiac effects, ",43,ChEMBL,1351974,20200619,15981237,242634543,1577,NULL,P20815,Curation Efforts|Research and Development,24712661,0,10.1021/jm4019299,1.14.14.1,P20815,NULL
1140001,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor &#xCE;&#xB2; agonist in clinical trials for the treatment of dyslipidemia._|__|_Abstract: The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor &#x3B2; (THR-&#x3B2;) in the liver, while adverse effects, including cardiac effects, ",43,ChEMBL,1351975,20200619,15981237,242634543,1557,NULL,P33261,Curation Efforts|Research and Development,24712661,0,10.1021/jm4019299,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1140002,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor &#xCE;&#xB2; agonist in clinical trials for the treatment of dyslipidemia._|__|_Abstract: The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor &#x3B2; (THR-&#x3B2;) in the liver, while adverse effects, including cardiac effects, ",43,ChEMBL,1351976,20200619,15981237,242634543,1559,NULL,P11712,Curation Efforts|Research and Development,24712661,0,10.1021/jm4019299,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1152003,100,Time dependent inhibition of CYP (unknown origin) at 50 uM,"Title: Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD._|__|_Abstract: Oral phosphodiesterase 4 (PDE4) inhibitors, such as cilomilast and roflumilast, have been shown to be efficacious against chronic obstructive pulmonary disease (COPD). However, these drugs have been hampered by mechanism-related side effects such as nausea and emesis at high doses. Compounds administered by inhalation are delivered directly to the site of action and may ",43,ChEMBL,1362407,20181004,44520546,242646524,NULL,NULL,NULL,Curation Efforts|Research and Development,24785301,0,10.1021/jm5001216,NULL,NULL,NULL
1153728,100,Intrinsic clearance in human liver microsomes,"Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361475,20181004,"74049853,74049854,90644304,90644305,90644306,90644307,90644308,90644309,90644310,90644311,90644312,90644313,90644314,90644315,90644316,90644317,90644318","242647200,242647201,242647202,242647203,242647204,242647205,242647206,242647207,242647208,242647209,242647210,242647211,242647212,242647213,242647214,242647215,242647216",NULL,NULL,NULL,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,NULL,NULL,NULL
1153730,100,"Lipophilicity, log D of the compound at pH 7.4","Title: Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability._|__|_Abstract: In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reduci",43,ChEMBL,1361477,20200618,"74049853,74049854,90644304,90644305,90644306,90644307,90644308,90644309,90644310,90644311,90644312,90644313,90644314,90644315,90644316,90644317,90644318","242647200,242647201,242647202,242647203,242647204,242647205,242647206,242647207,242647208,242647209,242647210,242647211,242647212,242647213,242647214,242647215,242647216",NULL,NULL,NULL,Curation Efforts|Research and Development,24837154,0,10.1016/j.bmc.2014.04.023,NULL,NULL,NULL
1157904,100,Time dependent inhibition of CYP1A2 in human liver microsomes assessed as shift at 10 uM,"Title: Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists._|__|_Abstract: A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization.",43,ChEMBL,1369169,20200618,"90645309,90645310,90645312","242650364,242651023,242651356",1544,NULL,P05177,Curation Efforts|Research and Development,24835202,0,10.1016/j.bmcl.2014.04.045,"1.14.14.1,4.2.1.152",P05177,NULL
1157905,100,Time dependent inhibition of CYP2C9 in human liver microsomes assessed as shift at 10 uM,"Title: Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists._|__|_Abstract: A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization.",43,ChEMBL,1369170,20181004,"90645309,90645310,90645312","242650364,242651023,242651356",1559,NULL,P11712,Curation Efforts|Research and Development,24835202,0,10.1016/j.bmcl.2014.04.045,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1157906,100,Time dependent inhibition of CYP2D6 in human liver microsomes assessed as shift at 10 uM,"Title: Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists._|__|_Abstract: A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization.",43,ChEMBL,1369171,20181004,"90645309,90645310,90645312","242650364,242651023,242651356",1565,NULL,P10635,Curation Efforts|Research and Development,24835202,0,10.1016/j.bmcl.2014.04.045,1.14.14.-,P10635,NULL
1157907,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as shift at 10 uM,"Title: Discovery of a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine and a 1-aryloxyisoquinoline series of TRPA1 antagonists._|__|_Abstract: A series of TRPA1 antagonists is described having a 4-aryloxy-1H-pyrrolo[3,2-c]pyridine or a 1-aryloxyisoquinoline scaffold. These compounds have high ligand efficiency and favorable physical properties and may thus serve as scaffolds for further optimization.",43,ChEMBL,1369172,20181004,"90645309,90645310,90645312","242650364,242651023,242651356",1576,NULL,P08684,Curation Efforts|Research and Development,24835202,0,10.1016/j.bmcl.2014.04.045,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1164168,100,Time dependent inhibition of HIV1 protease by standard fluorimetric assay,"Title: Impact of Stereochemistry on Ligand Binding: X-ray Crystallographic Analysis of an Epoxide-Based HIV Protease Inhibitor._|__|_Abstract: A new pseudopeptide epoxide inhibitor, designed for irreversible binding to HIV protease (HIV-PR), has been synthesized and characterized in solution and in the solid state. However, the crystal structure of the complex obtained by inhibitor-enzyme cocrystallization revealed that a minor isomer, with inverted configuration of the epoxide carbons, has been selected by",43,ChEMBL,1435364,20181005,118713643,312357663,NULL,NULL,Q9YQ12,Curation Efforts|Research and Development,25221650,0,10.1021/ml500092e,NULL,Q9YQ12,NULL
1165816,100,Drug degradation in buffer assessed as compound remaining at pH 2 after 24 hrs,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433176,20181005,"25225718,25225905,46190694","312360585,312360586,312360588",NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165817,2,Solubility of the compound in buffer at pH 7,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433177,20181005,"25225718,25225905","312360585,312360586",NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165818,2,Solubility of the compound in buffer at pH 2,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433178,20181005,"25225718,25225905","312360585,312360586",NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165819,2,Displacement of (S)-N-(2-(1H-pyrrol-1-yl)phenyl)-1-(2-([3H]-1-methyl-1H-benzo[d]imidazol-2-ylthio)acetyl)pyrrolidine-2-carboxamide from human OX2R expressed in CHO cells after 3 hrs by topcount analysis,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433179,20181005,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,58394291,71555054,118715605,118715606,118715607,118715608,118715609,118715610,118715611,118715612,118715613","312360586,312360587,312360588,312360589,312360590,312360591,312360592,312360593,312360594,312360595,312360596,312360597,312360598,312360599,312360600,312360601,312360602,312360603,312360604,312360605",3062,NULL,O43614,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,O43614,NULL
1165820,2,"Displacement of N-cyclobutyl-5-methyl-N-(2-([3H]-1-methyl-1H-benzo[d]imidazol-2-ylthio)ethyl)-2-(2H-1,2,3-triazol-2-yl)benzamide from human OX1R I408V mutant expressed in CHO cells by topcount analysis","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433180,20181005,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,58394291,71555054,118715605,118715606,118715607,118715608,118715609,118715610,118715611,118715612,118715613","312360586,312360587,312360588,312360589,312360590,312360591,312360592,312360593,312360594,312360595,312360596,312360597,312360598,312360599,312360600,312360601,312360602,312360603,312360604,312360605",3061,NULL,O43613,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,O43613,NULL
1165823,100,Selectivity ratio of Ki for human OX1R I408V mutant expressed in CHO cells to Ki for human OX2R expressed in CHO cells,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433183,20200625,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,58394291,71555054,118715605,118715606,118715607,118715608,118715609,118715610,118715611,118715612,118715613","312360586,312360587,312360588,312360589,312360590,312360591,312360592,312360593,312360594,312360595,312360596,312360597,312360598,312360599,312360600,312360601,312360602,312360603,312360604,312360605",NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165824,100,Selectivity ratio of IC50 for human OX1R Ile408Val mutant expressed in CHO cells to IC50 for human OX2R expressed in CHO cells,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433184,20200625,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,58394291,71555054,118715606,118715607,118715608,118715609,118715610,118715611,118715612,118715613","312360586,312360588,312360589,312360590,312360591,312360592,312360593,312360594,312360595,312360596,312360597,312360598,312360599,312360600,312360601,312360602,312360603,312360604,312360605",NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165825,100,Clearance in dog with cassette dosing,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433185,20181005,"25225718,45375925,46190694,46190695,46191662,46191726,46191727,46195690,49793266,118715605,118715606,118715611,118715612","312360586,312360587,312360588,312360589,312360590,312360592,312360595,312360596,312360598,312360600,312360601,312360603,312360605",NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165827,100,Ratio of Kinact to Ki for CYP3A4 (unknown origin),"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433187,20181005,"44633765,46190694,46190695","312360588,312360605,312360606",1576,NULL,P08684,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1165828,100,Plasma protein binding in human,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433188,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165829,100,"Lipophilicity, log D of the compound","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433189,20200625,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165830,100,Apparent permeability of the compound,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433190,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165831,100,Efflux ratio of permeability in mouse Pgp-based assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433191,20200625,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165832,100,Efflux ratio of permeability in rat Pgp-based assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433192,20200625,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165833,100,Efflux ratio of permeability in human Pgp-based assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433193,20200625,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165837,2,Activation of PXR (unknown origin),"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433197,20181005,46190695,312360605,8856,NULL,O75469,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,O75469,NULL
1165838,100,Activation of PXR (unknown origin) at 30 uM relative to rifampicin,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433198,20181005,46190695,312360605,8856,NULL,O75469,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,O75469,NULL
1165839,100,"Clearance in rat at 2 mg/kg, iv","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433199,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165840,100,"Volume of distribution at steady state in rat at 2 mg/kg, iv","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433200,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165841,100,"Half life in rat at 2 mg/kg, iv","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433201,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165842,100,"Clearance in dog at 1 mg/kg, iv","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433202,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165843,100,"Volume of distribution at steady state in dog at 1 mg/kg, iv","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433203,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165844,100,"Half life in dog at 1 mg/kg, iv","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433204,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165845,100,"AUC (0 to infinity) in rat at 5 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433205,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165846,2,"Cmax in rat at 5 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433206,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165847,100,"Tmax in rat at 5 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433207,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165848,100,Oral bioavailability in rat at 5 mg/kg,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433208,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165849,100,"AUC (0 to infinity) in dog at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433209,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165850,2,"Cmax in rat at dog at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433210,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165851,100,"Tmax in rat at dog at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433211,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165852,100,Oral bioavailability in rat at dog at 3 mg/kg,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433212,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165853,100,"Reduction in active wake sleep in mouse at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433213,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165854,100,"Increase in slow wave sleep in mouse at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433214,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165855,100,"Increase in rapid eye movement sleep in mouse at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433215,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165856,100,"Reduction in active wake sleep in Sprague-Dawley rat at 15 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433216,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165857,100,"Increase in slow wave sleep in Sprague-Dawley rat at 15 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433217,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165858,100,"Increase in rapid eye movement sleep in Sprague-Dawley rat at 15 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433218,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165859,100,"Reduction in active wake sleep in OX2R-knockout mouse at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433987,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165860,100,"Increase in slow wave sleep in OX2R-knockout mouse at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433988,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165861,100,"Increase in rapid eye movement sleep in OX2R-knockout mouse at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433989,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165862,100,"Reduction in active wake sleep in dog at 3 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433990,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165863,100,"Increase in slow wave sleep in dog at 3 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433991,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165864,100,"Increase in rapid eye movement sleep in dog at 3 mg/kg, po after 3.5 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433992,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165865,100,"Tmax in mouse at 100 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433993,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165866,2,"Cmax in mouse at 100 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433994,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165867,2,"Drug uptake in mouse CSF at 100 mg/kg, po after 2 hrs","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433995,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165868,2,Antagonist activity at mouse OX2R by FLIPR assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433996,20181005,46190695,312360605,387285,NULL,P58308,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,P58308,NULL
1165869,2,Antagonist activity at mouse OX1R by FLIPR assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433997,20181005,46190695,312360605,230777,NULL,P58307,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,P58307,NULL
1165870,100,"AUC in Sprague-Dawley rat at 15 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433998,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165871,100,"Tmax in Sprague-Dawley rat at 15 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1433999,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165872,2,"Cmax in Sprague-Dawley rat at 15 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434000,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165873,100,Plasma protein binding in Sprague-Dawley rat,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434001,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165874,2,"Drug uptake in Sprague-Dawley rat CSF at 15 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434002,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165875,2,Antagonist activity at Sprague-Dawley rat OX2R by FLIPR assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434003,20181005,46190695,312360605,25605,NULL,P56719,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,P56719,NULL
1165876,2,Antagonist activity at Sprague-Dawley rat OX1R by FLIPR assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434004,20181005,46190695,312360605,25593,NULL,P56718,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,P56718,NULL
1165877,100,"AUC in dog at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434005,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165878,100,"Tmax in dog at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434006,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165879,2,"Cmax in dog at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434007,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165880,100,Plasma protein binding in dog,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434008,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165881,2,"Drug uptake in dog CSF at 3 mg/kg, po","Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434009,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165882,2,Antagonist activity at dog OX2R by FLIPR assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434010,20181005,46190695,312360605,399545,NULL,Q9TUP7,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,Q9TUP7,NULL
1165883,2,Antagonist activity at dog OX1R by FLIPR assay,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434011,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165884,100,Ex vivo receptor occupancy at human OX2R expressed in transgenic rat at plasma concentration of 1.06 uM,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434012,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1165885,100,Ex vivo receptor occupancy at human OX2R expressed in transgenic rat at CSF concentration of 40 nM,"Title: Discovery of MK-3697: a selective orexin 2 receptor antagonist (2-SORA) for the treatment of insomnia._|__|_Abstract: Orexin receptor antagonists have demonstrated clinical utility for the treatment of insomnia. The majority of clinical efforts to date have focused on the development of dual orexin receptor antagonists (DORAs), small molecules that antagonize both the orexin 1 and orexin 2 receptors. Our group has recently disclosed medicinal chemistry efforts to identify highly potent, orally bioava",43,ChEMBL,1434013,20181005,46190695,312360605,NULL,NULL,NULL,Curation Efforts|Research and Development,25248679,0,10.1016/j.bmcl.2014.08.041,NULL,NULL,NULL
1170765,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic._|__|_Abstract: FFA2, also called GPR43, is a G-protein coupled receptor for short chain fatty acids which is involved in the mediation of inflammatory responses. A class of azetidines was developed as potent FFA2 antagonists. Multiparametric optimization of early hits with moderate potency and suboptimal ADME properties led to the identification of several compounds with n",43,ChEMBL,1440149,20181005,57520598,312367259,1576,NULL,P08684,Curation Efforts|Research and Development,25380412,0,10.1021/jm5012885,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1177185,100,Time dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate assessed as ratio of Kinact to Ki preincubated for 0 to 30 mins followed by NADPH addition in phosphate buffer at 50 uM,"Title: Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors._|__|_Abstract: A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines. Use of PI3K&#x3B1; mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chemistry designs. Detailed DMPK st",43,ChEMBL,1444986,20200625,"118720616,118720617,118720618,118720619,118720620,118720621,118720622","312368808,312368809,312368810,312368811,312368812,312368813,312368814",1576,NULL,P08684,Curation Efforts|Research and Development,25589927,0,10.1021/ml500353p,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1177186,100,Time dependent inhibition of CYP3A4 in rat liver microsomes using midazolam as substrate assessed as ratio of Kinact to Ki preincubated for 0 to 60 mins followed by NADPH addition in KH2PO4 at 20 uM,"Title: Structure-Based Drug Design of Novel Potent and Selective Tetrahydropyrazolo[1,5-a]pyrazines as ATR Inhibitors._|__|_Abstract: A saturation strategy focused on improving the selectivity and physicochemical properties of ATR inhibitor HTS hit 1 led to a novel series of highly potent and selective tetrahydropyrazolo[1,5-a]pyrazines. Use of PI3K&#x3B1; mutants as ATR crystal structure surrogates was instrumental in providing cocrystal structures to guide the medicinal chemistry designs. Detailed DMPK st",43,ChEMBL,1444987,20200625,"118720876,118720877,118720878","312369203,312369204,312369205",NULL,NULL,NULL,Curation Efforts|Research and Development,25589927,0,10.1021/ml500353p,NULL,NULL,NULL
1178765,100,Time-dependent inhibition of CYP2D6 in human liver microsomes at 10 uM by LC-MS/MS analysis,Title: Discovery of a series of aryl-N-(3-(alkylamino)-5-(trifluoromethyl)phenyl)benzamides as TRPA1 antagonists._|__|_Abstract: We describe the discovery and advancement of a novel series of TRPA1 antagonist having an aryl-N-(3-(alkylamino)-5-(trifluoromethyl)phenyl)benzamide scaffold. The physical and in vitro DMPK profiles are discussed.,43,ChEMBL,1454395,20181005,118707069,312347713,1565,NULL,P10635,Curation Efforts|Research and Development,24880903,0,10.1016/j.bmcl.2014.05.013,1.14.14.-,P10635,NULL
1190430,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexant._|__|_Abstract: Highly selective orexin receptor antagonists (SORAs) of the orexin 2 receptor (OX2R) have become attractive targets both as potential therapeutics for insomnia as well as biological tools to help further elucidate the underlying pharmacology of the orexin signaling pathway. Herein, we describe the discovery of a novel piperidine ether 2-SORA class identified by systematic lead optimi",43,ChEMBL,1462321,20181006,46212134,312378226,1576,NULL,P08684,Curation Efforts|Research and Development,25577040,0,10.1016/j.bmcl.2014.12.056,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1193170,2,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate compound preincubated for 30 mins with NADPH before substrate addition by LC-MS/MS analysis,"Title: Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators._|__|_Abstract: Early lead compounds in this gamma secretase modulator series were found to potently inhibit CYP3A4 and other human CYP isoforms increasing their risk of causing drug-drug-interactions (DDIs). Using structure-activity relationships and CYP3A4 structural information, analogs were developed that minimized this DDI potential. Three of these new analogs were fu",43,ChEMBL,1465542,20181006,"60172115,71288593,71288611,71288616,71288634,71288636,71288638,71288697,71288713,71288715,71288739,71288740,71288752,71288754","163322343,312383603,312383604,312383605,312383606,312383607,312383608,312383609,312383610,312383611,312383612,312383613,312383614,312383615",1576,NULL,P08684,Curation Efforts|Research and Development,25708617,0,10.1016/j.bmcl.2015.01.051,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1193171,100,Ratio of IC50 for CYP3A4 in human liver microsomes to IC50 for time-dependent inhibition of CYP3A4 in human liver microsomes,"Title: Minimization of drug-drug interaction risk and candidate selection in a natural product-based class of gamma-secretase modulators._|__|_Abstract: Early lead compounds in this gamma secretase modulator series were found to potently inhibit CYP3A4 and other human CYP isoforms increasing their risk of causing drug-drug-interactions (DDIs). Using structure-activity relationships and CYP3A4 structural information, analogs were developed that minimized this DDI potential. Three of these new analogs were fu",43,ChEMBL,1465543,20200625,"60172115,71288593,71288611,71288616,71288634,71288636,71288638,71288697,71288713,71288715,71288739,71288740,71288752,71288754","163322343,312383603,312383604,312383605,312383606,312383607,312383608,312383609,312383610,312383611,312383612,312383613,312383614,312383615",1576,NULL,P08684,Curation Efforts|Research and Development,25708617,0,10.1016/j.bmcl.2015.01.051,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1195727,100,Time-dependent inhibition of CYP3A4 (unknown origin) assessed as remaining activity at 10 uM after 30 mins,"Title: Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction._|__|_Abstract: Structure-based rational design and extensive structure-activity relationship studies led to the discovery of AMG 232 (1), a potent piperidinone inhibitor of the MDM2-p53 association, which is currently being evaluated in human clinical trials for the treatment of cancer. Further modifications of 1, including replacing the carboxylic acid with a 4-amidobenzoic acid, afforded AM-7209 ",43,ChEMBL,1469732,20181006,"68001087,77108133,90368833,118730175,118730185,118730190","194174783,312383869,312383870,312383881,312383887,312383888",1576,NULL,P08684,Curation Efforts|Research and Development,25384157,0,10.1021/jm501550p,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1196560,100,Time dependent inhibition of CYP3A4 in human liver microsomes at 10 uM using midazolam substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,"Title: Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization._|__|_Abstract: The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by cry",43,ChEMBL,1469331,20200625,"52912189,91809476,118732072,118732078,118732082,118732084","160683043,312386328,312386334,312386335,312386339,312386341",1576,NULL,P08684,Curation Efforts|Research and Development,25559428,0,10.1021/jm501504k,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1196561,100,Time dependent inhibition of CYP2D6 in human liver microsomes at 10 uM using dextromethorphan substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,"Title: Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization._|__|_Abstract: The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by cry",43,ChEMBL,1469332,20200625,"52912189,91809476,118732070,118732078,118732082,118732084","160683043,312386325,312386334,312386335,312386339,312386341",1565,NULL,P10635,Curation Efforts|Research and Development,25559428,0,10.1021/jm501504k,1.14.14.-,P10635,NULL
1196562,100,Time dependent inhibition of CYP2C9 in human liver microsomes at 10 uM using diclofenac substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,"Title: Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization._|__|_Abstract: The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by cry",43,ChEMBL,1469333,20200625,"46907787,52912189,91809476,118732069,118732076,118732078,118732082,118732084","136942413,160683043,312386324,312386332,312386334,312386335,312386339,312386341",1559,NULL,P11712,Curation Efforts|Research and Development,25559428,0,10.1021/jm501504k,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1196563,100,Time dependent inhibition of CYP1A2 in human liver microsomes at 10 uM using phenacetin substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,"Title: Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization._|__|_Abstract: The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by cry",43,ChEMBL,1469334,20200625,"52912189,91809476,118732078,118732082,118732084","160683043,312386334,312386335,312386339,312386341",1544,NULL,P05177,Curation Efforts|Research and Development,25559428,0,10.1021/jm501504k,"1.14.14.1,4.2.1.152",P05177,NULL
1196564,100,Time dependent inhibition of CYP2C19 in human liver microsomes at 10 uM using mephenytoin substrate preincubated for 5 mins before NADPH addition and measured after 20 mins post NADPH addition,"Title: Fragment-based drug discovery of 2-thiazolidinones as BRD4 inhibitors: 2. Structure-based optimization._|__|_Abstract: The signal transduction of acetylated histone can be processed through a recognition module, bromodomain. Several inhibitors targeting BRD4, one of the bromodomain members, are in clinical trials as anticancer drugs. Hereby, we report our efforts on discovery and optimization of a new series of 2-thiazolidinones as BRD4 inhibitors along our previous study. In this work, guided by cry",43,ChEMBL,1469335,20200625,"46907787,52912189,91809476,118732069,118732070,118732078,118732082,118732084","136942413,160683043,312386324,312386325,312386334,312386335,312386339,312386341",1557,NULL,P33261,Curation Efforts|Research and Development,25559428,0,10.1021/jm501504k,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1197563,100,Time-dependent inhibition of CYP1A2 (unknown origin),"Title: Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2._|__|_Abstract: Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.",43,ChEMBL,1469855,20200625,71727133,312385916,1544,NULL,P05177,Curation Efforts|Research and Development,25603482,0,10.1021/jm501921k,"1.14.14.1,4.2.1.152",P05177,NULL
1197564,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2._|__|_Abstract: Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.",43,ChEMBL,1469856,20181006,71727133,312385916,1559,NULL,P11712,Curation Efforts|Research and Development,25603482,0,10.1021/jm501921k,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1197565,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2._|__|_Abstract: Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.",43,ChEMBL,1469857,20181006,71727133,312385916,1557,NULL,P33261,Curation Efforts|Research and Development,25603482,0,10.1021/jm501921k,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1197566,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2._|__|_Abstract: Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.",43,ChEMBL,1469858,20181006,71727133,312385916,1565,NULL,P10635,Curation Efforts|Research and Development,25603482,0,10.1021/jm501921k,1.14.14.-,P10635,NULL
1197567,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2._|__|_Abstract: Using structure-based design, a novel series of pyridone ERK1/2 inhibitors was developed. Optimization led to the identification of (S)-14k, a potent, selective, and orally bioavailable agent that inhibited tumor growth in mouse xenograft models. On the basis of its in vivo efficacy and preliminary safety profiles, (S)-14k was selected for further preclinical evaluation.",43,ChEMBL,1469859,20181006,71727133,312385916,1576,NULL,P08684,Curation Efforts|Research and Development,25603482,0,10.1021/jm501921k,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1198868,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2._|__|_Abstract: Starting from advanced pyrrolidin-2-one lead compounds, this novel series of small-molecule orexin receptor antagonists was further optimized by fine-tuning of the C-3 substitution at the &#x3B3;-lactam ring. We discuss our design to align in vitro potency with metabolic stability and improved physicochemical/pharmacokinetic properties while avoiding P-glycoprotein-mediated efflux. Thes",43,ChEMBL,1468070,20200625,89789762,312386207,1576,NULL,P08684,Curation Efforts|Research and Development,25838147,0,10.1016/j.bmcl.2015.03.035,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1198869,100,Time dependent inhibition of CYP2C9 (unknown origin),"Title: Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2._|__|_Abstract: Starting from advanced pyrrolidin-2-one lead compounds, this novel series of small-molecule orexin receptor antagonists was further optimized by fine-tuning of the C-3 substitution at the &#x3B3;-lactam ring. We discuss our design to align in vitro potency with metabolic stability and improved physicochemical/pharmacokinetic properties while avoiding P-glycoprotein-mediated efflux. Thes",43,ChEMBL,1468071,20200625,89789762,312386207,1559,NULL,P11712,Curation Efforts|Research and Development,25838147,0,10.1016/j.bmcl.2015.03.035,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53",P11712,NULL
1198870,100,Time dependent inhibition of CYP2D6 (unknown origin),"Title: Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2._|__|_Abstract: Starting from advanced pyrrolidin-2-one lead compounds, this novel series of small-molecule orexin receptor antagonists was further optimized by fine-tuning of the C-3 substitution at the &#x3B3;-lactam ring. We discuss our design to align in vitro potency with metabolic stability and improved physicochemical/pharmacokinetic properties while avoiding P-glycoprotein-mediated efflux. Thes",43,ChEMBL,1468072,20200625,89789762,312386207,1565,NULL,P10635,Curation Efforts|Research and Development,25838147,0,10.1016/j.bmcl.2015.03.035,1.14.14.-,P10635,NULL
1219173,100,"Drug metabolism in plasma of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486146,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219174,100,"Plasma protein binding in iv dosed human multiple myeloma patient at 15 mg/m'2 in first cycle and escalated to 20 mg/m'2 thereafter administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486147,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219175,100,"Plasma clearance in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486148,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219176,100,"Plasma clearance in human patient with relapsed solid tumor at 20 mg/m'2, iv administered over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of 28-day cycle measured on day 1 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486149,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219177,100,"Half life in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486150,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219178,100,"Half life in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486151,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219179,100,"AUC infinity in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486152,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219180,100,"AUC infinity in human patient with relapsed solid tumor at 20 mg/m'2, iv administered over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of 28-day cycle measured on day 1 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486153,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219181,100,"AUC last in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486154,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219182,100,"AUC last in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486155,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219183,100,"Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 16 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486156,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219184,100,"Cmax in human patient with relapsed solid tumor at 20 mg/m'2, iv administered on days 1, 2, 8, 9 15 and 16 of 28-day cycle over 2 to 10 mins measured on day 1 of cycle 1 by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486157,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219185,100,"Drug level in plasma of human multiple myeloma patient treated with carfilzomib at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486158,20181007,"90092286,118753380,118753464","312467140,312467258,312467259",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219190,100,"Drug metabolism in plasma of human multiple myeloma patient assessed as morpholino-hPhe-Leu-Phe-Leu-diol metabolite formation at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486931,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219191,100,"Drug metabolism in plasma of human multiple myeloma patient assessed as morpholino-hPhe-Leu metabolite formation at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486932,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219192,100,"Drug metabolism in plasma of human multiple myeloma patient assessed as morpholino-hPhe metabolite formation at 15 mg/m'2, iv administered as single dose measured within first 30 mins after end of drug infusion by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486933,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219193,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP3A inhibitor ketoconazole,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486934,20200624,11556711,103652542,"1551,1576,1577,64816",NULL,"P08684,P20815,P24462,Q9HB55",Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73","P08684,P20815,P24462,Q9HB55",NULL
1219194,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP2D6 inhibitor quinidine,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486935,20181007,11556711,103652542,1565,NULL,P10635,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,1.14.14.-,P10635,NULL
1219195,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP2C19 inhibitor (+)-N-3-benzylnirvanol,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486936,20181007,11556711,103652542,1557,NULL,P33261,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1219196,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 10 uM CYP2C9 inhibitor sulfaphenazole,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1486937,20181007,11556711,103652542,1557,NULL,P33261,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,1.14.14.51,1.14.14.52,1.14.14.53,1.14.14.75",P33261,NULL
1219197,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 30 uM CYP2C8 inhibitor montelukast,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487760,20181007,11556711,103652542,1558,NULL,P10632,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,1.14.14.1,P10632,NULL
1219198,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis in presence of 30 uM CYP1A2 inhibitor furafylline,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487761,20200624,11556711,103652542,1544,NULL,P05177,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,4.2.1.152",P05177,NULL
1219199,100,Drug metabolism in pooled human hepatocytes assessed as disapperance rate at 1 uM by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487762,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219200,100,"Drug excretion in urine of human patient with relapsed and refractory hematological malignancies treated intravenously with carfilzomib on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487763,20181007,"90092286,118753380,118753464","312467140,312467258,312467259",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219201,100,"Drug level in plasma of human patient with relapsed and refractory hematological malignancies treated intravenously with carfilzomib on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487764,20181007,"90092286,118753380,118753464","312467140,312467258,312467259",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219202,100,"Drug excretion in urine of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu-Phe-Leu-diol metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487765,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219203,100,"Drug excretion in urine of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysi","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487766,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219204,100,"Drug excretion in urine of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487767,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219205,100,"Drug metabolism in plasma of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu-Phe-Leu-diol metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by L","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487768,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219206,100,"Drug metabolism in plasma of iv dosed human patient with relapsed and refractory hematological malignancies assessed as morpholino-hPhe-Leu metabolite formation administered on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analy","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487769,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219207,100,Decrease in CYP3A activity in rifampin-treated human hepatocytes assessed as 6-betahydroxytestosterone formation using testosterone as substrate at 2.5 uM after 30 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487830,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219208,100,Decrease in CYP3A gene expression in human hepatocytes at 2.5 uM after 3 days by qPCR analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487831,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219209,100,Decrease in CYP1A2 gene expression in human hepatocytes at 2.5 uM after 3 days by qPCR analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487832,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219210,100,"Half life in human multiple myeloma patient with normal renal function treated with carfilzomib at 15 mg/m'2, iv on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487833,20181007,"90092286,118753380,118753464","312467140,312467258,312467259",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219211,100,"Ratio of compound AUC (infinity) to carfilzomib AUC (infinity) in human multiple myeloma patient with normal renal function treated with carfilzomib at 15 mg/m'2, iv on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487834,20200624,"90092286,118753380,118753464","312467140,312467258,312467259",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219212,100,"Drug excretion in urine of human multiple myeloma patient with normal renal function treated with carfilzomib at 15 mg/m'2, iv on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis relative to total parent drug dose","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487835,20181007,"90092286,118753380","312467140,312467258",NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219213,100,"Drug excretion in urine of human multiple myeloma patient with normal renal function at 15 mg/m'2, iv on days 1, 2, 8, 9, 15 and 16 of 28-day cycle over 2 to 10 mins by LC-MS/MS analysis relative to total drug dose","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487836,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219215,100,"Cmax in solid tumor patient at 2 mg, po administered as single dose measured on day 7","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487838,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219216,100,"AUC(last) in solid tumor patient at 2 mg, po administered as single dose measured on day 7","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487839,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219217,100,"AUC(0 to 12 hrs) in solid tumor patient at 2 mg, po administered as single dose measured on day 7","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487840,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219218,100,"AUC(infinity) in solid tumor patient at 2 mg, po administered as single dose measured on day 7","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487841,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219219,100,"Tmax in solid tumor patient at 2 mg, po administered as single dose measured on day 7","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487842,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219220,100,"Half life in solid tumor patient at 2 mg, po administered as single dose measured on day 7","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487843,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219221,100,"Cmax in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487844,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219222,100,"AUC(last) in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487845,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219223,100,"AUC(0 to 12 hrs) in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487846,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219224,100,"AUC(infinity) in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487847,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219225,100,"Tmax in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487848,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219226,100,"Half life in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 1","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487849,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219227,100,"Cmax in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487850,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219228,100,"AUC(last) in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1487851,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219232,100,"AUC(0 to 12 hrs) in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488630,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219233,100,"AUC(infinity) in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488631,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219234,100,"Tmax in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488632,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219235,100,"Half life in solid tumor patient at 2 mg, po administered as single dose followed by co-treatment with 27 mg/m2, iv carfilzomib over 2 to 10 mins on days 1, 2, 8, 9, 15 and 16 of single 28-day cycle measured on day 16","Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1488633,20181007,4192,103189248,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219245,100,Decrease in CYP3A activity in human hepatocytes assessed as 6-betahydroxytestosterone formation using testosterone as substrate incubated for 3 days prior to substrate challenge for 30 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489455,20181007,11556711,103652542,NULL,NULL,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1219246,100,Decrease in CYP3A4 activity in human hepatocytes assessed as 6-betahydroxytestosterone formation using testosterone as substrate at 2.5 uM incubated for 3 days prior to substrate challenge for 30 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489456,20181007,11556711,103652542,1576,NULL,P08684,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1219247,100,Decrease in CYP1A2 activity in human hepatocytes assessed as acetaminophenol formation using phenacetin as substrate at 2.5 uM incubated for 3 days prior to substrate challenge for 60 mins by LC-MS/MS analysis,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489457,20200624,11556711,103652542,1544,NULL,P05177,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,"1.14.14.1,4.2.1.152",P05177,NULL
1219248,100,Cytotoxicity against human hepatocytes assessed as cell viability by MTT assay,"Title: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib._|__|_Abstract: Carfilzomib, an irreversible proteasome inhibitor, has a favorable safety profile and significant antitumor activity in patients with relapsed and refractory multiple myeloma (MM). Here we summarize the clinical pharmacokinetics (PK), metabolism, and drug-drug interaction (DDI) profile of carfilzomib. The PK of carfilzomib, infused over 2-10 minutes, was evaluated in patients with solid tumors or MM. Metab",43,ChEMBL,1489458,20181007,11556711,103652542,NULL,Toxicity,NULL,Curation Efforts|Research and Development,23118326,0,10.1124/dmd.112.047662,NULL,NULL,NULL
1229198,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes._|__|_Abstract: The imidazolyl-tetrahydro-&#x3B2;-carboline class of sstr3 antagonists have demonstrated efficacy in a murine model of glucose excursion and may have potential as a treatment for type 2 diabetes. The first candidate in this class caused unacceptable QTc interval prolongation in oral, telemetrized cardiovascular (CV) dogs. Herein, we describe our efforts to identify an acceptable ",43,ChEMBL,1498323,20200624,122179477,318374229,1576,NULL,P08684,Curation Efforts|Research and Development,26005524,0,10.1021/ml500514w,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1231769,100,Time dependent inhibition of CYP3A in human liver microsomes assessed as enzyme activity using midazolam as substrate at 10 uM incubated for 30 mins prior to substrate addition for 10 mins by LC-MS/MS analysis,"Title: Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methyl}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist._|__|_Abstract: The orexin/hypocretin receptors are a family of G protein-coupled receptors and consist of orexin-1 (OX1) and orexin-2 (OX2) receptor subtypes. Orexin receptors are expressed throughout the central nervous system and are involved in the regulation of the sleep/wake cycle. Because modulation",43,ChEMBL,1502027,20181008,"56944043,56944044,56944045,56944144,56944245,56944337,56944429,56944521,57388650,67281908,67282848,67283149,67473922,67473934,67473935,67473936,67473937,67473938,68058790,68058793,68083077,76534175,122179999,122180000,122180001,122180002","312362607,312468217,318374974,318374975,318374976,318374977,318374979,318374980,318374981,318374982,318374983,318374984,318374985,318374986,318374987,318374988,318374989,318374990,318374991,318374992,318374993,318374994,318374995,318374996,318374997,318374998",NULL,NULL,NULL,Curation Efforts|Research and Development,25953512,0,10.1021/acs.jmedchem.5b00217,NULL,NULL,NULL
1232917,100,Time-dependent inhibition of human CYP2C8 measured after 30 mins preincubation period,"Title: Chimeric derivatives of functionalized amino acids and &#xCE;&#xB1;-aminoamides: compounds with anticonvulsant activity in seizure models and inhibitory actions on central, peripheral, and cardiac isoforms of voltage-gated sodium channels._|__|_Abstract: Six novel 3&#x2033;-substituted (R)-N-(phenoxybenzyl) 2-N-acetamido-3-methoxypropionamides were prepared and then assessed using whole-cell, patch-clamp electrophysiology for their anticonvulsant activities in animal seizure models and for their sodi",43,ChEMBL,1503658,20200624,122181166,318376842,1558,NULL,P10632,Curation Efforts|Research and Development,25922183,0,10.1016/j.bmc.2015.04.014,1.14.14.1,P10632,NULL
1233919,2,Time dependent inhibition of Candida albicans ATCC 38247 membrane inositol phosphorylceramide synthase using ceramide as substrate,"Title: Generation of Broad-Spectrum Antifungal Drug Candidates from the Natural Product Compound Aureobasidin A._|__|_Abstract: The natural product aureobasidin A (AbA) is a potent, well-tolerated antifungal agent with robust efficacy in animals. Although native AbA is active against a number of fungi, it has little activity against Aspergillus fumigatus, an important human pathogen, and attempts to improve the activity against this organism by structural modifications have to date involved chemistries too ",43,ChEMBL,1503942,20200624,9919816,134434245,NULL,NULL,NULL,Curation Efforts|Research and Development,26101567,0,10.1021/acsmedchemlett.5b00029,NULL,NULL,NULL
1234553,100,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as remaining enzyme activity by measuring midazolam to 1'-hydroxymidazolam conversion at 5 uM pre-incubated for 30 mins before midazolam addition by LC-MS/MS method,"Title: Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors._|__|_Abstract: Because Janus kinases (JAKs) play a crucial role in cytokine-mediated signal transduction, JAKs are an attractive target for the treatment of organ transplant rejection and autoimmune diseases such as rheumatoid arthritis (RA). To identify JAK inhibitors, we focused on the 1H-pyrrolo[2,3-b]pyridine derivative 3, which exhibited moderate JAK3 and JAK1 inhibitory activities. Optimiz",43,ChEMBL,1505115,20181008,"15953425,57915982,67277276,67277840,67278047,67278151,67278165,122182021,122182022","318378002,318378008,318378009,318378010,318378011,318378012,318378013,318378014,318378015",1576,NULL,P08684,Curation Efforts|Research and Development,26059596,0,10.1016/j.bmc.2015.05.028,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1237221,100,Time-dependent inhibition of CYP450 in human liver microsomes,"Title: Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series._|__|_Abstract: The design and optimization of a novel trans-1,4-dioxycyclohexane GPR119 agonist series is described. A lead compound 21 was found to be a potent and efficacious GPR119 agonist across species, and possessed overall favorable pharmaceutical properties. Compound 21 demonstrated robust acute and chronic regulatory effects on glycemic parameters in the diabetic or non-diabetic rodent models.",43,ChEMBL,1506455,20181008,68230212,318380886,NULL,NULL,NULL,Curation Efforts|Research and Development,26048791,0,10.1016/j.bmcl.2015.04.102,NULL,NULL,NULL
1238626,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors._|__|_Abstract: As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview ",43,ChEMBL,1509542,20181009,58438322,318382043,1576,NULL,P08684,Curation Efforts|Research and Development,26181851,0,10.1021/acs.jmedchem.5b00810,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1238628,2,Time dependent inhibition of CYP3A4 in human liver microsomes,"Title: Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors._|__|_Abstract: As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo profile was selected as a clinical candidate and is currently in phase 1 clinical development. This article provides an overview ",43,ChEMBL,1509544,20181009,"53240420,58437582,58437683,58437687,58438170,58438199,58438284,67389741","318382044,318382118,318382119,318382120,318382121,318382122,318382123,318382124",1576,NULL,P08684,Curation Efforts|Research and Development,26181851,0,10.1021/acs.jmedchem.5b00810,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1242984,2,Time dependent inhibition of CYP3A4 in human liver microsomes assessed as reduction in testosterone 6beta-hydroxylation incubated for 60 mins in presence of NADPH generating system by LC-MS/MS method,"Title: Discovery of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers._|__|_Abstract: Chemical evolution of mibefradil resulted in the identification of novel bridged tetrahydronaphthalene derivatives as potent T/L-type calcium channel blockers. A SAR study, in vitro and in vivo DMPK properties as well as the in vivo antihypertensive effect in rats are presented.",43,ChEMBL,1512779,20181009,"60663,46203897","103229908,318386513",1576,NULL,P08684,Curation Efforts|Research and Development,26231163,0,10.1016/j.bmcl.2015.07.038,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1250720,100,Time-dependent inhibition of Trypanosoma brucei rhodesiense Rhodesain expressed in Pichia pastoris using Z-Phe-Arg-AMC as substrate assessed as ratio of Kinact to Ki preincubated for 30 mins followed by substrate addition measured for 7 mins by fluorescen,"Title: Identification of non-peptidic cysteine reactive fragments as inhibitors of cysteine protease rhodesain._|__|_Abstract: Rhodesain, the major cathepsin L-like cysteine protease in the protozoan Trypanosoma brucei rhodesiense, the causative agent of African sleeping sickness, is a well-validated drug target. In this work, we used a fragment-based approach to identify inhibitors of this cysteine protease, and identified inhibitors of T. brucei. To discover inhibitors active against rhodesain and T. bruc",43,ChEMBL,1518883,20181009,"90675742,90675744,118669138,122192445,122192446,122192447","242633875,242633877,318392863,318392864,318392865,318392866",NULL,NULL,Q95PM0,Curation Efforts|Research and Development,26342866,0,10.1016/j.bmcl.2015.08.074,NULL,Q95PM0,NULL
1270830,2,"Time dependent inhibition of human aromatase extracted from placental microsomes using [1beta,2beta-3H]-testosterone as substrate after 10 mins by scintillation counting analysis","Title: Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer._|__|_Abstract: Breast cancer, an emerging disease among the women population, occurs due to overexpression of estrogens. The enzyme aromatase plays a key rate limiting role in the biosynthesis of estrogens. Certain clinical advantages of the use of exemestane, a steroidal aromatase inhibitor over non-steroidal aromatase inhibitors have drawn the attention of researchers for the development of nove",43,ChEMBL,1547316,20180904,21121774,336870471,1588,NULL,P11511,Curation Efforts|Research and Development,26469743,0,10.1016/j.ejmech.2015.09.038,1.14.14.14,P11511,NULL
1270832,2,Time dependent inhibition of human aromatase extracted from placental microsomes,"Title: Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer._|__|_Abstract: Breast cancer, an emerging disease among the women population, occurs due to overexpression of estrogens. The enzyme aromatase plays a key rate limiting role in the biosynthesis of estrogens. Certain clinical advantages of the use of exemestane, a steroidal aromatase inhibitor over non-steroidal aromatase inhibitors have drawn the attention of researchers for the development of nove",43,ChEMBL,1547318,20180904,"124351848,124351849","336866015,336866016",1588,NULL,P11511,Curation Efforts|Research and Development,26469743,0,10.1016/j.ejmech.2015.09.038,1.14.14.14,P11511,NULL
1270836,2,"Time dependent inhibition of human aromatase extracted from placental microsomes using using [1beta,2beta-3H]androstenedione as substrate by scintillation counting analysis","Title: Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer._|__|_Abstract: Breast cancer, an emerging disease among the women population, occurs due to overexpression of estrogens. The enzyme aromatase plays a key rate limiting role in the biosynthesis of estrogens. Certain clinical advantages of the use of exemestane, a steroidal aromatase inhibitor over non-steroidal aromatase inhibitors have drawn the attention of researchers for the development of nove",43,ChEMBL,1547322,20180904,146141,336865588,1588,NULL,P11511,Curation Efforts|Research and Development,26469743,0,10.1016/j.ejmech.2015.09.038,1.14.14.14,P11511,NULL
1271374,100,Time dependent inhibition of CYP3A4 (unknown origin) using midazolam as substrate at 30 uM,"Title: Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment._|__|_Abstract: Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of conc",43,ChEMBL,1549444,20180904,"118701008,127036775","336884550,336884955",1576,NULL,P08684,Curation Efforts|Research and Development,26617966,0,10.1021/acsmedchemlett.5b00215,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1271375,100,Time dependent inhibition of CYP3A4 (unknown origin) using midazolam as substrate at 60 uM,"Title: Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment._|__|_Abstract: Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of conc",43,ChEMBL,1549445,20180904,"118701008,127036775","336884550,336884955",1576,NULL,P08684,Curation Efforts|Research and Development,26617966,0,10.1021/acsmedchemlett.5b00215,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1276846,100,Time-dependent inhibition of CYP3A4 in human liver microsomes up to 50 uM,"Title: Discovery of Vibegron: A Potent and Selective &#xCE;&#xB2;3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder._|__|_Abstract: The discovery of vibegron, a potent and selective human &#x3B2;3-AR agonist for the treatment of overactive bladder (OAB), is described. An early-generation clinical &#x3B2;3-AR agonist MK-0634 (3) exhibited efficacy in humans for the treatment of OAB, but development was discontinued due to unacceptable structure-based toxicity in preclinical species. Optimi",43,ChEMBL,1554645,20200623,44472635,160698341,1576,NULL,P08684,Curation Efforts|Research and Development,26709102,0,10.1021/acs.jmedchem.5b01372,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1277511,100,Time dependent inhibition of CYP3A4 (unknown origin) at 30 uM relative to control,Title: Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists._|__|_Abstract: Novel bicyclic adenosine A(2A) antagonists with an aminoquinazoline moiety were designed and synthesized. The optimization of the initial lead compound based on in vitro and in vivo activity has led to the discovery of a potent and selective class of adenosine A(2A) antagonists. The structure-activity relationships of this novel series of bicyclic aminoquinazoline derivatives as adenosine A(2A) ant,43,ChEMBL,1553988,20200623,127026188,336867082,1576,NULL,P08684,Curation Efforts|Research and Development,26781932,0,10.1016/j.bmcl.2015.11.048,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1277513,100,Time dependent inhibition of CYP3A4 (unknown origin),Title: Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists._|__|_Abstract: Novel bicyclic adenosine A(2A) antagonists with an aminoquinazoline moiety were designed and synthesized. The optimization of the initial lead compound based on in vitro and in vivo activity has led to the discovery of a potent and selective class of adenosine A(2A) antagonists. The structure-activity relationships of this novel series of bicyclic aminoquinazoline derivatives as adenosine A(2A) ant,43,ChEMBL,1553990,20180905,127025020,336865361,1576,NULL,P08684,Curation Efforts|Research and Development,26781932,0,10.1016/j.bmcl.2015.11.048,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1288250,100,Time-dependent inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cell microsomes at IC50 using MMTP as substrate preincubated for 5 mins followed by substrate addition measured after 5 to 60 mins by spectrophotometric analy,Title: Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors._|__|_Abstract: A novel series of substituted chalcones were designed and synthesized to be evaluated as selective human MAO-B inhibitors. A combination of either methylsulfonyl or trifluoromethyl substituents on the aromatic ketone moiety with a benzodioxol ring on the other end of the chalcone scaffold was investigated. The compounds were tested for their inhibitory activities on both human MAO-A and B. All c,43,ChEMBL,1565723,20180905,52643177,336875579,4129,NULL,P27338,Curation Efforts|Research and Development,26974383,0,10.1016/j.ejmech.2016.02.038,1.4.3.4,P27338,NULL
1289527,100,Time-dependent inhibition of CYP450 (unknown origin),"Title: Discovery of (3-(4-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)phenoxy)azetidin-1-yl)(5-(4-methoxyphenyl)-1,3,4-oxadiazol-2-yl)methanone (AZD1979), a Melanin Concentrating Hormone Receptor 1 (MCHr1) Antagonist with Favorable Physicochemical Properties._|__|_Abstract: A novel series of melanin concentrating hormone receptor 1 (MCHr1) antagonists were the starting point for a drug discovery program that culminated in the discovery of 103 (AZD1979). The lead optimization program was conducted with a focus o",43,ChEMBL,1566918,20180905,49801838,336877520,NULL,NULL,NULL,Curation Efforts|Research and Development,26741166,0,10.1021/acs.jmedchem.5b01654,NULL,NULL,NULL
1295427,2,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test._|__|_Abstract: To develop non-basic melanin-concentrating hormone receptor 1 (MCHR1) antagonists with a high probability of target selectivity and therapeutic window, we explored neutral bicyclic motifs that could replace the previously reported imidazo[1,2-a]pyridine or 1H-benzimidazole motif. The results indicated that the bi",43,ChEMBL,1572438,20180905,90469437,318372395,1576,NULL,P08684,Curation Efforts|Research and Development,27117261,0,10.1016/j.bmc.2016.04.013,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1298625,100,"Analgesic effect in ICR mouse assessed as tail flick latencies at at 50 mg/kg, ip measured 10 to 60 mins post dose by tail flick test","Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573074,20180906,"53251433,127046192,127046789,127047498,127047499,127047752","336898273,336898274,336899117,336900164,336900165,336900503",NULL,NULL,NULL,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,NULL,NULL,NULL
1298626,100,"Analgesic effect in ICR mouse assessed as tail flick latencies at at 20 to 40 mg/kg, ip measured 10 to 60 mins post dose by tail flick test","Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573075,20180906,"53251433,127047498,127047499","336898273,336900164,336900165",NULL,NULL,NULL,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,NULL,NULL,NULL
1298627,100,"Analgesic effect in ICR mouse assessed as tail flick latencies at at 20 to 100 mg/kg, ip measured 10 to 60 mins post dose by tail flick test","Title: Piperidinyl thiazole isoxazolines: A new series of highly potent, slowly reversible FAAH inhibitors with analgesic properties._|__|_Abstract: Fatty acid amide hydrolase (FAAH) is a membrane anchored serine hydrolase that has a principle role in the metabolism of the endogenous cannabinoid anandamide. Docking studies using representative FAAH crystal structures revealed that compounds containing a novel piperidinyl thiazole isoxazoline core fit within the ligand binding domains. New potential FAAH inh",43,ChEMBL,1573076,20180906,127046192,336898274,NULL,NULL,NULL,Curation Efforts|Research and Development,27130358,0,10.1016/j.bmcl.2016.02.061,NULL,NULL,NULL
1300201,100,"Fraction unbound in Beagle dog plasma at 0.5 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576628,20200624,"71479388,127052897","336907555,336907557",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300202,100,Substrate activity at human P-gp assessed as apparent permeability,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576629,20180906,"51036108,127052897","336907554,336907555",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300203,100,Substrate activity at rat P-gp assessed as efflux ratio of apparent permeability from basolateral to apical side to apical to basolateral side,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576630,20200624,"51036108,127052897","336907554,336907555",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300204,100,Substrate activity at rat P-gp assessed as apparent permeability,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576631,20180906,"51036108,127052897","336907554,336907555",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300205,2,Positive allosteric modulation of recombinant human mGlu2 receptor expressed in CHO cells assessed as potentiation of glutamate-induced effect preincubated for 5 mins followed by glutamate stimulation for 3 mins by Fluo-4AM staining-based FLIPR assay,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576632,20180906,"51036108,51036701,51036916,51037131,54761054,67056056,67056141,69929497,69929646,69929785,69930179,71128783,71479388,127052897","336888477,336901914,336902824,336902825,336902826,336902827,336902828,336907522,336907553,336907554,336907555,336907556,336907557,336907955",2912,NULL,Q14416,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,Q14416,NULL
1300206,2,Agonist activity at recombinant human mGlu2 receptor expressed in CHO cells assessed as potentiation of glutamate-induced effect preincubated for 5 mins followed by glutamate stimulation for 3 mins by Fluo-4AM staining-based FLIPR assay,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576633,20180906,"51036108,127052897","336907554,336907555",2912,NULL,Q14416,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,Q14416,NULL
1300207,100,Positive allosteric modulation of recombinant human mGlu2 receptor expressed in CHO cells assessed as decrease in glutamate EC50 at 1 uM preincubated for 5 mins followed by glutamate stimulation for 3 mins by Fluo-4AM staining-based FLIPR assay relative t,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576634,20200624,"51036108,127052897","336907554,336907555",2912,NULL,Q14416,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,Q14416,NULL
1300208,2,Positive allosteric modulation of mGlu3 receptor (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576635,20180906,"51036108,51036701,51036916,51037131,54761054,67056056,69929646,71479388,127052897","336888477,336901914,336902824,336902825,336902826,336907522,336907554,336907555,336907557",2913,NULL,Q14832,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,Q14832,NULL
1300209,2,Positive allosteric modulation of mGlu4 receptor (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576636,20180906,"51036108,51036701,51036916,51037131,54761054,67056056,69929646,71479388,127052897","336888477,336901914,336902824,336902825,336902826,336907522,336907554,336907555,336907557",2914,NULL,Q14833,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,Q14833,NULL
1300210,2,Positive allosteric modulation of mGlu5 receptor (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576637,20180906,"51036108,51036701,51036916,51037131,54761054,67056056,69929646,71479388,127052897","336888477,336901914,336902824,336902825,336902826,336907522,336907554,336907555,336907557",2915,NULL,P41594,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,P41594,NULL
1300211,2,Positive allosteric modulation of mGlu6 receptor (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576638,20180906,"51036108,51036701,51036916,51037131,54761054,67056056,69929646,71479388,127052897","336888477,336901914,336902824,336902825,336902826,336907522,336907554,336907555,336907557",2916,NULL,O15303,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,O15303,NULL
1300212,2,Solubility of compound at pH 7,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576639,20180906,"51036108,67056141,69929497,69929785,69930179,127052897","336902827,336902828,336907553,336907554,336907555,336907955",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300213,100,"Half life in Beagle dog at 0.5 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576640,20180906,"51036108,71479388,127052897","336907554,336907555,336907557",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300214,100,"Half life in Wistar Hannover rat at 2 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576641,20180906,"69929497,69930179,71479388,127052897","336907553,336907555,336907557,336907955",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300215,100,"Clearance in Beagle dog at 0.5 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576642,20180906,"51036108,127052897","336907554,336907555",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300216,100,"Clearance in Wistar Hannover rat at 2 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576643,20180906,"69929497,69930179,127052897","336907553,336907555,336907955",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300217,100,"Fraction unbound adjusted clearance in Wistar Hannover rat at 2 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576644,20180906,"69929497,69930179,71479388,127052897","336907553,336907555,336907557,336907955",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300218,100,"AUC in Wistar Hannover rat at 10 mg/kg, po administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576645,20180906,"51036108,67056141,69929497,69929785,69930179,127052897","336902827,336902828,336907553,336907554,336907555,336907955",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300219,100,"AUC in Beagle dog at 1 mg/kg, po administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576646,20180906,127052897,336907555,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300220,100,Oral bioavailability in Wistar Hannover rat at 10 mg/kg administered as single dose,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576647,20180906,"69929497,69930179,127052897","336907553,336907555,336907955",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300221,100,Oral bioavailability in Beagle dog at 1 mg/kg administered as single dose,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576648,20180906,127052897,336907555,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300222,100,Intrinsic clearance in dog liver microsomes at 10 uM incubated for 20 to 60 mins by LC-HRMS analysis in presence of NADPH/GSH,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576649,20180906,127052897,336907555,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300224,2,"Plasma concentration in Sprague-Dawley rat at 10 mg/kg, po","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576651,20180906,127052897,336907555,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300225,2,"Drug uptake in Sprague-Dawley rat cerebrospinal fluid at 10 mg/kg, po","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576652,20180906,127052897,336907555,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300228,100,"Fraction unbound adjusted clearance in Beagle dog at 0.5 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576655,20180906,"71479388,127052897","336907555,336907557",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300230,2,"Drug uptake in Sprague-Dawley rat cerebrospinal fluid at 30 mg/kg, po","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576657,20180906,71479388,336907557,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300231,100,Mutagenicity in Salmonella typhimurium by Ames test in presence of S9 liver fraction,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576658,20180906,71479388,336907557,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300232,100,Mutagenicity in Salmonella typhimurium by Ames test in absence of S9 liver fraction,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576659,20180906,71479388,336907557,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300233,100,"Fraction unbound in Wistar Hannover rat plasma at 2 mg/kg, iv administered as single dose","Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576660,20200624,"71479388,127052897","336907555,336907557",NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300234,100,Activity at dopamine D2 receptor (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576661,20180906,71479388,336907557,1813,NULL,P14416,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,P14416,NULL
1300235,100,Activity at 5HT2A receptor (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576662,20180906,71479388,336907557,3356,NULL,P28223,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,P28223,NULL
1300236,100,Activity at PDE10 (unknown origin),"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576663,20180906,71479388,336907557,NULL,NULL,NULL,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,NULL,NULL
1300237,2,Positive allosteric modulation of rat mGlu2 receptor assessed as potentiation of glutamate-induced effect by Fluo-4AM staining-based FLIPR assay,"Title: Optimization of Novel Aza-benzimidazolone mGluR2 PAMs with Respect to LLE and PK Properties and Mitigation of CYP TDI._|__|_Abstract: Investigation of a novel amino-aza-benzimidazolone structural class of positive allosteric modulators (PAMs) of metabotropic glutamate receptor 2 (mGluR2) identified [2.2.2]-bicyclic amine 12 as an intriguing lead structure due to its promising physicochemical properties and lipophilic ligand efficiency (LLE). Further optimization led to chiral amide 18, which exhibite",43,ChEMBL,1576664,20180906,127052897,336907555,24415,NULL,P31421,Curation Efforts|Research and Development,26985321,0,10.1021/acsmedchemlett.5b00459,NULL,P31421,NULL
1300275,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of Novel 3,3-Disubstituted Piperidines as Orally Bioavailable, Potent, and Efficacious HDM2-p53 Inhibitors._|__|_Abstract: A new subseries of substituted piperidines as p53-HDM2 inhibitors exemplified by 21 has been developed from the initial lead 1. Research focused on optimization of a crucial HDM2 Trp23-ligand interaction led to the identification of 2-(trifluoromethyl)thiophene as the preferred moiety. Further investigation of the Leu26 pocket resulted in potent, novel substituted piper",43,ChEMBL,1576774,20180906,59648133,336902845,1576,NULL,P08684,Curation Efforts|Research and Development,26985323,0,10.1021/acsmedchemlett.5b00472,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1305320,100,Time dependent inhibition of CYP3A4 in human liver microsomes preincubated for 5 mins followed by substrate addition by LC-MS/MS analysis in presence of NADPH,"Title: Discovery of Novel Tricyclic Heterocycles as Potent and Selective DPP-4 Inhibitors for the Treatment of Type 2 Diabetes._|__|_Abstract: In our efforts to develop second generation DPP-4 inhibitors, we endeavored to identify distinct structures with long-acting (once weekly) potential. Taking advantage of X-ray cocrystal structures of sitagliptin and other DPP-4 inhibitors, such as alogliptin and linagliptin bound to DPP-4, and aided by molecular modeling, we designed several series of heterocyclic co",43,ChEMBL,1581795,20180906,71203748,318446819,1576,NULL,P08684,Curation Efforts|Research and Development,27190600,0,10.1021/acsmedchemlett.6b00027,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1312663,2,Time-dependent inhibition of PAFAH1B2 (unknown origin) using 2-thiol-PAF as substrate by Ellman's assay,Title: Identification of selective covalent inhibitors of platelet activating factor acetylhydrolase 1B2 from the screening of an oxadiazolone-capped peptoid-azapeptoid hybrid library._|__|_Abstract: A potent and selective inhibitor of platelet-activating factor acetylhydrolase 1B2 (PAFAH1B2) is described. The compound was derived by improvement of a modest affinity primary hit isolated from the screening of a bead-displayed peptoid-azapeptoid hybrid library tethered to an oxadiazolone 'warhead'. The oxadia,43,ChEMBL,1589935,20180906,"101883550,127043994,127044002,127044615,127044786,127044947,127044953,127045427","336894458,336894893,336894906,336895923,336896178,336896422,336896432,336897169",5049,NULL,P68402,Curation Efforts|Research and Development,27160052,0,10.1016/j.bmc.2016.04.047,3.1.1.47,P68402,NULL
1312664,100,Time-dependent inhibition of PAFAH1B2 (unknown origin) at 10 to 100 uM by ABPP gel-based assay,Title: Identification of selective covalent inhibitors of platelet activating factor acetylhydrolase 1B2 from the screening of an oxadiazolone-capped peptoid-azapeptoid hybrid library._|__|_Abstract: A potent and selective inhibitor of platelet-activating factor acetylhydrolase 1B2 (PAFAH1B2) is described. The compound was derived by improvement of a modest affinity primary hit isolated from the screening of a bead-displayed peptoid-azapeptoid hybrid library tethered to an oxadiazolone 'warhead'. The oxadia,43,ChEMBL,1589936,20180906,"101883550,127043994,127044002,127044006,127044615,127044786,127044947,127044953,127045427","336894458,336894893,336894906,336894912,336895923,336896178,336896422,336896432,336897169",5049,NULL,P68402,Curation Efforts|Research and Development,27160052,0,10.1016/j.bmc.2016.04.047,3.1.1.47,P68402,NULL
1319212,100,Time dependent inhibition of CYP3A4 in human liver microsomes using testosterone as substrate up to 10 uM by HPLC analysis,"Title: Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor._|__|_Abstract: The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines",43,ChEMBL,1616318,20180906,86270720,374274874,1576,NULL,P08684,Curation Efforts|Research and Development,27548392,0,10.1021/acs.jmedchem.6b00989,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1319355,100,Time dependent inhibition of CYP3A4 in human hepatic microsomes assessed as reduction in probe substrate metabolism at 10 uM,"Title: Characterization of 3,3-dimethyl substituted N-aryl piperidines as potent microsomal prostaglandin E synthase-1 inhibitors._|__|_Abstract: Here we report on novel, potent 3,3-dimethyl substituted N-aryl piperidine inhibitors of microsomal prostaglandin E synthases-1(mPGES-1). Example 14 potently inhibited PGE2 synthesis in an ex vivo human whole blood (HWB) assay with an IC50 of 7nM. In addition, 14 had no activity in human COX-1 or COX-2 assays at 30&#x3BC;M, and failed to inhibit human mPGES-2 at 6",43,ChEMBL,1616461,20200624,"121313704,121313880,121313890","374304768,374315495,374328515",1576,NULL,P08684,Curation Efforts|Research and Development,27554445,0,10.1016/j.bmcl.2016.08.023,"1.14.14.1,1.14.14.55,1.14.14.56,1.14.14.73",P08684,NULL
1325505,100,Selectivity ratio of Ki for human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli to Ki for human recombinant DTT-activated caspase-5 expressed in Escherichia coli,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622628,20200624,"134136688,134149983,134156687","374285342,374333378,374357001",NULL,NULL,NULL,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,NULL,NULL,NULL
1325506,100,Selectivity ratio of Ki for human recombinant N-terminal His-tagged DTT-activated caspase-4 expressed in Escherichia coli to Ki for human recombinant DTT-activated caspase-5 expressed in Escherichia coli,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622629,20200624,"134136688,134149983,134156687","374285342,374333378,374357001",NULL,NULL,NULL,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,NULL,NULL,NULL
1325507,100,Selectivity ratio of Ki for human recombinant N-terminal His-tagged DTT-activated caspase-1 expressed in Escherichia coli to Ki for human recombinant N-terminal His-tagged DTT-activated caspase-4 expressed in Escherichia coli,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622630,20200624,134147411,374324090,NULL,NULL,NULL,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,NULL,NULL,NULL
1325508,100,Selectivity ratio of Ki for human recombinant DTT-activated caspase-5 expressed in Escherichia coli to Ki for human recombinant N-terminal His-tagged DTT-activated caspase-4 expressed in Escherichia coli,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622631,20200624,134147411,374324090,NULL,NULL,NULL,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,NULL,NULL,NULL
1325511,100,Ratio of IC50 for human recombinant DTT-activated caspase-5 expressed in Escherichia coli preincubated for 15 mins followed by Ac-WEHD-AMC substrate addition to IC50 for human recombinant DTT-activated caspase-5 expressed in Escherichia coli preincubated ,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622634,20200624,134136688,374285342,838,NULL,P51878,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.58,P51878,NULL
1325512,100,Ratio of IC50 for human recombinant DTT-activated caspase-5 expressed in Escherichia coli preincubated for 15 mins followed by Ac-WEHD-AMC substrate addition to IC50 for human recombinant DTT-activated caspase-5 expressed in Escherichia coli preincubated ,"Title: Variation of the aryl substituent on the piperazine ring within the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyrimidine scaffold unveils potent, non-competitive inhibitors of the inflammatory caspases._|__|_Abstract: The inflammatory caspases (caspase-1, -4 and -5) are potential therapeutic targets for autoimmune and inflammatory diseases due to their involvement in the immune response upon inflammasome formation. A series of small molecules based on the 4-(piperazin-1-yl)-2,6-di(pyrrolidin-1-yl)pyr",43,ChEMBL,1622635,20200624,134136688,374285342,838,NULL,P51878,Curation Efforts|Research and Development,27777011,0,10.1016/j.bmcl.2016.10.025,3.4.22.58,P51878,NULL
1336655,2,Time-dependent inhibition of TAB1 fused TAK1 (unknown origin) using FAM-LRRKtide as substrate by mobility shift assay,"Title: Structure-guided development of covalent TAK1 inhibitors._|__|_Abstract: TAK1 (transforming growth factor-&#x3B2;-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the 'DFG-motif' of the kinase activation loop. Co-crysta",43,ChEMBL,1633899,20200630,"131801160,131801161,132819862","374265964,374266263,374266435",6885,NULL,O43318,Curation Efforts|Research and Development,28011204,0,10.1016/j.bmc.2016.11.035,2.7.11.25,O43318,NULL
1336656,100,Time-dependent inhibition of TAB1 fused TAK1 (unknown origin) assessed as ratio of Kinact to Ki using FAM-LRRKtide as substrate by mobility shift assay,"Title: Structure-guided development of covalent TAK1 inhibitors._|__|_Abstract: TAK1 (transforming growth factor-&#x3B2;-activated kinase 1) is an essential intracellular mediator of cytokine and growth factor signaling and a potential therapeutic target for the treatment of immune diseases and cancer. Herein we report development of a series of 2,4-disubstituted pyrimidine covalent TAK1 inhibitors that target Cys174, a residue immediately adjacent to the 'DFG-motif' of the kinase activation loop. Co-crysta",43,ChEMBL,1633900,20200630,131801160,374266435,6885,NULL,O43318,Curation Efforts|Research and Development,28011204,0,10.1016/j.bmc.2016.11.035,2.7.11.25,O43318,NULL
1350335,100,Time dependent inhibition of CYP1A2 (unknown origin) up to 50 uM using phenacetin as substrate,"Title: Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1._|__|_Abstract: Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders. Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chemical structures, leadi",43,ChEMBL,1729691,20200618,137628648,404654469,NULL,NULL,NULL,Curation Efforts|Research and Development,29456796,0,10.1021/acsmedchemlett.7b00450,NULL,NULL,NULL
1350336,100,Time dependent inhibition of CYP2C9 (unknown origin) up to 50 uM using diclofenac as substrate,"Title: Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1._|__|_Abstract: Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders. Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chemical structures, leadi",43,ChEMBL,1729692,20200618,137628648,404654469,NULL,NULL,NULL,Curation Efforts|Research and Development,29456796,0,10.1021/acsmedchemlett.7b00450,NULL,NULL,NULL
1350337,100,Time dependent inhibition of CYP2C19 (unknown origin) up to 50 uM using S-mephenytoin as substrate,"Title: Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1._|__|_Abstract: Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders. Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chemical structures, leadi",43,ChEMBL,1729693,20200618,137628648,404654469,NULL,NULL,NULL,Curation Efforts|Research and Development,29456796,0,10.1021/acsmedchemlett.7b00450,NULL,NULL,NULL
1350338,100,Time dependent inhibition of CYP2D6 (unknown origin) up to 50 uM using DEX as substrate,"Title: Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1._|__|_Abstract: Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders. Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chemical structures, leadi",43,ChEMBL,1729694,20200618,137628648,404654469,NULL,NULL,NULL,Curation Efforts|Research and Development,29456796,0,10.1021/acsmedchemlett.7b00450,NULL,NULL,NULL
1350339,100,Time dependent inhibition of CYP3A4 (unknown origin) up to 50 uM using midazolam as substrate,"Title: Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1._|__|_Abstract: Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) plays an important role in triglyceride synthesis and is a target of interest for the treatment of metabolic disorders. Herein we describe the structure-activity relationship of a novel tetralone series of DGAT1 inhibitors and our strategies for overcoming genotoxic liability of the anilines embedded in the chemical structures, leadi",43,ChEMBL,1729695,20200618,137628648,404654469,NULL,NULL,NULL,Curation Efforts|Research and Development,29456796,0,10.1021/acsmedchemlett.7b00450,NULL,NULL,NULL
1354434,100,Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate preincubated for 20 mins followed by NADP addition,"Title: Discovery of Tirasemtiv, the First Direct Fast Skeletal Muscle Troponin Activator._|__|_Abstract: The identification and optimization of the first activators of fast skeletal muscle are reported. Compound 1 was identified from high-throughput screening (HTS) and subsequently found to improve muscle function via interaction with the troponin complex. Optimization of 1 for potency, metabolic stability, and physical properties led to the discovery of tirasemtiv (25), which has been extensively character",43,ChEMBL,1733795,20200618,23729157,174505061,NULL,NULL,NULL,Curation Efforts|Research and Development,29670700,0,10.1021/acsmedchemlett.7b00546,NULL,NULL,NULL
1364536,100,Time-dependent inhibition of CYP450 (unknown origin),"Title: Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR._|__|_Abstract: Mutant epidermal growth factor receptor (EGFR) is a major driver of non-small-cell lung cancer (NSCLC). Marketed first generation inhibitors, such as erlotinib, effect a transient beneficial respo",43,ChEMBL,1743924,20200618,91668194,374361832,NULL,NULL,NULL,Curation Efforts|Research and Development,28287730,0,10.1021/acs.jmedchem.6b01894,NULL,NULL,NULL
1372823,100,Time dependent inhibition of Escherichia coli BL21 at 4 uM,"Title: Influence of hydrocarbon-stapling on membrane interactions of synthetic antimicrobial peptides._|__|_Abstract: Cyclization has been recognized as a valuable technique for increasing the efficacy of small molecule and peptide therapeutics. Here we report the application of a hydrocarbon staple to a rationally-designed cationic antimicrobial peptide (CAP) that acquires increased membrane targeting and interaction vs. its linear counterpart. The previously-described CAP, 6K-F17 (KKKKKK-AAFAAWAAFAA-NH2) ",43,ChEMBL,1752230,20200618,"16139946,145976697","404675708,404691959",NULL,NULL,NULL,Curation Efforts|Research and Development,29275987,0,10.1016/j.bmc.2017.10.020,NULL,NULL,NULL
1372824,100,Time dependent inhibition of Escherichia coli BL21 at 8 uM,"Title: Influence of hydrocarbon-stapling on membrane interactions of synthetic antimicrobial peptides._|__|_Abstract: Cyclization has been recognized as a valuable technique for increasing the efficacy of small molecule and peptide therapeutics. Here we report the application of a hydrocarbon staple to a rationally-designed cationic antimicrobial peptide (CAP) that acquires increased membrane targeting and interaction vs. its linear counterpart. The previously-described CAP, 6K-F17 (KKKKKK-AAFAAWAAFAA-NH2) ",43,ChEMBL,1752231,20200618,"145964254,145975096","404673406,404689539",NULL,NULL,NULL,Curation Efforts|Research and Development,29275987,0,10.1016/j.bmc.2017.10.020,NULL,NULL,NULL
1372830,100,Time dependent inhibition of Escherichia coli BL21 at 2 uM,"Title: Influence of hydrocarbon-stapling on membrane interactions of synthetic antimicrobial peptides._|__|_Abstract: Cyclization has been recognized as a valuable technique for increasing the efficacy of small molecule and peptide therapeutics. Here we report the application of a hydrocarbon staple to a rationally-designed cationic antimicrobial peptide (CAP) that acquires increased membrane targeting and interaction vs. its linear counterpart. The previously-described CAP, 6K-F17 (KKKKKK-AAFAAWAAFAA-NH2) ",43,ChEMBL,1752237,20200618,145965310,404675038,NULL,NULL,NULL,Curation Efforts|Research and Development,29275987,0,10.1016/j.bmc.2017.10.020,NULL,NULL,NULL
1380798,100,Time-dependent inhibition of CYP3A4 in human liver microsomes up to 20 uM using midazolam as substrate in presence of NADPH by LC/MS/MS analysis,"Title: Rational Design of Novel 1,3-Oxazine Based &#xCE;&#xB2;-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust A&#xCE;&#xB2; Reduction in the Brain._|__|_Abstract: Accumulation of A&#x3B2; peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD. &#x3B2;-Secretase (BACE1) is a key enzyme responsible for producing A&#x3B2; peptides, and thus agents that inhibit BACE1 should be beneficial for disease-mod",43,ChEMBL,1760222,20200618,71466345,404677226,NULL,NULL,NULL,Curation Efforts|Research and Development,29733614,0,10.1021/acs.jmedchem.8b00002,NULL,NULL,NULL
1387148,100,Time dependent inhibition of His-6-tagged human KLK6 R74G/R76Q/N132Q mutant expressed in Escherichia coli DH10 pre-incubated up to 40 mins before N-Boc-FSR-AMC substrate addition and measured after 30 mins,"Title: Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity._|__|_Abstract: Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins (KLKs). Many KLKs are investigated as potential biomarkers for cancer as well as therapeutic drug targets for a number of pathologies. KLK6, in particular, has been implicated in neurodegenerative diseases and cancer, but target validation has be",43,ChEMBL,1766591,20200618,41583852,404672891,NULL,NULL,NULL,Curation Efforts|Research and Development,30212625,0,10.1021/acs.jmedchem.8b01106,NULL,NULL,NULL
1387550,100,Time-dependent inhibition of HDAC in human HeLaS3 cells assessed as increase in histone H3K9 acetylation at 10 uM by immunoblot analysis,"Title: Design, Synthesis, and Blood-Brain Barrier Transport Study of Pyrilamine Derivatives as Histone Deacetylase Inhibitors._|__|_Abstract: We designed and synthesized a pyrilamine derivative 1 as a selective class I HDAC inhibitor that targets pyrilamine-sensitive proton-coupled organic cation antiporter (PYSOCA) at the blood-brain barrier (BBB). Introduction of pyrilamine moiety to benzamide type HDAC inhibitors kept selective class I HDAC inhibitory activity and increased BBB permeability. Our BBB tran",43,ChEMBL,1766993,20200618,145964533,404673835,NULL,NULL,NULL,Curation Efforts|Research and Development,30258535,0,10.1021/acsmedchemlett.8b00099,NULL,NULL,NULL
1406229,2,Antileishmanial activity against Leishmania major promastigotes,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801038,20200619,"44411027,44411237,145980966,145987523,145990258,145993576","103487457,103487719,404698495,404708114,404712394,404717573",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406230,2,Antileishmanial activity against luciferase-fused Leishmania major amastigotes infected in BMDM after 24 hrs by luminescence assay,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801039,20200619,"11599792,11859052,44411027,44411149,44411237,145980966,145987523,145990258,145993576","103487457,103487618,103487719,103487850,103488025,404698495,404708114,404712394,404717573",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406231,2,Cytotoxicity against mouse J774 cells,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801040,20200619,"145980966,145990258,145993576","404698495,404712394,404717573",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1406239,100,Antileishmanial activity against Leishmania major promastigotes at 20 uM,"Title: New aziridine-based inhibitors of cathepsin L-like cysteine proteases with selectivity for the Leishmania cysteine protease LmCPB2.8._|__|_Abstract: In the present work a series of aziridine-2,3-dicarboxylate inhibitors of papain-like cysteine proteases was designed, synthesized and tested. The compounds displayed selectivity for the parasitic protozoon Leishmania mexicana cathepsin L-like cysteine protease LmCPB2.8. The computational methods of homology modelling and molecular docking predicted some",43,ChEMBL,1801048,20200619,"11599792,11859052,44411149","103487618,103487850,103488025",NULL,NULL,NULL,Curation Efforts|Research and Development,30029081,0,10.1016/j.ejmech.2018.07.012,NULL,NULL,NULL
1422413,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action._|__|_Abstract: Chronic hepatitis B virus (HBV) infection is a serious public health burden, and current therapies cannot achieve satisfactory cure rate. There are high unmet medical needs of novel therapeutic agents with differentiated mechanism of action (MOA) from the current standard of care. RG7834, a compound from the dihydroquinolizinone (D",43,ChEMBL,1796918,20200619,118261815,404714943,NULL,NULL,NULL,Curation Efforts|Research and Development,30286292,0,10.1021/acs.jmedchem.8b01245,NULL,NULL,NULL
1422414,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action._|__|_Abstract: Chronic hepatitis B virus (HBV) infection is a serious public health burden, and current therapies cannot achieve satisfactory cure rate. There are high unmet medical needs of novel therapeutic agents with differentiated mechanism of action (MOA) from the current standard of care. RG7834, a compound from the dihydroquinolizinone (D",43,ChEMBL,1796919,20200619,118261815,404714943,NULL,NULL,NULL,Curation Efforts|Research and Development,30286292,0,10.1021/acs.jmedchem.8b01245,NULL,NULL,NULL
1422415,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action._|__|_Abstract: Chronic hepatitis B virus (HBV) infection is a serious public health burden, and current therapies cannot achieve satisfactory cure rate. There are high unmet medical needs of novel therapeutic agents with differentiated mechanism of action (MOA) from the current standard of care. RG7834, a compound from the dihydroquinolizinone (D",43,ChEMBL,1796920,20200619,118261815,404714943,NULL,NULL,NULL,Curation Efforts|Research and Development,30286292,0,10.1021/acs.jmedchem.8b01245,NULL,NULL,NULL
1432654,100,Time-dependent inhibition of CYP450 (unknown origin),"Title: Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists._|__|_Abstract: In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX2R subtype and culminating in the discovery of 23, a highly potent, OX2R-selective molecule that exhibited a promising in vivo profile. Further st",43,ChEMBL,1650590,20200620,"74221903,74222492,118435993","381838158,381841848,381862674",NULL,NULL,NULL,Curation Efforts|Research and Development,28216403,0,10.1016/j.bmcl.2017.02.012,NULL,NULL,NULL
1436182,100,Time-dependent inhibition of JAK in human PBMC assessed as reduction in human recombinant IL-2/ mouse anti-human CD3 stimulated STAT5 phosphorylation at tyrosine residue at 10-fold IC50 preincubated with cells followed by compound washout and subsequent I,"Title: Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin._|__|_Abstract: By use of a structure-based computational method for identification of structurally novel Janus kinase (JAK) inhibitors predicted to bind beyond the ATP binding site, a potent series of indazoles was identified as selective pan-JAK inhibitors with a type 1.5 binding mode. Optimization of the ser",43,ChEMBL,1654139,20200620,135567293,374303766,NULL,NULL,NULL,Curation Efforts|Research and Development,27983835,0,10.1021/acs.jmedchem.6b01634,NULL,NULL,NULL
1436642,100,Time-dependent inhibition of CYP1A2 (unknown origin),"Title: Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents._|__|_Abstract: We attempted to optimize sulfonamide-based non-alkyne LpxC inhibitors by focusing on improvements in enzyme inhibitory and antibacterial activity. It was discovered that inhibitors possessing 2-aryl benzofuran as a hydrophobe exhibited good activity. In particular, compound 21 displayed impressive antibacterial activity (E. coli MIC=0.063&#x3BC;g/mL, K. pneumoniae MIC=0.5&#x3BC;g/mL, and P. aeruginosa M",43,ChEMBL,1654599,20200620,137646925,381859667,NULL,NULL,NULL,Curation Efforts|Research and Development,28082037,0,10.1016/j.bmcl.2016.12.059,NULL,NULL,NULL
1436643,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents._|__|_Abstract: We attempted to optimize sulfonamide-based non-alkyne LpxC inhibitors by focusing on improvements in enzyme inhibitory and antibacterial activity. It was discovered that inhibitors possessing 2-aryl benzofuran as a hydrophobe exhibited good activity. In particular, compound 21 displayed impressive antibacterial activity (E. coli MIC=0.063&#x3BC;g/mL, K. pneumoniae MIC=0.5&#x3BC;g/mL, and P. aeruginosa M",43,ChEMBL,1654600,20200620,137646925,381859667,NULL,NULL,NULL,Curation Efforts|Research and Development,28082037,0,10.1016/j.bmcl.2016.12.059,NULL,NULL,NULL
1436644,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents._|__|_Abstract: We attempted to optimize sulfonamide-based non-alkyne LpxC inhibitors by focusing on improvements in enzyme inhibitory and antibacterial activity. It was discovered that inhibitors possessing 2-aryl benzofuran as a hydrophobe exhibited good activity. In particular, compound 21 displayed impressive antibacterial activity (E. coli MIC=0.063&#x3BC;g/mL, K. pneumoniae MIC=0.5&#x3BC;g/mL, and P. aeruginosa M",43,ChEMBL,1654601,20200620,137646925,381859667,NULL,NULL,NULL,Curation Efforts|Research and Development,28082037,0,10.1016/j.bmcl.2016.12.059,NULL,NULL,NULL
1436645,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents._|__|_Abstract: We attempted to optimize sulfonamide-based non-alkyne LpxC inhibitors by focusing on improvements in enzyme inhibitory and antibacterial activity. It was discovered that inhibitors possessing 2-aryl benzofuran as a hydrophobe exhibited good activity. In particular, compound 21 displayed impressive antibacterial activity (E. coli MIC=0.063&#x3BC;g/mL, K. pneumoniae MIC=0.5&#x3BC;g/mL, and P. aeruginosa M",43,ChEMBL,1654602,20200620,137646925,381859667,NULL,NULL,NULL,Curation Efforts|Research and Development,28082037,0,10.1016/j.bmcl.2016.12.059,NULL,NULL,NULL
1436646,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Sulfonamide-based non-alkyne LpxC inhibitors as Gram-negative antibacterial agents._|__|_Abstract: We attempted to optimize sulfonamide-based non-alkyne LpxC inhibitors by focusing on improvements in enzyme inhibitory and antibacterial activity. It was discovered that inhibitors possessing 2-aryl benzofuran as a hydrophobe exhibited good activity. In particular, compound 21 displayed impressive antibacterial activity (E. coli MIC=0.063&#x3BC;g/mL, K. pneumoniae MIC=0.5&#x3BC;g/mL, and P. aeruginosa M",43,ChEMBL,1654603,20200620,137646925,381859667,NULL,NULL,NULL,Curation Efforts|Research and Development,28082037,0,10.1016/j.bmcl.2016.12.059,NULL,NULL,NULL
1437346,100,Time dependent inhibition of CYP2C19 in human liver microsomes using S-Mephentoin as substrate,"Title: Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin._|__|_Abstract: We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailabl",43,ChEMBL,1655306,20200620,71602803,381886035,NULL,NULL,NULL,Curation Efforts|Research and Development,28337324,0,10.1021/acsmedchemlett.6b00491,NULL,NULL,NULL
1437350,100,Time dependent inhibition of CYP3A4 using in human liver microsomes using midazolam as substrate,"Title: Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin._|__|_Abstract: We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailabl",43,ChEMBL,1655310,20200620,71602803,381886035,NULL,NULL,NULL,Curation Efforts|Research and Development,28337324,0,10.1021/acsmedchemlett.6b00491,NULL,NULL,NULL
1437351,100,Time dependent inhibition of CYP3A4 using in human liver microsomes using testosterone as substrate,"Title: Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin._|__|_Abstract: We report the discovery of a new potent allosteric effector of sickle cell hemoglobin, GBT440 (36), that increases the affinity of hemoglobin for oxygen and consequently inhibits its polymerization when subjected to hypoxic conditions. Unlike earlier allosteric activators that bind covalently to hemoglobin in a 2:1 stoichiometry, 36 binds with a 1:1 stoichiometry. Compound 36 is orally bioavailabl",43,ChEMBL,1655311,20200620,71602803,381886035,NULL,NULL,NULL,Curation Efforts|Research and Development,28337324,0,10.1021/acsmedchemlett.6b00491,NULL,NULL,NULL
1440064,100,Time-dependent inhibition of CYP3A4 in human liver microsomes at 10 to 50 uM,"Title: Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors._|__|_Abstract: A series of furano[3,2-d]pyrimidine Syk inhibitors were synthesized and optimized for their enzyme potency and selectivity versus other kinases. In addition, ADME properties were assessed and compounds were prepared with optimized profiles for in vivo experiments. Compound 23 was identified as having acceptable pharmacokinetic properties and demonstrated efficacy in a rat collag",43,ChEMBL,1658040,20200620,"67130050,137644496,137647884","381845459,381856063,381861063",NULL,NULL,NULL,Curation Efforts|Research and Development,27789138,0,10.1016/j.bmcl.2016.09.077,NULL,NULL,NULL
1442013,100,Time dependent inhibition of CYP3A4 (unknown origin) at 5 to 25 uM,"Title: Design, Synthesis, and Evaluation of a Novel Series of Oxadiazine Gamma Secretase Modulators for Familial Alzheimer's Disease._|__|_Abstract: Herein we describe the design, synthesis, and evaluation of a novel series of oxadiazine-based gamma secretase modulators obtained via isosteric amide replacement and critical consideration of conformational restriction. Oxadiazine lead 47 possesses good in vitro potency with excellent predicted CNS drug-like properties and desirable ADME/PK profile. This lead ",43,ChEMBL,1659997,20200620,124127413,381886357,NULL,NULL,NULL,Curation Efforts|Research and Development,28230986,0,10.1021/acs.jmedchem.6b01620,NULL,NULL,NULL
1443859,100,Time dependent inhibition of CYP3A4 (unknown origin),Title: Discovery and Pre-Clinical Characterization of Third-Generation 4-H Heteroaryldihydropyrimidine (HAP) Analogues as Hepatitis B Virus (HBV) Capsid Inhibitors._|__|_Abstract: Described herein are the discovery and structure-activity relationship (SAR) studies of the third-generation 4-H heteroaryldihydropyrimidines (4-H HAPs) featuring the introduction of a C6 carboxyl group as novel HBV capsid inhibitors. This new series of 4-H HAPs showed improved anti-HBV activity and better drug-like properties com,43,ChEMBL,1661845,20200620,89996234,381841459,NULL,NULL,NULL,Curation Efforts|Research and Development,28339215,0,10.1021/acs.jmedchem.7b00083,NULL,NULL,NULL
1448186,100,Time dependent inhibition of CYP1A2 in human liver microsomes at 100 uM,"Title: Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design._|__|_Abstract: Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was op",43,ChEMBL,1666203,20200620,118414016,381861745,NULL,NULL,NULL,Curation Efforts|Research and Development,28498658,0,10.1021/acs.jmedchem.7b00231,NULL,NULL,NULL
1448187,100,Time dependent inhibition of CYP2B6 in human liver microsomes at 100 uM,"Title: Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design._|__|_Abstract: Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was op",43,ChEMBL,1666204,20200620,118414016,381861745,NULL,NULL,NULL,Curation Efforts|Research and Development,28498658,0,10.1021/acs.jmedchem.7b00231,NULL,NULL,NULL
1448188,100,Time dependent inhibition of CYP2C8 in human liver microsomes at 100 uM,"Title: Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design._|__|_Abstract: Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was op",43,ChEMBL,1666205,20200620,118414016,381861745,NULL,NULL,NULL,Curation Efforts|Research and Development,28498658,0,10.1021/acs.jmedchem.7b00231,NULL,NULL,NULL
1448189,100,Time dependent inhibition of CYP2C9 in human liver microsomes at 100 uM,"Title: Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design._|__|_Abstract: Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was op",43,ChEMBL,1666206,20200620,118414016,381861745,NULL,NULL,NULL,Curation Efforts|Research and Development,28498658,0,10.1021/acs.jmedchem.7b00231,NULL,NULL,NULL
1448190,100,Time dependent inhibition of CYP2C19 in human liver microsomes at 100 uM,"Title: Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design._|__|_Abstract: Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was op",43,ChEMBL,1666207,20200620,118414016,381861745,NULL,NULL,NULL,Curation Efforts|Research and Development,28498658,0,10.1021/acs.jmedchem.7b00231,NULL,NULL,NULL
1448191,100,Time dependent inhibition of CYP2D6 in human liver microsomes at 100 uM,"Title: Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design._|__|_Abstract: Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was op",43,ChEMBL,1666208,20200620,118414016,381861745,NULL,NULL,NULL,Curation Efforts|Research and Development,28498658,0,10.1021/acs.jmedchem.7b00231,NULL,NULL,NULL
1450472,100,"Time dependent inhibition of CYP3A4 (unknown origin) by high throughput assay relative to 2-((3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl)-5-methyl-6-(4-(oxazol-4-yl)benzyl)isoindolin-1-one",Title: Design and Synthesis of &#xCE;&#xB3;- and &#xCE;&#xB4;-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity._|__|_Abstract: Recent data demonstrated that activation of the muscarinic M1 receptor by a subtype-selective positive allosteric modulator (PAM) contributes to the gastrointestinal (GI) and cardiovascular (CV) cholinergic adverse events (AEs) previously attributed to M2 and M3 activation. These studies were condu,43,ChEMBL,1668506,20200621,137642540,381853194,NULL,NULL,NULL,Curation Efforts|Research and Development,28598634,0,10.1021/acs.jmedchem.7b00597,NULL,NULL,NULL
1453561,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides._|__|_Abstract: This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The",43,ChEMBL,1685420,20200621,137635043,381842013,NULL,NULL,NULL,Curation Efforts|Research and Development,28522253,0,10.1016/j.bmcl.2017.05.014,NULL,NULL,NULL
1453562,100,Time-dependent inhibition of CYP1A2 (unknown origin),"Title: Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides._|__|_Abstract: This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The",43,ChEMBL,1685421,20200621,137635043,381842013,NULL,NULL,NULL,Curation Efforts|Research and Development,28522253,0,10.1016/j.bmcl.2017.05.014,NULL,NULL,NULL
1453563,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides._|__|_Abstract: This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The",43,ChEMBL,1685422,20200621,137635043,381842013,NULL,NULL,NULL,Curation Efforts|Research and Development,28522253,0,10.1016/j.bmcl.2017.05.014,NULL,NULL,NULL
1453564,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides._|__|_Abstract: This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The",43,ChEMBL,1685423,20200621,137635043,381842013,NULL,NULL,NULL,Curation Efforts|Research and Development,28522253,0,10.1016/j.bmcl.2017.05.014,NULL,NULL,NULL
1453565,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides._|__|_Abstract: This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c]pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The",43,ChEMBL,1685424,20200621,137635043,381842013,NULL,NULL,NULL,Curation Efforts|Research and Development,28522253,0,10.1016/j.bmcl.2017.05.014,NULL,NULL,NULL
1456863,100,Time-dependent inhibition of CYP3A4 in human liver microsomes using midazolam as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,"Title: Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation._|__|_Abstract: Preclinical evidence in support of the potential utility of mGlu5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no s",43,ChEMBL,1688728,20200621,60168069,174501478,NULL,NULL,NULL,Curation Efforts|Research and Development,28530802,0,10.1021/acs.jmedchem.7b00410,NULL,NULL,NULL
1456864,100,Time-dependent inhibition of CYP2D6 in human liver microsomes using dextromethorphan as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,"Title: Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation._|__|_Abstract: Preclinical evidence in support of the potential utility of mGlu5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no s",43,ChEMBL,1688729,20200621,60168069,174501478,NULL,NULL,NULL,Curation Efforts|Research and Development,28530802,0,10.1021/acs.jmedchem.7b00410,NULL,NULL,NULL
1456865,100,Time-dependent inhibition of CYP2C9 in human liver microsomes using diclofenac as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,"Title: Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation._|__|_Abstract: Preclinical evidence in support of the potential utility of mGlu5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no s",43,ChEMBL,1688730,20200621,60168069,174501478,NULL,NULL,NULL,Curation Efforts|Research and Development,28530802,0,10.1021/acs.jmedchem.7b00410,NULL,NULL,NULL
1456866,100,Time-dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate preincubated for 15 mins followed by NADPH addition measured after 8 mins by LC/MS/MS analysis,"Title: Discovery of N-(5-Fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy)picolinamide (VU0424238): A Novel Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Selected for Clinical Evaluation._|__|_Abstract: Preclinical evidence in support of the potential utility of mGlu5 NAMs for the treatment of a variety of psychiatric and neurodegenerative disorders is extensive, and multiple such molecules have entered clinical trials. Despite some promising results from clinical studies, no s",43,ChEMBL,1688731,20200621,60168069,174501478,NULL,NULL,NULL,Curation Efforts|Research and Development,28530802,0,10.1021/acs.jmedchem.7b00410,NULL,NULL,NULL
1464434,100,Time-dependent inhibition of JAK3 (unknown origin) using CSKtide as substrate in presence of [gamma32P]ATP by top-count liquid scintillation counting method,"Title: Discovery of highly potent, selective, covalent inhibitors of JAK3._|__|_Abstract: A useful and novel set of tool molecules have been identified which bind irreversibly to the JAK3 active site cysteine residue. The design was based on crystal structure information and a comparative study of several electrophilic warheads.",43,ChEMBL,1696341,20200621,137632228,381837775,NULL,NULL,NULL,Curation Efforts|Research and Development,28927786,0,10.1016/j.bmcl.2017.09.023,NULL,NULL,NULL
1464461,100,Time-dependent inhibition of full length human His-tagged BTK expressed in baculovirus expression system using GEEPLYWSFPAKKK-NH2 as substrate by topcount scintillation counting analysis,"Title: Discovery of highly potent, selective, covalent inhibitors of JAK3._|__|_Abstract: A useful and novel set of tool molecules have been identified which bind irreversibly to the JAK3 active site cysteine residue. The design was based on crystal structure information and a comparative study of several electrophilic warheads.",43,ChEMBL,1696368,20200621,137632228,381837775,NULL,NULL,NULL,Curation Efforts|Research and Development,28927786,0,10.1016/j.bmcl.2017.09.023,NULL,NULL,NULL
1464938,2,Displacement of [3H]-Dofetilide from recombinant human ERG expressed in CHOK1 cell membranes incubated for 4 hrs under dark condition by luminescence assay,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696845,20200622,"2267,25164128,25189510,25190195,25190435,131728656,131728658,137631458,137632738,137633326,137634700,137637727,137643918,137646827,137646948,137647842,137651292,137653149,137659034,137661121,137662184","103188977,381836615,381838540,381839444,381841487,381842408,381845324,381846040,381853272,381854860,381855232,381858451,381859521,381859706,381860953,381860993,381866098,381868886,381883040,381886127,381887703",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464939,100,"Dissociation constant, pKa of the compound","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696846,20200622,"25190195,131728656,137646827,137659034","381858451,381859521,381860953,381883040",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464940,100,"Drug level in CD Sprague-Dawley rat brain at 1 mg/kg, iv administered via bolus dose measured after 5 mins by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696847,20200622,"25164128,25190195,137634700,137659034","381841487,381854860,381858451,381883040",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464941,100,"Ratio of drug level in brain to blood in CD Sprague-Dawley rat at 1 mg/kg, iv administered via bolus dose after 5 mins by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696848,20200622,"25164128,25190195,137634700,137659034","381841487,381854860,381858451,381883040",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464942,100,"AUC (0 to last) in CD Sprague-Dawley rat brain at 3 mg/kg, po by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696849,20200622,"25164128,137634700,137659034,137662184","381841487,381854860,381883040,381887703",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464943,100,"Blood clearance in CD Sprague-Dawley rat at 1 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696850,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464944,100,"Volume of distribution at steady state in CD Sprague-Dawley rat at 1 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696851,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464945,100,"Elimination half life in CD Sprague-Dawley rat at 1 mg/kg, iv by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696852,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464946,100,Oral bioavailability in CD Sprague-Dawley rat at 10 mg/kg by LC-MS/MS analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696853,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464947,100,"Bioavailability in CD Sprague-Dawley rat at 2 mg/kg, sc by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696854,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464948,100,"Blood clearance in CD Sprague-Dawley rat at 1 mg/kg, iv or 3 mg/kg, po by LC-MS/MS analysis relative to liver blood flow","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696855,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464949,100,"Blood clearance in Beagle dog at 0.5 mg/kg, iv administered via bolus dose or 1 mg/kg, po administered via gavage by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696856,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464950,100,"Blood clearance in Beagle dog at 0.5 mg/kg, iv administered via bolus dose or 1 mg/kg, po administered via gavage by LC-MS/MS analysis relative to liver blood flow","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696857,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464951,100,"Volume of distribution at steady state in Beagle dog at 0.5 mg/kg, iv administered via bolus dose or 1 mg/kg, po administered via gavage by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696858,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464952,100,"Elimination half life in Beagle dog at 0.5 mg/kg, iv administered via bolus dose or 1 mg/kg, po administered via gavage by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696859,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464953,100,Oral bioavailability in Beagle dog at 1 to 2 mg/kg administered via gavage by LC-MS/MS analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696860,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464954,100,"Ratio of Cmax in CD Sprague-Dawley rat at 2 mg/kg, sc to Cmax in CD Sprague-Dawley rat at 3 mg/kg, po","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696861,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464955,100,"Drug excretion in Beagle dog urine at 1 mg/kg, po administered via gavage by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696862,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464956,100,"Drug excretion in Beagle dog urine at 0.5 mg/kg, iv administered via bolus dose by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696863,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464957,100,Protein binding in rat plasma at 10 ug/ml by ultrafiltration method,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696864,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464958,100,Protein binding in guinea pig plasma at 10 ug/ml by ultrafiltration method,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696865,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464959,100,Protein binding in dog plasma at 10 ug/ml by ultrafiltration method,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696866,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464960,100,Protein binding in human plasma at 10 ug/ml by ultrafiltration method,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696867,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464961,100,Drug metabolism in rat liver microsomes,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696868,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464962,100,Drug metabolism in human liver microsomes,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696869,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464963,100,Drug metabolism in dog liver microsomes,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696870,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464964,100,Drug metabolism in mouse liver microsomes,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696871,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464965,100,"Drug absorption in CD Sprague-Dawley rat hepatic portal vein at 3 mg/kg, po","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696872,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464966,100,Drug metabolism in human hepatocytes assessed as M11 formation by mass spectrometric analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696877,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464967,100,Drug metabolism in human hepatocytes assessed as M15 formation by mass spectrometric analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696878,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464968,100,Drug metabolism in human hepatocytes assessed as M19 formation by mass spectrometric analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696879,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464969,100,Drug metabolism in human hepatocytes assessed as M24 formation by mass spectrometric analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696880,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464970,100,Drug metabolism in human hepatocytes assessed as M26 formation by mass spectrometric analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696881,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464971,100,Drug level in human hepatocytes treated with N-(4-{4-[(6-Butyl-8-quinolinyl)oxy]-1-piperidinyl}butyl)ethanesulfonamide assessed metabolite formation by mass spectrometric method,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696882,20200622,NULL,"381891873,381891942,381892077,381892116,381892125",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464979,100,Bioavailability in sc dosed CD Sprague-Dawley rat by LC-MS/MS analysis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696890,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464982,100,Permeability in MDCK cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696893,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464983,100,"Drug level in CD Sprague-Dawley rat brain at 300 mg/kg, po measured after 30 mins by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696894,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464984,100,"Ratio of drug level in brain to blood in CD Sprague-Dawley rat at 300 mg/kg, po after 30 mins by LC-MS/MS analysis","Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696895,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464985,100,Antiallergic activity in ovalbumin-sensitized guinea pig model of histamine-induced allergic rhinitis assessed as reduction in congestion by measuring enhanced pause at 1 mg/ml administered intranasally pretreated for 3 hrs followed by histamine challenge,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696896,20200622,"2267,25164128","103188977,381854860",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464986,100,Antiallergic activity in ovalbumin-sensitized guinea pig model of histamine-induced allergic rhinitis assessed as reduction in congestion by measuring enhanced pause at 1 mg/ml administered intranasally pretreated for 24 hrs followed by histamine challeng,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696897,20200622,"2267,25164128","103188977,381854860",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464987,100,Drug uptake in arterial blood of ovalbumin-sensitized guinea pig model of histamine-induced allergic rhinitis at 1 mg/ml administered intranasally pretreated for 4 hrs followed by histamine challenge after 30 mins post atropine monohydrate hemisulfate add,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696898,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464988,100,Drug uptake in arterial blood of ovalbumin-sensitized guinea pig model of histamine-induced allergic rhinitis at 1 mg/ml administered intranasally pretreated for 24 hrs followed by histamine challenge after 30 mins post atropine monohydrate hemisulfate ad,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696899,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464989,100,Antiallergic activity in ovalbumin-sensitized guinea pig model of histamine-induced allergic rhinitis assessed as reduction in congestion by measuring enhanced pause at 1 mg/ml administered intranasally pretreated for 1 hr followed by histamine challenge ,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696900,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464990,2,Drug level in blood of ovalbumin-sensitized guinea pig model of histamine-induced allergic rhinitis,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696901,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464991,100,Pro-congestant activity in guinea pig assessed as effect on basline enhanced pause at 1 mg/ml administered intranasally measured after 3 to 24 hrs,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696902,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464992,100,Mutagenicity in Salmonella typhimurium up to higher concentration by Ames test,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696903,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464993,100,Clastogenicity in mouse Lymphoma cells up to higher concentration,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696904,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464994,2,Displacement of [3H]mesulergine from recombinant human 5-ht2B expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696905,20200622,"2267,25164128","103188977,381854860",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464995,2,Displacement of [3H]mesulergine from recombinant human 5-ht2C expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696906,20200622,"2267,25164128","103188977,381854860",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464996,2,Displacement of [3H]prazosin from rat salivary gland adrenergic alpha1a receptor,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696907,20200622,"2267,25164128","103188977,381854860",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464997,2,Displacement of [3H]AF-DX 384 from recombinant human M1 receptor expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696908,20200622,"2267,25164128","103188977,381854860",NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464998,100,Cardiotoxicity in rabbit heart assessed as QT prolongation,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696909,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1464999,100,Selectivity ratio of compound effect for displacement of [3H]mesulergine from recombinant human 5-ht2B expressed in CHO cells to compound effect for antagonist activity at human histamine H1 receptor expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696910,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1465000,100,Selectivity ratio of compound effect for displacement of [3H]mesulergine from recombinant human 5-ht2C expressed in CHO cells to compound effect for antagonist activity at human histamine H1 receptor expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696911,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1465001,100,Selectivity ratio of compound effect for displacement of [3H]prazosin from rat salivary gland alpha1a receptor to compound effect for antagonist activity at human histamine H1 receptor expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696912,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1465002,100,Selectivity ratio of compound effect for displacement of [3H]AF-DX 384 from recombinant human M1 receptor expressed in CHO cells to compound effect for antagonist activity at human histamine H1 receptor expressed in CHO cells,"Title: Identification of selective 8-(piperidin-4-yloxy)quinoline sulfone and sulfonamide histamine H1 receptor antagonists for use in allergic rhinitis._|__|_Abstract: A series of potent, selective and long-acting quinoline-based sulfonamide human H1 histamine receptor antagonists, designed for once-daily intranasal administration for the treatment of rhinitis were developed. Sulfonamide 33b had a slightly lower affinity for the H1 receptor than azelastine, had low oral bioavailability in the rat and dog, ",43,ChEMBL,1696913,20200622,25164128,381854860,NULL,NULL,NULL,Curation Efforts|Research and Development,28958623,0,10.1016/j.bmcl.2017.09.020,NULL,NULL,NULL
1466691,100,Time-dependent inhibition of CYP3A4 in human microsomes at 10 uM using midazolam as substrate preincubated for 5 mins followed by NADPH addition measured 20 mins relative to control,"Title: Design and optimization of purine derivatives as in vivo active PDE10A inhibitors._|__|_Abstract: Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-a]pyrazines and the PDE10A inhibitor",43,ChEMBL,1671588,20200622,"132502926,137633691,137636423,137651999,137655649,137656637","381839972,381844091,381865448,381867146,381872598,381877848",NULL,NULL,NULL,Curation Efforts|Research and Development,28462841,0,10.1016/j.bmc.2017.04.019,NULL,NULL,NULL
1466693,100,Time-dependent inhibition of CYP2D6 in human microsomes at 10 uM using dextromethorphan as substrate preincubated for 5 mins followed by NADPH addition measured 20 mins relative to control,"Title: Design and optimization of purine derivatives as in vivo active PDE10A inhibitors._|__|_Abstract: Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-a]pyrazines and the PDE10A inhibitor",43,ChEMBL,1671590,20200622,"132502926,137633691,137636423,137651999,137655649,137656637","381839972,381844091,381865448,381867146,381872598,381877848",NULL,NULL,NULL,Curation Efforts|Research and Development,28462841,0,10.1016/j.bmc.2017.04.019,NULL,NULL,NULL
1466695,100,Time-dependent inhibition of CYP2C9 in human microsomes at 10 uM using diclofenac as substrate preincubated for 5 mins followed by NADPH addition measured 20 mins relative to control,"Title: Design and optimization of purine derivatives as in vivo active PDE10A inhibitors._|__|_Abstract: Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-a]pyrazines and the PDE10A inhibitor",43,ChEMBL,1671592,20200622,"132502926,137633691,137636423,137651999,137655649,137656637","381839972,381844091,381865448,381867146,381872598,381877848",NULL,NULL,NULL,Curation Efforts|Research and Development,28462841,0,10.1016/j.bmc.2017.04.019,NULL,NULL,NULL
1466697,100,Time-dependent inhibition of CYP1A2 in human microsomes at 10 uM using phenacetin as substrate preincubated for 5 mins followed by NADPH addition measured 20 mins relative to control,"Title: Design and optimization of purine derivatives as in vivo active PDE10A inhibitors._|__|_Abstract: Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-a]pyrazines and the PDE10A inhibitor",43,ChEMBL,1671594,20200622,"132502926,137633691,137636423,137651999,137655649,137656637","381839972,381844091,381865448,381867146,381872598,381877848",NULL,NULL,NULL,Curation Efforts|Research and Development,28462841,0,10.1016/j.bmc.2017.04.019,NULL,NULL,NULL
1466699,100,Time-dependent inhibition of CYP2C19 in human microsomes at 10 uM using mephenytoin as substrate preincubated for 5 mins followed by NADPH addition measured 20 mins relative to control,"Title: Design and optimization of purine derivatives as in vivo active PDE10A inhibitors._|__|_Abstract: Phosphodiesterases are important enzymes regulating signal transduction mediated by second messenger molecules cAMP or cGMP. PDE10A is a unique member in the PDE family because of its selective expression in medium spiny neurons. It is recognized as anti-psychotic drug target. Based on the structural similarity between our previous chemistry work on 8-aminoimidazo[1,2-a]pyrazines and the PDE10A inhibitor",43,ChEMBL,1671596,20200622,"132502926,137633691,137636423,137651999,137655649,137656637","381839972,381844091,381865448,381867146,381872598,381877848",NULL,NULL,NULL,Curation Efforts|Research and Development,28462841,0,10.1016/j.bmc.2017.04.019,NULL,NULL,NULL
1474879,2,Time dependent inhibition of CYP3A4 (unknown origin) in presence of NADPH,"Title: Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores._|__|_Abstract: SAR in the previously described spirocyclic ROMK inhibitor series was further evolved from lead 4 by modification of the spirocyclic core and identification of novel right-side pharmacophores. In this process, it was discovered that the spiropyrrolidinone core with the carbonyl group &#x3B1; to the spirocenter was preferred for potent ROMK activity. Eff",43,ChEMBL,1679785,20200622,121313969,381840513,NULL,NULL,NULL,Curation Efforts|Research and Development,28431879,0,10.1016/j.bmcl.2017.03.086,NULL,NULL,NULL
1474880,2,Time dependent inhibition of CYP3A4 (unknown origin) in absence of NADPH,"Title: Improvement of hERG-ROMK index of spirocyclic ROMK inhibitors through scaffold optimization and incorporation of novel pharmacophores._|__|_Abstract: SAR in the previously described spirocyclic ROMK inhibitor series was further evolved from lead 4 by modification of the spirocyclic core and identification of novel right-side pharmacophores. In this process, it was discovered that the spiropyrrolidinone core with the carbonyl group &#x3B1; to the spirocenter was preferred for potent ROMK activity. Eff",43,ChEMBL,1679786,20200622,121313969,381840513,NULL,NULL,NULL,Curation Efforts|Research and Development,28431879,0,10.1016/j.bmcl.2017.03.086,NULL,NULL,NULL
1475614,100,Time dependent inhibition of CYP3A4 in human liver microsomes after 10 mins by LC/MS analysis,"Title: Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B._|__|_Abstract: Pyrrolo[3,2-d]pyrimidines were identified as a new series of potent and selective TLR7 agonists. Compounds were optimized for their activity and selectivity over TLR8. This presents an advantage over recently described scaffolds that have residual TLR8 activity, which may be detrimental to the tolerability of the candidate drug. Oral administratio",43,ChEMBL,1680520,20200622,86346192,381881060,NULL,NULL,NULL,Curation Efforts|Research and Development,28671847,0,10.1021/acs.jmedchem.7b00365,NULL,NULL,NULL
1478257,100,Time dependent inhibition of CYP3A4 in human liver microsomes,"Title: A Dipolar Cycloaddition Reaction To Access 6-Methyl-4,5,6,7-tetrahydro-1H-[1,2,3]triazolo[4,5-c]pyridines Enables the Discovery Synthesis and Preclinical Profiling of a P2X7 Antagonist Clinical Candidate._|__|_Abstract: A single pot dipolar cycloaddition reaction/Cope elimination sequence was developed to access novel 1,4,6,7-tetrahydro-5H-[1,2,3]triazolo[4,5-c]pyridine P2X7 antagonists that contain a synthetically challenging chiral center. The structure-activity relationships of the new compounds a",43,ChEMBL,1683165,20200622,"86271494,90408860","374294277,374305304",NULL,NULL,NULL,Curation Efforts|Research and Development,29211470,0,10.1021/acs.jmedchem.7b01279,NULL,NULL,NULL
1482073,100,Time-dependent inhibition of CYP1A2 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700206,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482074,100,Time-dependent inhibition of CYP2B6 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700207,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482075,100,Time-dependent inhibition of CYP2C8 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700208,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482076,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700209,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482077,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700210,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482078,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700211,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482079,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700212,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1482080,100,Time-dependent inhibition of CYP3A5 (unknown origin),"Title: Identification of the Clinical Candidate (R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methanone (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist._|__|_Abstract: The nonselective glucocorticoid receptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patients with Cushing's syndrome. While this drug is highly effective, lack of selectiv",43,ChEMBL,1700213,20200622,73051463,381838849,NULL,NULL,NULL,Curation Efforts|Research and Development,28368581,0,10.1021/acs.jmedchem.7b00162,NULL,NULL,NULL
1489463,100,Time-dependent inhibition of CYP1A2 (unknown origin),"Title: Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate._|__|_Abstract: Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment. IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function. As s",43,ChEMBL,1707608,20200622,23063810,381851679,NULL,NULL,NULL,Curation Efforts|Research and Development,29111717,0,10.1021/acs.jmedchem.7b00974,NULL,NULL,NULL
1489464,100,Time-dependent inhibition of CYP2C9 (unknown origin),"Title: Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate._|__|_Abstract: Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment. IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function. As s",43,ChEMBL,1707609,20200622,23063810,381851679,NULL,NULL,NULL,Curation Efforts|Research and Development,29111717,0,10.1021/acs.jmedchem.7b00974,NULL,NULL,NULL
1489465,100,Time-dependent inhibition of CYP2C19 (unknown origin),"Title: Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate._|__|_Abstract: Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment. IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function. As s",43,ChEMBL,1707610,20200622,23063810,381851679,NULL,NULL,NULL,Curation Efforts|Research and Development,29111717,0,10.1021/acs.jmedchem.7b00974,NULL,NULL,NULL
1489466,100,Time-dependent inhibition of CYP2D6 (unknown origin),"Title: Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate._|__|_Abstract: Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment. IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function. As s",43,ChEMBL,1707611,20200622,23063810,381851679,NULL,NULL,NULL,Curation Efforts|Research and Development,29111717,0,10.1021/acs.jmedchem.7b00974,NULL,NULL,NULL
1489467,100,Time-dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate._|__|_Abstract: Tumors use tryptophan-catabolizing enzymes such as indoleamine 2,3-dioxygenase (IDO-1) to induce an immunosuppressive environment. IDO-1 is induced in response to inflammatory stimuli and promotes immune tolerance through effector T-cell anergy and enhanced Treg function. As s",43,ChEMBL,1707612,20200622,23063810,381851679,NULL,NULL,NULL,Curation Efforts|Research and Development,29111717,0,10.1021/acs.jmedchem.7b00974,NULL,NULL,NULL
1497419,100,Time-dependent inhibition of human CYP450,"Title: Design and Synthesis of a Novel Series of Orally Bioavailable, CNS-Penetrant, Isoform Selective Phosphoinositide 3-Kinase &#xCE;&#xB3; (PI3K&#xCE;&#xB3;) Inhibitors with Potential for the Treatment of Multiple Sclerosis (MS)._|__|_Abstract: The lipid kinase phosphoinositide 3-kinase &#x3B3; (PI3K&#x3B3;) has attracted attention as a potential target to treat a variety of autoimmune disorders, including multiple sclerosis, due to its role in immune modulation and microglial activation. By minimizing t",43,ChEMBL,1714105,20200623,68045182,404670547,NULL,NULL,NULL,Curation Efforts|Research and Development,29847724,0,10.1021/acs.jmedchem.8b00085,NULL,NULL,NULL
1500816,100,Time dependent inhibition of CYP3A4 (unknown origin),"Title: Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors._|__|_Abstract: Recently we described a novel class of imidazopyridine compounds that showed exceptional anti-RSV potency in cell culture. However, unfavorable pharmacokinetic (PK) properties and glutathione (GSH) adduct liabilities impeded their further development. In a bid to address the PK and early safety concerns, a small compound library consisting of dozens of scaffold-hopping ",43,ChEMBL,1717514,20200623,72950813,404686340,NULL,NULL,NULL,Curation Efforts|Research and Development,28772235,0,10.1016/j.ejmech.2017.07.032,NULL,NULL,NULL
1505576,100,Time dependent inhibition of CYP450 in human liver microsomes,"Title: Identification and Pharmacological Profile of an Indane Based Series of Ghrelin Receptor Full Agonists._|__|_Abstract: Cachexia and muscle wasting are very common among patients suffering from cancer, chronic obstructive pulmonary disease, and other chronic diseases. Ghrelin stimulates growth hormone secretion via the ghrelin receptor, which subsequently leads to increase of IGF-1 plasma levels. The activation of the GH/IGF-1 axis leads to an increase of muscle mass and functional capacity. Ghrelin f",43,ChEMBL,1722274,20200623,145957574,404663656,NULL,NULL,NULL,Curation Efforts|Research and Development,29909635,0,10.1021/acs.jmedchem.8b00322,NULL,NULL,NULL
